<SEC-DOCUMENT>0001140361-12-024098.txt : 20120510
<SEC-HEADER>0001140361-12-024098.hdr.sgml : 20120510
<ACCEPTANCE-DATETIME>20120509194404
ACCESSION NUMBER:		0001140361-12-024098
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20120331
FILED AS OF DATE:		20120510
DATE AS OF CHANGE:		20120509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYTORI THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34375
		FILM NUMBER:		12827351

	BUSINESS ADDRESS:	
		STREET 1:		3020 CALLAN ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584580900

	MAIL ADDRESS:	
		STREET 1:		3020 CALLAN ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10q.htm
<DESCRIPTION>CYTORI THERAPEUTICS INC 10-Q 3-31-2012
<TEXT>
<html>
<head>
    <title>form10q.htm</title>
    <!--Licensed to: Thomson Reuters-->
    <!--Document Created using EDGARizer 2020 5.4.2.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: center">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div>
<hr style="COLOR: black" align="center" noshade size="1" width="20%">
</div>

<div>&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">FORM 10-Q </font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Mark One)</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline;" face="Wingdings">x</font></font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="5"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the quarterly period ended March 31, 2012 </font></font></font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="5"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OR</font></font></font></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to </font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Commission file number 001-34375 </font></font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 24pt">CYTORI THERAPEUTICS, INC.</font> </font></font></font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact name of Registrant as Specified in Its Charter)</font></font></font></font></div>
</div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DELAWARE</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">33-0827593</font></div>
</td>
</tr><tr>
<td valign="top" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or other jurisdiction </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of incorporation or organization)</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(I.R.S. Employer </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Identification No.)</font></div>
</td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3020 CALLAN ROAD, SAN DIEGO, CALIFORNIA</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">92121</font></div>
</td>
</tr><tr>
<td valign="top" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Address of principal executive offices)</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Zip Code)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Registrant&#8217;s telephone number, including area code:<font style="DISPLAY: inline; FONT-WEIGHT: bold"> (858) 458-0900</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant&#160;&#160;(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">x</font>&#160;&#160;No&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">x</font>&#160;&#160;No&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.&#160;&#160;See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act (Check one).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="25%" style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Large Accelerated Filer&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accelerated Filer <font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font></div>
</td>
<td valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-Accelerated Filer <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Smaller reporting company <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
</tr><tr>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="3" valign="top" width="25%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Do not check if a smaller reporting company)</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">x</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of April 30, 2012, there were 58,686,448 shares of the registrant&#8217;s common stock outstanding.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CYTORI THERAPEUTICS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="index">INDEX</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="top" width="85%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="5%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Page</font></font></td>
</tr><tr>
<td align="left" valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">PART I</font></div>
</td>
<td align="left" colspan="2" valign="top" width="85%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">FINANCIAL INFORMATION</font></div>
</td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="85%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 1.</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Financial Statements</font></div>
</td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#balance">Consolidated Condensed Balance Sheets as of March 31, 2012 and December 31, 2011 (unaudited)</a></font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#operations">Consolidated Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2012 and 2011 (unaudited)</a></font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><!--efplaceholder--><a href="#cash"><!--efplaceholder--><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consolidated Condensed Statements of Cash Flows for the three months ended </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 31, 2012 and 2011 (unaudited)</font></a></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#notes">Notes to Consolidated Condensed Financial Statements (unaudited)</a></font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 2.</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#managemen">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 3.</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#quantativ">Quantitative and Qualitative Disclosures about Market Risk</a></font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 4.</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#controls">Controls and Procedures</a></font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">PART II</font></div>
</td>
<td align="left" colspan="2" valign="top" width="85%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">OTHER INFORMATION</font></div>
</td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 1.</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#lega">Legal Proceedings</a></font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" nowrap valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 1A.&#160; </font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#ris">Risk Factors</a></font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 2.</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#unregistere">Unregistered Sales of Equity Securities and Use of Proceeds</a></font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">34</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 3.</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#default">Defaults Upon Senior Securities</a></font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">34</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 4.</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#reserve">Reserved</a></font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">34</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 5.</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#othe">Other Information</a></font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">34</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 6.</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#exhi">Exhibits</a></font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">35</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART I.&#160;&#160;FINANCIAL INFORMATION </font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 1.&#160;&#160;Financial Statements</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CYTORI THERAPEUTICS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSOLIDATED CONDENSED <a name="BALANCE">BALANCE</a> SHEETS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">As of March 31, </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BORDER-TOP: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; BORDER-TOP: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">As of December </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">31, </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Assets</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Current assets:</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">34,399,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">36,922,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts receivable, net of reserves of $187,000 and of $474,000 in 2012 and 2011, respectively</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,425,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,260,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Inventories, net</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,374,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,318,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other current assets</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,135,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">837,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total current assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">40,333,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,337,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Property and equipment, net</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,367,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,711,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restricted cash and cash equivalents</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">350,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">350,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Investment in joint venture</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">200,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">250,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,794,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,772,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intangibles, net</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">136,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">192,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Goodwill</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,922,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,922,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total assets</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">49,102,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">51,534,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liabilities and Stockholders&#8217; Equity (Deficit)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Current liabilities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable and accrued expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,046,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,334,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Current portion of long-term obligations</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,911,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,487,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total current liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,957,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,821,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred revenues, related party</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,520,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,520,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,176,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,244,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrant liability</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">757,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">627,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Option liability</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,640,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,910,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Long-term deferred rent</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">498,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">504,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Long-term obligations, net of discount, less current portion</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,704,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,962,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">42,252,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">41,588,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Commitments and contingencies</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stockholders&#8217; equity:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Preferred stock, $0.001 par value; 5,000,000 shares authorized; -0- shares issued and outstanding in 2012 and 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock, $0.001 par value; 95,000,000 shares authorized; 58,428,606 and 56,594,683 shares issued and outstanding in 2012 and 2011, respectively</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">58,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additional paid-in capital</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">258,566,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">252,338,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accumulated deficit</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(251,774,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(242,449,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total stockholders&#8217; equity</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,850,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,946,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total liabilities and stockholders&#8217; equity</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">49,102,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">51,534,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SEE NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CYTORI THERAPEUTICS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSOLIDATED CONDENSED STATEMENTS OF <a name="OPERATIONS">OPERATIONS</a> AND COMPREHENSIVE LOSS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Three Months</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Ended March 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Product revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,481,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,362,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cost of product revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">853,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">842,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gross profit</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">628,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">520,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Development revenues:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Development, related party</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,231,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research grants and other</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,235,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operating expenses:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,836,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,047,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sales and marketing</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,376,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,226,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,924,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,544,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in fair value of warrant liability</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">130,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,471,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in fair value of option liability</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(270,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(290,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total operating expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,996,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,998,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operating loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8,365,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(11,243,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other income (expense):</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest income</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(865,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(738,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other expense, net</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(47,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(47,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Equity loss from investment in joint venture</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(50,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(46,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total other expense</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(960,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(829,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(9,325,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(12,072,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Basic and diluted net loss per common share</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.16</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.23</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Basic and diluted weighted average common shares</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57,484,990</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">51,994,708</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SEE NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CYTORI THERAPEUTICS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><!--EFPlaceholder-->CONSOLIDATED CONDENSED STATEMENTS OF <a name="CASH">CASH</a> FLOWS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Three Months Ended March 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash flows from operating activities:</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(9,325,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(12,072,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Depreciation and amortization</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">220,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">194,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amortization of deferred financing costs and debt discount</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">237,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">240,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Increase (decrease) in allowance for doubtful accounts</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(24,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in fair value of warrant liability</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">130,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,471,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in fair value of option liability</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(270,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(290,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based compensation</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">942,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">881,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Equity loss from investment in joint venture</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">50,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">46,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Increases (decreases) in cash caused by changes in operating assets and liabilities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts receivable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">859,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">278,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Inventories</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(56,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(174,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other current assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(298,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(130,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(22,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(922,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable and accrued expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(83,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(854,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred revenues, related party</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,231,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(68,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(10,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Long-term deferred rent</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(12,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash used in operating activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(7,714,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(10,564,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash flows from investing activities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Purchases of property and equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(25,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(131,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash used in investing activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(25,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(131,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash flows from financing activities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Principal payments on long-term obligations</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(71,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from exercise of employee stock options and warrants</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">947,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">674,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from sale of common stock</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,396,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Costs from sale of common stock</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(56,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash provided by financing activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,216,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">674,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net decrease in cash and cash equivalents</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,523,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(10,021,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents at beginning of period</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">36,922,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52,668,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents at end of period</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">34,399,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">42,647,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Supplemental disclosure of cash flows information:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash paid during period for:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">625,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">499,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Supplemental schedule of non-cash operating, investing and financing activities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Capital equipment lease</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net increase in purchases of property and equipment included in accounts payable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">795,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SEE NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><!--EFPlaceholder--><!--EFPlaceholder--><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CYTORI THERAPEUTICS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><!--EFPlaceholder--><a name="NOTES">NOTES</a> TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" nowrap valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.&#160;&#160;&#160;&#160; </font></div>
</td>
<td align="left" valign="top" width="99%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Basis of Presentation</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our accompanying unaudited consolidated condensed financial statements as of March 31, 2012 and for the three months ended March 31, 2012 and 2011 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information.&#160;&#160;Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements.&#160;&#160;Our consolidated condensed balance sheet at March 31, 2012 has been derived from the audited financial statements at December 31, 2011, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.&#160;&#160;In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Cytori Therapeutics, Inc., and our subsidiaries (the Company) have been included.&#160;&#160;Operating results for the three months ended March 31, 2012 are not necessarily indicative of the results that may be expected for the year ending December 31, 2012.&#160;&#160;These financial statements should be read in conjunction with the consolidated financial statements and notes therein included in our annual report on Form 10-K for the year ended December 31, 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" nowrap valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.&#160;&#160;&#160;&#160; </font></div>
</td>
<td align="left" valign="top" width="99%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Use of Estimates</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period.&#160;&#160;Our most significant estimates and critical accounting policies involve recognizing revenue, evaluating goodwill for impairment, valuing our put option arrangement with Olympus Corporation, valuing warrants, determining the assumptions used in measuring share-based compensation expense and valuing allowances for doubtful accounts and inventories.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Actual results could differ from these estimates.&#160;&#160;Current economic conditions, including illiquid credit markets and volatile equity markets, contribute to the inherent uncertainty of such estimates.&#160;&#160;Management&#8217;s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the consolidated financial statements in the periods they are determined to be necessary.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" nowrap valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3.&#160;&#160;&#160;&#160; </font></div>
</td>
<td align="left" valign="top" width="99%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Capital Availability</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We incurred net losses of $9,325,000 and $12,072,000 for the three months ended March 31, 2012 and 2011, respectively.&#160;&#160;We have an accumulated deficit of $251,774,000 as of March 31, 2012.&#160;&#160;Additionally, we have used net cash of $7,714,000 and $10,564,000 to fund our operating activities for the three months ended March 31, 2012 and 2011, respectively<font style="DISPLAY: inline; FONT-WEIGHT: bold">.&#160;&#160;</font>To date, these operating losses have been funded primarily from outside sources of invested capital.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Management recognizes the need to generate positive cash flows in future periods and/or to obtain additional capital from various sources. In the continued absence of positive cash flows from operations, no assurance can be given that we can generate sufficient revenue to cover operating costs or that additional financing will be available to us and, if available, on terms acceptable to us in the future.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During 2011, we expanded our commercialization activities while simultaneously pursuing available financing sources to support operations and growth.&#160;&#160;We have had, and we will likely continue to have, an ongoing need to raise additional cash from outside sources to fund our operations for remainder of 2012 and beyond.&#160;&#160;If we cannot do so when required, we would need to reduce our research, development, and administrative operations, including reductions of our employee base, in order to offset lack of available funding.&#160;&#160;&#160;We continue to evaluate available financing opportunities as part of our normal course of business.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" nowrap valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4.&#160;&#160;&#160;&#160; </font></div>
</td>
<td align="left" valign="top" width="99%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recent Accounting Pronouncements</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In May 2011, the FASB revised the fair value measurement and disclosure requirements to align the requirements under GAAP and International Financial Reporting Standards (&#8220;IFRS&#8221;). The guidance clarifies the FASB&#8217;s intent about the application of existing fair value measurements and requires enhanced disclosures, most significantly related to unobservable inputs used in a fair value measurement that is categorized within Level 3 of the fair value hierarchy. The guidance is effective prospectively during interim and annual periods beginning after December 15, 2011. The adoption of this guidance did not have a material impact on our consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" nowrap valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5.&#160;&#160;&#160;&#160; </font></div>
</td>
<td align="left" valign="top" width="99%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Warrant Liability</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Warrants with exercise price reset features (down-round protection) are accounted for as liabilities, with changes in fair value included in net earnings (loss).&#160;&#160;The fair value of the liability associated with the warrants with this reset feature increased to $757,000 as of March 31, 2012, which resulted in a $130,000 loss from the change in fair value of warrants for the three months ended March 31, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Since these warrants do not qualify for hedge accounting, all future changes in the fair value of the warrants will be recognized currently in earnings until such time as the warrants are exercised or expire. These warrants are not traded in an active securities market, and as such, we estimated the fair value of these warrants using an option pricing model with the following assumptions:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">As of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31, 2012</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">As of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December&#160;31, 2011</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected term</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" colspan="2" nowrap valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.37 years</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" colspan="2" nowrap valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.61 years</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock market price</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.49</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.20</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk-free interest rate</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.26</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.19</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected volatility</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">71.61</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">69.98</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Resulting fair value (per warrant)</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.38</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.32</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Expected volatility is based primarily on historical volatility. Historical volatility was computed using daily pricing observations for recent periods that correspond to the expected term of the warrants. We believe this method produces an estimate that is representative of our expectations of future volatility over the expected term of these warrants. We currently have no reason to believe future volatility over the expected remaining life of these warrants is likely to differ materially from historical volatility. The expected life is based on the remaining contractual term of the warrants. The risk-free interest rate is the interest rate for treasury constant maturity instruments published by the Federal Reserve Board that is closest to the expected term of the warrants.&#160;&#160;&#160;The fair value of these warrants also incorporates our assumptions about future equity issuances and their impact to the down-round protection feature.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" nowrap valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">6.&#160;&#160;&#160;&#160; </font></div>
</td>
<td align="left" valign="top" width="99%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Long-term Debt</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On September 9, 2011 we entered into a Second Amendment to the Amended and Restated Loan and Security Agreement (loan agreement) with General Electric Capital Corporation (GECC), Silicon Valley Bank (SVB) and Oxford Finance Corporation (together, the &#8220;Lenders&#8221;), pursuant to which the Lenders increased the prior term loan made to the Company to a principal amount of $25.0 million (Term Loan), subject to the terms and conditions set forth in the loan agreement.&#160;&#160;The Term Loan accrues interest at a fixed rate of 9.87% per annum.&#160;&#160;Pursuant to the loan agreement, we are required to make (i) twelve (12) equal consecutive monthly principal payments of $20,833 on the first day of each calendar month, commencing on October 1, 2011, (ii) twenty-nine (29) equal consecutive monthly principal payments of $825,000 on the first day of each calendar month, commencing on October 1, 2012, and (iii) and one (1) final principal payment of $825,000 on March 1, 2015. In addition, the maturity date of the Term Loan has been extended until March 1, 2015, and at maturity of the Term Loan, the Company will make a final payment fee equal to 5% ($1,250,000) of the Term Loan.&#160;&#160;We may incur additional fees if we elect to prepay the Term Loan.&#160;&#160;In connection with the Term Loan, on September 9, 2011, we issued to the Lenders warrants to purchase up to an aggregate of 132,891 shares of our common stock at an exercise price of $3.01 per share.&#160;&#160;These warrants are immediately exercisable and will expire on September 9, 2018.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Term Loan amended the Amended and Restated Loan and Security Agreement, of which an aggregate balance of approximately $15.6 million remained outstanding along with a prorated final payment fee of $419,000. The net proceeds of the Term Loan, after payment of lender fees and expenses, were approximately $8.6 million.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We accounted for this amendment as debt modification since the terms of the amended Term Loan and the Original Term Loan were not substantially different and as present value of cash flows of the modified instrument (using a net method of comparing the present value of cash flows related to the lowest common principal balance between the old and the new loans) was within 10% of the original debt instrument.&#160;&#160;Accordingly, the fees associated with the amended Term Loan of $300,000, final payment fee of $1,250,000, and the existing unamortized debt discount from the Original Term Loan of $332,000 will be amortized as an adjustment of interest expense over the term of the Amended Term Loan using the effective interest method.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We allocated the aggregate proceeds of the Term Loan between the warrants and the debt obligations based on their relative fair values.&#160;&#160;The fair value of the warrants issued to the Lenders is calculated utilizing the Black-Scholes option-pricing model. We are amortizing the relative fair value of the warrants as a discount of $267,000 over the term of the loan using the effective interest method, with an effective interest rate of 13.63%. If the maturity of the debt is accelerated due to an event of default, then the amortization would be accelerated. The Term Loan is collateralized by the tangible assets of the company, including a security interest in substantially all of its existing and after-acquired assets, excluding its intellectual property assets; provided however, that if the Company does not maintain certain cash ratios, the security interest automatically will be deemed to include the Company&#8217;s intellectual property assets.&#160;&#160;As of March 31, 2012, we were in compliance with our financial and non-financial covenants.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" nowrap valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">7.&#160;&#160;&#160;&#160; </font></div>
</td>
<td align="left" valign="top" width="99%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Revenue Recognition</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Product Sales</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We recognize revenue from product sales when the following fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred, (iii) the price to the customer is fixed or determinable and (iv) collection of the resulting accounts receivable is reasonably assured.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For all sales, we use a binding purchase order or a signed agreement as evidence of an arrangement.&#160;&#160;Revenue for these product sales is recognized upon delivery to the customer, as all risks and rewards of ownership have been substantively transferred to the customer at that point.&#160;&#160;For sales to customers who arrange for and manage the shipping process, we recognize revenue upon shipment from our facilities.&#160;&#160;Shipping and handling costs that are billed to our customers are classified as revenue.&#160;&#160;The customer&#8217;s obligation to pay and the payment terms are set at the time of delivery and are not dependent on the subsequent use or resale of our products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For sales that include multiple deliverables, such as sales of our StemSource&#174; Cell Bank (cell bank), we allocate arrangement consideration at the inception of the arrangement to all deliverables using the relative selling price method.&#160;&#160;Stem cell banks typically consist of a complex array of equipment, proprietary knowledge, and services, including one or more StemSource&#174; devices, a cryogenic freezer, measuring and monitoring equipment, and a database patient tracking system. In addition, we typically provide consulting services, installation and training services concurrent with the installation of the cell bank.&#160;&#160;Web hosting and technical and maintenance services are generally provided for a period of up to one year subsequent to the date of sale.&#160;&#160;FASB authoritative guidance establishes a selling price hierarchy for determining the selling price of a deliverable, which is based on: (a) vendor-specific objective evidence (&#8220;VSOE&#8221;); (b) third-party evidence (&#8220;TPE&#8221;); or (c) management estimates.&#160;&#160;For our cell bank sales, we establish relative selling prices for all deliverables based on vendor-specific quotes for comparable services when available.&#160;&#160;In the absence of VSOE, we use competitors&#8217; products or services considered largely interchangeable with our own or management&#8217;s best estimate.&#160;&#160;A substantial amount of consulting services are provided to customers before the equipment installation and training has been completed, and therefore we treat this as a separate unit of accounting.&#160;&#160;The equipment with installation and initial training activities are treated as separate units of accounting.&#160;&#160;Also of standalone value to customers is the transfer of the proprietary knowledge, most notably in the form of standard operating procedures, and any license or exclusivity rights associated with the agreements.&#160;&#160;Revenue for the various deliverables is calculated and recognized based on the relative selling prices of each deliverable.&#160;&#160;Future services such as web hosting and ongoing maintenance are deferred and recognized into income during the year following the installation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Concentration of Significant Customers</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the three months ended March 31, 2012, two direct customers comprised 31% of our revenue recognized for the quarter.&#160;&#160;Our Asia-Pacific, North America and Australia region sales accounted for 69% of our revenue recognized for the three months ended March 31, 2012.&#160;&#160;Additionally, two direct customers accounted for 29% of total outstanding accounts receivable as of March 31, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the three months ended March 31, 2011, one direct customer and one distributor comprised 29% of our revenue recognized for the quarter.&#160;&#160;Our Asia-Pacific region sales accounted for 30% of our revenue recognized for the three months ended March 31, 2011.&#160;&#160;Additionally, one distributor and two direct customers accounted for 43% of total outstanding accounts receivable as of March 31, 2011.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and Development</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We earn revenue for performing tasks under research and development agreements with both commercial enterprises, such as Olympus and Senko, and governmental agencies like the National Institutes of Health (&#8220;NIH&#8221;).&#160;&#160;Revenue earned under development agreements is classified as either research grant or development revenues depending on the nature of the arrangement.&#160;&#160;Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with grants are recorded as research grant and other within development revenues.&#160;&#160;Research grant revenue is recorded at the gross amount of the reimbursement.&#160;&#160;The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations.&#160;&#160;Additionally, research and development arrangements we have with commercial enterprises such as Olympus and Senko are considered a key component of our central and ongoing operations.&#160;&#160;Accordingly, when recognized, the inflows from such arrangements are presented as revenues in our statements of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We received funds from Olympus and Olympus-Cytori, Inc. during 2005 and 2006.&#160;&#160;&#160;We recorded upfront fees totaling $28,311,000 as deferred revenues, related party.&#160;&#160;In exchange for these proceeds, we agreed to (a) provide Olympus-Cytori, Inc. an exclusive and perpetual license to our Celution&#174; System device technology and certain related intellectual property, and (b) provide future development contributions related to commercializing the Celution&#174; System platform.&#160;&#160;The license and development services are not separable and as a result the recognition of this deferred amount requires achievement of service related milestones, under a proportional performance methodology.&#160;&#160;If and as such revenues are recognized, deferred revenue will be decreased.&#160;&#160;Proportional performance methodology was elected due to the nature of our development obligations and efforts in support of the Joint Venture (&#8220;JV&#8221;), including product development activities and regulatory efforts to support the commercialization of the JV products. The application of this methodology uses the achievement of R&amp;D milestones as outputs of value to the JV.&#160;&#160;We received up-front, non-refundable payments in connection with these development obligations, which we have broken down into specific R&amp;D milestones that are definable and substantive in nature, and which will result in value to the JV when achieved.&#160;&#160;As our research and development efforts progress, we periodically evaluate,&#160;&#160;and modify if necessary, the milestone points in our proportional performance model to ensure that revenue recognition accurately reflects our best estimate of substantive value deliverable to the JV.&#160;&#160;Revenue will be recognized as the above mentioned R&amp;D milestones are completed.&#160;&#160;Of the amounts received and deferred, we recognized development revenues of $1,231,000 for the three months ended March 31, 2011.&#160;&#160;There was no development revenues recognized for the three months ended March 31, 2012.&#160;&#160;All related development costs are expensed as incurred and are included in research and development expense on our statements of operations.&#160;&#160;To date under the contract, of the $28,311,000 originally deferred, we have recognized a total of $24,791,000 through March 31, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Under a Distribution Agreement with Senko, we granted to Senko an exclusive license to sell and distribute certain Thin Film products in Japan.&#160;&#160;We have also earned or will be entitled to earn additional payments under the Distribution Agreement based on achieving certain defined and substantive research and development milestones.</font>&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt">There was no development revenue recognized related to this agreement during the three months ended March 31, 2012 and 2011, respectively.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" nowrap valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">8.&#160;&#160;&#160;&#160; </font></div>
</td>
<td align="left" valign="top" width="99%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Inventories</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Inventories are carried at the lower of cost or market, determined on the first-in, first-out (FIFO) method.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Inventories consisted of the following:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center">
<table cellpadding="0" cellspacing="0" width="90%" style="TEXT-ALIGN: center; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr style="TEXT-ALIGN: center;">
<td valign="bottom" width="66%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</td>
<td colspan="2" nowrap valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31,</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</td>
<td colspan="2" nowrap valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December&#160;31,</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</td>
</tr><tr>
<td valign="bottom" width="66%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</td>
</tr><tr>
<td valign="bottom" width="66%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" colspan="2" nowrap valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" colspan="2" nowrap valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Raw materials</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,518,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,503,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Work in process</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">838,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">790,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Finished goods</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,018,000</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,025,000</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,374,000</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,318,000</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" nowrap valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">9.&#160;&#160;&#160;&#160; </font></div>
</td>
<td align="left" valign="top" width="99%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Share-Based Compensation</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stock Options</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the first quarter of 2012, we issued to our directors and executive officers options to purchase an aggregate of up to 690,000 shares of our common stock, with four-year vesting for our officers and two-year vesting for our directors. The grant date fair value of the awards granted to our officers was $2.10 per share and to our directors was $1.35 per share. The resulting share-based compensation expense of $1,373,000, net of estimated forfeitures, will be recognized as expense over the respective vesting periods.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the first quarter of 2011, we issued to our directors, executive officers and certain non-executive employees options to purchase an aggregate of up to 692,500 shares of our common stock, with four-year vesting for our officers and employees and two-year vesting for our directors. The grant date fair value of the awards granted to our officers and employees was $3.46 and to our directors was $3.15 per share. The resulting share-based compensation expense of $2,375,000, net of estimated forfeitures, will be recognized as expense over the respective vesting periods.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Restricted Stock Awards</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the first quarter of 2012, we issued to our executive officers 190,000 shares of restricted stock.&#160;&#160;The stock award is scheduled to fully vest on January 10, 2013, subject to the officer&#8217;s continued employment with the Company through the vesting date.&#160;&#160;The resulting share-based compensation expense of $654,000 will be recognized as expense over the respective vesting period.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Performance-Based Restricted Stock Awards</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We granted 246,225 performance-based restricted stock awards under the 2004 Equity Incentive Plan in February 2011.&#160;&#160;The awards provide certain employees until January 1, 2012 to achieve certain performance goals established by the Compensation Committee. The performance goals were weighted based on the following achievements: obtaining certain FDA clearance or approval (40%), achieving a targeted revenue increase for the fiscal year ended December 31, 2011 (20%), and entering into a major collaboration for development and/or commercialization of the Company&#8217;s products (40%).&#160;&#160;To the extent that any of the performance goals were partially achieved, the Compensation Committee maintained the discretion to continue the vesting of all or a portion of the awards following January 1, 2012.&#160;&#160;Once earned, the awards would have remained unvested until January 1, 2013. Termination of employment prior to vesting would have resulted in the forfeiture of any earned (as well as unearned) awards. Effective January 2012, the outstanding awards were terminated in their entirety based upon the decision by the Compensation Committee that performance criteria had not been met as of January 1, 2012.&#160;&#160;No compensation expense was recognized related to these awards during the three months ended March 31, 2012 and 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In January 2012, we granted 276,375 performance-based restricted stock awards under the 2004 Equity Incentive Plan.&#160;&#160;The awards provide certain employees until December 31, 2012 to achieve certain performance goals established by the Compensation Committee. The performance goals are weighted based on the following achievements: entering into a major collaboration for development and/or commercialization of the Company&#8217;s products (40%), obtaining certain FDA clearance or approvals, which include FDA approval for and initiation of the ATHENA feasibility trial in chronic myocardial ischemia (40%), obtaining CE mark for certain products (15%), and achieving a targeted revenue increase for the fiscal year ended December 31, 2012 (5%).&#160;&#160;To the extent that any of the performance goals are partially achieved, the Compensation Committee maintains the discretion to continue the vesting of all or a portion of the awards following December 31, 2012.&#160;&#160;Once earned, the awards will remain unvested until January 10, 2014. Termination of employment prior to vesting will result in the forfeiture of the awards.&#160;&#160;No compensation expense was recognized related to these awards during the three months ended March 31, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table summarizes activity with respect to the performance based restricted stock awards during the three months ended March 31, 2012:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center">
<table cellpadding="0" cellspacing="0" width="90%" style="TEXT-ALIGN: center; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr style="TEXT-ALIGN: center;">
<td valign="bottom" width="66%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Restricted Stock </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Awards</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Average Grant-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Date Fair Value</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding at January 1, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">246,225</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.82</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">276,375</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.44</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Vested</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cancelled/forfeited</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(246,225 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.82</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding at March 31, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">276,375</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.44</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Vested at March 31, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" nowrap valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><!--efplaceholder-->10.&#160;&#160;</font></div>
</td>
<td align="left" valign="top" width="99%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Loss per Share</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but unexercised options, warrants, restricted stock and performance based restricted stock awards for all periods presented.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have excluded all potentially dilutive securities from the calculation of diluted loss per share attributable to common stockholders for the three months ended March 31, 2012 and 2011, as their inclusion would be antidilutive.&#160;&#160;Potentially dilutive common shares excluded from the calculations of diluted loss per share were 18,544,087 and 19,649,383 for the three month periods ended March 31, 2012 and 2011, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" nowrap valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">11.&#160;&#160; </font></div>
</td>
<td align="left" valign="top" width="99%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Commitments and Contingencies</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We have entered into agreements with various research organizations for pre-clinical and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements was estimated based on current schedules of pre-clinical and clinical studies in progress.&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">As of March 31, 2012, we have pre-clinical research study obligations of $60,000 (which are expected to be fully completed within a year) and clinical research study obligations of $12,600,000 ($4,100,000 of which are expected to be completed within a year).</font>&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt">Should the timing or the budgets of the pre-clinical and clinical trials change, the timing and amounts of the payments for these obligations would also change.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During 2008, we entered into a supply agreement with a minimum purchase requirements clause.&#160;&#160;As of March 31, 2012, we have minimum purchase obligations of $2,191,000 ($1,341,000 of which are expected to be paid within a year).</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have entered into several lease agreements for our headquarters office location as well as international office locations and corporate housing for our employees on international assignments. As of March 31, 2012, we have remaining lease obligations of $10,259,000 ($1,785,000 of which are expected to be completed within a year).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are subject to various claims and contingencies related to legal proceedings.&#160;&#160;Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions.&#160;&#160;Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate.&#160;&#160;Management believes that any liability to us that may arise as a result of currently pending legal proceedings will not have a material adverse effect on our financial condition, liquidity, or results of operations as a whole.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Refer to note 6 for a discussion of our commitments and contingencies related to our long-term obligations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Refer to note 12 for a discussion of our commitments and contingencies related to our transactions with Olympus, including (a) our obligation to the Joint Venture in future periods and (b) certain put and call rights embedded in the arrangements with Olympus.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" nowrap valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">12.&#160;&#160; </font></div>
</td>
<td align="left" valign="top" width="99%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Transactions with Olympus Corporation</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Initial Investment by Olympus Corporation in Cytori</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In 2005, we entered into a common stock purchase agreement with Olympus in which we received $11,000,000 in cash proceeds.&#160;&#160;We received an additional $11,000,000 from Olympus in August 2006 for the issuance of approximately 1,900,000 shares of our common stock at $5.75 per share.&#160;&#160;We received an additional $6,000,000 from Olympus in August 2008 for the issuance of 1,000,000 unregistered shares of our common stock at $6.00 per share and 500,000 common stock warrants (with an original exercise price of $8.50 per share) under a private placement offering.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of March 31, 2012, Olympus holds approximately 6.9% of our issued and outstanding shares.&#160;&#160;Additionally, Olympus has a right, which it has not yet exercised, to designate a director to serve on our Board of Directors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Formation of the Olympus-Cytori Joint Venture</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In 2005, we entered into a joint venture and other related agreements (the &#8220;Joint Venture Agreements&#8221;) with Olympus.&#160;&#160;The Joint Venture is owned equally by Olympus and us.&#160;&#160;We have determined that the Joint Venture is a variable interest entity or VIE, but that Cytori is not the VIE&#8217;s primary beneficiary.&#160;&#160;Accordingly, we have accounted for our interests in the Joint Venture using the equity method of accounting, since we can exert significant influence over the Joint Venture&#8217;s operations.&#160;&#160;At March 31, 2012, the carrying value of our investment in the Joint Venture is $200,000.&#160;&#160;We are under no obligation to provide additional funding to the Joint Venture, but may choose to do so.&#160;&#160;We made no cash contributions to the Joint Venture during the three months ended March 31, 2012 and 2011.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Put/Calls and Guarantees</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Shareholders&#8217; Agreement between Cytori and Olympus provides that in certain specified circumstances of our insolvency or if we experience a change in control, Olympus will have the rights to (i) repurchase our interests in the Joint Venture at the fair value of such interests or (ii) sell its own interests in the Joint Venture to Cytori (the &#8220;Put&#8221;) at the higher of (a) $22,000,000 or (b) the Put&#8217;s fair value.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At March 31, 2012 and December 31, 2011, the estimated fair value of the Put was $1,640,000 and $1,910,000, respectively.&#160;&#160;Fluctuations in the Put value are recorded in the consolidated condensed statements of operations as a component of change in fair value of option liabilities. The estimated fair value of the Put has been recorded as a long-term liability in the caption option liability in our consolidated condensed balance sheets.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The valuations of the Put were completed using an option pricing theory based simulation analysis (i.e., a Monte Carlo simulation).&#160;&#160;The valuations are based on assumptions as of the valuation date with regard to the market value of Cytori and the estimated fair value of the Joint Venture, the expected correlation between the values of Cytori and the Joint Venture, the expected volatility of Cytori and the Joint Venture, the bankruptcy recovery rate for Cytori, the bankruptcy threshold for Cytori, the probability of a change of control event for Cytori, and the risk free interest rate.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following assumptions were employed in estimating the value of the Put:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="66%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December&#160;31, </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</td>
</tr><tr>
<td valign="bottom" width="66%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" colspan="2" nowrap valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" colspan="2" nowrap valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected volatility of Cytori</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">76.45</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">76.07</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected volatility of the Joint Venture</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">76.45</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">76.07</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Bankruptcy recovery rate for Cytori</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28.00</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28.00</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Bankruptcy threshold for Cytori</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,138,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,594,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Probability of a change of control event for Cytori</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.08</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.33</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected correlation between fair values of Cytori and the Joint Venture in the future</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.00</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.00</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk free interest rate</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.23</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.89</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Put has no expiration date.&#160;&#160;Accordingly, we will continue to recognize a liability for the Put and mark it to market each quarter until it is exercised or until the arrangements with Olympus are amended.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" nowrap valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">13.&#160;&#160; </font></div>
</td>
<td align="left" valign="top" width="99%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair Value Measurements</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Fair value measurements are market-based measurements, not entity-specific measurements.&#160;&#160;Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability.&#160;&#160;We follow a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values.&#160;&#160;The basis for fair value measurements for each level within the hierarchy is described below:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Level 1: Quoted prices in active markets for identical assets or liabilities.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table provides a summary of the recognized assets and liabilities that we measure at fair value on a recurring basis:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="42%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Balance as of</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" nowrap valign="bottom" width="34%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Basis of Fair Value Measurements</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="42%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31, 2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level 1</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level 2</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level 3</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Assets:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash equivalents</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26,646,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26,646,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liabilities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Put option liability</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,640,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,640,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrant liability</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(757,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(757,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="42%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Balance as of</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" nowrap valign="bottom" width="34%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Basis of Fair Value Measurements</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="42%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December&#160;31, 2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level 1</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level 2</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level 3</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Assets:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash equivalents</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,646,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,646,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liabilities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Put option liability</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,910,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,910,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrant liability</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(627,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(627,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We use quoted market prices to determine the fair value of our cash equivalents, which consist of money market funds that are classified in Level 1 of the fair value hierarchy.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We value our put liability using an option pricing theory based simulation analysis (i.e., a Monte Carlo simulation) (see note 12). Because some of the inputs to our valuation model are either not observable quoted prices or are not derived principally from or corroborated by observable market data by correlation or other means, the put option liability is classified as Level 3 in the fair value hierarchy.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table summarizes the change in our Level 3 put option liability value:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center">
<table cellpadding="0" cellspacing="0" width="80%" style="TEXT-ALIGN: center; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr style="TEXT-ALIGN: center;">
<td valign="bottom" width="68%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three months ended</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="68%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Put option liability</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31, 2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="68%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="68%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Beginning balance</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,910,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Decrease in fair value recognized in operating expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">270,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Ending balance</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1.640,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><!--EFPlaceholder-->Common stock purchase warrants issued in connection with our August 2008 private equity placement do not trade in an active securities market, and as such, we estimate the fair value of these warrants using the option pricing model.&#160;&#160;Some of the significant inputs are observable in active markets, such as common stock market price, volatility, and risk free rate.&#160;&#160;The fair value of these warrants also incorporate our assumptions about future equity issuances and their impact to the down-round protection feature. Because some of the inputs to our valuation model are either not observable quoted prices or are not derived principally from or corroborated by observable market data by correlation or other means, the warrant liability is classified as Level 3 in the fair value hierarchy.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table summarizes the change in our Level 3 warrant liability value:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center">
<table cellpadding="0" cellspacing="0" width="80%" style="TEXT-ALIGN: center; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr style="TEXT-ALIGN: center;">
<td valign="bottom" width="68%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three months ended</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="68%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Warrant liability</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31, 2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="68%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="68%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Beginning balance</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(627,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Decrease (increase)&#160;&#160;in fair value recognized in operating expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(130,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Ending balance</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(757,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">No other assets or liabilities are measured at fair value on a recurring basis, or have been measured at fair value on a non-recurring basis subsequent to initial recognition, on the accompanying consolidated condensed balance sheet as of March 31, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" nowrap valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">14.&#160;&#160; </font></div>
</td>
<td align="left" valign="top" width="99%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair Value</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Financial Instruments</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We disclose fair value information about all financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate fair value. The disclosures of estimated fair value of financial instruments at March 31, 2012 and December 31, 2011, were determined using available market information and appropriate valuation methods. Considerable judgment is necessary to interpret market data and develop estimated fair value. The use of different market assumptions or estimation methods may have a material effect on the estimated fair value amounts.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The carrying amounts for cash and cash equivalents, accounts receivable, inventories, other current assets, accounts payable, accrued expenses and other liabilities approximate fair value due to the short-term nature of these instruments.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We utilize quoted market prices to estimate the fair value of our fixed rate debt, when available.&#160;&#160;If quoted market prices are not available, we calculate the fair value of our fixed rate debt based on a currently available market rate assuming the loans are outstanding through maturity and considering the collateral. In determining the current market rate for fixed rate debt, a market spread is added to the quoted yields on federal government treasury securities with similar terms to the debt.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At March 31, 2012 and December 31, 2011, the aggregate fair value and the carrying value of the Company&#8217;s fixed rate long-term debt were as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center">
<table cellpadding="0" cellspacing="0" width="90%" style="TEXT-ALIGN: center; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr style="TEXT-ALIGN: center;">
<td valign="bottom" width="42%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31, 2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, 2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="42%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair Value</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Carrying Value</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair Value</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Carrying Value</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fixed rate long-term debt</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,306,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,512,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,211,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,341,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Carrying value is net of debt discount of $1,613,000 and $1,847,000 as of March 31, 2012 and December 31, 2011, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" nowrap valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">15.&#160;&#160; </font></div>
</td>
<td align="left" valign="top" width="99%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stockholders&#8217; Equity</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Common Stock</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 13, 2010 we raised $10,000,000 in gross proceeds from a sale of 1,428,571 shares of unregistered common stock to Astellas Pharma Inc. for $7.00 per share in a private stock placement.&#160;&#160;Pursuant to the terms of the purchase agreement, we granted Astellas Pharma Inc. a two year right of first refusal to enter into a development and commercialization collaboration with us regarding the use of our technology, on a worldwide basis, for the treatment of liver conditions. In addition, we have agreed to use reasonable efforts to file a registration statement with the Securities and Exchange Commission to register the shares of common stock for resale upon the request of Astellas Pharma Inc.&#160;&#160;We also granted Astellas Pharma Inc. a non-voting observer seat on our Board of Directors and the right to designate a representative member to our Scientific Advisory Board.&#160;&#160;The $10,000,000 in total proceeds we received exceeded the market value of our stock at the completion of the purchase agreement.&#160;&#160;The $2,526,000 difference between the proceeds received and the fair market values of our common stock was recorded as a component of deferred revenues in the accompanying balance sheets.&#160;&#160;This difference was recorded as deferred revenue since, conceptually, the excess proceeds represent a value paid by Astellas Pharma Inc. attributable to the scientific advisory board seat, the non-voting observer seat on our Board of Directors, and the two year right of first refusal&#160;&#160;to enter into a development and commercialization collaboration with us regarding the use of our technology, on a worldwide basis, for the treatment of liver conditions, rather than an additional equity investment in Cytori.&#160;&#160;The recognition of this deferred amount is expected to occur upon the earlier of the expiration of the two year period or the termination of the agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On July 11, 2011, we entered into a common stock purchase agreement with Seaside 88, LP relating to the offering and sale of a total of up to 6,326,262 shares of our common stock.&#160;&#160;The agreement requires us to issue and Seaside to buy 1,326,262 shares of our common stock at an initial closing and 250,000 shares of our common stock once every two weeks, commencing 30 days after the initial closing, for up to an additional 20 closings, subject to the satisfaction of customary closing conditions. At the initial closing, the offering price was $4.52, which equaled to 88% of our common stock&#8217;s volume-weighted average trading prices, or VWAP, during the ten-day trading period immediately prior to the initial closing date, raising approximately $6,000,000 in gross proceeds. At subsequent closings, the offering price will equal 90.25% of our common stock&#8217;s volume-weighted average trading prices during the ten-day trading period immediately prior to each subsequent closing date.&#160;&#160;We raised approximately $17,684,000 in gross proceeds from the sale of 5,576,262 shares in our scheduled closings through March 31, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">14</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Warrant Adjustments</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our March 2009 offering of 4,771,174 shares of our common stock and warrants to purchase up to a total of 6,679,644 additional shares of our common stock with an exercise price of $2.59 per share, our May 2009 equity offering of 1,864,783 shares of our common stock and warrants to purchase up to a total of 3,263,380 additional shares of our common stock with an exercise price of $2.62 per share, our closings with Seaside 88, LP through March 31, 2012, our October 2010 offering of 4,600,000 shares of our common stock and our December 2010 sale of 1,428,571 shares of our common stock triggered an adjustment to the exercise price and number of shares issuable under the warrants issued to investors in our August 2008 private placement financing.&#160;&#160;As a result, as of March 31, 2012, the common stock warrants issued on August 11, 2008 are currently exercisable for 2,014,512 shares of our common stock at an exercise price of $5.75 per share.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other Related Party Transactions</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of March 31, 2012 and December 31, 2011, Green Hospital Supply, Inc., our distribution partner in Japan and a related party, was a beneficial owner of 5.1% and 5.3%, respectively, of our outstanding shares of common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the three months ended March 31, 2012 and 2011, we incurred approximately $27,000 and $28,000 in royalty costs in connection with our sales of our Celution&#174; 800/CRS System products to the European and Asia-Pacific reconstructive surgery market, pursuant to our License and Royalty Agreement and the Amended License/Commercial Agreement with the Olympus-Cytori, Inc. joint venture, respectively.&#160;&#160;Additionally, during the three months ended March 31, 2012, we purchased second generation Celution &#174; Systems and consumable sets from Olympus-Cytori, Inc. joint venture, at a formula-based transfer price aggregating to $1,048, 0000.&#160;&#160;As of March 31, 2012 and December 31, 2011, Olympus Corporation was a beneficial owner of 6.9% and 7.1%, respectively, of our outstanding shares of common stock and a beneficial owner of 50% of Olympus-Cytori, Inc. joint venture.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" nowrap valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">16.&#160;&#160; </font></div>
</td>
<td align="left" valign="top" width="99%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Subsequent Events</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have evaluated events after the balance sheet date of March 31, 2012 and up to the date we filed this report.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Subsequent to the quarter ended March 31, 2012, we completed one scheduled closing with Seaside 88, LP during the period of April 1, 2012 through our filing date raising in aggregate approximately $549,000 in gross proceeds from the <font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">sale of 250,000<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>shares</font> of our common stock in connection with the agreement we entered into with Seaside 88, LP on July 11, 2011.&#160;&#160;Effective, April 30<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font>, 2012, we terminated the agreement with Seaside 88, LP and we will not sell the remaining and final 500,000 shares that would otherwise have been sold under this agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">15</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div>&#160;</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 2 .&#160;&#160;<a name="Managemen">Managemen</a>t&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (MD&amp;A) includes the following sections:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 31.5pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Overview that discusses our operating results and some of the trends that affect our business.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 31.5pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Results of Operations that includes a more detailed discussion of our revenue and expenses.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 31.5pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Liquidity and Capital Resources which discusses key aspects of our statements of cash flows, changes in our financial position and our financial commitments.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 31.5pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Significant changes since our most recent Annual Report on Form 10-K in the Critical Accounting Policies and Significant Estimates that we believe are important to understanding the assumptions and judgments underlying our financial statements.</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">You should read this MD&amp;A in conjunction with the financial statements and related notes in Item 1 and our Annual Report on Form 10-K for the fiscal year ended December 31, 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This report contains certain statements that may be deemed &#8220;forward-looking statements&#8221; within the meaning of United States of America securities laws.&#160;&#160;All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These statements include, without limitation, statements about our anticipated expenditures, including those related to clinical research studies and general and administrative expenses; the potential size of the market for our products, future&#160;&#160;development and/or expansion of our products and therapies in our markets, our ability to generate&#160;&#160;product revenues or effectively manage our gross profit margins; our ability to obtain regulatory clearance; expectations as to our future performance; the &#8220;Liquidity and Capital Resources&#8221; section of this report, including our potential need for additional financing and the availability thereof; and the potential enhancement of our cash position through development, marketing, and licensing arrangements.&#160;&#160;&#160;Our actual results will likely differ, perhaps materially, from those anticipated in these forward-looking statements as a result of various factors, including: our need and ability to raise additional cash, our joint ventures, risks associated with&#160;&#160;laws or regulatory requirements applicable to us, market conditions, product performance, potential litigation, and competition within the regenerative medicine field, to name a few. The forward-looking statements included in this report are subject to a number of additional material risks and uncertainties, including but not limited to the risks described in our filings with the Securities and Exchange Commission and under the &#8220;Risk Factors&#8221; section in Part II below.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We encourage you to read the risks described under &#8220;Risk Factors&#8221; carefully.&#160;&#160;We caution you not to place undue reliance on the forward-looking statements contained in this report.&#160;&#160;These statements, like all statements in this report, speak only as of the date of this report (unless an earlier date is indicated) and we undertake no obligation to update or revise the statements except as required by law.&#160;&#160;Such forward-looking statements are not guarantees of future performance and actual results will likely differ, perhaps materially, from those suggested by such forward-looking statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Overview</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cytori Therapeutics, Inc. is developing cell therapies based on autologous adipose-derived stem and regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects.&#160;&#160;Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple &#8220;ischemic&#8221; conditions. These therapies are made available by our proprietary device, the Celution&#174; System, which automates the extraction and preparation of clinical grade ADRCs at the point-of-care.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our goal is to build shareholder value by focusing on novel, &#8216;high-value&#8217; cell-based therapeutics to market in core geographies: Europe, Asia, and the Americas. Celution&#174; is a platform technology that we believe could potentially address multiple diseases and conditions. To take advantage of our limited resources, we are committing our internal resources to cardiovascular disease and soft tissue defect repair, offering the technology to customers and/or partners to identify and explore additional potential indications, and are seeking partners to accelerate core or non-core opportunities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">16</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Pipeline</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The primary therapeutic area within our clinical development pipeline is cardiovascular disease. We have completed and reported results from three clinical trials, moved from APOLLO to ADVANCE in Europe for heart attacks, have been approved to initiate a feasibility trial in the U.S. for chronic myocardial ischemia, and are seeking approval in Europe for chronic myocardial ischemia.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the U.S., we received approval to begin our ATHENA feasibility trial in chronic myocardial ischemia, which will be a prospective, double blind, placebo-controlled, multi-center trial in up to 45 patients. The ATHENA trial will utilize our Celution&#174; One device that was developed and manufactured by the Olympus-Cytori, Inc. joint venture.&#160;&#160;Enrollment is expected to begin in the second quarter of 2012 and be completed within 12 to 18 months.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In our ADVANCE trial, we are amending our European clinical protocol to conform to the evolving country-specific regulatory policies for good manufacturing practices, harmonize our regulatory, reimbursement and market access strategies, while simplifying the trial to a single arm pivotal design and optimizing enrollment criteria.&#160;&#160;In aggregate, these protocol amendments should accelerate country approvals and enrollment rates and increase the likelihood of success in this trial.&#160;&#160;We are also implementing a protocol change of the cell processing system used in the study from Celution&#174; One to Celution&#174; 800. The Celution&#174; 800 platform is the system that was successfully used to support the APOLLO (acute STEMI) and PRECISE (chronic myocardial ischemia) pilot studies. The encouraging safety and feasibility results from APOLLO and PRECISE give us confidence that the Celution&#174; 800 System gives us the best opportunity for a successful trial from both an operational and clinical perspective.&#160;&#160;Additionally, several improvements in software and hardware have been incorporated to further improve this system&#8217;s performance. This change is being implemented for a number of reasons, including those described above, and our expectation that the Celution 800 device will receive a CE Mark approval for No Option Chronic Myocardial Ischemia claims sometime this year.&#160;&#160;In the meantime, we have already qualified 27 sites with an emphasis on sites in the European G5. We have been in discussions with the leading EU competent authorities and expect to have a revised timeline for the trial by the end of the second quarter of 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our CE Mark application for the Celution&#174; System in no-option chronic myocardial ischemia patients is currently under review.&#160;&#160;Recently, our notified body in Europe has requested some additional information that we are gathering and will provide later this month.&#160;&#160;Barring delays or requests for further data, we anticipate a decision before the end of the year.&#160;&#160;Should we receive approval, we would target select hospital customers in the G5 countries and likely implement a patient registry. This registry will allow us to collect further data to support reimbursement and government payors, and help expand market access.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Commercial Business</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The 2012 goals for our commercial business are twofold. The first is to expand market access so that we can grow product revenue significantly over time and the second is to achieve a positive contribution margin in the near term. Today, our sales activities remain largely opportunistic and focused on obtaining and maintaining successful early clinical adopters of our products. Looking forward, we intend to target larger market segments and grow therapeutically oriented consumable revenue.&#160;&#160;To accomplish this goal, we are focusing on driving essential market access elements such as published clinical and health economics data, physician education and indication-specific therapeutic claims, while maintaining a critical eye on expenses. In late 2011, Cytori reduced its sales and marketing headcount. The impact of this reduction along with other sales and marketing costs will result in reduced overall spend in 2012, while maintaining our ability to achieve 2012 growth objectives.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our most advanced therapeutic indication is breast reconstruction. In Europe, the NHS National Innovation Centre in the UK indicated that our technology may be cost-effective for lumpectomy breast reconstruction. Furthermore, the use of ADRCs was acknowledged by the British Association of Plastic, Reconstructive &amp; Aesthetic Surgeons (BPRAS) in their latest breast surgery guidelines, demonstrating progress in developing market access. In May, we submitted a technology assessment application in the UK specific to our Celution&#174; System for the RESTORE procedure as a way to both improve healthcare and lower the overall costs of breast reconstruction for women who have had a lumpectomy for breast cancer.&#160;&#160;This will help support our reimbursement efforts in the UK. In a similar fashion to the UK, we are working with other key competent authorities in Europe to expand coverage. In Japan, we are working with the Pharmaceuticals and Medical Devices Agency (PMDA), to utilize our global clinical data for Japanese approval of our technology for breast reconstruction. In other geographic markets, we intend to grow product sales where we are approved to sell.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Corporate</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our corporate priorities are to expand global regulatory approvals, complete strategic development and commercialization partnerships, strengthen the balance sheet and continue to manage expenses.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">One of our top priorities is to establish a strategic partnership, which could accelerate core or non-core opportunities and potentially bring in significant additional capital. Completing one or more substantive partnerships is achievable this year. Due to the platform nature of our technology and products, we are able to simultaneously pursue transactions for multiple indications in core areas like cardiovascular disease and other non-core areas such as liver disease for which Astellas Pharma has acquired negotiation rights through December 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">17</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have been actively streamlining our operations and reducing costs wherever possible, focusing the company and seeking to minimize cash operating costs.&#160;&#160;Our 2012 budget calls for a reduction of approximately $6 million in combined Sales &amp; Marketing and General and Administrative expenses for 2012 as compared to 2011. This will support an estimated $3 million anticipated increase in R&amp;D expenses for 2012, principally to fund our cardiac cell therapy clinical trials.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Regulatory processes are well underway in the US, Canada, the EU, Australia, Japan, Russia and other countries.&#160;&#160;We expect progress in many of these markets during 2012 that could expand our commercial opportunities.&#160;&#160;In the US, receiving the IDE approval was a key development for the company that signals a positive and clearer pathway with the FDA.&#160;&#160;We also feel that the multiple opportunities we have in other countries increase the possibility that one or more meaningful markets could open up for Cytori. Two countries of note where we have made recent progress include Australia and India. We will provide greater detail on these markets as these opportunities mature and grow.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Olympus Partnership</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On November 4, 2005, we entered into a strategic development and manufacturing joint venture agreement and other related agreements with Olympus.&#160;&#160;As part of the terms of these agreements, we formed a joint venture, Olympus-Cytori, Inc. (Joint Venture), to develop and manufacture future generation devices based on our Celution&#174; System platform.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under the Joint Venture Agreements:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Olympus paid $30,000,000 for its 50% interest in the Joint Venture.&#160;&#160;Moreover, Olympus simultaneously entered into a License/Joint Development Agreement with the Joint Venture and us to develop a second generation commercial system and manufacturing capabilities.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We licensed our device technology, including the Celution&#174; System platform and certain related intellectual property, to the Joint Venture for use in future generation devices.&#160;&#160;These devices will process and purify adult stem and regenerative cells residing in adipose (fat) tissue for various therapeutic clinical applications.&#160;&#160;In exchange for this license, we received a 50% interest in the Joint Venture, as well as an initial $11,000,000 payment from the Joint Venture; the source of this payment was the $30,000,000 contributed to the Joint Venture by Olympus.&#160;&#160;Moreover, upon receipt of a CE Mark for the first generation Celution&#174; System platform in January 2006, we received an additional $11,000,000 development milestone payment from the Joint Venture.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Joint Venture currently has exclusive access to our Celution&#174; System device technology for the development, manufacture, and supply of such systems to us.&#160;&#160;Once a second generation Celution&#174; System is developed and approved by regulatory agencies, the Joint Venture will exclusively supply us with these systems at a formula-based transfer price.&#160;&#160;We have retained all marketing rights (subject to our various distribution agreements and regulatory rights) to sell the Celution&#174; System devices for all therapeutic applications of adipose stem and regenerative cells.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have worked closely with Olympus&#8217; team of scientists and engineers to design the future generations of the Celution&#174; System so that it will contain certain product enhancements and that can be manufactured in a streamlined manner.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In August 2007, we entered into a License and Royalty Agreement with the Joint Venture which provides us the ability to commercially launch the Celution&#174; System platform earlier than we could have otherwise done so under the terms of the Joint Venture Agreements.&#160;&#160;Subsequently, in November 2007, we amended the License/Commercial Agreement to substantially incorporate the terms of the Royalty Agreement (effective on the expiration of the Royalty Agreement) to continue to allow us to manufacture the Cytori-developed Celution&#174; System platform, including the Celution&#174; 800/CRS, until such&#160;&#160;time as the Joint Venture&#8217;s products are commercially available for the same market served by the Cytori platform, subject to a reasonable royalty that will be payable to the Joint Venture for all such sales.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Results of Operations</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><!--EFPlaceholder--><font style="DISPLAY: inline; TEXT-DECORATION: underline">Product revenues</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Product revenues consisted of revenues primarily from our Celution&#174; and Puregraft&#174; Systems and StemSource&#174; Cell Banks.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">18</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table summarizes the components for the three months ended March 31, 2012 and 2011:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the three months ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Product revenues - third party</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,481,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,362,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Beginning in March of 2008, we began sales and shipments of our Celution&#174; 800/CRS System to the European and Asia-Pacific reconstructive surgery markets and during 2010 we began sales of our Puregraft&#174; System in the United States and Europe.&#160;&#160;Assuming all other applicable revenue recognition criteria have been met, revenue for these product sales is recognized upon delivery to the customer, as all risks and rewards of ownership have been substantively transferred to the customer at that point.&#160;&#160;For product sales to customers who arrange for and manage all aspects of the shipping process, we recognize revenue upon shipment from our facilities.&#160;&#160;Beginning in 2011, for product sales that include a combination of equipment, services, or other multiple deliverables that will be provided in the future, we defer an estimate based on relative selling price method for those future deliverables from product revenue until such deliverables have been provided or earned.&#160;&#160;Shipping and handling costs that are billed to our customers are classified as revenue.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We experienced some growth in product revenue during the quarter ended March 31, 2012 as compared to the same period in 2011, primarily due to the product mix comprising revenue for each quarter.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">The future</font>:&#160;&#160;We expect to continue to generate product revenues from a mix of Celution &#174; and StemSource&#174; System and consumables sales as well as Puregraft&#174; orders.&#160;&#160;We will sell the products to a diverse group of customers in Europe, Asia and the U.S., who may apply the products towards reconstructive surgery, soft tissue repair, research, aesthetics, and cell and tissue banking as approved in each country.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Cost of product revenues</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cost of product revenues relate primarily to Celution&#174; System products and StemSource&#174; Cell Banks and includes material, manufacturing labor, and overhead costs.&#160;&#160;The following table summarizes the components of our cost of revenues for the three months ended March 31, 2012 and 2011:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the three months ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cost of product revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">836,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">825,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Share-based compensation</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total cost of product revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">853,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">842,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total cost of product revenues as % of product revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">61.8</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cost of product revenues as a percentage of product revenues was 57.6% and 61.8% for the three months ended March 31, 2012 and 2011, respectively.&#160;&#160;Fluctuation in this percentage is to be expected due to the product mix as well as mix of distributor and direct sales comprising the revenue for the period.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 27pt"></font><font style="FONT-STYLE: italic; DISPLAY: inline">The future:</font> We expect to continue to see variation in our gross profit margin as the product mix comprising revenues fluctuates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Development revenues</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table summarizes the components of our development revenues for the three months ended March 31, 2012 and 2011:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the three months ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Development (Olympus)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,231,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Service plan and other</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total development revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,235,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">19</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We recognize deferred revenues, related party, as development revenue when certain performance obligations are met (i.e., using a proportional performance approach).&#160;&#160;During the quarter ended March 31, 2011, we recognized $1,231,000 of revenue associated with our arrangements with Olympus as a result of achieving a product development milestone related to the preproduction development of the next-generation Celution&#174; One System.&#160;&#160;We did not recognize any similar revenue during the quarter ended March 31, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">The future</font>:&#160;&#160;We may recognize additional development revenues during 2012, as the anticipated completion for the next revenue recognition milestones related to our Joint Venture with Olympus is in 2012.&#160;&#160;The exact timing of whether additional development revenue will be recognized and when amounts will be reported in revenue will depend on certain factors including obtaining certain regulatory clearances and/or approvals related to the Celution&#174; System.&#160;&#160;However, the cash related to the joint venture agreements was received when these agreements were signed and no further related cash payments will be made to us even if we recognize additional development revenue related to the joint venture.&#160;&#160;To date, of the $28,311,000 originally deferred, we have recognized a total of $24,791,000 through March 31, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We will continue to recognize revenue from the Thin Film development work we are performing on behalf of Senko, based on the relative fair value of the milestones completed as compared to the total efforts expected to be necessary to obtain regulatory clearance from the MHLW.&#160;&#160;We have determined that we will need to conduct a clinical trial to receive an approval from the MHLW in order for initial commercialization to occur.&#160;&#160;We are currently working on the trial design, timeline and budget for the trial.&#160;&#160;Accordingly, we expect to recognize approximately $1,129,000 (consisting of $879,000 in deferred revenues plus a non-refundable payment of $250,000 to be received upon commercialization) in revenues associated with this milestone arrangement if and when regulatory approval is achieved.&#160;&#160;Moreover, we expect to recognize $500,000 per year associated with deferred Senko license fees over a three-year period following commercialization, if achieved, as the refund rights associated with the license payment expire.&#160;&#160;There can be no assurance given of whether, or when, this regulatory approval might be received to allow us to proceed with commercialization.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Research and development expenses</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and development expenses include costs associated with the design, development, testing and enhancement of our products, regulatory fees, the purchase of laboratory supplies, pre-clinical studies and clinical studies.&#160;&#160;The following table summarizes the components of our research and development expenses for the three months ended March 31, 2012 and 2011:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the three months ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General research and development</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,580,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,572,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Development milestone (Joint Venture)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">356,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Share-based compensation</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">155,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">119,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total research and development expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,836,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,047,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and development expenses relate to the development of a technology platform that involves using adipose tissue as a source of autologous regenerative cells for therapeutic applications.&#160;&#160;These expenses, in conjunction with continued development efforts related to our Celution&#174; System, result primarily from the broad expansion of our research and development efforts enabled by the funding we received from Olympus in 2005 and 2006 and from other investors during the last few years.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The decrease in research and development expenses for the three months ended March 31, 2012 as compared to the same period in 2011 is due to the decrease clinical study expense of $410,000 primarily related to the timing of clinical study activities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Expenditures related to the Joint Venture with Olympus, which are included in the variation analysis above, include costs that are necessary to support the commercialization of our products, including the next generation Celution&#174; System.&#160;&#160;These development activities, include performing pre-clinical and clinical studies, seeking regulatory approval, and performing product development related to therapeutic applications for adipose stem and regenerative cells for multiple large markets. The costs associated with the development of the device were comprised of labor and related benefits, consulting and other professional services, supplies and other miscellaneous expenses.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">The future</font>:&#160;&#160;We expect research and development expenditures to increase in the remainder of 2012 as we are scheduled to continue enrollment in the ADVANCE cardiac trial, start enrollment in our US trial ATHENA, seek additional regulatory clearances and potentially seek to initiate additional trials or patient registries during 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">20</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Sales and marketing expenses</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Sales and marketing expenses include costs associated with sales and marketing personnel, tradeshows, physician training, and promotional activities and materials.&#160;&#160;&#160;The following table summarizes the components of our sales and marketing expenses for the three months ended March 31, 2012 and 2011:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the three months ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sales and marketing</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,180,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,979,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Share-based compensation</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">196,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">247,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total sales and marketing expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,376,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,226,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The decrease in sales and marketing expense during the three months ended March 31, 2012 as compared to the same period in 2011 was mainly attributed to the decrease in salary and related benefits expense (excluding share-based compensation) of $445,000 due to a decrease in headcount, decrease in travel related expenses of $168,000, and a decrease in advertising and promotion related expenses of $130,000, as a result of targeted reductions in staff and external costs made prior to year end in 2011 as well as subsequent reductions made in early 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">The future:</font>&#160;&#160;We expect sales and marketing expenditures to decrease during remainder of 2012 based on the targeted reductions in staff and external costs in 2011 and subsequent reductions made in early 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">General and administrative expenses</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">General and administrative expenses include costs for administrative personnel, legal and other professional expenses, and general corporate expenses.&#160;&#160;The following table summarizes the general and administrative expenses for the three months ended March 31, 2012 and 2011:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the three months ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,350,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,046,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Share-based compensation</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">574,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">498,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total general and administrative expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,924,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,544,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the three months ended March 31, 2012 as compared to the same period in 2011, the increase in general and administrative expenses (excluding share-based compensation) occurred primarily due to an increase in salary and related benefits expense (excluding share-based compensation) of $294,000 caused by an increase in headcount in addition to certain headcount and overhead reallocations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">The future:</font>&#160;&#160;We expect general and administrative expenses to remain relatively stable through the remainder of in 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Share-based compensation expenses</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Stock-based compensation expenses include charges related to options issued to employees, directors and non-employees.&#160;&#160;We measure stock-based compensation expense based on the grant-date fair value of any awards granted to our employees.&#160;&#160;Such expense is recognized over the period of time that employees provide service to us and earn all rights to the awards.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table summarizes the components of our share-based compensation expenses for the three months ended March 31, 2012 and 2011:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the three months ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cost of product revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development-related</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">155,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">119,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sales and marketing-related</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">196,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">247,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative-related</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">574,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">498,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total share-based compensation expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">942,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">881,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">21</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Most of the share-based compensation expenses for the three months ended March 31, 2012 and 2011 related to the vesting of stock option awards to employees.&#160;&#160;The increase in share-based compensation for the three months ended March 31, 2012 as compared to the same period in 2011 is primarily due to the grant of restricted stock awards.&#160;&#160;See Notes to Consolidated Condensed Financial Statements included elsewhere herein for disclosure and discussion of share based compensation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><!--EFPlaceholder--><font style="FONT-STYLE: italic; DISPLAY: inline">The future: </font>We expect to continue to grant options and stock awards (which will result in an expense) to our employees, directors, and, as appropriate, to non-employee service providers.&#160;&#160;In addition, previously-granted options will continue to vest in accordance with their original terms.&#160;&#160;As of March 31, 2012, the total compensation cost related to non-vested stock options and stock awards not yet recognized for all our plans is approximately $7,956,000. Of this amount, $7,005,000 is expected to be recognized as a result of vesting under service conditions over a weighted average period of 1.72 years.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Change in fair value of warrant liability</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following is a table summarizing the change in fair value of our warrant liability for the three months ended March 31, 2012 and 2011:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the three months ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in fair value of warrant liability</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">130,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,471,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Changes in fair value of our warrant liability are primarily due to fluctuations in the valuation inputs, such as stock price, volatility, remaining life and others.&#160;&#160;See Notes to Consolidated Condensed Financial Statements included elsewhere herein for disclosure and discussion of our warrant liability.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><!--EFPlaceholder--><font style="FONT-STYLE: italic; DISPLAY: inline">The future:</font> Future changes in the fair value of the warrant liability will be recognized currently in earnings until such time as the warrants are exercised or expire.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Change in fair value of option liability</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following is a table summarizing the change in fair value of our put option liability for the three months ended March 31, 2012 and 2011:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the three months ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in fair value of option liability</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(270,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(290,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">The future:</font> The Put has no expiration date.&#160;&#160;Accordingly, we will continue to recognize a liability for the Put until it is exercised or until the arrangements with Olympus are amended.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Financing items</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table summarizes interest income, interest expense, and other income and expense for the three months ended March 31, 2012 and 2011:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the three months ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest income</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(865,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(738,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other income (expense)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(47,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(47,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(910,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(783,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Interest expense increased for the three months ended March 31, 2012 as compared to the same period in 2011 due to cash interest and non-cash amortization of debt issuance costs and debt discount for our $25.0 million term loan.&#160;&#160;In September 2011, we entered into a second amendment to the Amended and Restated Loan and Security Agreement, pursuant to which the lenders funded an additional principal increasing the total principal balance to $25.0 million.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">22</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">The future: </font>Interest income earned in 2012 will be dependent on our levels of funds available for investment as well as general economic conditions.&#160;&#160;Subject to our future financing activities, we expect interest expense in 2012 to increase as we continue to pay interest on the $25.0 million term loan that was amended in September 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Equity loss from investment in Joint Venture</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table summarizes our equity loss from investment in joint venture for the three months ended March 31, 2012 and 2011:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the three months ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Equity loss from investment in joint venture</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(50,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(46,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><!--EFPlaceholder-->The losses relate entirely to our 50% equity interest in the Joint Venture, which we account for using the equity method of accounting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">The future:</font>&#160;&#160;We do not expect to recognize significant losses from the activities of the Joint Venture in the foreseeable future.&#160;&#160;Over the next one to two years, the Joint Venture is expected to incur labor costs related to the development of our second generation commercial system as well as general and administrative expenses, offset by royalty and other revenue expected to be generated by our current Celution&#174; 800/CRS and future generation devices.&#160;&#160;Though we have no obligation to do so, we may contribute funding to the Joint Venture to cover any costs should the Joint Venture deplete its cash balance.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><!--EFPlaceholder--><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liquidity and Capital Resources</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Short-term and long-term liquidity</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following is a summary of our key liquidity measures at March 31, 2012 and December 31, 2011:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="TEXT-ALIGN: center; BORDER-TOP: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">As of March&#160;31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; BORDER-TOP: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-TOP: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="TEXT-ALIGN: center; BORDER-TOP: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">As of December&#160;31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td nowrap valign="bottom" width="56%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">34,399,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">36,922,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Current assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">40,333,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,337,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Current liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,957,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,821,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Working capital</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">29,376,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">35,516,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We incurred net losses of $9,325,000 and $12,072,000 for the three months ended March 31, 2012 and 2011, respectively.&#160;&#160;We have an accumulated deficit of $251,774,000 as of March 31, 2012.&#160;&#160;Additionally, we have used net cash of $7,714,000 and $10,564,000 to fund our operating activities for the three months ended March 31, 2012 and 2011, respectively<font style="DISPLAY: inline; FONT-WEIGHT: bold">.&#160;&#160;</font>To date these operating losses have been funded primarily from outside sources of invested or borrowed capital.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Management recognizes the need to generate positive cash flows in future periods and/or to obtain additional capital from various sources. In the continued absence of positive cash flows from operations, no assurance can be given that we can generate sufficient revenue to cover operating costs or that additional financing will be available to us and, if available, on terms acceptable to us in the future.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During 2011, we expanded our commercialization activities while simultaneously pursuing available financing sources to support operations and growth.&#160;&#160;We have had, and will likely continue to have, an ongoing need to raise additional cash from outside sources to fund our operations for 2012 and beyond.&#160;&#160;If we cannot do so when required, we would need to reduce our research, development, and administrative operations, including reductions of our employee base, in order to offset lack of available funding.&#160;&#160;&#160;We continue to evaluate available strategic and financing opportunities as part of our normal course of business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">23</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following summarizes our contractual obligations and other commitments at March 31, 2012, and the effect such obligations could have on our liquidity and cash flow in future periods:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="18" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Payments due by period</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contractual Obligations</font></div>
</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Less than 1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">year</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1 &#8211; 3 years</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3 &#8211; 5 years</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">More than</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5 years</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Long-term obligations</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26,228,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,108,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,095,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest commitment on long-term obligations</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,477,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,392,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,083,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operating lease obligations</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,259,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,785,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,645,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,716,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,113,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Minimum purchase requirements</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,191,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,341,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">850,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pre-clinical research study obligations</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Clinical research study obligations</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,600,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,100,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,000,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">55,815,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,786,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">34,673,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,243,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,113,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cash (used in) provided by operating, investing, and financing activities for the three months ended March 31, 2012 and 2011is summarized as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the three months ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash used in operating activities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(7,714,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(10,564,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash used in investing activities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(25,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(131,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash provided by financing activities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,216,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">674,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><!--EFPlaceholder--><font style="DISPLAY: inline; TEXT-DECORATION: underline">Operating activities</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Operational activities, inclusive of research and development, sales and marketing, and general and administrative efforts, offset in part by product sales, generated an operating loss of $8,365,000 for the three months ended March 31, 2012.&#160;&#160;The operating cash impact of this loss was $7,714,000, after adjusting for the consideration of non-cash share-based compensation and other adjustments for material non-cash activities, such as depreciation, amortization, change in fair value of option and warrant liabilities, and changes in working capital due to timing of product shipments (accounts receivable) and payment of liabilities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Operational activities, inclusive of research and development, sales and marketing, and general and administrative efforts, offset in part by product sales, generated an operating loss of $11,243,000 for the three months ended March 31, 2011.&#160;&#160;The operating cash impact of this loss was $10,564,000, after adjusting for the recognition of non-cash development revenue of $1,231,000, the consideration of non-cash share-based compensation, other adjustments for material non-cash activities, such as depreciation, amortization, change in fair value of option and warrant liabilities, and changes in working capital due to timing of product shipments (accounts receivable) and payment of liabilities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Investing activities</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net cash used in investing activities for the three months ended March 31, 2012 and 2011 resulted from cash outflow for purchases of property and equipment.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Financing Activities</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The net cash provided by financing activities for the three months ended March 31, 2012 related primarily to a sale of 1,500,000 shares for approximately $4,396,000 in gross proceeds in connection with our common stock purchase agreement with Seaside entered into on July 11, 2011 and proceeds from exercise of warrants and employee stock options of $947,000.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The net cash provided by financing activities for the three months ended March 31, 2011 related to proceeds from exercise of warrants and employee stock options of $674,000.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Critical Accounting Policies and Significant Estimates</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of our assets, liabilities, revenues and expenses, and that affect our recognition and disclosure of contingent assets and liabilities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">While our estimates are based on assumptions we consider reasonable at the time they were made, our actual results may differ from our estimates, perhaps significantly.&#160;&#160;If results differ materially from our estimates, we will make adjustments to our financial statements prospectively as we become aware of the necessity for an adjustment.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">24</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We believe it is important for you to understand our most critical accounting policies.&#160;&#160;These are our policies that require us to make our most significant judgments and, as a result, could have the greatest impact on our future financial results.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Warrant Liability</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">See Notes to Consolidated Condensed Financial Statements included elsewhere herein for disclosure and discussion of our warrant liability.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Revenue Recognition</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">See Notes to Consolidated Condensed Financial Statements included elsewhere herein for disclosure and discussion of revenue recognition.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><!--EFPlaceholder-->Goodwill Impairment Testing</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In late 2002, we purchased StemSource, Inc. and recognized over $4,600,000 in goodwill associated with the acquisition, of which $3,922,000 remains on our balance sheet as of March 31, 2012.&#160;&#160;We test this goodwill at least annually, as of November 30, for impairment as well as when an event occurs or circumstances change such that it is reasonably possible that impairment may exist.&#160;&#160;The application of the goodwill impairment test involves a substantial amount of judgment.&#160;&#160;The judgments employed may have an effect on whether a goodwill impairment loss is recognized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">No impairment triggering events occurred during the three months ended March 31, 2012 that would require us to perform an impairment test.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Variable Interest Entity (Olympus-Cytori Joint Venture)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">See Notes to Consolidated Condensed Financial Statements included elsewhere herein for disclosure and discussion of the Olympus-Cytori Joint Venture.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Income Taxes</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Income taxes are accounted for under the asset and liability method.&#160;&#160;Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards.&#160;&#160;Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled.&#160;&#160;Due to our history of losses, a full valuation allowance is recognized against our deferred tax assets.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><!--EFPlaceholder-->Recently Adopted Accounting Pronouncements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">See Notes to Consolidated Condensed Financial Statements included elsewhere herein for disclosure and discussion of new accounting standards.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><!--EFPlaceholder-->Item 3.&#160;&#160;<a name="quantativ">Quantitativ</a>e and Qualitative Disclosures about Market Risk</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are exposed to market risk related to fluctuations in interest rates and in foreign currency exchange rates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Interest Rate Exposure</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><!--EFPlaceholder-->We are not subject to market risk due to fluctuations in interest rates on our long-term obligations as they bear a fixed rate of interest.&#160;&#160;Our exposure relates primarily to short-term investments, including funds classified as cash equivalents.&#160;&#160;As of March 31, 2012, all excess funds were invested in money market funds and other highly liquid investments, therefore our interest rate exposure is not considered to be material.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">25</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Foreign Currency Exchange Rate Exposure</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our exposure to market risk due to fluctuations in foreign currency exchange rates relates primarily to our activities in Europe and Japan.&#160;&#160;Transaction gains or losses resulting from cash balances and revenues have not been significant in the past and we are not currently engaged in any hedging activity in the Euro, the Yen or other currencies.&#160;&#160;Based on our cash balances and revenues derived from markets other than the United States for the three months ended March 31, 2012, a hypothetical 10% adverse change in the Euro or Yen against the U.S. dollar would not result in a material foreign currency exchange loss.&#160;&#160;Consequently, we do not expect that reductions in the value of such sales denominated in foreign currencies resulting from even a sudden or significant fluctuation in foreign exchange rates would have a direct material impact on our financial position, results of operations or cash flows.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Notwithstanding the foregoing, the indirect effect of fluctuations in interest rates and foreign currency exchange rates could have a material adverse effect on our business, financial condition and results of operations.&#160;&#160;For example, foreign currency exchange rate fluctuations may affect international demand for our products.&#160;&#160;In addition, interest rate fluctuations may affect our customers&#8217; buying patterns.&#160;&#160;Furthermore, interest rate and currency exchange rate fluctuations may broadly influence the United States and foreign economies resulting in a material adverse effect on our business, financial condition and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under our Japanese Thin Film agreement with Senko, we would receive payments in the nature of royalties based on Senko&#8217;s net sales, which would be Yen denominated.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><!--EFPlaceholder-->Item 4. <a name="Controls">Controls</a> and Procedures</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Evaluation of Disclosure Controls and Procedures</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed or furnished pursuant to the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure.&#160;&#160;In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As required by Rule 13a-15(b) under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this Quarterly Report of Form 10-Q.&#160;&#160;Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Changes in Internal Control over Financial Reporting</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There have been no changes in our internal control over financial reporting during the quarter ended March 31, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><!--EFPlaceholder--><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART II. OTHER INFORMATION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><!--EFPlaceholder--><font style="DISPLAY: inline; FONT-WEIGHT: bold">It</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">em 1</font> . <font style="DISPLAY: inline; FONT-WEIGHT: bold"><a name="Lega">Legal</a> Proceedings</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">From time to time, we have been involved in routine litigation incidental to the conduct of our business. As of March 31, 2012, we were not a party to any material legal proceeding.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><!--EFPlaceholder-->Item 1A. <a name="Ris">Ris</a>k Factors</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In analyzing our company, you should consider carefully the following risk factors together with all of the other information included in this quarterly report on Form 10-Q.&#160;&#160;Factors that could adversely affect our business, operating results, and financial condition, as well as adversely affect the value of an investment in our common stock, include those discussed below, as well as those discussed above in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere throughout this quarterly report on Form 10-Q.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">26</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are subject to the following significant risks, among others:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">We will likely need to raise more cash in the future</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have almost always had negative cash flows from operations.&#160;&#160;Our business will continue to result in a substantial requirement for research and development expenses for several years, during which we may not be able to bring in sufficient cash and/or revenues to offset these expenses.&#160;&#160;We will likely be required to raise capital from one or more sources in the future to continue funding our operations to profitability.&#160;&#160;We do not currently believe that our cash balance and the revenues from our operations will be sufficient to fund the development and marketing efforts required to reach profitability without raising additional capital from accessible sources of financing in the future.&#160;&#160;In addition, our Amended and Restated Loan and Security Agreement with General Electric Capital Corporation, Silicon Valley Bank and Oxford Finance Corporation requires us to maintain certain minimum cash requirements, and if our cash reserves fall below those minimum requirements, then we could be in default under our loan agreement and subject to potential adverse remedies by the lenders, which would have a substantial and material adverse effect on our business, financial condition, results of operations, the value of our common stock and warrants and our ability to raise capital.&#160;&#160;There is no guarantee that adequate funds will be available when needed from additional debt or equity financing, arrangements with development and commercialization partners, increased results of operations, or from other sources, or on terms attractive to us.&#160;&#160;Our inability to obtain sufficient additional funds in the future would, at a minimum, require us to delay, scale back, or eliminate some or all of our research or product development, manufacturing operations, clinical or regulatory activities, which could have a substantial negative effect on our results of operations and financial condition.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Continued turmoil in the economy could harm our business</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Negative trends in the general economy, including trends resulting from an actual or perceived recession, tightening credit markets, increased cost of commodities, including oil, actual or threatened military action by the United States and threats of terrorist attacks in the United States and abroad, could cause a reduction of investment in and available funding for companies in certain industries, including ours and our customers.&#160;&#160;Our ability to raise capital has been and may in the future be adversely affected by downturns in current credit conditions, financial markets and the global economy.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">We have never been profitable on an operational basis and expect significant operating losses for the next few years</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have incurred net operating losses in each year since we started business.&#160;&#160;As our focus on the Celution&#174; System platform and development of therapeutic applications for its cellular output has increased, losses have resulted primarily from expenses associated with research and development activities and general and administrative expenses.&#160;&#160;While we work continuously to implement cost reduction measures where possible, we nonetheless expect to continue operating in a loss position on a consolidated basis and that recurring operating expenses will be at high levels for the next several years, in order to perform clinical trials, additional pre-clinical research, product development, and marketing.&#160;&#160;As a result of our historic losses, we have been, and are likely to continue to be, reliant on raising outside capital to fund our operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Our business strategy is high-risk</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are focusing our resources and efforts primarily on development of the Celution&#174; System family of products and the therapeutic applications of its cellular output, which requires extensive cash needs for research, development, and commercialization activities.&#160;&#160;This is a high-risk strategy because there is no assurance that our future products will ever become commercially viable (commercial risk), that we will prevent other companies from depriving us of market share and profit margins by selling products based on our inventions and developments (legal risk), that we will successfully manage a company in a new area of business (regenerative medicine) and on a different scale than we have operated in the past (operational risk), that we will be able to achieve the desired therapeutic results using stem and regenerative cells (scientific risk), or that our cash resources will be adequate to develop our products until we become profitable, if ever (financial risk).&#160;&#160;We are using our cash in one of the riskiest industries in the economy (strategic risk).&#160;&#160;This may make our stock an unsuitable investment for many investors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">The development and manufacture of future generation Celution &#174; System devices is important to us</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have given Olympus-Cytori, Inc. an exclusive license to manufacture future generation Celution&#174; System devices.&#160;&#160;If Olympus-Cytori, Inc. does not successfully develop and manufacture these devices, we may experience disruptions and/or delays of our commercialization of these devices into the market.&#160;&#160;Any significant disruption of our commercialization of these devices could affect our operations and commercialization efforts (clinical, regulatory and/or commercial sales), and be harmful to our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We and Olympus must overcome contractual and cultural barriers.&#160;&#160;Although our relationship is formally measured by a set of complex contracts, many aspects of the relationship will be non-contractual and must be worked out between the parties and the responsible individuals.&#160;&#160;The joint venture is intended to have a long life, and it is difficult to maintain cooperative relationships over a long period of time in the face of various kinds of change.&#160;&#160;Cultural differences, including language barrier to some degree, may affect the efficiency of the relationship.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">27</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Olympus-Cytori, Inc. is 50% owned by us and 50% owned by Olympus.&#160;&#160;By contract, each side must consent before any of a wide variety of important business actions can occur.&#160;&#160;This situation possesses a risk of potentially time-consuming and difficult negotiations which could at some point delay the joint venture from pursuing its business strategies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Olympus is entitled to designate the joint venture's chief executive officer and a majority of its board of directors, which means that day-to-day decisions which are not subject to a contractual veto are subject to be controlled by Olympus.&#160;&#160;In addition, Olympus-Cytori, Inc. may require more money than its current capitalization in order to complete development and production of future generation devices.&#160;&#160;If we are unable to help provide future financing for Olympus-Cytori, Inc., our relative equity interest in Olympus-Cytori, Inc. may decrease.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Furthermore, under a License/Joint Development Agreement among Olympus-Cytori, Inc., Olympus, and us, Olympus may have a significant role in the development of Olympus-Cytori, Inc.&#8217;s next generation devices.&#160;&#160;Although Olympus has extensive experience in developing medical devices, this arrangement has resulted in a reduction of our control over the development and manufacturing of the next generation devices.&#160;&#160;Any significant&#160;&#160;disruption of activity by Olympus in connection with our business relationship and/or the development of Olympus-Cytori&#8217;s next generation devices and our joint venture could be harmful to our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In 2011 Olympus experienced issues which have led to a significant change in the management structure at Olympus. In 2012 these changes have continued to develop, with the recent restructuring of the Olympus board of directors and the management structure.&#160;&#160;We are in ongoing discussions with Olympus about the future of the Joint Venture, and we are working to ensure that changes to the joint venture (if any) that may occur would be beneficial to both parties.&#160;&#160;Notwithstanding our good faith discussions, if our relationship changes in a manner that significantly disrupts our operations and commercialization efforts (clinical, regulatory and/or commercial sales), then our business could be harmed.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">We have a limited operating history; operating results and stock price can be volatile like many life science companies</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our prospects must be evaluated in light of the risks and difficulties frequently encountered by emerging companies and particularly by such companies in rapidly evolving and technologically advanced biotech and medical device fields.&#160;&#160;From time to time, we have tried to update our investors&#8217; expectations as to our operating results by periodically announcing financial guidance.&#160;&#160;However, we have in the past been forced to revise or withdraw such guidance due to lack of visibility and predictability of product demand.&#160;&#160;Our stock price has a history of significant volatility, which may harm our ability to raise additional capital and may cause an investment in Cytori to be unsuitable for some investors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">We are vulnerable to competition and technological change, and also to physicians&#8217; inertia</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We compete with many domestic and foreign companies in developing our technology and products, including biotechnology, medical device, and pharmaceutical companies.&#160;&#160;Many current and potential competitors have substantially greater financial, technological, research and development, marketing, and personnel resources.&#160;&#160;There is no assurance that our competitors will not succeed in developing alternative products that are more effective, easier to use, or more economical than those which we have developed or are in the process of developing, or that would render our products obsolete and non-competitive.&#160;&#160;In general, we may not be able to prevent others from developing and marketing competitive products similar to ours or which perform similar functions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Competitors may have greater experience in developing therapies or devices, conducting clinical trials, obtaining regulatory clearances or approvals, manufacturing and commercialization.&#160;&#160;It is possible that competitors may obtain patent protection, approval, or clearance from the FDA or achieve commercialization earlier than we can, any of which could have a substantial negative effect on our business.&#160;&#160;Finally, Olympus and our other partners might pursue parallel development of other technologies or products, which may result in a partner developing additional products competitive with ours.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We compete against cell-based therapies derived from alternate sources, such as bone marrow, umbilical cord blood and potentially embryos.&#160;&#160;Doctors historically are slow to adopt new technologies like ours, regardless of the perceived merits, when older technologies continue to be supported by established providers.&#160;&#160;Overcoming such inertia often requires very significant marketing expenditures or definitive product performance and/or pricing superiority.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We expect physicians&#8217; inertia and skepticism to also be a significant barrier as we attempt to gain market penetration with our future products. We believe we will continue to need to finance lengthy time-consuming clinical studies to provide evidence of the medical benefit of our products and resulting therapies in order to overcome this inertia and skepticism particularly in reconstructive surgery, cell preservation, the cardiovascular area and many other indications.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">28</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Most potential applications of our technology are pre-commercialization, which subjects us to development and marketing risks</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are in a relatively early stage of the path to commercialization with many of our products.&#160;&#160;We believe that our long-term viability and growth will depend in large part on our ability to develop commercial quality cell processing devices and useful procedure-specific consumables, and to establish the safety and efficacy of our therapies through clinical trials and studies.&#160;&#160;With our Celution&#174; System platform, we are pursuing new approaches for reconstructive surgery, preservation of stem and regenerative cells for potential future use, therapies for cardiovascular disease, soft tissue defects, and other conditions.&#160;&#160;There is no assurance that our development programs will be successfully completed or that required regulatory clearances or approvals will be obtained on a timely basis, if at all.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There is no proven path for commercializing the Celution&#174; System platform in a way to earn a durable profit commensurate with the medical benefit.&#160;&#160;Although we began to commercialize our reconstructive surgery products in Europe and certain Asian markets, and our cell banking products in Japan, Europe, and certain Asian markets in 2008, additional market opportunities for many of our products and/or services may not materialize for a number of years.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Successful development and market acceptance of our products is subject to developmental risks, including failure of inventive imagination, ineffectiveness, lack of safety, unreliability, failure to receive necessary regulatory clearances or approvals, high commercial cost, preclusion or obsolescence resulting from third parties&#8217; proprietary rights or superior or equivalent products, competition from copycat products, and general economic conditions affecting purchasing patterns.&#160;&#160;There is no assurance that we or our partners will successfully develop and commercialize our products, or that our competitors will not develop competing technologies that are less expensive or superior.&#160;&#160;Failure to successfully develop and market our products would have a substantial negative effect on our results of operations and financial condition.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Market acceptance of new technology such as ours can be difficult to obtain</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">New and emerging cell therapy and cell banking technologies, such as those provided by the Celution&#174; System family of products, may have difficulty or encounter significant delays in obtaining market acceptance in some or all countries around the world due to the novelty of our cell therapy and cell banking technologies. Therefore, the market adoption of our cell therapy and cell banking technologies may be slow and lengthy with no assurances that significant market adoption will be successful. The lack of market adoption or reduced or minimal market adoption of our cell therapy and cell banking technologies may have a significant impact on our ability to successfully sell our product(s) into a country or region.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Future clinical trial results may differ significantly from our expectations</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">While we have proceeded incrementally with our clinical trials in an effort to gauge the risks of proceeding with larger and more expensive trials, we cannot guarantee that we will not experience negative results larger and much more expensive clinical trials than we have conducted to date, such as the new ADVANCE acute heart attack trial in Europe, and the coming ATHENA feasibility trial in chronic myocardial ischemia. Poor results in our clinical trials could result in substantial delays in commercialization, substantial negative effects on the perception of our products, and substantial additional costs.&#160;&#160;These risks are increased by our reliance on third parties in the performance of many of the clinical trial functions, including the clinical investigators, hospitals, and other third party service providers.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Manufacturing Risk</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Although we have significant experience in manufacturing the Celution&#174; System platform or its consumables at a commercial level, and although Olympus is a highly capable and experienced manufacturer of medical devices, there can be no guarantee that we or the Olympus-Cytori Joint Venture will be able to successfully develop and manufacture future generation Celution&#174; Systems in a manner that is cost-effective or commercially viable, or that development and manufacturing capabilities might not take much longer than currently anticipated to be ready for the market.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Although we have been manufacturing the the Celution&#174; 800 System and the StemSource&#174; 900-based Cell Bank since 2008, we cannot assure that we will be able to manufacture sufficient numbers of such products to meet the demand, or that we will be able to overcome unforeseen manufacturing difficulties for these sophisticated medical devices.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the event that the Olympus-Cytori Joint Venture is not successful in the development and manufacture of the next generation Celution&#174; One System, Cytori may not have the resources or ability to self-manufacture sufficient numbers of devices and consumables to meet market demand, and this failure may substantially extend the time it would take for us to bring a more advanced commercial device to market.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">29</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">We may not be able to protect our proprietary rights</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our success depends in part on whether we can maintain our existing patents, obtain additional patents, maintain trade secret protection, and operate without infringing on the proprietary rights of third parties.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There can be no assurance that any of our pending patent applications will be approved or that we will develop additional proprietary products that are patentable. There is also no assurance that any patents issued to us will not become the subject of a re-examination, will provide us with competitive advantages, will not be challenged by any third parties, or that the patents of others will not prevent the commercialization of products incorporating our technology.&#160;&#160;Furthermore, there can be no guarantee that others will not independently develop similar products, duplicate any of our products, or design around our patents.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our commercial success will also depend, in part, on our ability to avoid infringing on patents issued to others.&#160;&#160;If we were judicially determined to be infringing on any third-party patent, we could be required to pay damages, alter our products or processes, obtain licenses, or cease certain activities.&#160;&#160;If we are required in the future to obtain any licenses from third parties for some of our products, there can be no guarantee that we would be able to do so on commercially favorable terms, if at all.&#160;&#160;U.S. patent applications are not immediately made public, so we might be surprised by the grant to someone else of a patent on a technology we are actively using.&#160;&#160;As noted above and in the case of the University of Pittsburgh lawsuit, even patents issued to us or our licensors might be judicially determined to belong in full or in part to third parties.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Litigation, which would result in substantial costs to us and diversion of effort on our part, may be necessary to enforce or confirm the ownership of any patents issued or licensed to us, or to determine the scope and validity of third-party proprietary rights.&#160;&#160;If our competitors claim technology also claimed by us and prepare and file patent applications in the United States, we may have to participate in interference proceedings declared by the U.S. Patent and Trademark Office or a foreign patent office to determine priority of invention, which could result in substantial costs to and diversion of effort, even if the eventual outcome is favorable to us.&#160;&#160;Any such litigation or interference proceeding, regardless of outcome, could be expensive and time-consuming.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Successful challenges to our patents through oppositions, reexamination proceedings or interference proceedings could result in a loss of patent rights in the relevant jurisdiction. If we are unsuccessful in actions we bring against the patents of other parties and it is determined that we infringe the patents of third-parties, we may be subject to litigation, or otherwise prevented from commercializing potential products in the relevant jurisdiction, or may be required to obtain licenses to those patents or develop or obtain alternative technologies, any of which could harm our business. Furthermore, if such challenges to our patent rights are not resolved in our favor, we could be delayed or prevented from entering into new collaborations or from commercializing certain products, which could adversely affect our business and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Competitors or third parties may infringe our patents. We may be required to file patent infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or that the third party&#8217;s technology does not in fact infringe upon our patents. An adverse determination of any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our related pending patent applications at risk of not issuing. Litigation may fail and, even if successful, may result in substantial costs and be a distraction to our management. We may not be able to prevent misappropriation of our proprietary rights, particularly in countries outside the U.S. where patent rights may be more difficult to enforce.&#160;&#160;Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential or sensitive information could be compromised by disclosure in the event of litigation. In addition, during the course of litigation there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition to patents, which alone may not be able to protect the fundamentals of our business, we also rely on unpatented trade secrets and proprietary technological expertise.&#160;&#160;Some of our intended future cell-related therapeutic products may fit into this category.&#160;&#160;We rely, in part, on confidentiality agreements with our partners, employees, advisors, vendors, and consultants to protect our trade secrets and proprietary technological expertise. There can be no guarantee that these agreements will not be breached, or that we will have adequate remedies for any breach, or that our unpatented trade secrets and proprietary technological expertise will not otherwise become known or be independently discovered by competitors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our amended regenerative cell technology license agreement with the Regents of the University of California (UC) which includes issued U.S. patent number 7,470,537, contains certain developmental milestones, which if not achieved could result in the loss of exclusivity or loss of the license rights. The loss of such rights could impact our ability to develop certain regenerative cell technology products.&#160;&#160;Also, our power as licensee to successfully use these rights to exclude competitors from the market is untested.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">30</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Failure to obtain or maintain patent protection, or protect trade secrets, for any reason (or third-party claims against our patents, trade secrets, or proprietary rights, or our involvement in disputes over our patents, trade secrets, or proprietary rights, including involvement in litigation), could have a substantial negative effect on our results of operations and financial condition.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">We may not be able to protect our intellectual property in countries outside the United States</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Intellectual property law outside the United States is uncertain and in many countries is currently undergoing review and revisions.&#160;&#160;The laws of some countries do not protect our patent and other intellectual property rights to the same extent as United States laws.&#160;&#160;This is particularly relevant to us as most of our current commercial product sales and clinical trials are outside of the United States.&#160;&#160;Third parties may attempt to oppose the issuance of patents to us in foreign countries by initiating opposition proceedings. Opposition proceedings against any of our patent filings in a foreign country could have an adverse effect on our corresponding patents that are issued or pending in the United States. It may be necessary or useful for us to participate in proceedings to determine the validity of our patents or our competitors&#8217; patents that have been issued in countries other than the U.S. This could result in substantial costs, divert our efforts and attention from other aspects of our business, and could have a material adverse effect on our results of operations and financial condition. We currently have pending patent applications in Europe, Australia, Japan, Canada, China, Korea, and Singapore, among others.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">We and our Olympus-Cytori, Inc. joint venture are subject to FDA regulation</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As medical devices, the Celution&#174; System family of products, Puregraft &#174; family of products and the Celbrush&#174; must receive regulatory clearances or approvals from the FDA and, in many instances, from non-U.S. and state governments prior to their sale.&#160;&#160;The Celution&#174; System family of products is subject to stringent government regulation in the United States by the FDA under the Federal Food, Drug and Cosmetic Act.&#160;&#160;The FDA regulates the design/development process, clinical testing, manufacture, safety, labeling, sale, distribution, and promotion of medical devices and drugs.&#160;&#160;Included among these regulations are pre-market clearance and pre-market approval requirements, design control requirements, and the Quality System Regulations/Good Manufacturing Practices.&#160;&#160;Other statutory and regulatory requirements govern, among other things, establishment registration and inspection, medical device listing, prohibitions against misbranding and adulteration, labeling and post-market reporting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The regulatory process can be lengthy, expensive, and uncertain.&#160;&#160;Before any new medical device may be introduced to the U.S. market, the manufacturer generally must obtain FDA clearance or approval through either the 510(k) pre-market notification process or the lengthier pre-market approval application, or PMA, process.&#160;&#160;It generally takes from three to 12 months from submission to obtain 510(k) pre-market clearance, although it may take longer.&#160;&#160;Approval of a PMA could take four or more years from the time the process is initiated.&#160;&#160;The 510(k) and PMA processes can be expensive, uncertain, and lengthy, and there is no guarantee of ultimate clearance or approval.&#160;&#160;We expect that some of our products under development today or in the future, as well as Olympus-Cytori&#8217;s, will be subject to the lengthier PMA process.&#160;&#160;Securing FDA clearances and approvals may require the submission of extensive clinical data and supporting information to the FDA, and there can be no guarantee of ultimate clearance or approval.&#160;&#160;Failure to comply with applicable requirements can result in application integrity proceedings, fines, recalls or seizures of products, injunctions, civil penalties, total or partial suspensions of production, withdrawals of existing product approvals or clearances, refusals to approve or clear new applications or notifications, and criminal prosecution.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Medical devices are also subject to post-market reporting requirements for deaths or serious injuries when the device may have caused or contributed to the death or serious injury, and for certain device malfunctions that would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.&#160;&#160;If safety or effectiveness problems occur after the product reaches the market, the FDA may take steps to prevent or limit further marketing of the product.&#160;&#160;Additionally, the FDA actively enforces regulations prohibiting marketing and promotion of devices for indications or uses that have not been cleared or approved by the FDA.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There can be no guarantee that we will be able to obtain the necessary 510(k) clearances or PMA approvals to market and manufacture our other products in the United States for their intended use on a timely basis, if at all.&#160;&#160;Delays in receipt of or failure to receive such clearances or approvals, the loss of previously received clearances or approvals, or failure to comply with existing or future regulatory requirements could have a substantial negative effect on our results of operations and financial condition.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">To sell in international markets, we will be subject to regulation in foreign countries</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In cooperation with our distribution partners, we intend to market our current and future products both domestically and in many foreign markets. A number of risks are inherent in international transactions.&#160;&#160;In order for us to market our products in Europe, Canada, Japan and certain other non-U.S. jurisdictions, we need to obtain and maintain required regulatory approvals or clearances and must comply with extensive regulations regarding safety, manufacturing processes and quality.&#160;&#160;For example, we still have not obtained regulatory approval for our Thin Film products in Japan.&#160;&#160;These regulations, including the requirements for approvals or clearances to market, may differ from the FDA regulatory scheme.&#160;&#160;International sales also may be limited or disrupted by political instability, price controls, trade restrictions and changes in tariffs.&#160;&#160;Additionally, fluctuations in currency exchange rates may adversely affect demand for our products by increasing the price of our products in the currency of the countries in which the products are sold.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">31</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There can be no assurance that we will obtain regulatory approvals or clearances in all of the countries where we intend to market our products, or that we will not incur significant costs in obtaining or maintaining foreign regulatory approvals or clearances, or that we will be able to successfully commercialize current or future products in various foreign markets.&#160;&#160;Delays in receipt of approvals or clearances to market our products in foreign countries, failure to receive such approvals or clearances or the future loss of previously received approvals or clearances could have a substantial negative effect on our results of operations and financial condition.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Changing, new and/or emerging government regulations may adversely affect us</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Government regulations can change without notice. Given the fact that Cytori operates in various international markets, our access to such markets could change with little to no warning due to a change in government regulations that suddenly up-regulate our product(s) and create greater regulatory burden for our cell therapy and cell banking technology products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Due to the fact that there are new and emerging cell therapy and cell banking regulations that have recently been drafted and/or implemented in various countries around the world, the application and subsequent implementation of these new and emerging regulations have little to no precedence. Therefore, the level of complexity and stringency is not known and may vary from country to country, creating greater uncertainty for the international regulatory process.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Anticipated or unanticipated changes in the way or manner in which the FDA regulates products or classes/groups of products can delay, further burden, or alleviate regulatory pathways that were once available to other products.&#160;&#160;There are no guarantees that such changes in FDA&#8217;s approach to the regulatory process will not deleteriously affect some or all of our products or product applications.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We do not know if the current FDA proposed changes to the 510(k) system will have any material effect on any of our current or future 510(k) applications.&#160;&#160;Depending on if and how these proposed changes are ultimately adopted and implemented, our current or future applications for FDA approval for our products may be adversely affected and our business could be harmed as a result.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">We may have difficulty obtaining health insurance reimbursement for our products</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">New and emerging cell therapy and cell banking technologies, such as those provided by the Celution&#174; System family of products, may have difficulty or encounter significant delays in obtaining health care reimbursement in some or all countries around the world due to the&#160;&#160;novelty of our cell therapy and cell banking technology and subsequent lack of existing reimbursement schemes / pathways. Therefore, the creation of new reimbursement pathways may be complex and lengthy with no assurances that such reimbursements will be successful. The lack of health insurance reimbursement or reduced or minimal reimbursement pricing may have a significant impact on our ability to successfully sell our cell therapy and cell banking technology product(s) into a county or region, which would negatively impact our operating results.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Our concentration of sales in Japan may enhance the negative effects on our business of any crisis in that region</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have a significant concentration of sales in Japan, the United States, and Europe given our early stage of commercialization.&#160;&#160;As a result of this regional concentration of sales, changes in the regulatory environment in these countries, or any other countries in which we have a significant concentration of sales, could adversely impact our sales.&#160;&#160;If the government of any of these countries significantly curtailed or prohibited the sale of our products, our revenues would be adversely affected. Recently, the earthquake, tsunami and subsequent problems affecting nuclear power plants in Japan have dramatically impacted Japan&#8217;s manufacturing capacity and business activities. The long-term effect of these issues is still uncertain. While we expect that the situation has stabilized and will improve, if it does not, these circumstances could be harmful to our business since a substantial portion of our sales have come from Japan.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Our global operations expose us to additional risk and uncertainties.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have operations in a number of regions around the world, including the United States, Japan, and Europe. Our global operations may be subject to risks that may limit our ability to operate our business. We sell our products globally, which exposes us to a number of risks that can arise from international trade transactions, local business practices and cultural considerations, including:</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">political unrest, terrorism and economic or financial instability;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
</div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">32</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">unexpected changes and uncertainty in regulatory requirements and systems related</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">nationalization programs that may be implemented by foreign governments;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">import-export regulations;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">difficulties in enforcing agreements and collecting receivables;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">difficulties in ensuring compliance with the laws and regulations of multiple jurisdictions;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">changes in labor practices, including wage inflation, labor unrest and unionization policies;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">longer payment cycles by international customers;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">currency exchange fluctuations;</font></font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">disruptions of service from utilities or telecommunications providers, including electricity shortages;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">difficulties in staffing foreign branches and subsidiaries and in managing an expatriate workforce, and differing employment practices and labor issues;</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">potentially adverse tax consequences;</font></font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We also face risks associated with currency exchange and convertibility, inflation and repatriation of earnings as a result of our foreign operations. We are also vulnerable to appreciation or depreciation of foreign currencies against the U.S. dollar. Although we have significant operations in Asia, a substantial portion of transactions are denominated in U.S. dollars. As appreciation against the U.S. dollar increases, it will result in an increase in the cost of our business expenses abroad. Conversely, downward fluctuations in the value of foreign currencies relative to the U.S. dollar may make our products less price competitive than local solutions. From time to time, we may engage in currency hedging activities, but such activities may not be able to limit the risks of currency fluctuations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">We and our joint venture with Olympus have to maintain quality assurance certification and manufacturing approvals</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The manufacture of our products are, and the manufacture of any future cell-related therapeutic products would be, subject to periodic inspection by regulatory authorities and distribution partners.&#160;&#160;The manufacture of devices and products for human use is subject to regulation and inspection from time to time by the FDA for compliance with the FDA&#8217;s Quality System Regulation, or QSR, requirements, as well as equivalent requirements and inspections by state and non-U.S. regulatory authorities.&#160;&#160;There can be no guarantee that the FDA or other authorities will not, during the course of an inspection of existing or new facilities, identify what they consider to be deficiencies in our compliance with QSRs or other requirements and request, or seek remedial action.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Failure to comply with such regulations or a potential delay in attaining compliance may adversely affect our manufacturing activities and could result in, among other things, injunctions, civil penalties, FDA refusal to grant pre-market approvals or clearances of future or pending product submissions, fines, recalls or seizures of products, total or partial suspensions of production, and criminal prosecution.&#160;&#160;There can be no assurance after such occurrences that we will be able to obtain additional necessary regulatory approvals or clearances on a timely basis, if at all.&#160;&#160;Delays in receipt of or failure to receive such approvals or clearances, or the loss of previously received approvals or clearances could have a substantial negative effect on our results of operations and financial condition.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">We depend on a few key officers</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our performance is substantially dependent on the performance of our executive officers and other key scientific and sales staff, including Christopher J. Calhoun, our Chief Executive Officer, and Marc Hedrick, MD, our President.&#160;&#160;We rely upon them for strategic business decisions and guidance. We believe that our future success in developing marketable products and achieving a competitive position will depend in large part upon whether we can attract and retain additional qualified management and scientific personnel.&#160;&#160;Competition for such personnel is intense, and there can be no assurance that we will be able to continue to attract and retain such personnel.&#160;&#160;The loss of the services of one or more of our executive officers or key scientific staff, or the inability to attract and retain additional personnel and develop expertise as needed could have a substantial negative effect on our results of operations and financial condition.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">33</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">We may not have enough product liability insurance</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The testing, manufacturing, marketing, and sale of our regenerative cell products involve an inherent risk that product liability claims will be asserted against us, our distribution partners, or licensees.&#160;&#160;There can be no guarantee that our clinical trial and commercial product liability insurance is adequate or will continue to be available in sufficient amounts or at an acceptable cost, if at all.&#160;&#160;A product liability claim, product recall, or other claim, as well as any claims for uninsured liabilities or in excess of insured liabilities, could have a substantial negative effect on our results of operations and financial condition.&#160;&#160;Also, well-publicized claims could cause our stock to fall sharply, even before the merits of the claims are decided by a court.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Our charter documents contain anti-takeover provisions and we have adopted a Stockholder Rights Plan to prevent hostile takeovers</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our Amended and Restated Certificate of Incorporation and Bylaws contain certain provisions that could prevent or delay the&#160;&#160;acquisition of Cytori by means of a tender offer, proxy contest, or otherwise.&#160;&#160;They could discourage a third party from attempting to acquire control of Cytori, even if such events would be beneficial to the interests of our stockholders.&#160;&#160;Such provisions may have the effect of delaying, deferring, or preventing a change of control of Cytori and consequently could adversely affect the market price of our shares. Also, in 2003 we adopted a Stockholder Rights Plan of the kind often referred to as a poison pill. The purpose of the Stockholder Rights Plan is to prevent coercive takeover tactics that may otherwise be utilized in takeover attempts. The existence of such a rights plan may also prevent or delay a change in control of Cytori, and this prevention or delay adversely affect the market price of our shares.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">We pay no dividends</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have never paid cash dividends in the past, and currently do not intend to pay any cash dividends in the foreseeable future.&#160;&#160;This could make an investment in our company inappropriate for some investors, and may serve to narrow our potential sources of additional capital.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><!--EFPlaceholder--><!--EFPlaceholder--><!--EFPlaceholder--><!--EFPlaceholder--><!--EFPlaceholder--><!--EFPlaceholder--><!--EFPlaceholder--><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><!--EFPlaceholder-->Item 2. <a name="Unregistere">Unregistere</a>d Sales of Equity Securities and Use of Proceeds</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">None</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><!--EFPlaceholder-->Item 3. <a name="Default">Default</a>s Upon Senior Securities</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">None</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><!--EFPlaceholder-->Item 4. (<a name="Reserve">Reserve</a>d)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><!--EFPlaceholder-->Item 5.&#160;<a name="Othe">Othe</a>r Information</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">None</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">34</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 6.&#160;&#160;<a name="EXHI">Exhibits</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exhibit No.</font></div>
</td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Description</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="ex31_1.htm">31.1</a></font></div>
</td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="ex31_2.htm">31.2</a></font></div>
</td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="ex32_1.htm">32.1*</a></font></div>
</td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certifications Pursuant to 18 U.S.C. Section 1350/ Securities Exchange Act Rule 13a-14(b), as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002 (filed herewith).</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.INS</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Instance Document</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.SCH</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Schema Document</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.CAL</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Calculation Linkbase Document</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.LAB</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Label Linkbase Document</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.PRE</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Presentation Linkbase Document</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">*&#160;&#160;&#160;&#160;&#160;&#160;These certifications are being furnished solely to accompany this report pursuant to 18 U.S.C. 1350 and are not being filed for purposes of Section 18 of the Securities and Exchange Act of 1934 and are not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><!--EFPlaceholder--><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">35</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#index">Index</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" colspan="2" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CYTORI THERAPEUTICS, INC.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" nowrap valign="top" width="4%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:&#160;&#160; </font></div>
</td>
<td align="left" valign="top" width="46%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Christopher J. Calhoun</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dated: May 9, 2012</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Christopher J. Calhoun</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Executive Officer</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="4%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="top" width="46%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Mark E. Saad</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dated: May 9, 2012</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Mark E. Saad</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">36</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31_1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
<head>
    <title>ex31_1.htm</title>
    <!--Licensed to: Thomson Reuters-->
    <!--Document Created using EDGARizer 2020 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<div>
<hr style="COLOR: black" align="left" noshade size="4" width="100%">
</div>
</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT 31.1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Certification of Principal Executive Officer Pursuant to</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Securities Exchange Act Rule 13a-14(a),</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">as Adopted Pursuant to</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Section 302 of the Sarbanes-Oxley Act of 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I, Christopher J. Calhoun, certify that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I have reviewed this quarterly report on Form 10-Q of Cytori Therapeutics, Inc.;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">4.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(a)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(b)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(c)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report- based on such evaluation; and</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(d)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">5.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(a)</font></font></div>
</td>
<td>
<div align="left">

<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information; and</font></font></font></font></div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(b)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="top" width="100%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: May 9, 2012</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Christopher J. Calhoun</font></div>
</td>
<td align="left" valign="top" width="65%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="100%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Christopher J. Calhoun,</font></div>
</td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="100%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Executive Officer</font></div>
</td>
</tr></table>
</div>
</div>

<div>&#160;</div>

<div>&#160;</div>

<div>
<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31_2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
<head>
    <title>ex31_2.htm</title>
    <!--Licensed to: Thomson Reuters-->
    <!--Document Created using EDGARizer 2020 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div><a name="eolPage39"><!--EFPlaceholder--></a><a name="EX31_2_HTM"><!--EFPlaceholder--></a><a name="FIS_EXHIBIT_31_2"><!--EFPlaceholder--></a>

<div>
<hr style="COLOR: black" align="left" noshade size="4" width="100%">
</div>
</div>

<div style="TEXT-ALIGN: right">E<font style="DISPLAY: inline; FONT-WEIGHT: bold">XHIBIT 31.2</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Certification of Principal Financial Officer Pursuant to</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Securities Exchange Act Rule 13a-14(a),</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">as Adopted Pursuant to</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Section 302 of the Sarbanes-Oxley Act of 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I, Mark E. Saad, certify that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">1.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">I have reviewed this quarterly report on Form 10-Q of Cytori Therapeutics, Inc.;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">4.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(a)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(b)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(c)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report- based on such evaluation; and</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(d)</font></font></div>
</td>
<td>
<div align="left">
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></font></div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">5.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(a)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information; and</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(b)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="top" width="100%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: May 9, 2012</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Mark E. Saad</font></div>
</td>
<td align="left" valign="top" width="65%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="100%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Mark E. Saad</font></div>
</td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="100%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div>&#160;</div>

<div>
<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32_1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
<head>
    <title>ex32_1.htm</title>
    <!--Licensed to: Thomson Reuters-->
    <!--Document Created using EDGARizer 2020 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<div>
<hr style="COLOR: black" align="left" noshade size="4" width="100%">
</div>
</div>

<div style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-WEIGHT: bold">EXHIBIT 32.1</font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_CERTIFICATION"><!--EFPlaceholder--></a><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350/ SECURITIES EXCHANGE ACT RULE 13a-14(b), AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the Quarterly Report on Form 10-Q of Cytori Therapeutics, Inc. for the quarterly period ended March 31, 2012 as filed with the Securities and Exchange Commission on the date hereof, Christopher J. Calhoun, as Chief Executive Officer of Cytori Therapeutics, Inc., and Mark E. Saad, as Chief Financial Officer of Cytori Therapeutics, Inc., each hereby certifies, respectively, that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">1.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">The Form 10-Q report of Cytori Therapeutics, Inc. that this certification accompanies fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934.</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="HANGINGINDENT"><!--EFPlaceholder--></a><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">The information contained in the Form 10-Q report of Cytori Therapeutics, Inc. that this certification accompanies fairly presents, in all material respects, the financial condition and results of operations of Cytori Therapeutics, Inc.</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" nowrap valign="top" width="4%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:&#160;&#160; </font></div>
</td>
<td align="left" valign="top" width="46%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Christopher J. Calhoun</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dated:&#160;&#160;May 9, 2012</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Christopher J. Calhoun</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Executive Officer</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="4%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="top" width="46%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Mark E. Saad</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dated:&#160;&#160;May 9, 2012</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Mark E. Saad</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>
</div>

<div>&#160;</div>

<div>&#160;</div>

<div>
<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>cytx-20120331.xml
<DESCRIPTION>INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Thomson Reuters Accelus-->
<xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:curr="http://xbrl.sec.gov/currency/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2011-01-31" xmlns:cytx="http://cytori.com/20120331" xmlns="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:href="cytx-20120331.xsd" />
  <xbrli:context id="c20120101to20120331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20110630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20111231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20110101to20110331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20101231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20110331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="U001">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U002">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U003">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <!--Accounts receivable, net of reserves of $187,000 and of $474,000 in 2012 and 2011, respectively-->
  <us-gaap:AccountsReceivableNetCurrent contextRef="c20120331" unitRef="U001" decimals="0">1425000</us-gaap:AccountsReceivableNetCurrent>
  <!--Accounts receivable, net of reserves of $187,000 and of $474,000 in 2012 and 2011, respectively-->
  <us-gaap:AccountsReceivableNetCurrent contextRef="c20111231" unitRef="U001" decimals="0">2260000</us-gaap:AccountsReceivableNetCurrent>
  <!--Additional paid-in capital-->
  <us-gaap:AdditionalPaidInCapital contextRef="c20120331" unitRef="U001" decimals="0">258566000</us-gaap:AdditionalPaidInCapital>
  <!--Additional paid-in capital-->
  <us-gaap:AdditionalPaidInCapital contextRef="c20111231" unitRef="U001" decimals="0">252338000</us-gaap:AdditionalPaidInCapital>
  <!--Amortization of deferred financing costs and debt discount-->
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c20120101to20120331" unitRef="U001" decimals="0">237000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <!--Amortization of deferred financing costs and debt discount-->
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c20110101to20110331" unitRef="U001" decimals="0">240000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <!--Accounts receivable, reserves-->
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c20120331" unitRef="U001" decimals="0">187000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <!--Accounts receivable, reserves-->
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c20111231" unitRef="U001" decimals="0">474000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <!--Cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20120331" unitRef="U001" decimals="0">34399000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20111231" unitRef="U001" decimals="0">36922000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20101231" unitRef="U001" decimals="0">52668000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20110331" unitRef="U001" decimals="0">42647000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Interest-->
  <us-gaap:InterestPaid contextRef="c20120101to20120331" unitRef="U001" decimals="0">625000</us-gaap:InterestPaid>
  <!--Interest-->
  <us-gaap:InterestPaid contextRef="c20110101to20110331" unitRef="U001" decimals="0">499000</us-gaap:InterestPaid>
  <!--Accounts payable and accrued expenses-->
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c20120101to20120331" unitRef="U001" decimals="0">-83000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <!--Accounts payable and accrued expenses-->
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c20110101to20110331" unitRef="U001" decimals="0">-854000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <!--Increase (Decrease) in Accounts Receivable-->
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c20120101to20120331" unitRef="U001" decimals="0">-859000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <!--Increase (Decrease) in Accounts Receivable-->
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c20110101to20110331" unitRef="U001" decimals="0">-278000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <!--Increase (Decrease) in Inventories-->
  <us-gaap:IncreaseDecreaseInInventories contextRef="c20120101to20120331" unitRef="U001" decimals="0">56000</us-gaap:IncreaseDecreaseInInventories>
  <!--Increase (Decrease) in Inventories-->
  <us-gaap:IncreaseDecreaseInInventories contextRef="c20110101to20110331" unitRef="U001" decimals="0">174000</us-gaap:IncreaseDecreaseInInventories>
  <!--Commitments and Contingencies Disclosure [Text Block]-->
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="top" style="width: 3%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;11.&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="top" style="width: 93%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;Commitments and Contingencies&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-size: 10pt;"&gt;We have entered into agreements with various research organizations for pre-clinical and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements was estimated based on current schedules of pre-clinical and clinical studies in progress.&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="display: inline; font-size: 10pt;"&gt;As of March 31, 2012, we have pre-clinical research study obligations of $60,000 (which are expected to be fully completed within a year) and clinical research study obligations of $12,600,000 ($4,100,000 of which are expected to be completed within a year).&lt;/font&gt;&amp;#160;&amp;#160;&lt;font style="display: inline; font-size: 10pt;"&gt;Should the timing or the budgets of the pre-clinical and clinical trials change, the timing and amounts of the payments for these obligations would also change.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;During 2008, we entered into a supply agreement with a minimum purchase requirements clause.&amp;#160;&amp;#160;As of March 31, 2012, we have minimum purchase obligations of $2,191,000 ($1,341,000 of which are expected to be paid within a year).&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;We have entered into several lease agreements for our headquarters office location as well as international office locations and corporate housing for our employees on international assignments. As of March 31, 2012, we have remaining lease obligations of $10,259,000 ($1,785,000 of which are expected to be completed within a year).&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;We are subject to various claims and contingencies related to legal proceedings.&amp;#160;&amp;#160;Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions.&amp;#160;&amp;#160;Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate.&amp;#160;&amp;#160;Management believes that any liability to us that may arise as a result of currently pending legal proceedings will not have a material adverse effect on our financial condition, liquidity, or results of operations as a whole.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Refer to note 6 for a discussion of our commitments and contingencies related to our long-term obligations.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Refer to note 12 for a discussion of our commitments and contingencies related to our transactions with Olympus, including (a) our obligation to the Joint Venture in future periods and (b) certain put and call rights embedded in the arrangements with Olympus.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <!--Common stock, shares authorized (in shares)-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c20120331" unitRef="U002" decimals="0">95000000</us-gaap:CommonStockSharesAuthorized>
  <!--Common stock, shares authorized (in shares)-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c20111231" unitRef="U002" decimals="0">95000000</us-gaap:CommonStockSharesAuthorized>
  <!--Common stock, shares issued (in shares)-->
  <us-gaap:CommonStockSharesIssued contextRef="c20120331" unitRef="U002" decimals="0">58428606</us-gaap:CommonStockSharesIssued>
  <!--Common stock, shares issued (in shares)-->
  <us-gaap:CommonStockSharesIssued contextRef="c20111231" unitRef="U002" decimals="0">56594683</us-gaap:CommonStockSharesIssued>
  <!--Common Stock, Shares, Outstanding-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20120331" unitRef="U002" decimals="0">58428606</us-gaap:CommonStockSharesOutstanding>
  <!--Common Stock, Shares, Outstanding-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20111231" unitRef="U002" decimals="0">56594683</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, $0.001 par value; 95,000,000 shares authorized; 58,428,606 and 56,594,683 shares issued and outstanding in 2012 and 2011, respectively-->
  <us-gaap:CommonStockValue contextRef="c20120331" unitRef="U001" decimals="0">58000</us-gaap:CommonStockValue>
  <!--Common stock, $0.001 par value; 95,000,000 shares authorized; 58,428,606 and 56,594,683 shares issued and outstanding in 2012 and 2011, respectively-->
  <us-gaap:CommonStockValue contextRef="c20111231" unitRef="U001" decimals="0">57000</us-gaap:CommonStockValue>
  <!--Cost of product revenues-->
  <us-gaap:CostOfGoodsSold contextRef="c20120101to20120331" unitRef="U001" decimals="0">853000</us-gaap:CostOfGoodsSold>
  <!--Cost of product revenues-->
  <us-gaap:CostOfGoodsSold contextRef="c20110101to20110331" unitRef="U001" decimals="0">842000</us-gaap:CostOfGoodsSold>
  <!--Liabilities, Current-->
  <us-gaap:LiabilitiesCurrent contextRef="c20120331" unitRef="U001" decimals="0">10957000</us-gaap:LiabilitiesCurrent>
  <!--Liabilities, Current-->
  <us-gaap:LiabilitiesCurrent contextRef="c20111231" unitRef="U001" decimals="0">7821000</us-gaap:LiabilitiesCurrent>
  <!--Long-term obligations, net of discount, less current portion-->
  <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c20120331" unitRef="U001" decimals="0">19704000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
  <!--Long-term obligations, net of discount, less current portion-->
  <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c20111231" unitRef="U001" decimals="0">21962000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
  <!--Basic and diluted net loss per common share (in dollars per share)-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20120101to20120331" unitRef="U003" decimals="2">-0.16</us-gaap:EarningsPerShareDiluted>
  <!--Basic and diluted net loss per common share (in dollars per share)-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20110101to20110331" unitRef="U003" decimals="2">-0.23</us-gaap:EarningsPerShareDiluted>
  <!--Income (Loss) from Equity Method Investments-->
  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c20120101to20120331" unitRef="U001" decimals="0">-50000</us-gaap:IncomeLossFromEquityMethodInvestments>
  <!--Income (Loss) from Equity Method Investments-->
  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c20110101to20110331" unitRef="U001" decimals="0">-46000</us-gaap:IncomeLossFromEquityMethodInvestments>
  <!--Stock-based compensation-->
  <us-gaap:ShareBasedCompensation contextRef="c20120101to20120331" unitRef="U001" decimals="0">942000</us-gaap:ShareBasedCompensation>
  <!--Stock-based compensation-->
  <us-gaap:ShareBasedCompensation contextRef="c20110101to20110331" unitRef="U001" decimals="0">881000</us-gaap:ShareBasedCompensation>
  <!--Equity Method Investments-->
  <us-gaap:EquityMethodInvestments contextRef="c20120331" unitRef="U001" decimals="0">200000</us-gaap:EquityMethodInvestments>
  <!--Equity Method Investments-->
  <us-gaap:EquityMethodInvestments contextRef="c20111231" unitRef="U001" decimals="0">250000</us-gaap:EquityMethodInvestments>
  <!--General and administrative-->
  <us-gaap:GeneralAndAdministrativeExpense contextRef="c20120101to20120331" unitRef="U001" decimals="0">3924000</us-gaap:GeneralAndAdministrativeExpense>
  <!--General and administrative-->
  <us-gaap:GeneralAndAdministrativeExpense contextRef="c20110101to20110331" unitRef="U001" decimals="0">3544000</us-gaap:GeneralAndAdministrativeExpense>
  <!--Gross Profit-->
  <us-gaap:GrossProfit contextRef="c20120101to20120331" unitRef="U001" decimals="0">628000</us-gaap:GrossProfit>
  <!--Gross Profit-->
  <us-gaap:GrossProfit contextRef="c20110101to20110331" unitRef="U001" decimals="0">520000</us-gaap:GrossProfit>
  <!--Intangibles, net-->
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c20120331" unitRef="U001" decimals="0">136000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <!--Intangibles, net-->
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c20111231" unitRef="U001" decimals="0">192000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <!--Goodwill-->
  <us-gaap:Goodwill contextRef="c20120331" unitRef="U001" decimals="0">3922000</us-gaap:Goodwill>
  <!--Goodwill-->
  <us-gaap:Goodwill contextRef="c20111231" unitRef="U001" decimals="0">3922000</us-gaap:Goodwill>
  <!--Interest Expense-->
  <us-gaap:InterestExpense contextRef="c20120101to20120331" unitRef="U001" decimals="0">865000</us-gaap:InterestExpense>
  <!--Interest Expense-->
  <us-gaap:InterestExpense contextRef="c20110101to20110331" unitRef="U001" decimals="0">738000</us-gaap:InterestExpense>
  <!--Inventories, net-->
  <us-gaap:InventoryNet contextRef="c20120331" unitRef="U001" decimals="0">3374000</us-gaap:InventoryNet>
  <!--Inventories, net-->
  <us-gaap:InventoryNet contextRef="c20111231" unitRef="U001" decimals="0">3318000</us-gaap:InventoryNet>
  <!--Liabilities-->
  <us-gaap:Liabilities contextRef="c20120331" unitRef="U001" decimals="0">42252000</us-gaap:Liabilities>
  <!--Liabilities-->
  <us-gaap:Liabilities contextRef="c20111231" unitRef="U001" decimals="0">41588000</us-gaap:Liabilities>
  <!--Liabilities and Equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20120331" unitRef="U001" decimals="0">49102000</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Liabilities and Equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20111231" unitRef="U001" decimals="0">51534000</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Current portion of long-term obligations-->
  <us-gaap:LongTermDebtCurrent contextRef="c20120331" unitRef="U001" decimals="0">4911000</us-gaap:LongTermDebtCurrent>
  <!--Current portion of long-term obligations-->
  <us-gaap:LongTermDebtCurrent contextRef="c20111231" unitRef="U001" decimals="0">2487000</us-gaap:LongTermDebtCurrent>
  <!--Net Cash Provided by (Used in) Financing Activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c20120101to20120331" unitRef="U001" decimals="0">5216000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net Cash Provided by (Used in) Financing Activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c20110101to20110331" unitRef="U001" decimals="0">674000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net Cash Provided by (Used in) Investing Activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c20120101to20120331" unitRef="U001" decimals="0">-25000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net Cash Provided by (Used in) Investing Activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c20110101to20110331" unitRef="U001" decimals="0">-131000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net Cash Provided by (Used in) Operating Activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c20120101to20120331" unitRef="U001" decimals="0">-7714000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net Cash Provided by (Used in) Operating Activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c20110101to20110331" unitRef="U001" decimals="0">-10564000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net loss-->
  <us-gaap:NetIncomeLoss contextRef="c20120101to20120331" unitRef="U001" decimals="0">-9325000</us-gaap:NetIncomeLoss>
  <!--Net loss-->
  <us-gaap:NetIncomeLoss contextRef="c20110101to20110331" unitRef="U001" decimals="0">-12072000</us-gaap:NetIncomeLoss>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20120101to20120331" unitRef="U001" decimals="0">-2523000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20110101to20110331" unitRef="U001" decimals="0">-10021000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]-->
  <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="top" style="width: 3%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;4.&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="top" style="width: 93%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;In May 2011, the FASB revised the fair value measurement and disclosure requirements to align the requirements under GAAP and International Financial Reporting Standards ("IFRS"). The guidance clarifies the FASB's intent about the application of existing fair value measurements and requires enhanced disclosures, most significantly related to unobservable inputs used in a fair value measurement that is categorized within Level 3 of the fair value hierarchy. The guidance is effective prospectively during interim and annual periods beginning after December 15, 2011. The adoption of this guidance did not have a material impact on our consolidated financial statements.&lt;/div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20120101to20120331" unitRef="U001" decimals="0">-960000</us-gaap:NonoperatingIncomeExpense>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20110101to20110331" unitRef="U001" decimals="0">-829000</us-gaap:NonoperatingIncomeExpense>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20120101to20120331" unitRef="U001" decimals="0">-8365000</us-gaap:OperatingIncomeLoss>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20110101to20110331" unitRef="U001" decimals="0">-11243000</us-gaap:OperatingIncomeLoss>
  <!--Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]-->
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="top" style="width: 3%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;1.&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="top" style="width: 93%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;Basis of Presentation&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Our accompanying unaudited consolidated condensed financial statements as of March 31, 2012 and for the three months ended March 31, 2012 and 2011 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information.&amp;#160;&amp;#160;Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements.&amp;#160;&amp;#160;Our consolidated condensed balance sheet at March 31, 2012 has been derived from the audited financial statements at December 31, 2011, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.&amp;#160;&amp;#160;In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Cytori Therapeutics, Inc., and our subsidiaries (the Company) have been included.&amp;#160;&amp;#160;Operating results for the three months ended March 31, 2012 are not necessarily indicative of the results that may be expected for the year ending December 31, 2012.&amp;#160;&amp;#160;These financial statements should be read in conjunction with the consolidated financial statements and notes therein included in our annual report on Form 10-K for the year ended December 31, 2011.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <!--Other Assets, Current-->
  <us-gaap:OtherAssetsCurrent contextRef="c20120331" unitRef="U001" decimals="0">1135000</us-gaap:OtherAssetsCurrent>
  <!--Other Assets, Current-->
  <us-gaap:OtherAssetsCurrent contextRef="c20111231" unitRef="U001" decimals="0">837000</us-gaap:OtherAssetsCurrent>
  <!--Other Nonoperating Income (Expense)-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20120101to20120331" unitRef="U001" decimals="0">-47000</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Other Nonoperating Income (Expense)-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20110101to20110331" unitRef="U001" decimals="0">-47000</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Preferred stock, shares authorized (in shares)-->
  <us-gaap:PreferredStockSharesAuthorized contextRef="c20120331" unitRef="U002" decimals="0">5000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Preferred stock, shares authorized (in shares)-->
  <us-gaap:PreferredStockSharesAuthorized contextRef="c20111231" unitRef="U002" decimals="0">5000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Preferred stock, shares issued (in shares)-->
  <us-gaap:PreferredStockSharesIssued contextRef="c20120331" unitRef="U002" decimals="0">0</us-gaap:PreferredStockSharesIssued>
  <!--Preferred stock, shares issued (in shares)-->
  <us-gaap:PreferredStockSharesIssued contextRef="c20111231" unitRef="U002" decimals="0">0</us-gaap:PreferredStockSharesIssued>
  <!--Preferred stock, shares outstanding (in shares)-->
  <us-gaap:PreferredStockSharesOutstanding contextRef="c20120331" unitRef="U002" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
  <!--Preferred stock, shares outstanding (in shares)-->
  <us-gaap:PreferredStockSharesOutstanding contextRef="c20111231" unitRef="U002" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
  <!--Preferred stock, par value (in dollars per share)-->
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c20120331" unitRef="U003" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <!--Preferred stock, par value (in dollars per share)-->
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c20111231" unitRef="U003" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <!--Proceeds from sale of common stock-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20120101to20120331" unitRef="U001" decimals="0">4396000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Proceeds from sale of common stock-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20110101to20110331" unitRef="U001" decimals="0">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Property and equipment, net-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c20120331" unitRef="U001" decimals="0">2367000</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Property and equipment, net-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c20111231" unitRef="U001" decimals="0">1711000</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Increase (decrease) in allowance for doubtful accounts-->
  <us-gaap:ProvisionForDoubtfulAccounts contextRef="c20120101to20120331" unitRef="U001" decimals="0">-24000</us-gaap:ProvisionForDoubtfulAccounts>
  <!--Increase (decrease) in allowance for doubtful accounts-->
  <us-gaap:ProvisionForDoubtfulAccounts contextRef="c20110101to20110331" unitRef="U001" decimals="0">21000</us-gaap:ProvisionForDoubtfulAccounts>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20120101to20120331" unitRef="U001" decimals="0">25000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20110101to20110331" unitRef="U001" decimals="0">131000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Related Party Transactions Disclosure [Text Block]-->
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="top" style="width: 3%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;12.&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="top" style="width: 93%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;Transactions with Olympus Corporation&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Initial Investment by Olympus Corporation in Cytori&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;In 2005, we entered into a common stock purchase agreement with Olympus in which we received $11,000,000 in cash proceeds.&amp;#160;&amp;#160;We received an additional $11,000,000 from Olympus in August 2006 for the issuance of approximately 1,900,000 shares of our common stock at $5.75 per share.&amp;#160;&amp;#160;We received an additional $6,000,000 from Olympus in August 2008 for the issuance of 1,000,000 unregistered shares of our common stock at $6.00 per share and 500,000 common stock warrants (with an original exercise price of $8.50 per share) under a private placement offering.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;As of March 31, 2012, Olympus holds approximately 6.9% of our issued and outstanding shares.&amp;#160;&amp;#160;Additionally, Olympus has a right, which it has not yet exercised, to designate a director to serve on our Board of Directors.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Formation of the Olympus-Cytori Joint Venture&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;In 2005, we entered into a joint venture and other related agreements (the "Joint Venture Agreements") with Olympus.&amp;#160;&amp;#160;The Joint Venture is owned equally by Olympus and us.&amp;#160;&amp;#160;We have determined that the Joint Venture is a variable interest entity or VIE, but that Cytori is not the VIE's primary beneficiary.&amp;#160;&amp;#160;Accordingly, we have accounted for our interests in the Joint Venture using the equity method of accounting, since we can exert significant influence over the Joint Venture's operations.&amp;#160;&amp;#160;At March 31, 2012, the carrying value of our investment in the Joint Venture is $200,000.&amp;#160;&amp;#160;We are under no obligation to provide additional funding to the Joint Venture, but may choose to do so.&amp;#160;&amp;#160;We made no cash contributions to the Joint Venture during the three months ended March 31, 2012 and 2011.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Put/Calls and Guarantees&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;The Shareholders' Agreement between Cytori and Olympus provides that in certain specified circumstances of our insolvency or if we experience a change in control, Olympus will have the rights to (i) repurchase our interests in the Joint Venture at the fair value of such interests or (ii) sell its own interests in the Joint Venture to Cytori (the "Put") at the higher of (a) $22,000,000 or (b) the Put's fair value.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;At March 31, 2012 and December 31, 2011, the estimated fair value of the Put was $1,640,000 and $1,910,000, respectively.&amp;#160;&amp;#160;Fluctuations in the Put value are recorded in the consolidated condensed statements of operations as a component of change in fair value of option liabilities. The estimated fair value of the Put has been recorded as a long-term liability in the caption option liability in our consolidated condensed balance sheets.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;The valuations of the Put were completed using an option pricing theory based simulation analysis (i.e., a Monte Carlo simulation).&amp;#160;&amp;#160;The valuations are based on assumptions as of the valuation date with regard to the market value of Cytori and the estimated fair value of the Joint Venture, the expected correlation between the values of Cytori and the Joint Venture, the expected volatility of Cytori and the Joint Venture, the bankruptcy recovery rate for Cytori, the bankruptcy threshold for Cytori, the probability of a change of control event for Cytori, and the risk free interest rate.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;The following assumptions were employed in estimating the value of the Put:&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;a name="FIS_UNIDENTIFIED_TABLE_6"&gt;&lt;/a&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 66%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;"&gt;March 31,&lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;"&gt;2012&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;"&gt;December 31, &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;"&gt;2011&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 66%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 1.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 1.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Expected volatility of Cytori&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;76.45&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;76.07&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Expected volatility of the Joint Venture&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;76.45&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;76.07&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Bankruptcy recovery rate for Cytori&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;28.00&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;28.00&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Bankruptcy threshold for Cytori&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;7,138,000&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;8,594,000&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Probability of a change of control event for Cytori&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;3.08&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;3.33&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Expected correlation between fair values of Cytori and the Joint Venture in the future&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;99.00&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;99.00&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Risk free interest rate&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;2.23&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;1.89&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;The Put has no expiration date.&amp;#160;&amp;#160;Accordingly, we will continue to recognize a liability for the Put and mark it to market each quarter until it is exercised or until the arrangements with Olympus are amended.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <!--Repayments of Long-term Debt-->
  <us-gaap:RepaymentsOfLongTermDebt contextRef="c20120101to20120331" unitRef="U001" decimals="0">71000</us-gaap:RepaymentsOfLongTermDebt>
  <!--Repayments of Long-term Debt-->
  <us-gaap:RepaymentsOfLongTermDebt contextRef="c20110101to20110331" unitRef="U001" decimals="0">0</us-gaap:RepaymentsOfLongTermDebt>
  <!--Accumulated deficit-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20120331" unitRef="U001" decimals="0">-251774000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Accumulated deficit-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20111231" unitRef="U001" decimals="0">-242449000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Product revenues-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c20120101to20120331" unitRef="U001" decimals="0">1481000</us-gaap:SalesRevenueGoodsNet>
  <!--Product revenues-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c20110101to20110331" unitRef="U001" decimals="0">1362000</us-gaap:SalesRevenueGoodsNet>
  <!--Inventory Disclosure [Text Block]-->
  <us-gaap:InventoryDisclosureTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="top" style="width: 3%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;8.&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="top" style="width: 93%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;Inventories&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Inventories are carried at the lower of cost or market, determined on the first-in, first-out (FIFO) method.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Inventories consisted of the following:&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;table cellpadding="0" cellspacing="0" style="text-align: center; width: 90%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr style="text-align: center;"&gt;&lt;td valign="bottom" style="width: 66%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;"&gt;March 31,&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 66%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;"&gt;2012&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;"&gt;2011&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 66%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 1.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 1.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Raw materials&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;1,518,000&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;1,503,000&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Work in process&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;838,000&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;790,000&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Finished goods&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="border-bottom: black 2px solid; width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="border-bottom: black 2px solid; width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;1,018,000&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="border-bottom: black 2px solid; width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="border-bottom: black 2px solid; width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;1,025,000&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="border-bottom: black 4px double; width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="border-bottom: black 4px double; width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;3,374,000&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="border-bottom: black 4px double; width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="border-bottom: black 4px double; width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;3,318,000&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <!--Schedule of Subsequent Events [Table Text Block]-->
  <us-gaap:ScheduleOfSubsequentEventsTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="top" style="width: 3%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;16.&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="top" style="width: 93%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;Subsequent Events&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;We have evaluated events after the balance sheet date of March 31, 2012 and up to the date we filed this report.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Subsequent to the quarter ended March 31, 2012, we completed one scheduled closing with Seaside 88, LP during the period of April 1, 2012 through our filing date raising in aggregate approximately $549,000 in gross proceeds from the &lt;font style="font-family: Times New Roman; font-size: 10pt;"&gt;sale of 250,000&lt;font style="display: inline; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;shares&lt;/font&gt; of our common stock in connection with the agreement we entered into with Seaside 88, LP on July 11, 2011.&amp;#160;&amp;#160;Effective, April 30&lt;font style="display: inline; font-size: 70%; vertical-align: text-top;"&gt;th&lt;/font&gt;, 2012, we terminated the agreement with Seaside 88, LP and we will not sell the remaining and final 500,000 shares that would otherwise have been sold under this agreement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfSubsequentEventsTextBlock>
  <!--Sales and marketing-->
  <us-gaap:SellingAndMarketingExpense contextRef="c20120101to20120331" unitRef="U001" decimals="0">2376000</us-gaap:SellingAndMarketingExpense>
  <!--Sales and marketing-->
  <us-gaap:SellingAndMarketingExpense contextRef="c20110101to20110331" unitRef="U001" decimals="0">3226000</us-gaap:SellingAndMarketingExpense>
  <!--Payments of Stock Issuance Costs-->
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c20120101to20120331" unitRef="U001" decimals="0">56000</us-gaap:PaymentsOfStockIssuanceCosts>
  <!--Payments of Stock Issuance Costs-->
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c20110101to20110331" unitRef="U001" decimals="0">0</us-gaap:PaymentsOfStockIssuanceCosts>
  <!--Stockholders' Equity Note Disclosure [Text Block]-->
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="top" style="width: 3%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;15.&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="top" style="width: 93%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;Stockholders' Equity&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Common Stock&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;On December 13, 2010 we raised $10,000,000 in gross proceeds from a sale of 1,428,571 shares of unregistered common stock to Astellas Pharma Inc. for $7.00 per share in a private stock placement.&amp;#160;&amp;#160;Pursuant to the terms of the purchase agreement, we granted Astellas Pharma Inc. a two year right of first refusal to enter into a development and commercialization collaboration with us regarding the use of our technology, on a worldwide basis, for the treatment of liver conditions. In addition, we have agreed to use reasonable efforts to file a registration statement with the Securities and Exchange Commission to register the shares of common stock for resale upon the request of Astellas Pharma Inc.&amp;#160;&amp;#160;We also granted Astellas Pharma Inc. a non-voting observer seat on our Board of Directors and the right to designate a representative member to our Scientific Advisory Board.&amp;#160;&amp;#160;The $10,000,000 in total proceeds we received exceeded the market value of our stock at the completion of the purchase agreement.&amp;#160;&amp;#160;The $2,526,000 difference between the proceeds received and the fair market values of our common stock was recorded as a component of deferred revenues in the accompanying balance sheets.&amp;#160;&amp;#160;This difference was recorded as deferred revenue since, conceptually, the excess proceeds represent a value paid by Astellas Pharma Inc. attributable to the scientific advisory board seat, the non-voting observer seat on our Board of Directors, and the two year right of first refusal&amp;#160;&amp;#160;to enter into a development and commercialization collaboration with us regarding the use of our technology, on a worldwide basis, for the treatment of liver conditions, rather than an additional equity investment in Cytori.&amp;#160;&amp;#160;The recognition of this deferred amount is expected to occur upon the earlier of the expiration of the two year period or the termination of the agreement.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;On July 11, 2011, we entered into a common stock purchase agreement with Seaside 88, LP relating to the offering and sale of a total of up to 6,326,262 shares of our common stock.&amp;#160;&amp;#160;The agreement requires us to issue and Seaside to buy 1,326,262 shares of our common stock at an initial closing and 250,000 shares of our common stock once every two weeks, commencing 30 days after the initial closing, for up to an additional 20 closings, subject to the satisfaction of customary closing conditions. At the initial closing, the offering price was $4.52, which equaled to 88% of our common stock's volume-weighted average trading prices, or VWAP, during the ten-day trading period immediately prior to the initial closing date, raising approximately $6,000,000 in gross proceeds. At subsequent closings, the offering price will equal 90.25% of our common stock's volume-weighted average trading prices during the ten-day trading period immediately prior to each subsequent closing date.&amp;#160;&amp;#160;We raised approximately $17,684,000 in gross proceeds from the sale of 5,576,262 shares in our scheduled closings through March 31, 2012.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;div&gt;&lt;div style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 8pt;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Warrant Adjustments&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Our March 2009 offering of 4,771,174 shares of our common stock and warrants to purchase up to a total of 6,679,644 additional shares of our common stock with an exercise price of $2.59 per share, our May 2009 equity offering of 1,864,783 shares of our common stock and warrants to purchase up to a total of 3,263,380 additional shares of our common stock with an exercise price of $2.62 per share, our closings with Seaside 88, LP through March 31, 2012, our October 2010 offering of 4,600,000 shares of our common stock and our December 2010 sale of 1,428,571 shares of our common stock triggered an adjustment to the exercise price and number of shares issuable under the warrants issued to investors in our August 2008 private placement financing.&amp;#160;&amp;#160;As a result, as of March 31, 2012, the common stock warrants issued on August 11, 2008 are currently exercisable for 2,014,512 shares of our common stock at an exercise price of $5.75 per share.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Other Related Party Transactions&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;As of March 31, 2012 and December 31, 2011, Green Hospital Supply, Inc., our distribution partner in Japan and a related party, was a beneficial owner of 5.1% and 5.3%, respectively, of our outstanding shares of common stock.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;During the three months ended March 31, 2012 and 2011, we incurred approximately $27,000 and $28,000 in royalty costs in connection with our sales of our Celution&amp;#174; 800/CRS System products to the European and Asia-Pacific reconstructive surgery market, pursuant to our License and Royalty Agreement and the Amended License/Commercial Agreement with the Olympus-Cytori, Inc. joint venture, respectively.&amp;#160;&amp;#160;Additionally, during the three months ended March 31, 2012, we purchased second generation Celution &amp;#174; Systems and consumable sets from Olympus-Cytori, Inc. joint venture, at a formula-based transfer price aggregating to $1,048, 0000.&amp;#160;&amp;#160;As of March 31, 2012 and December 31, 2011, Olympus Corporation was a beneficial owner of 6.9% and 7.1%, respectively, of our outstanding shares of common stock and a beneficial owner of 50% of Olympus-Cytori, Inc. joint venture.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <!--Assets, Current-->
  <us-gaap:AssetsCurrent contextRef="c20120331" unitRef="U001" decimals="0">40333000</us-gaap:AssetsCurrent>
  <!--Assets, Current-->
  <us-gaap:AssetsCurrent contextRef="c20111231" unitRef="U001" decimals="0">43337000</us-gaap:AssetsCurrent>
  <!--Basic and diluted weighted average common shares (in shares)-->
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c20120101to20120331" unitRef="U002" decimals="0">57484990</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <!--Basic and diluted weighted average common shares (in shares)-->
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c20110101to20110331" unitRef="U002" decimals="0">51994708</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <!--Restricted cash and cash equivalents-->
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c20120331" unitRef="U001" decimals="0">350000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <!--Restricted cash and cash equivalents-->
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c20111231" unitRef="U001" decimals="0">350000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20120101to20120331" unitRef="U001" decimals="0">2836000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20110101to20110331" unitRef="U001" decimals="0">3047000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Assets-->
  <us-gaap:Assets contextRef="c20120331" unitRef="U001" decimals="0">49102000</us-gaap:Assets>
  <!--Assets-->
  <us-gaap:Assets contextRef="c20111231" unitRef="U001" decimals="0">51534000</us-gaap:Assets>
  <!--Investment Income, Interest-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20120101to20120331" unitRef="U001" decimals="0">2000</us-gaap:InvestmentIncomeInterest>
  <!--Investment Income, Interest-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20110101to20110331" unitRef="U001" decimals="0">2000</us-gaap:InvestmentIncomeInterest>
  <!--Disclosure of Compensation Related Costs, Share-based Payments [Text Block]-->
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="top" style="width: 3%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;9.&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="top" style="width: 93%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;Share-Based Compensation&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Stock Options&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;During the first quarter of 2012, we issued to our directors and executive officers options to purchase an aggregate of up to 690,000 shares of our common stock, with four-year vesting for our officers and two-year vesting for our directors. The grant date fair value of the awards granted to our officers was $2.10 per share and to our directors was $1.35 per share. The resulting share-based compensation expense of $1,373,000, net of estimated forfeitures, will be recognized as expense over the respective vesting periods.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;During the first quarter of 2011, we issued to our directors, executive officers and certain non-executive employees options to purchase an aggregate of up to 692,500 shares of our common stock, with four-year vesting for our officers and employees and two-year vesting for our directors. The grant date fair value of the awards granted to our officers and employees was $3.46 and to our directors was $3.15 per share. The resulting share-based compensation expense of $2,375,000, net of estimated forfeitures, will be recognized as expense over the respective vesting periods.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Restricted Stock Awards&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;During the first quarter of 2012, we issued to our executive officers 190,000 shares of restricted stock.&amp;#160;&amp;#160;The stock award is scheduled to fully vest on January 10, 2013, subject to the officer's continued employment with the Company through the vesting date.&amp;#160;&amp;#160;The resulting share-based compensation expense of $654,000 will be recognized as expense over the respective vesting period.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Performance-Based Restricted Stock Awards&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;We granted 246,225 performance-based restricted stock awards under the 2004 Equity Incentive Plan in February 2011.&amp;#160;&amp;#160;The awards provide certain employees until January 1, 2012 to achieve certain performance goals established by the Compensation Committee. The performance goals were weighted based on the following achievements: obtaining certain FDA clearance or approval (40%), achieving a targeted revenue increase for the fiscal year ended December 31, 2011 (20%), and entering into a major collaboration for development and/or commercialization of the Company's products (40%).&amp;#160;&amp;#160;To the extent that any of the performance goals were partially achieved, the Compensation Committee maintained the discretion to continue the vesting of all or a portion of the awards following January 1, 2012.&amp;#160;&amp;#160;Once earned, the awards would have remained unvested until January 1, 2013. Termination of employment prior to vesting would have resulted in the forfeiture of any earned (as well as unearned) awards. Effective January 2012, the outstanding awards were terminated in their entirety based upon the decision by the Compensation Committee that performance criteria had not been met as of January 1, 2012.&amp;#160;&amp;#160;No compensation expense was recognized related to these awards during the three months ended March 31, 2012 and 2011.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;In January 2012, we granted 276,375 performance-based restricted stock awards under the 2004 Equity Incentive Plan.&amp;#160;&amp;#160;The awards provide certain employees until December 31, 2012 to achieve certain performance goals established by the Compensation Committee. The performance goals are weighted based on the following achievements: entering into a major collaboration for development and/or commercialization of the Company's products (40%), obtaining certain FDA clearance or approvals, which include FDA approval for and initiation of the ATHENA feasibility trial in chronic myocardial ischemia (40%), obtaining CE mark for certain products (15%), and achieving a targeted revenue increase for the fiscal year ended December 31, 2012 (5%).&amp;#160;&amp;#160;To the extent that any of the performance goals are partially achieved, the Compensation Committee maintains the discretion to continue the vesting of all or a portion of the awards following December 31, 2012.&amp;#160;&amp;#160;Once earned, the awards will remain unvested until January 10, 2014. Termination of employment prior to vesting will result in the forfeiture of the awards.&amp;#160;&amp;#160;No compensation expense was recognized related to these awards during the three months ended March 31, 2012.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;The following table summarizes activity with respect to the performance based restricted stock awards during the three months ended March 31, 2012:&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;table cellpadding="0" cellspacing="0" style="text-align: center; width: 90%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr style="text-align: center;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 66%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Restricted Stock &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Awards&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Weighted &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Average Grant-&lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Date Fair Value&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Outstanding at January 1, 2012&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;246,225&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;5.82&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Granted&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;276,375&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;3.44&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Vested&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;0&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Cancelled/forfeited&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(246,225 &lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;5.82&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Outstanding at March 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;276,375&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; padding-bottom: 4px; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;3.44&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Vested at March 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;0&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <!--Fair Value, Measurement Inputs, Disclosure [Table Text Block]-->
  <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="top" style="width: 3%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;13.&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="top" style="width: 93%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Fair value measurements are market-based measurements, not entity-specific measurements.&amp;#160;&amp;#160;Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability.&amp;#160;&amp;#160;We follow a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values.&amp;#160;&amp;#160;The basis for fair value measurements for each level within the hierarchy is described below:&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 9pt; display: block; margin-left: 18pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;#183;&lt;/font&gt;&lt;font style="display: inline; font-family: Times New Roman; font-size: 10pt;"&gt;Level 1: Quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 9pt; display: block; margin-left: 9pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;#183;&lt;/font&gt;&lt;font style="display: inline; font-family: Times New Roman; font-size: 10pt;"&gt;Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 9pt; display: block; margin-left: 9pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;#183;&lt;/font&gt;&lt;font style="display: inline; font-family: Times New Roman; font-size: 10pt;"&gt;Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;The following table provides a summary of the recognized assets and liabilities that we measure at fair value on a recurring basis:&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="padding-bottom: 2px; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Balance as of&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 34%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Basis of Fair Value Measurements&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;March 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Level 1&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Level 2&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Level 3&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Assets:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Cash equivalents&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;26,646,000&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;26,646,000&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td valign="bottom" style="width: 42%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Put option liability&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(1,640,000&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(1,640,000&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Warrant liability&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(757,000&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(757,000&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="padding-bottom: 2px; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Balance as of&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 34%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Basis of Fair Value Measurements&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;December 31, 2011&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Level 1&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Level 2&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Level 3&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Assets:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Cash equivalents&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;30,646,000&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;30,646,000&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td valign="bottom" style="width: 42%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Put option liability&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(1,910,000&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(1,910,000&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Warrant liability&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(627,000&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(627,000&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;a name="FIS_UNIDENTIFIED_TABLE_7"&gt;&lt;/a&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;We use quoted market prices to determine the fair value of our cash equivalents, which consist of money market funds that are classified in Level 1 of the fair value hierarchy.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;We value our put liability using an option pricing theory based simulation analysis (i.e., a Monte Carlo simulation) (see note 12). Because some of the inputs to our valuation model are either not observable quoted prices or are not derived principally from or corroborated by observable market data by correlation or other means, the put option liability is classified as Level 3 in the fair value hierarchy.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;The following table summarizes the change in our Level 3 put option liability value:&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;table cellpadding="0" cellspacing="0" style="text-align: center; width: 80%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr style="text-align: center;"&gt;&lt;td valign="bottom" style="width: 68%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Three months ended&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="border-bottom: black 2px solid; width: 68%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Put option liability&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;March 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 68%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 68%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Beginning balance&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(1,910,000 &lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 68%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Decrease in fair value recognized in operating expenses&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;270,000&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 68%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Ending balance&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(1.640,000 &lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;&lt;a name="FIS_UNIDENTIFIED_TABLE_8"&gt;&lt;/a&gt;Common stock purchase warrants issued in connection with our August 2008 private equity placement do not trade in an active securities market, and as such, we estimate the fair value of these warrants using the option pricing model.&amp;#160;&amp;#160;Some of the significant inputs are observable in active markets, such as common stock market price, volatility, and risk free rate.&amp;#160;&amp;#160;The fair value of these warrants also incorporate our assumptions about future equity issuances and their impact to the down-round protection feature. Because some of the inputs to our valuation model are either not observable quoted prices or are not derived principally from or corroborated by observable market data by correlation or other means, the warrant liability is classified as Level 3 in the fair value hierarchy.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;The following table summarizes the change in our Level 3 warrant liability value:&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;table cellpadding="0" cellspacing="0" style="text-align: center; width: 80%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr style="text-align: center;"&gt;&lt;td valign="bottom" style="width: 68%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Three months ended&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="border-bottom: black 2px solid; width: 68%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Warrant liability&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;March 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 68%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 68%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Beginning balance&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(627,000 &lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 68%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Decrease (increase)&amp;#160;&amp;#160;in fair value recognized in operating expenses&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(130,000 &lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 68%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Ending balance&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(757,000 &lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;No other assets or liabilities are measured at fair value on a recurring basis, or have been measured at fair value on a non-recurring basis subsequent to initial recognition, on the accompanying consolidated condensed balance sheet as of March 31, 2012.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
  <!--Capital equipment lease-->
  <us-gaap:CapitalLeaseObligationsIncurred contextRef="c20120101to20120331" unitRef="U001" decimals="0">0</us-gaap:CapitalLeaseObligationsIncurred>
  <!--Capital equipment lease-->
  <us-gaap:CapitalLeaseObligationsIncurred contextRef="c20110101to20110331" unitRef="U001" decimals="0">101000</us-gaap:CapitalLeaseObligationsIncurred>
  <!--Fair Value Disclosures [Text Block]-->
  <us-gaap:FairValueDisclosuresTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="top" style="width: 3%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;14.&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="top" style="width: 93%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;Fair Value&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Financial Instruments&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;We disclose fair value information about all financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate fair value. The disclosures of estimated fair value of financial instruments at March 31, 2012 and December 31, 2011, were determined using available market information and appropriate valuation methods. Considerable judgment is necessary to interpret market data and develop estimated fair value. The use of different market assumptions or estimation methods may have a material effect on the estimated fair value amounts.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;The carrying amounts for cash and cash equivalents, accounts receivable, inventories, other current assets, accounts payable, accrued expenses and other liabilities approximate fair value due to the short-term nature of these instruments.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;We utilize quoted market prices to estimate the fair value of our fixed rate debt, when available.&amp;#160;&amp;#160;If quoted market prices are not available, we calculate the fair value of our fixed rate debt based on a currently available market rate assuming the loans are outstanding through maturity and considering the collateral. In determining the current market rate for fixed rate debt, a market spread is added to the quoted yields on federal government treasury securities with similar terms to the debt.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;At March 31, 2012 and December 31, 2011, the aggregate fair value and the carrying value of the Company's fixed rate long-term debt were as follows:&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;table cellpadding="0" cellspacing="0" style="text-align: center; width: 90%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr style="text-align: center;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 22%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;March 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 22%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;December 31, 2011&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 42%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Fair Value&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Carrying Value&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Fair Value&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Carrying Value&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 42%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Fixed rate long-term debt&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;24,306,000&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;24,512,000&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;24,211,000&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;24,341,000&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 18pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;Carrying value is net of debt discount of $1,613,000 and $1,847,000 as of March 31, 2012 and December 31, 2011, respectively.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <!--Deferred Revenue-->
  <us-gaap:DeferredRevenue contextRef="c20120331" unitRef="U001" decimals="0">5176000</us-gaap:DeferredRevenue>
  <!--Deferred Revenue-->
  <us-gaap:DeferredRevenue contextRef="c20111231" unitRef="U001" decimals="0">5244000</us-gaap:DeferredRevenue>
  <!--Other Assets, Noncurrent-->
  <us-gaap:OtherAssetsNoncurrent contextRef="c20120331" unitRef="U001" decimals="0">1794000</us-gaap:OtherAssetsNoncurrent>
  <!--Other Assets, Noncurrent-->
  <us-gaap:OtherAssetsNoncurrent contextRef="c20111231" unitRef="U001" decimals="0">1772000</us-gaap:OtherAssetsNoncurrent>
  <!--Operating Expenses-->
  <us-gaap:OperatingExpenses contextRef="c20120101to20120331" unitRef="U001" decimals="0">8996000</us-gaap:OperatingExpenses>
  <!--Operating Expenses-->
  <us-gaap:OperatingExpenses contextRef="c20110101to20110331" unitRef="U001" decimals="0">12998000</us-gaap:OperatingExpenses>
  <!--Deferred Rent Credit, Noncurrent-->
  <us-gaap:DeferredRentCreditNoncurrent contextRef="c20120331" unitRef="U001" decimals="0">498000</us-gaap:DeferredRentCreditNoncurrent>
  <!--Deferred Rent Credit, Noncurrent-->
  <us-gaap:DeferredRentCreditNoncurrent contextRef="c20111231" unitRef="U001" decimals="0">504000</us-gaap:DeferredRentCreditNoncurrent>
  <!--Common stock, par value (in dollars per share)-->
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c20120331" unitRef="U003" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Common stock, par value (in dollars per share)-->
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c20111231" unitRef="U003" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Stockholders' Equity Attributable to Parent-->
  <us-gaap:StockholdersEquity contextRef="c20120331" unitRef="U001" decimals="0">6850000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-->
  <us-gaap:StockholdersEquity contextRef="c20111231" unitRef="U001" decimals="0">9946000</us-gaap:StockholdersEquity>
  <!--Preferred stock, $0.001 par value; 5,000,000 shares authorized; -0- shares issued and outstanding in 2012 and 2011-->
  <us-gaap:PreferredStockValue contextRef="c20120331" unitRef="U001" decimals="0">0</us-gaap:PreferredStockValue>
  <!--Preferred stock, $0.001 par value; 5,000,000 shares authorized; -0- shares issued and outstanding in 2012 and 2011-->
  <us-gaap:PreferredStockValue contextRef="c20111231" unitRef="U001" decimals="0">0</us-gaap:PreferredStockValue>
  <!--Long-term Debt [Text Block]-->
  <us-gaap:LongTermDebtTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="top" style="width: 3%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;6.&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="top" style="width: 93%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;Long-term Debt&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;On September 9, 2011 we entered into a Second Amendment to the Amended and Restated Loan and Security Agreement (loan agreement) with General Electric Capital Corporation (GECC), Silicon Valley Bank (SVB) and Oxford Finance Corporation (together, the "Lenders"), pursuant to which the Lenders increased the prior term loan made to the Company to a principal amount of $25.0 million (Term Loan), subject to the terms and conditions set forth in the loan agreement.&amp;#160;&amp;#160;The Term Loan accrues interest at a fixed rate of 9.87% per annum.&amp;#160;&amp;#160;Pursuant to the loan agreement, we are required to make (i) twelve (12) equal consecutive monthly principal payments of $20,833 on the first day of each calendar month, commencing on October 1, 2011, (ii) twenty-nine (29) equal consecutive monthly principal payments of $825,000 on the first day of each calendar month, commencing on October 1, 2012, and (iii) and one (1) final principal payment of $825,000 on March 1, 2015. In addition, the maturity date of the Term Loan has been extended until March 1, 2015, and at maturity of the Term Loan, the Company will make a final payment fee equal to 5% ($1,250,000) of the Term Loan.&amp;#160;&amp;#160;We may incur additional fees if we elect to prepay the Term Loan.&amp;#160;&amp;#160;In connection with the Term Loan, on September 9, 2011, we issued to the Lenders warrants to purchase up to an aggregate of 132,891 shares of our common stock at an exercise price of $3.01 per share.&amp;#160;&amp;#160;These warrants are immediately exercisable and will expire on September 9, 2018.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;The Term Loan amended the Amended and Restated Loan and Security Agreement, of which an aggregate balance of approximately $15.6 million remained outstanding along with a prorated final payment fee of $419,000. The net proceeds of the Term Loan, after payment of lender fees and expenses, were approximately $8.6 million.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;We accounted for this amendment as debt modification since the terms of the amended Term Loan and the Original Term Loan were not substantially different and as present value of cash flows of the modified instrument (using a net method of comparing the present value of cash flows related to the lowest common principal balance between the old and the new loans) was within 10% of the original debt instrument.&amp;#160;&amp;#160;Accordingly, the fees associated with the amended Term Loan of $300,000, final payment fee of $1,250,000, and the existing unamortized debt discount from the Original Term Loan of $332,000 will be amortized as an adjustment of interest expense over the term of the Amended Term Loan using the effective interest method.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;We allocated the aggregate proceeds of the Term Loan between the warrants and the debt obligations based on their relative fair values.&amp;#160;&amp;#160;The fair value of the warrants issued to the Lenders is calculated utilizing the Black-Scholes option-pricing model. We are amortizing the relative fair value of the warrants as a discount of $267,000 over the term of the loan using the effective interest method, with an effective interest rate of 13.63%. If the maturity of the debt is accelerated due to an event of default, then the amortization would be accelerated. The Term Loan is collateralized by the tangible assets of the company, including a security interest in substantially all of its existing and after-acquired assets, excluding its intellectual property assets; provided however, that if the Company does not maintain certain cash ratios, the security interest automatically will be deemed to include the Company's intellectual property assets.&amp;#160;&amp;#160;As of March 31, 2012, we were in compliance with our financial and non-financial covenants.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
  <!--Earnings Per Share [Text Block]-->
  <us-gaap:EarningsPerShareTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="top" style="width: 3%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;&lt;a name="fis_unidentified_table_5"&gt;&lt;/a&gt;10.&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="top" style="width: 93%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;Loss per Share&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but unexercised options, warrants, restricted stock and performance based restricted stock awards for all periods presented.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;We have excluded all potentially dilutive securities from the calculation of diluted loss per share attributable to common stockholders for the three months ended March 31, 2012 and 2011, as their inclusion would be antidilutive.&amp;#160;&amp;#160;Potentially dilutive common shares excluded from the calculations of diluted loss per share were 18,544,087 and 19,649,383 for the three month periods ended March 31, 2012 and 2011, respectively.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <!--Depreciation and amortization-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20120101to20120331" unitRef="U001" decimals="0">220000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Depreciation and amortization-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20110101to20110331" unitRef="U001" decimals="0">194000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Commitments and contingencies-->
  <us-gaap:CommitmentsAndContingencies contextRef="c20120331" unitRef="U001" xsi:nil="true" />
  <!--Commitments and contingencies-->
  <us-gaap:CommitmentsAndContingencies contextRef="c20111231" unitRef="U001" xsi:nil="true" />
  <!--Accounts Payable and Accrued Liabilities, Current-->
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c20120331" unitRef="U001" decimals="0">6046000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <!--Accounts Payable and Accrued Liabilities, Current-->
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c20111231" unitRef="U001" decimals="0">5334000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <!--Net increase in purchases of property and equipment included in accounts payable-->
  <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="c20120101to20120331" unitRef="U001" decimals="0">795000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
  <!--Net increase in purchases of property and equipment included in accounts payable-->
  <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="c20110101to20110331" unitRef="U001" decimals="0">0</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
  <!--Amendment Flag-->
  <dei:AmendmentFlag contextRef="c20120101to20120331">false</dei:AmendmentFlag>
  <!--Current Fiscal Year End Date-->
  <dei:CurrentFiscalYearEndDate contextRef="c20120101to20120331">--12-31</dei:CurrentFiscalYearEndDate>
  <!--Document Period End Date-->
  <dei:DocumentPeriodEndDate contextRef="c20120101to20120331">2012-03-31</dei:DocumentPeriodEndDate>
  <!--Entity Well-known Seasoned Issuer-->
  <dei:EntityWellKnownSeasonedIssuer contextRef="c20120101to20120331">No</dei:EntityWellKnownSeasonedIssuer>
  <!--Entity Voluntary Filers-->
  <dei:EntityVoluntaryFilers contextRef="c20120101to20120331">No</dei:EntityVoluntaryFilers>
  <!--Entity Current Reporting Status-->
  <dei:EntityCurrentReportingStatus contextRef="c20120101to20120331">Yes</dei:EntityCurrentReportingStatus>
  <!--Entity Filer Category-->
  <dei:EntityFilerCategory contextRef="c20120101to20120331">Accelerated Filer</dei:EntityFilerCategory>
  <!--Entity Public Float-->
  <dei:EntityPublicFloat contextRef="c20110630" unitRef="U001" decimals="0">227294414</dei:EntityPublicFloat>
  <!--Entity Registrant Name-->
  <dei:EntityRegistrantName contextRef="c20120101to20120331">CYTORI THERAPEUTICS, INC.</dei:EntityRegistrantName>
  <!--Entity Central Index Key-->
  <dei:EntityCentralIndexKey contextRef="c20120101to20120331">0001095981</dei:EntityCentralIndexKey>
  <!--Entity Common Stock, Shares Outstanding-->
  <dei:EntityCommonStockSharesOutstanding contextRef="c20120430" unitRef="U002" decimals="0">58686448</dei:EntityCommonStockSharesOutstanding>
  <!--Document Fiscal Year Focus-->
  <dei:DocumentFiscalYearFocus contextRef="c20120101to20120331">2012</dei:DocumentFiscalYearFocus>
  <!--Document Fiscal Period Focus-->
  <dei:DocumentFiscalPeriodFocus contextRef="c20120101to20120331">Q1</dei:DocumentFiscalPeriodFocus>
  <!--Document Type-->
  <dei:DocumentType contextRef="c20120101to20120331">10-Q</dei:DocumentType>
  <!--Deferred revenues, related party-->
  <cytx:DeferredRevenuesRelatedParty contextRef="c20120331" unitRef="U001" decimals="0">3520000</cytx:DeferredRevenuesRelatedParty>
  <!--Deferred revenues, related party-->
  <cytx:DeferredRevenuesRelatedParty contextRef="c20111231" unitRef="U001" decimals="0">3520000</cytx:DeferredRevenuesRelatedParty>
  <!--Warrant Liability-->
  <cytx:WarrantLiability contextRef="c20120331" unitRef="U001" decimals="0">757000</cytx:WarrantLiability>
  <!--Warrant Liability-->
  <cytx:WarrantLiability contextRef="c20111231" unitRef="U001" decimals="0">627000</cytx:WarrantLiability>
  <!--Option Liability-->
  <cytx:OptionLiability contextRef="c20120331" unitRef="U001" decimals="0">1640000</cytx:OptionLiability>
  <!--Option Liability-->
  <cytx:OptionLiability contextRef="c20111231" unitRef="U001" decimals="0">1910000</cytx:OptionLiability>
  <!--Development related party-->
  <cytx:DevelopmentRelatedParty contextRef="c20120101to20120331" unitRef="U001" decimals="0">0</cytx:DevelopmentRelatedParty>
  <!--Development related party-->
  <cytx:DevelopmentRelatedParty contextRef="c20110101to20110331" unitRef="U001" decimals="0">1231000</cytx:DevelopmentRelatedParty>
  <!--Research grants and other-->
  <cytx:ResearchGrantsAndOther contextRef="c20120101to20120331" unitRef="U001" decimals="0">3000</cytx:ResearchGrantsAndOther>
  <!--Research grants and other-->
  <cytx:ResearchGrantsAndOther contextRef="c20110101to20110331" unitRef="U001" decimals="0">4000</cytx:ResearchGrantsAndOther>
  <!--Total Development Revenues-->
  <cytx:TotalDevelopmentRevenues contextRef="c20120101to20120331" unitRef="U001" decimals="0">3000</cytx:TotalDevelopmentRevenues>
  <!--Total Development Revenues-->
  <cytx:TotalDevelopmentRevenues contextRef="c20110101to20110331" unitRef="U001" decimals="0">1235000</cytx:TotalDevelopmentRevenues>
  <!--Change in fair value of warrants-->
  <cytx:ChangeInFairValueOfWarrants contextRef="c20120101to20120331" unitRef="U001" decimals="0">130000</cytx:ChangeInFairValueOfWarrants>
  <!--Change in fair value of warrants-->
  <cytx:ChangeInFairValueOfWarrants contextRef="c20110101to20110331" unitRef="U001" decimals="0">3471000</cytx:ChangeInFairValueOfWarrants>
  <!--Change in fair value of option liability-->
  <cytx:ChangeInFairValueOfOptionLiability contextRef="c20120101to20120331" unitRef="U001" decimals="0">-270000</cytx:ChangeInFairValueOfOptionLiability>
  <!--Change in fair value of option liability-->
  <cytx:ChangeInFairValueOfOptionLiability contextRef="c20110101to20110331" unitRef="U001" decimals="0">-290000</cytx:ChangeInFairValueOfOptionLiability>
  <!--Change In Fair Value Of Options-->
  <cytx:ChangeInFairValueOfOptions contextRef="c20120101to20120331" unitRef="U001" decimals="0">-270000</cytx:ChangeInFairValueOfOptions>
  <!--Change In Fair Value Of Options-->
  <cytx:ChangeInFairValueOfOptions contextRef="c20110101to20110331" unitRef="U001" decimals="0">-290000</cytx:ChangeInFairValueOfOptions>
  <!--Increase Decrease Other Current Assets-->
  <cytx:IncreaseDecreaseOtherCurrentAssets contextRef="c20120101to20120331" unitRef="U001" decimals="0">298000</cytx:IncreaseDecreaseOtherCurrentAssets>
  <!--Increase Decrease Other Current Assets-->
  <cytx:IncreaseDecreaseOtherCurrentAssets contextRef="c20110101to20110331" unitRef="U001" decimals="0">130000</cytx:IncreaseDecreaseOtherCurrentAssets>
  <!--Increase Decrease Other Assets-->
  <cytx:IncreaseDecreaseOtherAssets contextRef="c20120101to20120331" unitRef="U001" decimals="0">22000</cytx:IncreaseDecreaseOtherAssets>
  <!--Increase Decrease Other Assets-->
  <cytx:IncreaseDecreaseOtherAssets contextRef="c20110101to20110331" unitRef="U001" decimals="0">922000</cytx:IncreaseDecreaseOtherAssets>
  <!--Increase Decrease Deferred Revenue Related Party-->
  <cytx:IncreaseDecreaseDeferredRevenueRelatedParty contextRef="c20120101to20120331" unitRef="U001" decimals="0">0</cytx:IncreaseDecreaseDeferredRevenueRelatedParty>
  <!--Increase Decrease Deferred Revenue Related Party-->
  <cytx:IncreaseDecreaseDeferredRevenueRelatedParty contextRef="c20110101to20110331" unitRef="U001" decimals="0">1231000</cytx:IncreaseDecreaseDeferredRevenueRelatedParty>
  <!--Increase Decrease Of Deferred Revenue-->
  <cytx:IncreaseDecreaseOfDeferredRevenue contextRef="c20120101to20120331" unitRef="U001" decimals="0">68000</cytx:IncreaseDecreaseOfDeferredRevenue>
  <!--Increase Decrease Of Deferred Revenue-->
  <cytx:IncreaseDecreaseOfDeferredRevenue contextRef="c20110101to20110331" unitRef="U001" decimals="0">10000</cytx:IncreaseDecreaseOfDeferredRevenue>
  <!--Increase Decrease Long Term Deferred Rent Liabiilty-->
  <cytx:IncreaseDecreaseLongTermDeferredRentLiabiilty contextRef="c20120101to20120331" unitRef="U001" decimals="0">6000</cytx:IncreaseDecreaseLongTermDeferredRentLiabiilty>
  <!--Increase Decrease Long Term Deferred Rent Liabiilty-->
  <cytx:IncreaseDecreaseLongTermDeferredRentLiabiilty contextRef="c20110101to20110331" unitRef="U001" decimals="0">12000</cytx:IncreaseDecreaseLongTermDeferredRentLiabiilty>
  <!--Proceeds from exercise of employee stock options and warrants-->
  <cytx:ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants contextRef="c20120101to20120331" unitRef="U001" decimals="0">947000</cytx:ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants>
  <!--Proceeds from exercise of employee stock options and warrants-->
  <cytx:ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants contextRef="c20110101to20110331" unitRef="U001" decimals="0">674000</cytx:ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants>
  <!--Use Of Estimates [Text Block]-->
  <cytx:UseOfEstimatesTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="top" style="width: 3%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;2.&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="top" style="width: 93%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;Use of Estimates&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period.&amp;#160;&amp;#160;Our most significant estimates and critical accounting policies involve recognizing revenue, evaluating goodwill for impairment, valuing our put option arrangement with Olympus Corporation, valuing warrants, determining the assumptions used in measuring share-based compensation expense and valuing allowances for doubtful accounts and inventories.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Actual results could differ from these estimates.&amp;#160;&amp;#160;Current economic conditions, including illiquid credit markets and volatile equity markets, contribute to the inherent uncertainty of such estimates.&amp;#160;&amp;#160;Management's estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the consolidated financial statements in the periods they are determined to be necessary.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;</cytx:UseOfEstimatesTextBlock>
  <!--Capital Availability [Text Block]-->
  <cytx:CapitalAvailabilityTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="top" style="width: 3%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;3.&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="top" style="width: 93%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;Capital Availability&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;We incurred net losses of $9,325,000 and $12,072,000 for the three months ended March 31, 2012 and 2011, respectively.&amp;#160;&amp;#160;We have an accumulated deficit of $251,774,000 as of March 31, 2012.&amp;#160;&amp;#160;Additionally, we have used net cash of $7,714,000 and $10,564,000 to fund our operating activities for the three months ended March 31, 2012 and 2011, respectively&lt;font style="display: inline; font-weight: bold;"&gt;.&amp;#160;&amp;#160;&lt;/font&gt;To date, these operating losses have been funded primarily from outside sources of invested capital.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Management recognizes the need to generate positive cash flows in future periods and/or to obtain additional capital from various sources. In the continued absence of positive cash flows from operations, no assurance can be given that we can generate sufficient revenue to cover operating costs or that additional financing will be available to us and, if available, on terms acceptable to us in the future.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;During 2011, we expanded our commercialization activities while simultaneously pursuing available financing sources to support operations and growth.&amp;#160;&amp;#160;We have had, and we will likely continue to have, an ongoing need to raise additional cash from outside sources to fund our operations for remainder of 2012 and beyond.&amp;#160;&amp;#160;If we cannot do so when required, we would need to reduce our research, development, and administrative operations, including reductions of our employee base, in order to offset lack of available funding.&amp;#160;&amp;#160;&amp;#160;We continue to evaluate available financing opportunities as part of our normal course of business.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;</cytx:CapitalAvailabilityTextBlock>
  <!--Warrant Liability [Text Block]-->
  <cytx:WarrantLiabilityTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="top" style="width: 3%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;5.&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="top" style="width: 93%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;Warrant Liability&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Warrants with exercise price reset features (down-round protection) are accounted for as liabilities, with changes in fair value included in net earnings (loss).&amp;#160;&amp;#160;The fair value of the liability associated with the warrants with this reset feature increased to $757,000 as of March 31, 2012, which resulted in a $130,000 loss from the change in fair value of warrants for the three months ended March 31, 2012.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Since these warrants do not qualify for hedge accounting, all future changes in the fair value of the warrants will be recognized currently in earnings until such time as the warrants are exercised or expire. These warrants are not traded in an active securities market, and as such, we estimated the fair value of these warrants using an option pricing model with the following assumptions:&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;a name="FIS_UNIDENTIFIED_TABLE_3"&gt;&lt;/a&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 80%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;"&gt;March 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;"&gt;As of&lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;"&gt;December 31, 2011&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Expected term&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 1.8pt;"&gt;1.37 years&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 1.8pt;"&gt;1.61 years&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Common stock market price&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;2.49&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;2.20&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;0.26&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;0.19&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;71.61&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;69.98&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Resulting fair value (per warrant)&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;0.38&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 9%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;0.32&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Expected volatility is based primarily on historical volatility. Historical volatility was computed using daily pricing observations for recent periods that correspond to the expected term of the warrants. We believe this method produces an estimate that is representative of our expectations of future volatility over the expected term of these warrants. We currently have no reason to believe future volatility over the expected remaining life of these warrants is likely to differ materially from historical volatility. The expected life is based on the remaining contractual term of the warrants. The risk-free interest rate is the interest rate for treasury constant maturity instruments published by the Federal Reserve Board that is closest to the expected term of the warrants.&amp;#160;&amp;#160;&amp;#160;The fair value of these warrants also incorporates our assumptions about future equity issuances and their impact to the down-round protection feature.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;</cytx:WarrantLiabilityTextBlock>
  <!--Revenue Recognition [Text Block]-->
  <cytx:RevenueRecognitionTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="top" style="width: 3%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;7.&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="top" style="width: 93%;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"&gt;Revenue Recognition&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Product Sales&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;We recognize revenue from product sales when the following fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred, (iii) the price to the customer is fixed or determinable and (iv) collection of the resulting accounts receivable is reasonably assured.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;For all sales, we use a binding purchase order or a signed agreement as evidence of an arrangement.&amp;#160;&amp;#160;Revenue for these product sales is recognized upon delivery to the customer, as all risks and rewards of ownership have been substantively transferred to the customer at that point.&amp;#160;&amp;#160;For sales to customers who arrange for and manage the shipping process, we recognize revenue upon shipment from our facilities.&amp;#160;&amp;#160;Shipping and handling costs that are billed to our customers are classified as revenue.&amp;#160;&amp;#160;The customer's obligation to pay and the payment terms are set at the time of delivery and are not dependent on the subsequent use or resale of our products.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;For sales that include multiple deliverables, such as sales of our StemSource&amp;#174; Cell Bank (cell bank), we allocate arrangement consideration at the inception of the arrangement to all deliverables using the relative selling price method.&amp;#160;&amp;#160;Stem cell banks typically consist of a complex array of equipment, proprietary knowledge, and services, including one or more StemSource&amp;#174; devices, a cryogenic freezer, measuring and monitoring equipment, and a database patient tracking system. In addition, we typically provide consulting services, installation and training services concurrent with the installation of the cell bank.&amp;#160;&amp;#160;Web hosting and technical and maintenance services are generally provided for a period of up to one year subsequent to the date of sale.&amp;#160;&amp;#160;FASB authoritative guidance establishes a selling price hierarchy for determining the selling price of a deliverable, which is based on: (a) vendor-specific objective evidence ("VSOE"); (b) third-party evidence ("TPE"); or (c) management estimates.&amp;#160;&amp;#160;For our cell bank sales, we establish relative selling prices for all deliverables based on vendor-specific quotes for comparable services when available.&amp;#160;&amp;#160;In the absence of VSOE, we use competitors' products or services considered largely interchangeable with our own or management's best estimate.&amp;#160;&amp;#160;A substantial amount of consulting services are provided to customers before the equipment installation and training has been completed, and therefore we treat this as a separate unit of accounting.&amp;#160;&amp;#160;The equipment with installation and initial training activities are treated as separate units of accounting.&amp;#160;&amp;#160;Also of standalone value to customers is the transfer of the proprietary knowledge, most notably in the form of standard operating procedures, and any license or exclusivity rights associated with the agreements.&amp;#160;&amp;#160;Revenue for the various deliverables is calculated and recognized based on the relative selling prices of each deliverable.&amp;#160;&amp;#160;Future services such as web hosting and ongoing maintenance are deferred and recognized into income during the year following the installation.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; font-style: italic; text-indent: 18pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;Concentration of Significant Customers&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;For the three months ended March 31, 2012, two direct customers comprised 31% of our revenue recognized for the quarter.&amp;#160;&amp;#160;Our Asia-Pacific, North America and Australia region sales accounted for 69% of our revenue recognized for the three months ended March 31, 2012.&amp;#160;&amp;#160;Additionally, two direct customers accounted for 29% of total outstanding accounts receivable as of March 31, 2012.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;For the three months ended March 31, 2011, one direct customer and one distributor comprised 29% of our revenue recognized for the quarter.&amp;#160;&amp;#160;Our Asia-Pacific region sales accounted for 30% of our revenue recognized for the three months ended March 31, 2011.&amp;#160;&amp;#160;Additionally, one distributor and two direct customers accounted for 43% of total outstanding accounts receivable as of March 31, 2011.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; font-style: italic; text-indent: 18pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;Research and Development&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;We earn revenue for performing tasks under research and development agreements with both commercial enterprises, such as Olympus and Senko, and governmental agencies like the National Institutes of Health ("NIH").&amp;#160;&amp;#160;Revenue earned under development agreements is classified as either research grant or development revenues depending on the nature of the arrangement.&amp;#160;&amp;#160;Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with grants are recorded as research grant and other within development revenues.&amp;#160;&amp;#160;Research grant revenue is recorded at the gross amount of the reimbursement.&amp;#160;&amp;#160;The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations.&amp;#160;&amp;#160;Additionally, research and development arrangements we have with commercial enterprises such as Olympus and Senko are considered a key component of our central and ongoing operations.&amp;#160;&amp;#160;Accordingly, when recognized, the inflows from such arrangements are presented as revenues in our statements of operations.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;We received funds from Olympus and Olympus-Cytori, Inc. during 2005 and 2006.&amp;#160;&amp;#160;&amp;#160;We recorded upfront fees totaling $28,311,000 as deferred revenues, related party.&amp;#160;&amp;#160;In exchange for these proceeds, we agreed to (a) provide Olympus-Cytori, Inc. an exclusive and perpetual license to our Celution&amp;#174; System device technology and certain related intellectual property, and (b) provide future development contributions related to commercializing the Celution&amp;#174; System platform.&amp;#160;&amp;#160;The license and development services are not separable and as a result the recognition of this deferred amount requires achievement of service related milestones, under a proportional performance methodology.&amp;#160;&amp;#160;If and as such revenues are recognized, deferred revenue will be decreased.&amp;#160;&amp;#160;Proportional performance methodology was elected due to the nature of our development obligations and efforts in support of the Joint Venture ("JV"), including product development activities and regulatory efforts to support the commercialization of the JV products. The application of this methodology uses the achievement of R&amp;amp;D milestones as outputs of value to the JV.&amp;#160;&amp;#160;We received up-front, non-refundable payments in connection with these development obligations, which we have broken down into specific R&amp;amp;D milestones that are definable and substantive in nature, and which will result in value to the JV when achieved.&amp;#160;&amp;#160;As our research and development efforts progress, we periodically evaluate,&amp;#160;&amp;#160;and modify if necessary, the milestone points in our proportional performance model to ensure that revenue recognition accurately reflects our best estimate of substantive value deliverable to the JV.&amp;#160;&amp;#160;Revenue will be recognized as the above mentioned R&amp;amp;D milestones are completed.&amp;#160;&amp;#160;Of the amounts received and deferred, we recognized development revenues of $1,231,000 for the three months ended March 31, 2011.&amp;#160;&amp;#160;There was no development revenues recognized for the three months ended March 31, 2012.&amp;#160;&amp;#160;All related development costs are expensed as incurred and are included in research and development expense on our statements of operations.&amp;#160;&amp;#160;To date under the contract, of the $28,311,000 originally deferred, we have recognized a total of $24,791,000 through March 31, 2012.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-size: 10pt;"&gt;Under a Distribution Agreement with Senko, we granted to Senko an exclusive license to sell and distribute certain Thin Film products in Japan.&amp;#160;&amp;#160;We have also earned or will be entitled to earn additional payments under the Distribution Agreement based on achieving certain defined and substantive research and development milestones.&lt;/font&gt;&amp;#160;&amp;#160;&lt;font style="display: inline; font-size: 10pt;"&gt;There was no development revenue recognized related to this agreement during the three months ended March 31, 2012 and 2011, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;</cytx:RevenueRecognitionTextBlock>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cytx-20120331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Thomson Reuters Accelus-->
<xs:schema targetNamespace="http://cytori.com/20120331" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:cytx="http://cytori.com/20120331" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="cytx-20120331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cytx-20120331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cytx-20120331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://cytori.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytori.com/role/ConsolidatedCondensedBalanceSheetsUnaudited" id="ConsolidatedCondensedBalanceSheetsUnaudited">
        <link:definition>010000 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytori.com/role/ConsolidatedCondensedBalanceSheetsUnauditedParenthetical" id="ConsolidatedCondensedBalanceSheetsUnauditedParenthetical">
        <link:definition>010100 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytori.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" id="ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossUnaudited">
        <link:definition>020000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytori.com/role/ConsolidatedCondensedStatementsOfCashFlowsUnaudited" id="ConsolidatedCondensedStatementsOfCashFlowsUnaudited">
        <link:definition>030000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytori.com/role/BasisOfPresentation" id="BasisOfPresentation">
        <link:definition>060100 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytori.com/role/UseOfEstimates" id="UseOfEstimates">
        <link:definition>060200 - Disclosure - Use of Estimates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytori.com/role/CapitalAvailability" id="CapitalAvailability">
        <link:definition>060300 - Disclosure - Capital Availability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytori.com/role/RecentAccountingPronouncements" id="RecentAccountingPronouncements">
        <link:definition>060400 - Disclosure - Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytori.com/role/WarrantLiability" id="WarrantLiability">
        <link:definition>060500 - Disclosure - Warrant Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytori.com/role/LongtermDebt" id="LongtermDebt">
        <link:definition>060600 - Disclosure - Long-term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytori.com/role/RevenueRecognition" id="RevenueRecognition">
        <link:definition>060700 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytori.com/role/Inventories" id="Inventories">
        <link:definition>060800 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytori.com/role/SharebasedCompensation" id="SharebasedCompensation">
        <link:definition>060900 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytori.com/role/LossPerShare" id="LossPerShare">
        <link:definition>061000 - Disclosure - Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytori.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>061100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytori.com/role/TransactionsWithOlympusCorporation" id="TransactionsWithOlympusCorporation">
        <link:definition>061200 - Disclosure - Transactions with Olympus Corporation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytori.com/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>061300 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytori.com/role/FairValue" id="FairValue">
        <link:definition>061400 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytori.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>061500 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytori.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>061600 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/invest/2011-01-31" schemaLocation="http://xbrl.sec.gov/invest/2011/invest-2011-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2011-01-31" schemaLocation="http://xbrl.sec.gov/country/2011/country-2011-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2011-01-31" schemaLocation="http://xbrl.sec.gov/currency/2011/currency-2011-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2011-01-31" schemaLocation="http://xbrl.sec.gov/exch/2011/exch-2011-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-types-2011-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:element name="DeferredRevenuesRelatedParty" id="cytx_DeferredRevenuesRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="WarrantLiability" id="cytx_WarrantLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="OptionLiability" id="cytx_OptionLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="DevelopmentRevenuesAbstract" id="cytx_DevelopmentRevenuesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DevelopmentRelatedParty" id="cytx_DevelopmentRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ResearchGrantsAndOther" id="cytx_ResearchGrantsAndOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="TotalDevelopmentRevenues" id="cytx_TotalDevelopmentRevenues" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ChangeInFairValueOfWarrants" id="cytx_ChangeInFairValueOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ChangeInFairValueOfOptionLiability" id="cytx_ChangeInFairValueOfOptionLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ChangeInFairValueOfOptions" id="cytx_ChangeInFairValueOfOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="IncreaseDecreaseOtherCurrentAssets" id="cytx_IncreaseDecreaseOtherCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="IncreaseDecreaseOtherAssets" id="cytx_IncreaseDecreaseOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="IncreaseDecreaseDeferredRevenueRelatedParty" id="cytx_IncreaseDecreaseDeferredRevenueRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="IncreaseDecreaseOfDeferredRevenue" id="cytx_IncreaseDecreaseOfDeferredRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="IncreaseDecreaseLongTermDeferredRentLiabiilty" id="cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants" id="cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="CashPaidDuringPeriodForAbstract" id="cytx_CashPaidDuringPeriodForAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="BasisOfPresentationAbstract" id="cytx_BasisOfPresentationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="UseOfEstimatesAbstract" id="cytx_UseOfEstimatesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="UseOfEstimatesTextBlock" id="cytx_UseOfEstimatesTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CapitalAvailabilityAbstract" id="cytx_CapitalAvailabilityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CapitalAvailabilityTextBlock" id="cytx_CapitalAvailabilityTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="RecentlyAccountingPronouncementsAbstract" id="cytx_RecentlyAccountingPronouncementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WarrantLiabilityAbstract" id="cytx_WarrantLiabilityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WarrantLiabilityTextBlock" id="cytx_WarrantLiabilityTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="RevenueRecognitionTextBlock" id="cytx_RevenueRecognitionTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="InventoriesAbstract" id="cytx_InventoriesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LossPerShareAbstract" id="cytx_LossPerShareAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FairValueAbstract" id="cytx_FairValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DocumentAndEntityInformationAbstract" id="cytx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cytx-20120331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Thomson Reuters Accelus-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://cytori.com/role/ConsolidatedCondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" xlink:href="cytx-20120331.xsd#ConsolidatedCondensedStatementsOfCashFlowsUnaudited" />
  <link:roleRef roleURI="http://cytori.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" xlink:href="cytx-20120331.xsd#ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" />
  <link:roleRef roleURI="http://cytori.com/role/ConsolidatedCondensedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="cytx-20120331.xsd#ConsolidatedCondensedBalanceSheetsUnaudited" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cytori.com/role/ConsolidatedCondensedBalanceSheetsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="PreferredStockValue" xlink:title="calculation: StockholdersEquity to PreferredStockValue" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquity" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquity" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="CommitmentsAndContingencies" xlink:title="calculation: LiabilitiesAndStockholdersEquity to CommitmentsAndContingencies" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="LongTermDebtAndCapitalLeaseObligations" xlink:title="LongTermDebtAndCapitalLeaseObligations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LongTermDebtAndCapitalLeaseObligations" xlink:title="calculation: Liabilities to LongTermDebtAndCapitalLeaseObligations" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="DeferredRentCreditNoncurrent" xlink:title="DeferredRentCreditNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="DeferredRentCreditNoncurrent" xlink:title="calculation: Liabilities to DeferredRentCreditNoncurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_OptionLiability" xlink:label="OptionLiability" xlink:title="OptionLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="OptionLiability" xlink:title="calculation: Liabilities to OptionLiability" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_WarrantLiability" xlink:label="WarrantLiability" xlink:title="WarrantLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="WarrantLiability" xlink:title="calculation: Liabilities to WarrantLiability" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="DeferredRevenue" xlink:title="DeferredRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="DeferredRevenue" xlink:title="calculation: Liabilities to DeferredRevenue" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_DeferredRevenuesRelatedParty" xlink:label="DeferredRevenuesRelatedParty" xlink:title="DeferredRevenuesRelatedParty" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="DeferredRevenuesRelatedParty" xlink:title="calculation: Liabilities to DeferredRevenuesRelatedParty" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="LongTermDebtCurrent" xlink:title="calculation: LiabilitiesCurrent to LongTermDebtCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableAndAccruedLiabilitiesCurrent" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" order="7.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="Goodwill" xlink:title="calculation: Assets to Goodwill" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="IntangibleAssetsNetExcludingGoodwill" xlink:title="calculation: Assets to IntangibleAssetsNetExcludingGoodwill" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="OtherAssetsNoncurrent" xlink:title="calculation: Assets to OtherAssetsNoncurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="EquityMethodInvestments" xlink:title="EquityMethodInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="EquityMethodInvestments" xlink:title="calculation: Assets to EquityMethodInvestments" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="RestrictedCashAndCashEquivalentsNoncurrent" xlink:title="RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="RestrictedCashAndCashEquivalentsNoncurrent" xlink:title="calculation: Assets to RestrictedCashAndCashEquivalentsNoncurrent" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="OtherAssetsCurrent" xlink:title="OtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="OtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to OtherAssetsCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="InventoryNet" xlink:title="calculation: AssetsCurrent to InventoryNet" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="AccountsReceivableNetCurrent" xlink:title="calculation: AssetsCurrent to AccountsReceivableNetCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="7.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cytori.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromEquityMethodInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="IncomeLossFromEquityMethodInvestments" xlink:title="calculation: NonoperatingIncomeExpense to IncomeLossFromEquityMethodInvestments" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="calculation: NonoperatingIncomeExpense to OtherNonoperatingIncomeExpense" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="InterestExpense" xlink:title="calculation: NonoperatingIncomeExpense to InterestExpense" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="InvestmentIncomeInterest" xlink:title="calculation: NonoperatingIncomeExpense to InvestmentIncomeInterest" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="NonoperatingIncomeExpense" xlink:title="calculation: NetIncomeLoss to NonoperatingIncomeExpense" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_ChangeInFairValueOfOptionLiability" xlink:label="ChangeInFairValueOfOptionLiability" xlink:title="ChangeInFairValueOfOptionLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ChangeInFairValueOfOptionLiability" xlink:title="calculation: OperatingExpenses to ChangeInFairValueOfOptionLiability" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_ChangeInFairValueOfWarrants" xlink:label="ChangeInFairValueOfWarrants" xlink:title="ChangeInFairValueOfWarrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ChangeInFairValueOfWarrants" xlink:title="calculation: OperatingExpenses to ChangeInFairValueOfWarrants" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="GeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpenses to GeneralAndAdministrativeExpense" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="SellingAndMarketingExpense" xlink:title="SellingAndMarketingExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="SellingAndMarketingExpense" xlink:title="calculation: OperatingExpenses to SellingAndMarketingExpense" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpense" order="5.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="OperatingExpenses" xlink:title="calculation: OperatingIncomeLoss to OperatingExpenses" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_TotalDevelopmentRevenues" xlink:label="TotalDevelopmentRevenues" xlink:title="TotalDevelopmentRevenues" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_ResearchGrantsAndOther" xlink:label="ResearchGrantsAndOther" xlink:title="ResearchGrantsAndOther" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="TotalDevelopmentRevenues" xlink:to="ResearchGrantsAndOther" xlink:title="calculation: TotalDevelopmentRevenues to ResearchGrantsAndOther" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_DevelopmentRelatedParty" xlink:label="DevelopmentRelatedParty" xlink:title="DevelopmentRelatedParty" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="TotalDevelopmentRevenues" xlink:to="DevelopmentRelatedParty" xlink:title="calculation: TotalDevelopmentRevenues to DevelopmentRelatedParty" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="TotalDevelopmentRevenues" xlink:title="calculation: OperatingIncomeLoss to TotalDevelopmentRevenues" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="GrossProfit" xlink:title="GrossProfit" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="SalesRevenueGoodsNet" xlink:title="SalesRevenueGoodsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="GrossProfit" xlink:to="SalesRevenueGoodsNet" xlink:title="calculation: GrossProfit to SalesRevenueGoodsNet" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="CostOfGoodsSold" xlink:title="CostOfGoodsSold" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="GrossProfit" xlink:to="CostOfGoodsSold" xlink:title="calculation: GrossProfit to CostOfGoodsSold" order="0.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="GrossProfit" xlink:title="calculation: OperatingIncomeLoss to GrossProfit" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="OperatingIncomeLoss" xlink:title="calculation: NetIncomeLoss to OperatingIncomeLoss" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cytori.com/role/ConsolidatedCondensedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentsOfStockIssuanceCosts" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfCommonStock" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants" xlink:label="ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants" xlink:title="ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="RepaymentsOfLongTermDebt" xlink:title="RepaymentsOfLongTermDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="RepaymentsOfLongTermDebt" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to RepaymentsOfLongTermDebt" order="7.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to NetCashProvidedByUsedInFinancingActivities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquirePropertyPlantAndEquipment" order="3.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to NetCashProvidedByUsedInInvestingActivities" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty" xlink:label="IncreaseDecreaseLongTermDeferredRentLiabiilty" xlink:title="IncreaseDecreaseLongTermDeferredRentLiabiilty" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseLongTermDeferredRentLiabiilty" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseLongTermDeferredRentLiabiilty" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_IncreaseDecreaseOfDeferredRevenue" xlink:label="IncreaseDecreaseOfDeferredRevenue" xlink:title="IncreaseDecreaseOfDeferredRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseOfDeferredRevenue" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseOfDeferredRevenue" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_IncreaseDecreaseDeferredRevenueRelatedParty" xlink:label="IncreaseDecreaseDeferredRevenueRelatedParty" xlink:title="IncreaseDecreaseDeferredRevenueRelatedParty" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseDeferredRevenueRelatedParty" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseDeferredRevenueRelatedParty" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_IncreaseDecreaseOtherAssets" xlink:label="IncreaseDecreaseOtherAssets" xlink:title="IncreaseDecreaseOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseOtherAssets" order="5.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_IncreaseDecreaseOtherCurrentAssets" xlink:label="IncreaseDecreaseOtherCurrentAssets" xlink:title="IncreaseDecreaseOtherCurrentAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseOtherCurrentAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseOtherCurrentAssets" order="6.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInInventories" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInInventories" order="7.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsReceivable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsReceivable" order="8.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromEquityMethodInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncomeLossFromEquityMethodInvestments" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncomeLossFromEquityMethodInvestments" order="9.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ShareBasedCompensation" order="10.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_ChangeInFairValueOfOptions" xlink:label="ChangeInFairValueOfOptions" xlink:title="ChangeInFairValueOfOptions" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ChangeInFairValueOfOptions" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ChangeInFairValueOfOptions" order="11.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_ChangeInFairValueOfWarrants" xlink:label="ChangeInFairValueOfWarrants" xlink:title="ChangeInFairValueOfWarrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ChangeInFairValueOfWarrants" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ChangeInFairValueOfWarrants" order="12.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="ProvisionForDoubtfulAccounts" xlink:title="ProvisionForDoubtfulAccounts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ProvisionForDoubtfulAccounts" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ProvisionForDoubtfulAccounts" order="13.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfFinancingCostsAndDiscounts" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfFinancingCostsAndDiscounts" order="15.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="DepreciationDepletionAndAmortization" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to DepreciationDepletionAndAmortization" order="16.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NetIncomeLoss" order="17.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to NetCashProvidedByUsedInOperatingActivities" order="3.0" weight="1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>cytx-20120331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Thomson Reuters Accelus-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsReceivableNetCurrent_lbl">Accounts receivable, net of reserves of $187,000 and of $474,000 in 2012 and 2011, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:title="label: AccountsReceivableNetCurrent to us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl">Amortization of deferred financing costs and debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:title="label: AmortizationOfFinancingCostsAndDiscounts to us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="AllowanceForDoubtfulAccountsReceivableCurrent" xlink:title="AllowanceForDoubtfulAccountsReceivableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US" id="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl">Accounts receivable, reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:title="label: AllowanceForDoubtfulAccountsReceivableCurrent to us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfFinancialPositionAbstract_lbl">CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:title="label: StatementOfFinancialPositionAbstract to us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1">Cash and cash equivalents at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="InterestPaid" xlink:title="InterestPaid" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPaid_lbl" xml:lang="en-US" id="us-gaap_InterestPaid_lbl">Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:title="label: InterestPaid to us-gaap_InterestPaid_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:title="label: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:title="label: IncreaseDecreaseInAccountsReceivable to us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1">Increase (Decrease) in Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xlink:title="label: IncreaseDecreaseInAccountsReceivable to us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInInventories_lbl">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:title="label: IncreaseDecreaseInInventories to us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInInventories_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInInventories_lbl1">Increase (Decrease) in Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl1" xlink:title="label: IncreaseDecreaseInInventories to us-gaap_IncreaseDecreaseInInventories_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl">Increases (decreases) in cash caused by changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl1">Common Stock, Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="us-gaap_CommonStockValue_lbl">Common stock, $0.001 par value; 95,000,000 shares authorized; 58,428,606 and 56,594,683 shares issued and outstanding in 2012 and 2011, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="CostOfGoodsSold" xlink:title="CostOfGoodsSold" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfGoodsSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US" id="us-gaap_CostOfGoodsSold_lbl">Cost of product revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl" xlink:title="label: CostOfGoodsSold to us-gaap_CostOfGoodsSold_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract_lbl">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="LongTermDebtAndCapitalLeaseObligations" xlink:title="LongTermDebtAndCapitalLeaseObligations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl">Long-term obligations, net of discount, less current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtAndCapitalLeaseObligations" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl" xlink:title="label: LongTermDebtAndCapitalLeaseObligations to us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted_lbl">Basic and diluted net loss per common share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromEquityMethodInvestments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US" id="us-gaap_IncomeLossFromEquityMethodInvestments_lbl">Equity loss from investment in joint venture</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:title="label: IncomeLossFromEquityMethodInvestments to us-gaap_IncomeLossFromEquityMethodInvestments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_IncomeLossFromEquityMethodInvestments_lbl1" xml:lang="en-US" id="us-gaap_IncomeLossFromEquityMethodInvestments_lbl1">Equity loss from investment in joint venture</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl1" xlink:title="label: IncomeLossFromEquityMethodInvestments to us-gaap_IncomeLossFromEquityMethodInvestments_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeLossFromEquityMethodInvestments_lbl2" xml:lang="en-US" id="us-gaap_IncomeLossFromEquityMethodInvestments_lbl2">Income (Loss) from Equity Method Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl2" xlink:title="label: IncomeLossFromEquityMethodInvestments to us-gaap_IncomeLossFromEquityMethodInvestments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract_lbl">Share-Based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="EquityMethodInvestments" xlink:title="EquityMethodInvestments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US" id="us-gaap_EquityMethodInvestments_lbl">Investment in joint venture</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl" xlink:title="label: EquityMethodInvestments to us-gaap_EquityMethodInvestments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityMethodInvestments_lbl1" xml:lang="en-US" id="us-gaap_EquityMethodInvestments_lbl1">Equity Method Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl1" xlink:title="label: EquityMethodInvestments to us-gaap_EquityMethodInvestments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense_lbl">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="GrossProfit" xlink:title="GrossProfit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_GrossProfit_lbl" xml:lang="en-US" id="us-gaap_GrossProfit_lbl">Gross profit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:title="label: GrossProfit to us-gaap_GrossProfit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GrossProfit_lbl1" xml:lang="en-US" id="us-gaap_GrossProfit_lbl1">Gross Profit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrossProfit" xlink:to="us-gaap_GrossProfit_lbl1" xlink:title="label: GrossProfit to us-gaap_GrossProfit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementAbstract_lbl">CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:title="label: IncomeStatementAbstract to us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" id="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl">Intangibles, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:title="label: IntangibleAssetsNetExcludingGoodwill to us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Goodwill_lbl" xml:lang="en-US" id="us-gaap_Goodwill_lbl">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:title="label: Goodwill to us-gaap_Goodwill_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="us-gaap_InterestExpense_lbl">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:title="label: InterestExpense to us-gaap_InterestExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpense_lbl1" xml:lang="en-US" id="us-gaap_InterestExpense_lbl1">Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="us-gaap_InterestExpense_lbl1" xlink:title="label: InterestExpense to us-gaap_InterestExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryNet_lbl" xml:lang="en-US" id="us-gaap_InventoryNet_lbl">Inventories, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:title="label: InventoryNet to us-gaap_InventoryNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Liabilities_lbl" xml:lang="en-US" id="us-gaap_Liabilities_lbl">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Liabilities_lbl1" xml:lang="en-US" id="us-gaap_Liabilities_lbl1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl1" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl">Liabilities and Stockholders' Equity (Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtCurrent_lbl">Current portion of long-term obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" xlink:title="label: LongTermDebtCurrent to us-gaap_LongTermDebtCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl1">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl">Net decrease in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:title="label: CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" xlink:title="label: CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:title="ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:title="label: ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock to us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl1">Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl1" xlink:title="label: ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock to us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl">Total other expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl1" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl1">Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl">Operating loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl1">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl1">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl1" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="OtherAssetsCurrent" xlink:title="OtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_OtherAssetsCurrent_lbl">Other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:title="label: OtherAssetsCurrent to us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherAssetsCurrent_lbl1">Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl1" xlink:title="label: OtherAssetsCurrent to us-gaap_OtherAssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncomeExpense_lbl">Other expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:title="label: OtherNonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherNonoperatingIncomeExpense_lbl1" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncomeExpense_lbl1">Other Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl1" xlink:title="label: OtherNonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncomeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized_lbl">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesIssued_lbl">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:title="label: PreferredStockSharesIssued to us-gaap_PreferredStockSharesIssued_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding_lbl">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="us-gaap_PreferredStockParOrStatedValuePerShare_lbl">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:title="label: PreferredStockParOrStatedValuePerShare to us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl">Proceeds from sale of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="ProvisionForDoubtfulAccounts" xlink:title="ProvisionForDoubtfulAccounts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US" id="us-gaap_ProvisionForDoubtfulAccounts_lbl">Increase (decrease) in allowance for doubtful accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:title="label: ProvisionForDoubtfulAccounts to us-gaap_ProvisionForDoubtfulAccounts_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl">Transactions with Olympus Corporation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:title="label: RelatedPartyTransactionsDisclosureTextBlock to us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xlink:title="label: RelatedPartyTransactionsDisclosureTextBlock to us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="RepaymentsOfLongTermDebt" xlink:title="RepaymentsOfLongTermDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" id="us-gaap_RepaymentsOfLongTermDebt_lbl">Principal payments on long-term obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:title="label: RepaymentsOfLongTermDebt to us-gaap_RepaymentsOfLongTermDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RepaymentsOfLongTermDebt_lbl1" xml:lang="en-US" id="us-gaap_RepaymentsOfLongTermDebt_lbl1">Repayments of Long-term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl1" xlink:title="label: RepaymentsOfLongTermDebt to us-gaap_RepaymentsOfLongTermDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="SalesRevenueGoodsNet" xlink:title="SalesRevenueGoodsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US" id="us-gaap_SalesRevenueGoodsNet_lbl">Product revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet_lbl" xlink:title="label: SalesRevenueGoodsNet to us-gaap_SalesRevenueGoodsNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="InventoryDisclosureTextBlock" xlink:title="InventoryDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_InventoryDisclosureTextBlock_lbl">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:title="label: InventoryDisclosureTextBlock to us-gaap_InventoryDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_InventoryDisclosureTextBlock_lbl1">Inventory Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl1" xlink:title="label: InventoryDisclosureTextBlock to us-gaap_InventoryDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:label="ScheduleOfSubsequentEventsTextBlock" xlink:title="ScheduleOfSubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSubsequentEventsTextBlock" xlink:to="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl" xlink:title="label: ScheduleOfSubsequentEventsTextBlock to us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl1">Schedule of Subsequent Events [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSubsequentEventsTextBlock" xlink:to="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl1" xlink:title="label: ScheduleOfSubsequentEventsTextBlock to us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="SellingAndMarketingExpense" xlink:title="SellingAndMarketingExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US" id="us-gaap_SellingAndMarketingExpense_lbl">Sales and marketing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" xlink:title="label: SellingAndMarketingExpense to us-gaap_SellingAndMarketingExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfCashFlowsAbstract_lbl">CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:title="label: StatementOfCashFlowsAbstract to us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="us-gaap_PaymentsOfStockIssuanceCosts_lbl">Costs from sale of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:title="label: PaymentsOfStockIssuanceCosts to us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsOfStockIssuanceCosts_lbl1" xml:lang="en-US" id="us-gaap_PaymentsOfStockIssuanceCosts_lbl1">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl1" xlink:title="label: PaymentsOfStockIssuanceCosts to us-gaap_PaymentsOfStockIssuanceCosts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl">Stockholders' equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl1">Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl1" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl">Stockholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="us-gaap_SupplementalCashFlowInformationAbstract_lbl">Supplemental disclosure of cash flows information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:title="label: SupplementalCashFlowInformationAbstract to us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl">Basic and diluted weighted average common shares (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="RestrictedCashAndCashEquivalentsNoncurrent" xlink:title="RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xml:lang="en-US" id="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl">Restricted cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:title="label: RestrictedCashAndCashEquivalentsNoncurrent to us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense_lbl">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Assets_lbl" xml:lang="en-US" id="us-gaap_Assets_lbl">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl" xlink:title="label: Assets to us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Assets_lbl1" xml:lang="en-US" id="us-gaap_Assets_lbl1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl1" xlink:title="label: Assets to us-gaap_Assets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" id="us-gaap_InvestmentIncomeInterest_lbl">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:title="label: InvestmentIncomeInterest to us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentIncomeInterest_lbl1" xml:lang="en-US" id="us-gaap_InvestmentIncomeInterest_lbl1">Investment Income, Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl1" xlink:title="label: InvestmentIncomeInterest to us-gaap_InvestmentIncomeInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl">Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAbstract_lbl2" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl2">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl2" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="FairValueMeasurementInputsDisclosureTextBlock" xlink:title="FairValueMeasurementInputsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:title="label: FairValueMeasurementInputsDisclosureTextBlock to us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl1">Fair Value, Measurement Inputs, Disclosure [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl1" xlink:title="label: FairValueMeasurementInputsDisclosureTextBlock to us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="CapitalLeaseObligationsIncurred" xlink:title="CapitalLeaseObligationsIncurred" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CapitalLeaseObligationsIncurred_lbl" xml:lang="en-US" id="us-gaap_CapitalLeaseObligationsIncurred_lbl">Capital equipment lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeaseObligationsIncurred" xlink:to="us-gaap_CapitalLeaseObligationsIncurred_lbl" xlink:title="label: CapitalLeaseObligationsIncurred to us-gaap_CapitalLeaseObligationsIncurred_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueDisclosuresTextBlock_lbl">Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:title="label: FairValueDisclosuresTextBlock to us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FairValueDisclosuresTextBlock_lbl1">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl1" xlink:title="label: FairValueDisclosuresTextBlock to us-gaap_FairValueDisclosuresTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="DeferredRevenue" xlink:title="DeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="us-gaap_DeferredRevenue_lbl">Deferred revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:title="label: DeferredRevenue to us-gaap_DeferredRevenue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredRevenue_lbl1" xml:lang="en-US" id="us-gaap_DeferredRevenue_lbl1">Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl1" xlink:title="label: DeferredRevenue to us-gaap_DeferredRevenue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OtherAssetsNoncurrent_lbl">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:title="label: OtherAssetsNoncurrent to us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAssetsNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherAssetsNoncurrent_lbl1">Other Assets, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl1" xlink:title="label: OtherAssetsNoncurrent to us-gaap_OtherAssetsNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract_lbl">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl1">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="DeferredRentCreditNoncurrent" xlink:title="DeferredRentCreditNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" id="us-gaap_DeferredRentCreditNoncurrent_lbl">Long-term deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:title="label: DeferredRentCreditNoncurrent to us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredRentCreditNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_DeferredRentCreditNoncurrent_lbl1">Deferred Rent Credit, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl1" xlink:title="label: DeferredRentCreditNoncurrent to us-gaap_DeferredRentCreditNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtAbstract" xlink:label="LongTermDebtAbstract" xlink:title="LongTermDebtAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtAbstract_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtAbstract_lbl">Long-term Debt [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtAbstract_lbl" xlink:title="label: LongTermDebtAbstract to us-gaap_LongTermDebtAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare_lbl">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl">Total stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl1">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="us-gaap_PreferredStockValue_lbl">Preferred stock, $0.001 par value; 5,000,000 shares authorized; -0- shares issued and outstanding in 2012 and 2011</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:title="label: PreferredStockValue to us-gaap_PreferredStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="LongTermDebtTextBlock" xlink:title="LongTermDebtTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtTextBlock_lbl">Long-term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:title="label: LongTermDebtTextBlock to us-gaap_LongTermDebtTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtTextBlock_lbl1" xml:lang="en-US" id="us-gaap_LongTermDebtTextBlock_lbl1">Long-term Debt [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl1" xlink:title="label: LongTermDebtTextBlock to us-gaap_LongTermDebtTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl">Supplemental schedule of non-cash operating, investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:title="label: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="EarningsPerShareTextBlock" xlink:title="EarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareTextBlock_lbl">Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:title="label: EarningsPerShareTextBlock to us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareTextBlock_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareTextBlock_lbl1">Earnings Per Share [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl1" xlink:title="label: EarningsPerShareTextBlock to us-gaap_EarningsPerShareTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="us-gaap_DepreciationDepletionAndAmortization_lbl">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:title="label: DepreciationDepletionAndAmortization to us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies_lbl">Commitments and contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:title="label: AccountsPayableAndAccruedLiabilitiesCurrent to us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" xlink:title="label: AccountsPayableAndAccruedLiabilitiesCurrent to us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="OtherIncomeAndExpensesAbstract" xlink:title="OtherIncomeAndExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US" id="us-gaap_OtherIncomeAndExpensesAbstract_lbl">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:title="label: OtherIncomeAndExpensesAbstract to us-gaap_OtherIncomeAndExpensesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl">Commitments and Contingencies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_FairValueDisclosuresAbstract_lbl">Fair Value Measurements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:title="label: FairValueDisclosuresAbstract to us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsAbstract_lbl">Transactions with Olympus Corporation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:title="label: RelatedPartyTransactionsAbstract to us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventsAbstract_lbl">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:title="label: SubsequentEventsAbstract to us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:label="NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:title="NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" xml:lang="en-US" id="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl">Net increase in purchases of property and equipment included in accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" xlink:title="label: NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 to us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="RevenueRecognitionAbstract" xlink:title="RevenueRecognitionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueRecognitionAbstract_lbl" xml:lang="en-US" id="us-gaap_RevenueRecognitionAbstract_lbl">Revenue Recognition [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionAbstract" xlink:to="us-gaap_RevenueRecognitionAbstract_lbl" xlink:title="label: RevenueRecognitionAbstract to us-gaap_RevenueRecognitionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="dei_CurrentFiscalYearEndDate_lbl">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:title="label: CurrentFiscalYearEndDate to dei_CurrentFiscalYearEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:label xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="dei_EntityWellKnownSeasonedIssuer_lbl">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:title="label: EntityWellKnownSeasonedIssuer to dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:label xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="dei_EntityVoluntaryFilers_lbl">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:title="label: EntityVoluntaryFilers to dei_EntityVoluntaryFilers_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="dei_EntityCurrentReportingStatus_lbl">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:title="label: EntityCurrentReportingStatus to dei_EntityCurrentReportingStatus_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="dei_EntityFilerCategory_lbl">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:label xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="dei_EntityPublicFloat_lbl">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:title="label: EntityPublicFloat to dei_EntityPublicFloat_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="dei_EntityCommonStockSharesOutstanding_lbl">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:title="label: EntityCommonStockSharesOutstanding to dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_DeferredRevenuesRelatedParty" xlink:label="DeferredRevenuesRelatedParty" xlink:title="DeferredRevenuesRelatedParty" />
    <link:label xlink:type="resource" xlink:label="cytx_DeferredRevenuesRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="cytx_DeferredRevenuesRelatedParty_lbl" xml:lang="en-US" id="cytx_DeferredRevenuesRelatedParty_lbl">Related parties deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenuesRelatedParty" xlink:to="cytx_DeferredRevenuesRelatedParty_lbl" xlink:title="label: DeferredRevenuesRelatedParty to cytx_DeferredRevenuesRelatedParty_lbl" />
    <link:label xlink:type="resource" xlink:label="cytx_DeferredRevenuesRelatedParty_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_DeferredRevenuesRelatedParty_lbl1" xml:lang="en-US" id="cytx_DeferredRevenuesRelatedParty_lbl1">Deferred revenues, related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenuesRelatedParty" xlink:to="cytx_DeferredRevenuesRelatedParty_lbl1" xlink:title="label: DeferredRevenuesRelatedParty to cytx_DeferredRevenuesRelatedParty_lbl1" />
    <link:label xlink:type="resource" xlink:label="cytx_DeferredRevenuesRelatedParty_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="cytx_DeferredRevenuesRelatedParty_lbl2" xml:lang="en-US" id="cytx_DeferredRevenuesRelatedParty_lbl2">Deferred revenues, related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenuesRelatedParty" xlink:to="cytx_DeferredRevenuesRelatedParty_lbl2" xlink:title="label: DeferredRevenuesRelatedParty to cytx_DeferredRevenuesRelatedParty_lbl2" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_WarrantLiability" xlink:label="WarrantLiability" xlink:title="WarrantLiability" />
    <link:label xlink:type="resource" xlink:label="cytx_WarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="cytx_WarrantLiability_lbl" xml:lang="en-US" id="cytx_WarrantLiability_lbl">Fair Value of warrants which are accounted for as fair value liabilities with changes in fair value included in net earnings (loss). Fair value for these warrants is measured on a recurring basis using model-derived valuations in which all significant inputs are observable in active markets (Level 3).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantLiability" xlink:to="cytx_WarrantLiability_lbl" xlink:title="label: WarrantLiability to cytx_WarrantLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="cytx_WarrantLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_WarrantLiability_lbl1" xml:lang="en-US" id="cytx_WarrantLiability_lbl1">Warrant Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantLiability" xlink:to="cytx_WarrantLiability_lbl1" xlink:title="label: WarrantLiability to cytx_WarrantLiability_lbl1" />
    <link:label xlink:type="resource" xlink:label="cytx_WarrantLiability_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="cytx_WarrantLiability_lbl2" xml:lang="en-US" id="cytx_WarrantLiability_lbl2">Warrant liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantLiability" xlink:to="cytx_WarrantLiability_lbl2" xlink:title="label: WarrantLiability to cytx_WarrantLiability_lbl2" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_OptionLiability" xlink:label="OptionLiability" xlink:title="OptionLiability" />
    <link:label xlink:type="resource" xlink:label="cytx_OptionLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="cytx_OptionLiability_lbl" xml:lang="en-US" id="cytx_OptionLiability_lbl">Fair Value of option liability for the period which are included in the statement of income (or changes in net assets) in operating expenses; the fair value of which was or is measured on a recurring basis using valuation techniques in which one or more significant inputs are unobservable in active markets (Level 3).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OptionLiability" xlink:to="cytx_OptionLiability_lbl" xlink:title="label: OptionLiability to cytx_OptionLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="cytx_OptionLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_OptionLiability_lbl1" xml:lang="en-US" id="cytx_OptionLiability_lbl1">Option Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OptionLiability" xlink:to="cytx_OptionLiability_lbl1" xlink:title="label: OptionLiability to cytx_OptionLiability_lbl1" />
    <link:label xlink:type="resource" xlink:label="cytx_OptionLiability_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="cytx_OptionLiability_lbl2" xml:lang="en-US" id="cytx_OptionLiability_lbl2">Option liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OptionLiability" xlink:to="cytx_OptionLiability_lbl2" xlink:title="label: OptionLiability to cytx_OptionLiability_lbl2" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_DevelopmentRevenuesAbstract" xlink:label="DevelopmentRevenuesAbstract" xlink:title="DevelopmentRevenuesAbstract" />
    <link:label xlink:type="resource" xlink:label="cytx_DevelopmentRevenuesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_DevelopmentRevenuesAbstract_lbl1" xml:lang="en-US" id="cytx_DevelopmentRevenuesAbstract_lbl1">Development revenues: [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DevelopmentRevenuesAbstract" xlink:to="cytx_DevelopmentRevenuesAbstract_lbl1" xlink:title="label: DevelopmentRevenuesAbstract to cytx_DevelopmentRevenuesAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="cytx_DevelopmentRevenuesAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="cytx_DevelopmentRevenuesAbstract_lbl2" xml:lang="en-US" id="cytx_DevelopmentRevenuesAbstract_lbl2">Development revenues:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DevelopmentRevenuesAbstract" xlink:to="cytx_DevelopmentRevenuesAbstract_lbl2" xlink:title="label: DevelopmentRevenuesAbstract to cytx_DevelopmentRevenuesAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_DevelopmentRelatedParty" xlink:label="DevelopmentRelatedParty" xlink:title="DevelopmentRelatedParty" />
    <link:label xlink:type="resource" xlink:label="cytx_DevelopmentRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="cytx_DevelopmentRelatedParty_lbl" xml:lang="en-US" id="cytx_DevelopmentRelatedParty_lbl">The amount of previously reported related party deferred or unearned revenue that was recognized as revenue during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DevelopmentRelatedParty" xlink:to="cytx_DevelopmentRelatedParty_lbl" xlink:title="label: DevelopmentRelatedParty to cytx_DevelopmentRelatedParty_lbl" />
    <link:label xlink:type="resource" xlink:label="cytx_DevelopmentRelatedParty_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_DevelopmentRelatedParty_lbl1" xml:lang="en-US" id="cytx_DevelopmentRelatedParty_lbl1">Development related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DevelopmentRelatedParty" xlink:to="cytx_DevelopmentRelatedParty_lbl1" xlink:title="label: DevelopmentRelatedParty to cytx_DevelopmentRelatedParty_lbl1" />
    <link:label xlink:type="resource" xlink:label="cytx_DevelopmentRelatedParty_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="cytx_DevelopmentRelatedParty_lbl2" xml:lang="en-US" id="cytx_DevelopmentRelatedParty_lbl2">Development, related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DevelopmentRelatedParty" xlink:to="cytx_DevelopmentRelatedParty_lbl2" xlink:title="label: DevelopmentRelatedParty to cytx_DevelopmentRelatedParty_lbl2" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_ResearchGrantsAndOther" xlink:label="ResearchGrantsAndOther" xlink:title="ResearchGrantsAndOther" />
    <link:label xlink:type="resource" xlink:label="cytx_ResearchGrantsAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="cytx_ResearchGrantsAndOther_lbl" xml:lang="en-US" id="cytx_ResearchGrantsAndOther_lbl">Revenue earned during the period from non-product related activities and revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchGrantsAndOther" xlink:to="cytx_ResearchGrantsAndOther_lbl" xlink:title="label: ResearchGrantsAndOther to cytx_ResearchGrantsAndOther_lbl" />
    <link:label xlink:type="resource" xlink:label="cytx_ResearchGrantsAndOther_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_ResearchGrantsAndOther_lbl1" xml:lang="en-US" id="cytx_ResearchGrantsAndOther_lbl1">Research grants and other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchGrantsAndOther" xlink:to="cytx_ResearchGrantsAndOther_lbl1" xlink:title="label: ResearchGrantsAndOther to cytx_ResearchGrantsAndOther_lbl1" />
    <link:label xlink:type="resource" xlink:label="cytx_ResearchGrantsAndOther_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="cytx_ResearchGrantsAndOther_lbl2" xml:lang="en-US" id="cytx_ResearchGrantsAndOther_lbl2">Research grants and other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchGrantsAndOther" xlink:to="cytx_ResearchGrantsAndOther_lbl2" xlink:title="label: ResearchGrantsAndOther to cytx_ResearchGrantsAndOther_lbl2" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_TotalDevelopmentRevenues" xlink:label="TotalDevelopmentRevenues" xlink:title="TotalDevelopmentRevenues" />
    <link:label xlink:type="resource" xlink:label="cytx_TotalDevelopmentRevenues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="cytx_TotalDevelopmentRevenues_lbl" xml:lang="en-US" id="cytx_TotalDevelopmentRevenues_lbl">Aggregate revenue earned during the period from recognition of related party deferred revenue, non-product related activities and revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TotalDevelopmentRevenues" xlink:to="cytx_TotalDevelopmentRevenues_lbl" xlink:title="label: TotalDevelopmentRevenues to cytx_TotalDevelopmentRevenues_lbl" />
    <link:label xlink:type="resource" xlink:label="cytx_TotalDevelopmentRevenues_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_TotalDevelopmentRevenues_lbl1" xml:lang="en-US" id="cytx_TotalDevelopmentRevenues_lbl1">Total Development Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TotalDevelopmentRevenues" xlink:to="cytx_TotalDevelopmentRevenues_lbl1" xlink:title="label: TotalDevelopmentRevenues to cytx_TotalDevelopmentRevenues_lbl1" />
    <link:label xlink:type="resource" xlink:label="cytx_TotalDevelopmentRevenues_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="cytx_TotalDevelopmentRevenues_lbl2" xml:lang="en-US" id="cytx_TotalDevelopmentRevenues_lbl2">Total development revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TotalDevelopmentRevenues" xlink:to="cytx_TotalDevelopmentRevenues_lbl2" xlink:title="label: TotalDevelopmentRevenues to cytx_TotalDevelopmentRevenues_lbl2" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_ChangeInFairValueOfWarrants" xlink:label="ChangeInFairValueOfWarrants" xlink:title="ChangeInFairValueOfWarrants" />
    <link:label xlink:type="resource" xlink:label="cytx_ChangeInFairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="cytx_ChangeInFairValueOfWarrants_lbl" xml:lang="en-US" id="cytx_ChangeInFairValueOfWarrants_lbl">Change in fair value of warrants for the period which are included in the statement of income (or changes in net assets) in operating expenses; the fair value of which was or is measured on a recurring basis using model-derived valuations in which all significant inputs are observable in active markets (Level 3).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInFairValueOfWarrants" xlink:to="cytx_ChangeInFairValueOfWarrants_lbl" xlink:title="label: ChangeInFairValueOfWarrants to cytx_ChangeInFairValueOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="cytx_ChangeInFairValueOfWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_ChangeInFairValueOfWarrants_lbl1" xml:lang="en-US" id="cytx_ChangeInFairValueOfWarrants_lbl1">Change in fair value of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInFairValueOfWarrants" xlink:to="cytx_ChangeInFairValueOfWarrants_lbl1" xlink:title="label: ChangeInFairValueOfWarrants to cytx_ChangeInFairValueOfWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="cytx_ChangeInFairValueOfWarrants_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="cytx_ChangeInFairValueOfWarrants_lbl2" xml:lang="en-US" id="cytx_ChangeInFairValueOfWarrants_lbl2">Change in fair value of warrant liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInFairValueOfWarrants" xlink:to="cytx_ChangeInFairValueOfWarrants_lbl2" xlink:title="label: ChangeInFairValueOfWarrants to cytx_ChangeInFairValueOfWarrants_lbl2" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_ChangeInFairValueOfOptionLiability" xlink:label="ChangeInFairValueOfOptionLiability" xlink:title="ChangeInFairValueOfOptionLiability" />
    <link:label xlink:type="resource" xlink:label="cytx_ChangeInFairValueOfOptionLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="cytx_ChangeInFairValueOfOptionLiability_lbl" xml:lang="en-US" id="cytx_ChangeInFairValueOfOptionLiability_lbl">Change in fair value of option liability for the period which are included in the statement of income (or changes in net assets) in operating expenses; the fair value of which was or is measured on a recurring basis using valuation techniques in which one or more significant inputs are unobservable in active markets (Level 3).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInFairValueOfOptionLiability" xlink:to="cytx_ChangeInFairValueOfOptionLiability_lbl" xlink:title="label: ChangeInFairValueOfOptionLiability to cytx_ChangeInFairValueOfOptionLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="cytx_ChangeInFairValueOfOptionLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_ChangeInFairValueOfOptionLiability_lbl1" xml:lang="en-US" id="cytx_ChangeInFairValueOfOptionLiability_lbl1">Change in fair value of option liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInFairValueOfOptionLiability" xlink:to="cytx_ChangeInFairValueOfOptionLiability_lbl1" xlink:title="label: ChangeInFairValueOfOptionLiability to cytx_ChangeInFairValueOfOptionLiability_lbl1" />
    <link:label xlink:type="resource" xlink:label="cytx_ChangeInFairValueOfOptionLiability_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="cytx_ChangeInFairValueOfOptionLiability_lbl2" xml:lang="en-US" id="cytx_ChangeInFairValueOfOptionLiability_lbl2">Change in fair value of option liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInFairValueOfOptionLiability" xlink:to="cytx_ChangeInFairValueOfOptionLiability_lbl2" xlink:title="label: ChangeInFairValueOfOptionLiability to cytx_ChangeInFairValueOfOptionLiability_lbl2" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_ChangeInFairValueOfOptions" xlink:label="ChangeInFairValueOfOptions" xlink:title="ChangeInFairValueOfOptions" />
    <link:label xlink:type="resource" xlink:label="cytx_ChangeInFairValueOfOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="cytx_ChangeInFairValueOfOptions_lbl" xml:lang="en-US" id="cytx_ChangeInFairValueOfOptions_lbl">Change in fair value of option liability for the period which are included in the statement of income (or changes in net assets) in operating expenses; the fair value of which was or is measured on a recurring basis using valuation techniques in which one or more significant inputs are unobservable in active markets (Level 3).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInFairValueOfOptions" xlink:to="cytx_ChangeInFairValueOfOptions_lbl" xlink:title="label: ChangeInFairValueOfOptions to cytx_ChangeInFairValueOfOptions_lbl" />
    <link:label xlink:type="resource" xlink:label="cytx_ChangeInFairValueOfOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_ChangeInFairValueOfOptions_lbl1" xml:lang="en-US" id="cytx_ChangeInFairValueOfOptions_lbl1">Change In Fair Value Of Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInFairValueOfOptions" xlink:to="cytx_ChangeInFairValueOfOptions_lbl1" xlink:title="label: ChangeInFairValueOfOptions to cytx_ChangeInFairValueOfOptions_lbl1" />
    <link:label xlink:type="resource" xlink:label="cytx_ChangeInFairValueOfOptions_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="cytx_ChangeInFairValueOfOptions_lbl2" xml:lang="en-US" id="cytx_ChangeInFairValueOfOptions_lbl2">Change in fair value of option liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInFairValueOfOptions" xlink:to="cytx_ChangeInFairValueOfOptions_lbl2" xlink:title="label: ChangeInFairValueOfOptions to cytx_ChangeInFairValueOfOptions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_IncreaseDecreaseOtherCurrentAssets" xlink:label="IncreaseDecreaseOtherCurrentAssets" xlink:title="IncreaseDecreaseOtherCurrentAssets" />
    <link:label xlink:type="resource" xlink:label="cytx_IncreaseDecreaseOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="cytx_IncreaseDecreaseOtherCurrentAssets_lbl" xml:lang="en-US" id="cytx_IncreaseDecreaseOtherCurrentAssets_lbl">The net change during the reporting period in the aggregate value of other current assets. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseOtherCurrentAssets" xlink:to="cytx_IncreaseDecreaseOtherCurrentAssets_lbl" xlink:title="label: IncreaseDecreaseOtherCurrentAssets to cytx_IncreaseDecreaseOtherCurrentAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="cytx_IncreaseDecreaseOtherCurrentAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_IncreaseDecreaseOtherCurrentAssets_lbl1" xml:lang="en-US" id="cytx_IncreaseDecreaseOtherCurrentAssets_lbl1">Increase Decrease Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseOtherCurrentAssets" xlink:to="cytx_IncreaseDecreaseOtherCurrentAssets_lbl1" xlink:title="label: IncreaseDecreaseOtherCurrentAssets to cytx_IncreaseDecreaseOtherCurrentAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="cytx_IncreaseDecreaseOtherCurrentAssets_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="cytx_IncreaseDecreaseOtherCurrentAssets_lbl2" xml:lang="en-US" id="cytx_IncreaseDecreaseOtherCurrentAssets_lbl2">Other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseOtherCurrentAssets" xlink:to="cytx_IncreaseDecreaseOtherCurrentAssets_lbl2" xlink:title="label: IncreaseDecreaseOtherCurrentAssets to cytx_IncreaseDecreaseOtherCurrentAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_IncreaseDecreaseOtherAssets" xlink:label="IncreaseDecreaseOtherAssets" xlink:title="IncreaseDecreaseOtherAssets" />
    <link:label xlink:type="resource" xlink:label="cytx_IncreaseDecreaseOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="cytx_IncreaseDecreaseOtherAssets_lbl" xml:lang="en-US" id="cytx_IncreaseDecreaseOtherAssets_lbl">The net change during the reporting period in the aggregate value of other noncurrent assets. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseOtherAssets" xlink:to="cytx_IncreaseDecreaseOtherAssets_lbl" xlink:title="label: IncreaseDecreaseOtherAssets to cytx_IncreaseDecreaseOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="cytx_IncreaseDecreaseOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_IncreaseDecreaseOtherAssets_lbl1" xml:lang="en-US" id="cytx_IncreaseDecreaseOtherAssets_lbl1">Increase Decrease Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseOtherAssets" xlink:to="cytx_IncreaseDecreaseOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseOtherAssets to cytx_IncreaseDecreaseOtherAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="cytx_IncreaseDecreaseOtherAssets_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="cytx_IncreaseDecreaseOtherAssets_lbl2" xml:lang="en-US" id="cytx_IncreaseDecreaseOtherAssets_lbl2">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseOtherAssets" xlink:to="cytx_IncreaseDecreaseOtherAssets_lbl2" xlink:title="label: IncreaseDecreaseOtherAssets to cytx_IncreaseDecreaseOtherAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_IncreaseDecreaseDeferredRevenueRelatedParty" xlink:label="IncreaseDecreaseDeferredRevenueRelatedParty" xlink:title="IncreaseDecreaseDeferredRevenueRelatedParty" />
    <link:label xlink:type="resource" xlink:label="cytx_IncreaseDecreaseDeferredRevenueRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="cytx_IncreaseDecreaseDeferredRevenueRelatedParty_lbl" xml:lang="en-US" id="cytx_IncreaseDecreaseDeferredRevenueRelatedParty_lbl">The net change during the reporting period in related party deferred revenue liability, including the portion taken into income, reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseDeferredRevenueRelatedParty" xlink:to="cytx_IncreaseDecreaseDeferredRevenueRelatedParty_lbl" xlink:title="label: IncreaseDecreaseDeferredRevenueRelatedParty to cytx_IncreaseDecreaseDeferredRevenueRelatedParty_lbl" />
    <link:label xlink:type="resource" xlink:label="cytx_IncreaseDecreaseDeferredRevenueRelatedParty_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_IncreaseDecreaseDeferredRevenueRelatedParty_lbl1" xml:lang="en-US" id="cytx_IncreaseDecreaseDeferredRevenueRelatedParty_lbl1">Increase Decrease Deferred Revenue Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseDeferredRevenueRelatedParty" xlink:to="cytx_IncreaseDecreaseDeferredRevenueRelatedParty_lbl1" xlink:title="label: IncreaseDecreaseDeferredRevenueRelatedParty to cytx_IncreaseDecreaseDeferredRevenueRelatedParty_lbl1" />
    <link:label xlink:type="resource" xlink:label="cytx_IncreaseDecreaseDeferredRevenueRelatedParty_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="cytx_IncreaseDecreaseDeferredRevenueRelatedParty_lbl2" xml:lang="en-US" id="cytx_IncreaseDecreaseDeferredRevenueRelatedParty_lbl2">Deferred revenues, related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseDeferredRevenueRelatedParty" xlink:to="cytx_IncreaseDecreaseDeferredRevenueRelatedParty_lbl2" xlink:title="label: IncreaseDecreaseDeferredRevenueRelatedParty to cytx_IncreaseDecreaseDeferredRevenueRelatedParty_lbl2" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_IncreaseDecreaseOfDeferredRevenue" xlink:label="IncreaseDecreaseOfDeferredRevenue" xlink:title="IncreaseDecreaseOfDeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="cytx_IncreaseDecreaseOfDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="cytx_IncreaseDecreaseOfDeferredRevenue_lbl" xml:lang="en-US" id="cytx_IncreaseDecreaseOfDeferredRevenue_lbl">The net change during the reporting period in deferred revenue liability, including the portion taken into income, reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseOfDeferredRevenue" xlink:to="cytx_IncreaseDecreaseOfDeferredRevenue_lbl" xlink:title="label: IncreaseDecreaseOfDeferredRevenue to cytx_IncreaseDecreaseOfDeferredRevenue_lbl" />
    <link:label xlink:type="resource" xlink:label="cytx_IncreaseDecreaseOfDeferredRevenue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_IncreaseDecreaseOfDeferredRevenue_lbl1" xml:lang="en-US" id="cytx_IncreaseDecreaseOfDeferredRevenue_lbl1">Increase Decrease Of Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseOfDeferredRevenue" xlink:to="cytx_IncreaseDecreaseOfDeferredRevenue_lbl1" xlink:title="label: IncreaseDecreaseOfDeferredRevenue to cytx_IncreaseDecreaseOfDeferredRevenue_lbl1" />
    <link:label xlink:type="resource" xlink:label="cytx_IncreaseDecreaseOfDeferredRevenue_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="cytx_IncreaseDecreaseOfDeferredRevenue_lbl2" xml:lang="en-US" id="cytx_IncreaseDecreaseOfDeferredRevenue_lbl2">Deferred revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseOfDeferredRevenue" xlink:to="cytx_IncreaseDecreaseOfDeferredRevenue_lbl2" xlink:title="label: IncreaseDecreaseOfDeferredRevenue to cytx_IncreaseDecreaseOfDeferredRevenue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty" xlink:label="IncreaseDecreaseLongTermDeferredRentLiabiilty" xlink:title="IncreaseDecreaseLongTermDeferredRentLiabiilty" />
    <link:label xlink:type="resource" xlink:label="cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty_lbl" xml:lang="en-US" id="cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty_lbl">The net change in the long term deferred rent liability balance during the reporting period. Long term deferred liability is a cumulative difference between the rental payments required by a lease agreement and the rental expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in expense more than one year after the balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseLongTermDeferredRentLiabiilty" xlink:to="cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty_lbl" xlink:title="label: IncreaseDecreaseLongTermDeferredRentLiabiilty to cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty_lbl" />
    <link:label xlink:type="resource" xlink:label="cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty_lbl1" xml:lang="en-US" id="cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty_lbl1">Increase Decrease Long Term Deferred Rent Liabiilty</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseLongTermDeferredRentLiabiilty" xlink:to="cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty_lbl1" xlink:title="label: IncreaseDecreaseLongTermDeferredRentLiabiilty to cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty_lbl1" />
    <link:label xlink:type="resource" xlink:label="cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty_lbl2" xml:lang="en-US" id="cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty_lbl2">Long-term deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseLongTermDeferredRentLiabiilty" xlink:to="cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty_lbl2" xlink:title="label: IncreaseDecreaseLongTermDeferredRentLiabiilty to cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty_lbl2" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants" xlink:label="ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants" xlink:title="ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants" />
    <link:label xlink:type="resource" xlink:label="cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants_lbl" xml:lang="en-US" id="cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants_lbl">The cash inflow associated with the amount received from holders exercising their stock options and warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants" xlink:to="cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants_lbl" xlink:title="label: ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants to cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants_lbl1" xml:lang="en-US" id="cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants_lbl1">Proceeds from exercise of employee stock options and warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants" xlink:to="cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants_lbl1" xlink:title="label: ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants to cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants_lbl2" xml:lang="en-US" id="cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants_lbl2">Proceeds from exercise of employee stock options and warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants" xlink:to="cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants_lbl2" xlink:title="label: ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants to cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants_lbl2" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_CashPaidDuringPeriodForAbstract" xlink:label="CashPaidDuringPeriodForAbstract" xlink:title="CashPaidDuringPeriodForAbstract" />
    <link:label xlink:type="resource" xlink:label="cytx_CashPaidDuringPeriodForAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_CashPaidDuringPeriodForAbstract_lbl1" xml:lang="en-US" id="cytx_CashPaidDuringPeriodForAbstract_lbl1">Cash paid during period for: [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashPaidDuringPeriodForAbstract" xlink:to="cytx_CashPaidDuringPeriodForAbstract_lbl1" xlink:title="label: CashPaidDuringPeriodForAbstract to cytx_CashPaidDuringPeriodForAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="cytx_CashPaidDuringPeriodForAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="cytx_CashPaidDuringPeriodForAbstract_lbl2" xml:lang="en-US" id="cytx_CashPaidDuringPeriodForAbstract_lbl2">Cash paid during period for:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashPaidDuringPeriodForAbstract" xlink:to="cytx_CashPaidDuringPeriodForAbstract_lbl2" xlink:title="label: CashPaidDuringPeriodForAbstract to cytx_CashPaidDuringPeriodForAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_BasisOfPresentationAbstract" xlink:label="BasisOfPresentationAbstract" xlink:title="BasisOfPresentationAbstract" />
    <link:label xlink:type="resource" xlink:label="cytx_BasisOfPresentationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_BasisOfPresentationAbstract_lbl1" xml:lang="en-US" id="cytx_BasisOfPresentationAbstract_lbl1">Basis of Presentation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfPresentationAbstract" xlink:to="cytx_BasisOfPresentationAbstract_lbl1" xlink:title="label: BasisOfPresentationAbstract to cytx_BasisOfPresentationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_UseOfEstimatesAbstract" xlink:label="UseOfEstimatesAbstract" xlink:title="UseOfEstimatesAbstract" />
    <link:label xlink:type="resource" xlink:label="cytx_UseOfEstimatesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_UseOfEstimatesAbstract_lbl1" xml:lang="en-US" id="cytx_UseOfEstimatesAbstract_lbl1">Use of Estimates [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimatesAbstract" xlink:to="cytx_UseOfEstimatesAbstract_lbl1" xlink:title="label: UseOfEstimatesAbstract to cytx_UseOfEstimatesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_UseOfEstimatesTextBlock" xlink:label="UseOfEstimatesTextBlock" xlink:title="UseOfEstimatesTextBlock" />
    <link:label xlink:type="resource" xlink:label="cytx_UseOfEstimatesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="cytx_UseOfEstimatesTextBlock_lbl" xml:lang="en-US" id="cytx_UseOfEstimatesTextBlock_lbl">Provides an entity's explanation that the preparation of financial statements in conformity with generally accepted accounting principles requires the use of management estimates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimatesTextBlock" xlink:to="cytx_UseOfEstimatesTextBlock_lbl" xlink:title="label: UseOfEstimatesTextBlock to cytx_UseOfEstimatesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="cytx_UseOfEstimatesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_UseOfEstimatesTextBlock_lbl1" xml:lang="en-US" id="cytx_UseOfEstimatesTextBlock_lbl1">Use Of Estimates [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimatesTextBlock" xlink:to="cytx_UseOfEstimatesTextBlock_lbl1" xlink:title="label: UseOfEstimatesTextBlock to cytx_UseOfEstimatesTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="cytx_UseOfEstimatesTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="cytx_UseOfEstimatesTextBlock_lbl2" xml:lang="en-US" id="cytx_UseOfEstimatesTextBlock_lbl2">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimatesTextBlock" xlink:to="cytx_UseOfEstimatesTextBlock_lbl2" xlink:title="label: UseOfEstimatesTextBlock to cytx_UseOfEstimatesTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_CapitalAvailabilityAbstract" xlink:label="CapitalAvailabilityAbstract" xlink:title="CapitalAvailabilityAbstract" />
    <link:label xlink:type="resource" xlink:label="cytx_CapitalAvailabilityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_CapitalAvailabilityAbstract_lbl1" xml:lang="en-US" id="cytx_CapitalAvailabilityAbstract_lbl1">Capital Availability [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalAvailabilityAbstract" xlink:to="cytx_CapitalAvailabilityAbstract_lbl1" xlink:title="label: CapitalAvailabilityAbstract to cytx_CapitalAvailabilityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_CapitalAvailabilityTextBlock" xlink:label="CapitalAvailabilityTextBlock" xlink:title="CapitalAvailabilityTextBlock" />
    <link:label xlink:type="resource" xlink:label="cytx_CapitalAvailabilityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="cytx_CapitalAvailabilityTextBlock_lbl" xml:lang="en-US" id="cytx_CapitalAvailabilityTextBlock_lbl">Capital Availability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalAvailabilityTextBlock" xlink:to="cytx_CapitalAvailabilityTextBlock_lbl" xlink:title="label: CapitalAvailabilityTextBlock to cytx_CapitalAvailabilityTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="cytx_CapitalAvailabilityTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_CapitalAvailabilityTextBlock_lbl1" xml:lang="en-US" id="cytx_CapitalAvailabilityTextBlock_lbl1">Capital Availability [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalAvailabilityTextBlock" xlink:to="cytx_CapitalAvailabilityTextBlock_lbl1" xlink:title="label: CapitalAvailabilityTextBlock to cytx_CapitalAvailabilityTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="cytx_CapitalAvailabilityTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="cytx_CapitalAvailabilityTextBlock_lbl2" xml:lang="en-US" id="cytx_CapitalAvailabilityTextBlock_lbl2">Capital Availability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalAvailabilityTextBlock" xlink:to="cytx_CapitalAvailabilityTextBlock_lbl2" xlink:title="label: CapitalAvailabilityTextBlock to cytx_CapitalAvailabilityTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_RecentlyAccountingPronouncementsAbstract" xlink:label="RecentlyAccountingPronouncementsAbstract" xlink:title="RecentlyAccountingPronouncementsAbstract" />
    <link:label xlink:type="resource" xlink:label="cytx_RecentlyAccountingPronouncementsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_RecentlyAccountingPronouncementsAbstract_lbl1" xml:lang="en-US" id="cytx_RecentlyAccountingPronouncementsAbstract_lbl1">Recently Accounting Pronouncements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RecentlyAccountingPronouncementsAbstract" xlink:to="cytx_RecentlyAccountingPronouncementsAbstract_lbl1" xlink:title="label: RecentlyAccountingPronouncementsAbstract to cytx_RecentlyAccountingPronouncementsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_WarrantLiabilityAbstract" xlink:label="WarrantLiabilityAbstract" xlink:title="WarrantLiabilityAbstract" />
    <link:label xlink:type="resource" xlink:label="cytx_WarrantLiabilityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_WarrantLiabilityAbstract_lbl1" xml:lang="en-US" id="cytx_WarrantLiabilityAbstract_lbl1">Warrant Liability [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantLiabilityAbstract" xlink:to="cytx_WarrantLiabilityAbstract_lbl1" xlink:title="label: WarrantLiabilityAbstract to cytx_WarrantLiabilityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_WarrantLiabilityTextBlock" xlink:label="WarrantLiabilityTextBlock" xlink:title="WarrantLiabilityTextBlock" />
    <link:label xlink:type="resource" xlink:label="cytx_WarrantLiabilityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="cytx_WarrantLiabilityTextBlock_lbl" xml:lang="en-US" id="cytx_WarrantLiabilityTextBlock_lbl">Disclosure for warrants which are accounted for as fair value liabilities with changes in fair value included in net earnings (loss). Fair value for these warrants is measured on a recurring basis using valuation techniques in which one or more significant inputs are unobservable in active markets (Level 3).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantLiabilityTextBlock" xlink:to="cytx_WarrantLiabilityTextBlock_lbl" xlink:title="label: WarrantLiabilityTextBlock to cytx_WarrantLiabilityTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="cytx_WarrantLiabilityTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_WarrantLiabilityTextBlock_lbl1" xml:lang="en-US" id="cytx_WarrantLiabilityTextBlock_lbl1">Warrant Liability [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantLiabilityTextBlock" xlink:to="cytx_WarrantLiabilityTextBlock_lbl1" xlink:title="label: WarrantLiabilityTextBlock to cytx_WarrantLiabilityTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="cytx_WarrantLiabilityTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="cytx_WarrantLiabilityTextBlock_lbl2" xml:lang="en-US" id="cytx_WarrantLiabilityTextBlock_lbl2">Warrant Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantLiabilityTextBlock" xlink:to="cytx_WarrantLiabilityTextBlock_lbl2" xlink:title="label: WarrantLiabilityTextBlock to cytx_WarrantLiabilityTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_RevenueRecognitionTextBlock" xlink:label="RevenueRecognitionTextBlock" xlink:title="RevenueRecognitionTextBlock" />
    <link:label xlink:type="resource" xlink:label="cytx_RevenueRecognitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="cytx_RevenueRecognitionTextBlock_lbl" xml:lang="en-US" id="cytx_RevenueRecognitionTextBlock_lbl">Describes accounting policy for product as well as research and development revenue recognition. If there are different policies for different types of revenue transactions, the policy for each material type of transaction should be disclosed. If a sales transaction has multiple element arrangements, the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionTextBlock" xlink:to="cytx_RevenueRecognitionTextBlock_lbl" xlink:title="label: RevenueRecognitionTextBlock to cytx_RevenueRecognitionTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="cytx_RevenueRecognitionTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_RevenueRecognitionTextBlock_lbl1" xml:lang="en-US" id="cytx_RevenueRecognitionTextBlock_lbl1">Revenue Recognition [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionTextBlock" xlink:to="cytx_RevenueRecognitionTextBlock_lbl1" xlink:title="label: RevenueRecognitionTextBlock to cytx_RevenueRecognitionTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="cytx_RevenueRecognitionTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="cytx_RevenueRecognitionTextBlock_lbl2" xml:lang="en-US" id="cytx_RevenueRecognitionTextBlock_lbl2">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionTextBlock" xlink:to="cytx_RevenueRecognitionTextBlock_lbl2" xlink:title="label: RevenueRecognitionTextBlock to cytx_RevenueRecognitionTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_InventoriesAbstract" xlink:label="InventoriesAbstract" xlink:title="InventoriesAbstract" />
    <link:label xlink:type="resource" xlink:label="cytx_InventoriesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_InventoriesAbstract_lbl1" xml:lang="en-US" id="cytx_InventoriesAbstract_lbl1">Inventories [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoriesAbstract" xlink:to="cytx_InventoriesAbstract_lbl1" xlink:title="label: InventoriesAbstract to cytx_InventoriesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_LossPerShareAbstract" xlink:label="LossPerShareAbstract" xlink:title="LossPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="cytx_LossPerShareAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_LossPerShareAbstract_lbl1" xml:lang="en-US" id="cytx_LossPerShareAbstract_lbl1">Loss per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossPerShareAbstract" xlink:to="cytx_LossPerShareAbstract_lbl1" xlink:title="label: LossPerShareAbstract to cytx_LossPerShareAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_FairValueAbstract" xlink:label="FairValueAbstract" xlink:title="FairValueAbstract" />
    <link:label xlink:type="resource" xlink:label="cytx_FairValueAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_FairValueAbstract_lbl1" xml:lang="en-US" id="cytx_FairValueAbstract_lbl1">Fair Value [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAbstract" xlink:to="cytx_FairValueAbstract_lbl1" xlink:title="label: FairValueAbstract to cytx_FairValueAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="cytx_DocumentAndEntityInformationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cytx_DocumentAndEntityInformationAbstract_lbl1" xml:lang="en-US" id="cytx_DocumentAndEntityInformationAbstract_lbl1">Document and Entity Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="cytx_DocumentAndEntityInformationAbstract_lbl1" xlink:title="label: DocumentAndEntityInformationAbstract to cytx_DocumentAndEntityInformationAbstract_lbl1" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>cytx-20120331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Thomson Reuters Accelus-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://cytori.com/role/SubsequentEvents" xlink:type="simple" xlink:href="cytx-20120331.xsd#SubsequentEvents" />
  <link:roleRef roleURI="http://cytori.com/role/StockholdersEquity" xlink:type="simple" xlink:href="cytx-20120331.xsd#StockholdersEquity" />
  <link:roleRef roleURI="http://cytori.com/role/FairValue" xlink:type="simple" xlink:href="cytx-20120331.xsd#FairValue" />
  <link:roleRef roleURI="http://cytori.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cytx-20120331.xsd#FairValueMeasurements" />
  <link:roleRef roleURI="http://cytori.com/role/TransactionsWithOlympusCorporation" xlink:type="simple" xlink:href="cytx-20120331.xsd#TransactionsWithOlympusCorporation" />
  <link:roleRef roleURI="http://cytori.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="cytx-20120331.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://cytori.com/role/LossPerShare" xlink:type="simple" xlink:href="cytx-20120331.xsd#LossPerShare" />
  <link:roleRef roleURI="http://cytori.com/role/SharebasedCompensation" xlink:type="simple" xlink:href="cytx-20120331.xsd#SharebasedCompensation" />
  <link:roleRef roleURI="http://cytori.com/role/Inventories" xlink:type="simple" xlink:href="cytx-20120331.xsd#Inventories" />
  <link:roleRef roleURI="http://cytori.com/role/RevenueRecognition" xlink:type="simple" xlink:href="cytx-20120331.xsd#RevenueRecognition" />
  <link:roleRef roleURI="http://cytori.com/role/LongtermDebt" xlink:type="simple" xlink:href="cytx-20120331.xsd#LongtermDebt" />
  <link:roleRef roleURI="http://cytori.com/role/WarrantLiability" xlink:type="simple" xlink:href="cytx-20120331.xsd#WarrantLiability" />
  <link:roleRef roleURI="http://cytori.com/role/RecentAccountingPronouncements" xlink:type="simple" xlink:href="cytx-20120331.xsd#RecentAccountingPronouncements" />
  <link:roleRef roleURI="http://cytori.com/role/CapitalAvailability" xlink:type="simple" xlink:href="cytx-20120331.xsd#CapitalAvailability" />
  <link:roleRef roleURI="http://cytori.com/role/UseOfEstimates" xlink:type="simple" xlink:href="cytx-20120331.xsd#UseOfEstimates" />
  <link:roleRef roleURI="http://cytori.com/role/BasisOfPresentation" xlink:type="simple" xlink:href="cytx-20120331.xsd#BasisOfPresentation" />
  <link:roleRef roleURI="http://cytori.com/role/ConsolidatedCondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" xlink:href="cytx-20120331.xsd#ConsolidatedCondensedStatementsOfCashFlowsUnaudited" />
  <link:roleRef roleURI="http://cytori.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" xlink:href="cytx-20120331.xsd#ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" />
  <link:roleRef roleURI="http://cytori.com/role/ConsolidatedCondensedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="cytx-20120331.xsd#ConsolidatedCondensedBalanceSheetsUnauditedParenthetical" />
  <link:roleRef roleURI="http://cytori.com/role/ConsolidatedCondensedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="cytx-20120331.xsd#ConsolidatedCondensedBalanceSheetsUnaudited" />
  <link:roleRef roleURI="http://cytori.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="cytx-20120331.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytori.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCentralIndexKey" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: DocumentAndEntityInformationAbstract to CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityWellKnownSeasonedIssuer" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityWellKnownSeasonedIssuer" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityVoluntaryFilers" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityVoluntaryFilers" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCurrentReportingStatus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityFilerCategory" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityPublicFloat" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityPublicFloat" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentFiscalYearFocus" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentFiscalPeriodFocus" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentType" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentType" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: DocumentAndEntityInformationAbstract to AmendmentFlag" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentPeriodEndDate" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cytori.com/role/ConsolidatedCondensedBalanceSheetsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AccountsReceivableNetCurrent" xlink:title="presentation: AssetsCurrentAbstract to AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="InventoryNet" xlink:title="presentation: AssetsCurrentAbstract to InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="OtherAssetsCurrent" xlink:title="OtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="OtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to OtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsAbstract to PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="RestrictedCashAndCashEquivalentsNoncurrent" xlink:title="RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="RestrictedCashAndCashEquivalentsNoncurrent" xlink:title="presentation: AssetsAbstract to RestrictedCashAndCashEquivalentsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="EquityMethodInvestments" xlink:title="EquityMethodInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="EquityMethodInvestments" xlink:title="presentation: AssetsAbstract to EquityMethodInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="presentation: AssetsAbstract to OtherAssetsNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="IntangibleAssetsNetExcludingGoodwill" xlink:title="presentation: AssetsAbstract to IntangibleAssetsNetExcludingGoodwill" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Goodwill" xlink:title="presentation: AssetsAbstract to Goodwill" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableAndAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LongTermDebtCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LongTermDebtCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_DeferredRevenuesRelatedParty" xlink:label="DeferredRevenuesRelatedParty" xlink:title="DeferredRevenuesRelatedParty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="DeferredRevenuesRelatedParty" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to DeferredRevenuesRelatedParty" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="DeferredRevenue" xlink:title="DeferredRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="DeferredRevenue" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to DeferredRevenue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_WarrantLiability" xlink:label="WarrantLiability" xlink:title="WarrantLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="WarrantLiability" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to WarrantLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_OptionLiability" xlink:label="OptionLiability" xlink:title="OptionLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OptionLiability" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to OptionLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="DeferredRentCreditNoncurrent" xlink:title="DeferredRentCreditNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="DeferredRentCreditNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to DeferredRentCreditNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="LongTermDebtAndCapitalLeaseObligations" xlink:title="LongTermDebtAndCapitalLeaseObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LongTermDebtAndCapitalLeaseObligations" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LongTermDebtAndCapitalLeaseObligations" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to Liabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to CommitmentsAndContingencies" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockValue" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cytori.com/role/ConsolidatedCondensedBalanceSheetsUnauditedParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="AllowanceForDoubtfulAccountsReceivableCurrent" xlink:title="AllowanceForDoubtfulAccountsReceivableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AllowanceForDoubtfulAccountsReceivableCurrent" xlink:title="presentation: AssetsCurrentAbstract to AllowanceForDoubtfulAccountsReceivableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cytori.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="SalesRevenueGoodsNet" xlink:title="SalesRevenueGoodsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="SalesRevenueGoodsNet" xlink:title="presentation: IncomeStatementAbstract to SalesRevenueGoodsNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="CostOfGoodsSold" xlink:title="CostOfGoodsSold" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="CostOfGoodsSold" xlink:title="presentation: IncomeStatementAbstract to CostOfGoodsSold" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="GrossProfit" xlink:title="GrossProfit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="GrossProfit" xlink:title="presentation: IncomeStatementAbstract to GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_DevelopmentRevenuesAbstract" xlink:label="DevelopmentRevenuesAbstract" xlink:title="DevelopmentRevenuesAbstract" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_DevelopmentRelatedParty" xlink:label="DevelopmentRelatedParty" xlink:title="DevelopmentRelatedParty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DevelopmentRevenuesAbstract" xlink:to="DevelopmentRelatedParty" xlink:title="presentation: DevelopmentRevenuesAbstract to DevelopmentRelatedParty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_ResearchGrantsAndOther" xlink:label="ResearchGrantsAndOther" xlink:title="ResearchGrantsAndOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DevelopmentRevenuesAbstract" xlink:to="ResearchGrantsAndOther" xlink:title="presentation: DevelopmentRevenuesAbstract to ResearchGrantsAndOther" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_TotalDevelopmentRevenues" xlink:label="TotalDevelopmentRevenues" xlink:title="TotalDevelopmentRevenues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DevelopmentRevenuesAbstract" xlink:to="TotalDevelopmentRevenues" xlink:title="presentation: DevelopmentRevenuesAbstract to TotalDevelopmentRevenues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="DevelopmentRevenuesAbstract" xlink:title="presentation: IncomeStatementAbstract to DevelopmentRevenuesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: OperatingExpensesAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="SellingAndMarketingExpense" xlink:title="SellingAndMarketingExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="SellingAndMarketingExpense" xlink:title="presentation: OperatingExpensesAbstract to SellingAndMarketingExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: OperatingExpensesAbstract to GeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_ChangeInFairValueOfWarrants" xlink:label="ChangeInFairValueOfWarrants" xlink:title="ChangeInFairValueOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ChangeInFairValueOfWarrants" xlink:title="presentation: OperatingExpensesAbstract to ChangeInFairValueOfWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_ChangeInFairValueOfOptionLiability" xlink:label="ChangeInFairValueOfOptionLiability" xlink:title="ChangeInFairValueOfOptionLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ChangeInFairValueOfOptionLiability" xlink:title="presentation: OperatingExpensesAbstract to ChangeInFairValueOfOptionLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: OperatingExpensesAbstract to OperatingExpenses" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to OperatingExpensesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to OperatingIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="OtherIncomeAndExpensesAbstract" xlink:title="OtherIncomeAndExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeAndExpensesAbstract" xlink:to="InvestmentIncomeInterest" xlink:title="presentation: OtherIncomeAndExpensesAbstract to InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeAndExpensesAbstract" xlink:to="InterestExpense" xlink:title="presentation: OtherIncomeAndExpensesAbstract to InterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeAndExpensesAbstract" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="presentation: OtherIncomeAndExpensesAbstract to OtherNonoperatingIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromEquityMethodInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeAndExpensesAbstract" xlink:to="IncomeLossFromEquityMethodInvestments" xlink:title="presentation: OtherIncomeAndExpensesAbstract to IncomeLossFromEquityMethodInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeAndExpensesAbstract" xlink:to="NonoperatingIncomeExpense" xlink:title="presentation: OtherIncomeAndExpensesAbstract to NonoperatingIncomeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OtherIncomeAndExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to OtherIncomeAndExpensesAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareDiluted" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cytori.com/role/ConsolidatedCondensedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DepreciationDepletionAndAmortization" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfFinancingCostsAndDiscounts" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfFinancingCostsAndDiscounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="ProvisionForDoubtfulAccounts" xlink:title="ProvisionForDoubtfulAccounts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ProvisionForDoubtfulAccounts" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ProvisionForDoubtfulAccounts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_ChangeInFairValueOfWarrants" xlink:label="ChangeInFairValueOfWarrants" xlink:title="ChangeInFairValueOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ChangeInFairValueOfWarrants" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ChangeInFairValueOfWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_ChangeInFairValueOfOptions" xlink:label="ChangeInFairValueOfOptions" xlink:title="ChangeInFairValueOfOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ChangeInFairValueOfOptions" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ChangeInFairValueOfOptions" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromEquityMethodInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncomeLossFromEquityMethodInvestments" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncomeLossFromEquityMethodInvestments" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsReceivable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInInventories" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_IncreaseDecreaseOtherCurrentAssets" xlink:label="IncreaseDecreaseOtherCurrentAssets" xlink:title="IncreaseDecreaseOtherCurrentAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseOtherCurrentAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseOtherCurrentAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_IncreaseDecreaseOtherAssets" xlink:label="IncreaseDecreaseOtherAssets" xlink:title="IncreaseDecreaseOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseOtherAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_IncreaseDecreaseDeferredRevenueRelatedParty" xlink:label="IncreaseDecreaseDeferredRevenueRelatedParty" xlink:title="IncreaseDecreaseDeferredRevenueRelatedParty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseDeferredRevenueRelatedParty" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseDeferredRevenueRelatedParty" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_IncreaseDecreaseOfDeferredRevenue" xlink:label="IncreaseDecreaseOfDeferredRevenue" xlink:title="IncreaseDecreaseOfDeferredRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseOfDeferredRevenue" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseOfDeferredRevenue" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty" xlink:label="IncreaseDecreaseLongTermDeferredRentLiabiilty" xlink:title="IncreaseDecreaseLongTermDeferredRentLiabiilty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseLongTermDeferredRentLiabiilty" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseLongTermDeferredRentLiabiilty" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="RepaymentsOfLongTermDebt" xlink:title="RepaymentsOfLongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="RepaymentsOfLongTermDebt" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to RepaymentsOfLongTermDebt" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants" xlink:label="ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants" xlink:title="ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentsOfStockIssuanceCosts" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to NetCashProvidedByUsedInFinancingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="presentation: StatementOfCashFlowsAbstract to CashAndCashEquivalentsPeriodIncreaseDecrease" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: StatementOfCashFlowsAbstract to CashAndCashEquivalentsAtCarryingValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue_2" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue_2" xlink:title="presentation: StatementOfCashFlowsAbstract to CashAndCashEquivalentsAtCarryingValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_CashPaidDuringPeriodForAbstract" xlink:label="CashPaidDuringPeriodForAbstract" xlink:title="CashPaidDuringPeriodForAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="InterestPaid" xlink:title="InterestPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidDuringPeriodForAbstract" xlink:to="InterestPaid" xlink:title="presentation: CashPaidDuringPeriodForAbstract to InterestPaid" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="CashPaidDuringPeriodForAbstract" xlink:title="presentation: SupplementalCashFlowInformationAbstract to CashPaidDuringPeriodForAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to SupplementalCashFlowInformationAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="CapitalLeaseObligationsIncurred" xlink:title="CapitalLeaseObligationsIncurred" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="CapitalLeaseObligationsIncurred" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to CapitalLeaseObligationsIncurred" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:label="NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:title="NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cytori.com/role/BasisOfPresentation">
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_BasisOfPresentationAbstract" xlink:label="BasisOfPresentationAbstract" xlink:title="BasisOfPresentationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasisOfPresentationAbstract" xlink:to="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="presentation: BasisOfPresentationAbstract to OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cytori.com/role/UseOfEstimates">
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_UseOfEstimatesAbstract" xlink:label="UseOfEstimatesAbstract" xlink:title="UseOfEstimatesAbstract" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_UseOfEstimatesTextBlock" xlink:label="UseOfEstimatesTextBlock" xlink:title="UseOfEstimatesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UseOfEstimatesAbstract" xlink:to="UseOfEstimatesTextBlock" xlink:title="presentation: UseOfEstimatesAbstract to UseOfEstimatesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cytori.com/role/CapitalAvailability">
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_CapitalAvailabilityAbstract" xlink:label="CapitalAvailabilityAbstract" xlink:title="CapitalAvailabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_CapitalAvailabilityTextBlock" xlink:label="CapitalAvailabilityTextBlock" xlink:title="CapitalAvailabilityTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CapitalAvailabilityAbstract" xlink:to="CapitalAvailabilityTextBlock" xlink:title="presentation: CapitalAvailabilityAbstract to CapitalAvailabilityTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cytori.com/role/RecentAccountingPronouncements">
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_RecentlyAccountingPronouncementsAbstract" xlink:label="RecentlyAccountingPronouncementsAbstract" xlink:title="RecentlyAccountingPronouncementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:title="ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RecentlyAccountingPronouncementsAbstract" xlink:to="ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:title="presentation: RecentlyAccountingPronouncementsAbstract to ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cytori.com/role/WarrantLiability">
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_WarrantLiabilityAbstract" xlink:label="WarrantLiabilityAbstract" xlink:title="WarrantLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_WarrantLiabilityTextBlock" xlink:label="WarrantLiabilityTextBlock" xlink:title="WarrantLiabilityTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantLiabilityAbstract" xlink:to="WarrantLiabilityTextBlock" xlink:title="presentation: WarrantLiabilityAbstract to WarrantLiabilityTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cytori.com/role/LongtermDebt">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtAbstract" xlink:label="LongTermDebtAbstract" xlink:title="LongTermDebtAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="LongTermDebtTextBlock" xlink:title="LongTermDebtTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDebtAbstract" xlink:to="LongTermDebtTextBlock" xlink:title="presentation: LongTermDebtAbstract to LongTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cytori.com/role/RevenueRecognition">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="RevenueRecognitionAbstract" xlink:title="RevenueRecognitionAbstract" />
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_RevenueRecognitionTextBlock" xlink:label="RevenueRecognitionTextBlock" xlink:title="RevenueRecognitionTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRecognitionAbstract" xlink:to="RevenueRecognitionTextBlock" xlink:title="presentation: RevenueRecognitionAbstract to RevenueRecognitionTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cytori.com/role/Inventories">
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_InventoriesAbstract" xlink:label="InventoriesAbstract" xlink:title="InventoriesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="InventoryDisclosureTextBlock" xlink:title="InventoryDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAbstract" xlink:to="InventoryDisclosureTextBlock" xlink:title="presentation: InventoriesAbstract to InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cytori.com/role/SharebasedCompensation">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="presentation: ShareBasedCompensationAbstract to DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cytori.com/role/LossPerShare">
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_LossPerShareAbstract" xlink:label="LossPerShareAbstract" xlink:title="LossPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="EarningsPerShareTextBlock" xlink:title="EarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareAbstract" xlink:to="EarningsPerShareTextBlock" xlink:title="presentation: LossPerShareAbstract to EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cytori.com/role/CommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cytori.com/role/TransactionsWithOlympusCorporation">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="presentation: RelatedPartyTransactionsAbstract to RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cytori.com/role/FairValueMeasurements">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="FairValueMeasurementInputsDisclosureTextBlock" xlink:title="FairValueMeasurementInputsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueMeasurementInputsDisclosureTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueMeasurementInputsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cytori.com/role/FairValue">
    <link:loc xlink:type="locator" xlink:href="cytx-20120331.xsd#cytx_FairValueAbstract" xlink:label="FairValueAbstract" xlink:title="FairValueAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAbstract" xlink:to="FairValueDisclosuresTextBlock" xlink:title="presentation: FairValueAbstract to FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cytori.com/role/StockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquityNoteDisclosureTextBlock" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cytori.com/role/SubsequentEvents">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:label="ScheduleOfSubsequentEventsTextBlock" xlink:title="ScheduleOfSubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="ScheduleOfSubsequentEventsTextBlock" xlink:title="presentation: SubsequentEventsAbstract to ScheduleOfSubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_RecentlyAccountingPronouncementsAbstract', window );"><strong>Recently Accounting Pronouncements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Pronouncements</a></td>
        <td class="text"><div><div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="top" style="width: 3%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">4.</div></td><td align="left" valign="top" style="width: 93%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">Recent Accounting Pronouncements</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">In May 2011, the FASB revised the fair value measurement and disclosure requirements to align the requirements under GAAP and International Financial Reporting Standards ("IFRS"). The guidance clarifies the FASB's intent about the application of existing fair value measurements and requires enhanced disclosures, most significantly related to unobservable inputs used in a fair value measurement that is categorized within Level 3 of the fair value hierarchy. The guidance is effective prospectively during interim and annual periods beginning after December 15, 2011. The adoption of this guidance did not have a material impact on our consolidated financial statements.</div><br /></div></div><div></div><div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_RecentlyAccountingPronouncementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_RecentlyAccountingPronouncementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e765-108305<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Accounting Change<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6503790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6801783&amp;loc=d3e22583-107794<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 28<br><br> -Paragraph 23, 24<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.10-01.(b)(6))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6958853&amp;loc=d3e46468-122699<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e725-108305<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 01<br><br> -Paragraph b<br><br> -Subparagraph 6<br><br> -Article 10<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Direct Effects of a Change in Accounting Principle<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510796<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 154<br><br> -Paragraph 2, 17, 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Change in Accounting Principle<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507316<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Retrospective Application<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523989<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6801783&amp;loc=d3e22580-107794<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6801783&amp;loc=d3e22499-107794<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Indirect Effects of a Change in Accounting Principle<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515603<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>12
<FILENAME>0001140361-12-024098-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-12-024098-xbrl.zip
M4$L#!!0````(`&8PJD#FC3VW:ET``+2O`P`1`!P`8WET>"TR,#$R,#,S,2YX
M;6Q55`D``V"2JT]@DJM/=7@+``$$)0X```0Y`0``[#UK<]LXDM^O:O\#UI>9
MB:LD6]3+4C+)EN,D4[Z=C%UQ9G:KMNX#1$(29BB2"Y"VM;_^NAO@0Q0E40\G
M]GFJ9BHR"?0+C48WT`W^^+?[F<]NA=(R#-X<.2>M(R8"-_1D,'ESE.@FUZZ4
M1W][^Y?_^O&OS>9/(A"*Q\)CHSG[,@UG.@S89Y'$`("=NZ[PH4L3&]^/E,\`
M=J!?X4_YYF@:Q]&KT].[N[L3?'(2JLEIN]7JG,I`QSQPQ9%M[\O@CS7-\?6(
MZZSY_5+[NPZU=H;#X2F]S9IJ6=40P#JG__ST\XT[%3/>+-.#Z+V\8Y&:_JEY
MF3:5.NRVG;-US)H668?@5NAX$;86[LDDO#TU[Z";XS1;3K/CI)U`QA/.HZS7
MF.L18;`O*KIX0E8C@1<5S8-D5LV#%ZO3>!Z)4V@AE'2S#F%0HT\8-$O]W#`)
M8C6OILV^K*#/391:T0?>@`)7=0JX='5U+WI5T45+M[H#O*AJ'D<KR,(W%1W$
MO3NM[H!OJAB?Q_=9!_@C5/+$#6?8LMWJ9.WJS#:8I8S]B-/CE2;%_RS&C*;+
M*QRM-T=:SB(?9P$]FRHQ?G.$^)LILI-[[1VQ4P.(9CF,9Q"+^YA)#]I2.Z?E
MQ&%&'K7-6HL@EO'</LN>2@^?CZ50C`@3"]RD`KJX_/O1VQ;,W-:P-QPX/YZ6
M.Z>H3BMP64P1J&+HE?&#?%3\'JS<6R0;Y=_*P.?O2IU$X!6Z=&#(<L1>H4/Z
MM(`Z?61EMTZ<3JO?:3T)(1HUB]\:%>XW.ZT,N'US"'FT6]VG)P_0C^Z#R>.I
M3+)%>13GRR'EX3CMIR</IPDB>2!Y9.;8>3*:LF".G>W-L?-PYKCU%-6K]9#J
M]524:G%Y.I3Y20)IA/$KT%R2PTQPG2CQU@8`KWZ]>9]"2E\5H2.H5:#;*T#;
M.3'E2NA=87=*L#UY"^(NBP][_(*>/`</-'NY+:]%`5=#+*![+X)P)H/U"#=)
MH(QQ&6CZML#WLM@@$H9@%Z,3S91PA;SE(U\T6"!B%H[AD18*8C?\_<(9G#5`
MA1D///J[>]:EOV7`<.VCYZB%#>P6"3>6M\*?4Q`-F&Q$]RI%]SG#]HN(+RC6
MB9G5Q,_DH.>1`-)+ST@;F2=<.>,^Q`;@,3G==@^H^/&T#H(GP;19ZM<RW6[W
M6SLP[7DREF'`?19QZ36!!Y=',N;^$KU9RVMH>!E<F&:[C$^[-^CU^XO$5D-_
M0#KKB+37[G0&V]$Y"U4L_\.Q#2J')\8").ZQ,4S$P)7!!`C1H&2H))X8Q<R3
MFL9IB8\"I*OQQ[3[!?8^AV7>=M,5`[`8E:YGL7.VR%]-K(^)X;+?MY[A;FM/
MAJO,1&H?EGCR_?`.-R0^ANI]F(SB<>(OS\M]3-V@-'[;(/P6/-68=F!/#\#3
M!==34CH7?XA_)]#,AP9+_&!#&&G\YT/>ZCR^X$K-015^XWXB=AF;3K<S'"YP
M4@O5U^*@QDAT^L-V^_%RT-K,0:_=[P\>+P<U#%:WW>^>[<'!)6"$J;QD;M/G
MN([MMX;T2]Y6$?)^9&QEV;NER59)1F;I(CY'JT%CRUU7);!DB?M(!'K9XET&
MK@(_6[P7YM_+(`5S;:#`:)P;&#]+/I(^N`ABSX6Y.>B4N-F%AD?!]U:CV!ST
MNH=D/.W.7J8`CM%1S^21+R#UN<_[[#O&O;+*;D;YK3C;;A3;9X.#<W89W(*A
M"Y6LHZF%QOL-4J^_@9$"IJ_&P5:#X9QMFE%5+%R$LYF,9[BTD+&X`!)@<1'@
M'@-!Z!?[(6X]L']]P5VR=W[H_O&_2ZMB#@17K"*('`+VI^X;!^KM]W[\VI.W
MWT_BU[5^QD:5A>]'W#/'_JTC^EM'W$W_UO'<%V^.[J073U\QI]7Z[C4;`RG-
M,9])?_Z*Q7(&/`?BCJEPQ@/[5LO_"&P>Q:^/,H0J^P7VU9>3X,V1+\;Q$;NU
M?\5A5,;8^2X'`,2G;U$43>KUBB&,UXR>R`!W"%\QQ(O!5.1S('&$`MQ$]HRK
MB0R:",SV+S-B'MP).9E"DU'H>UDO99ZU3@8IPXYS@B2?%@1^&GL["&#X5"6P
M=I*LD<UIKB>GI*/97XMZO""(=6QGTALI=EH'V#Y2_4)2_06D^KE"JLZ@4JPE
M&18G#;9-B<L0R\"7@5@QU?XAV)3?"B;(Q_.@<1PR/E%"F+&XD_$4%$[),-$4
MR'+E3EFH)CRPL;X&P(I%2C1=P"-=[ALW/_W#$[?"#R,$!Z0E'HQG@]U-)8`A
MS)$*;Z7.`+D8G_H^@3YAOX(H%8NG`B2K9K1K"'_`<I"3V*#78':]4&D#S8/W
M1+2(Y]@%PV_I@J1EX/J)9[92`B]Q4<4RKC!0!^]'TD-D000J]'W\*P)R#*Y9
M".L#V'=X:)DQ^S$\YO"#^W,M]0D#A\J(+TGI7R"9Q?,(9>//+46"C84P_&>T
M(E@EY&R4*$W=D)/4P3QA7U`F<H:$P/,H1>A!;+0"Z1W7#+QX6,XH,PO6*X^%
M`7/M_@(>L'B);[9F5P]GRC4LPB!K@*[UR?=\%KW^;Z??>EWXA=,&56YWW3PG
M4CZ1QG6<!NT)@^J(5&\*)&::B>3!F(]@4EKMQ(WE?HOVE5\:M>.PUJ(@790#
MJ/L(Q)_@8+@AIK+@4U1[X)"S.8`]7I3`!EQ`(S@Z!M^+;L.QO^'52NRK\)XL
M"G&%E+<7[,TT3'S/3"NK0F:2C1)O(N)TFJW1@EA)<(J8.^5@HQM%2!0.S8SC
MG())E7,<IFI9%-H=$0/@0@OO9$EW=C7F%:O4&NOY+):)]PD9KW:K-:"YM&CX
MF4ZB"&9"9C;,`L`9C*V<)3,6):#YZ(\KW,)1UK2X/D^TJ+0#ZR?Q$MCR;&HW
MG*%C)Y/3Z'2=C9,)3S4JYU'1@7ANSD'E,J]A958PF7T*L`HK!<[3,%%L*KCW
M[X0KRML-QV-8EQ@0:HXH8#6Y@X4:_Y4(->#V6*G4T*QD;JBB$'."&=@>C1J8
M(A%@^\(Y+G\`=!$2UQK$1S2=L/6*!)K(09<`KN%FR2JW&NW>,%.DLT%O3ZO\
M##4(9:23T>\@)!11ZA7"Y)>S=)2+H:T2/K?B],4$#QQ5Z`J!_E>US_`>G!=H
M#$N$5`RT`$+:!F"$X5GJ#YIR&_HP\#*8"O)?$O`;50Q*$,NBI]>`12UF01@S
M'Q8H0TX#"$U4S%2"WIW&P^E)&$NK+B,1WPD!PST>&W6(8`:DCMXDA#E#*HGZ
MZ5*/2EX^@3<X,284U%C@?W9-#4=F<XU<4PC<K=^';"[*+]]9A-]`?MH-GI]"
M#\_$_18N"%O<<CPGDLI-9B9[%UB#Z<DC0!K!BAU7F^@"J2/A2W%+(#D0'LP+
M:&%D$OMBQH$*)=%J(&G@$24^^:?6F805!/Q4STS'\LC=2;`:."`T<6%I`;K0
MG6#<PPH#F(<D>#0':!_L\:<Y>#9GQ@V@"E8?^&/>0-?%X*>)'D:8&V+,#I)V
M-PU]\3QG[&<\0,91`UD+UB<MXZ0UB=;VD!D%[)9"[Y63&!O[83!I8BQ6M+!_
MRE<PIWT8`<>*!]H:%N-\7?GS693`5,ZCUY?\F!KG8V#M)ON?$`P@^PUPX8XB
M+%KCA'Z9S#2#_^7HF%E;"8Y7;$_E8%(2AQ`DSD;"\\A+()A<*73+"QL"EJ2U
M?E5I")_!X_1WX8!QJUW;A1UC&%(=PT-8`"E/C?$DGH8*U!(&$`;&/#VNVB<.
M@QOL>4,MSO-N-4[>VZ4=[R$>2"Z>F:Y&\+7IKSAW?T#ZI=;)EK1?FBX[R+TW
MZ+8'_59_#=T&^->BN8:L>_W>L-L?=+:F^<;0;)HTV%42H_>"AFXCM86V#R3F
M`H:O1/=A1+V&;JLC+UHGK9:#WBV>*"3B-1M24$2!T=*D?<UZ@P9(JP'BHA6C
MUV\`$0V@HJ1ME,U9X&^[;,X"(SOG"_4&JZ9\*2?E_X,\:F0?]<[JRD/'9O<W
MQ,UQH.M6!,GR$2NVNQK_%()#<1/Z>R:]#'J=$G4+P`].W%8GOF`?:A%72)AH
M,)M`5R:LT&:?/,76L#2<RW`/358-%3L;M)W:5%7%$%F&>)K5"D$>1,W9\42$
MV:5AL$0]P/H"H-Z+44RI7)1%_#/N`5T5MH!V$?3PK+5XW%\/UV-BLTYJMC/L
MM_=A\QW7TC6'8-)/,))!#FE?`X(."GY"ZWZ0(^*%OL^5>4E/EWR2#USA3IZ^
M%HK6LO<6[E9FIE/DLWWTMMDZ<0KK_`H<CX"KM?:I@JMVISY7EP$0#@3_#'P<
ML[$*9PP3'^,Y^R1@8?,HKT:;@*4BKP;Z8L^/T,]T,[T*G?9,X^JURODUFU%^
M0^:VR^3J+N4_;<$<K=9-<VB+&],BT+S*4-"PO\-F%X56^PW+L+0(5N-X*%*W
M6Z\'SC:DUM:/^NJ^N6ZB%)!N&OF#TUBK7F<[&LV%+^:,F'MXJ*=CW(:]7<J8
MM"TQU72AW0>3V+"?HG:&[<45>P.VKT#_5MK;Z75WI%_APG2MPK%<\N_HG7FU
M;W;Z8EA5`+PW(5N)J==N;23D,H!P:R)'OC`N5T6VO'U_KK6(]2\B_G!OMU?1
MO:=#BEV\QD[9RF_&\[!$UYCNSK"].]'I@Z7AWD.*G7*US/Y8ZQ3I;,2:5D(P
M.P%7U6`<Q)H-^M75(.7)OR]16\V]LTXY'7T545DB]`I5-N_GH%L[:4AG*1<[
M!W@8*NIH3,<IBZ."BD(HO";XWD4*W7:[UUX5=N^+OTZ!H=,;#+;!3RNL\2;6
MD`+K'3F1T]#WA-+6`]I%/D.GM5(^E5@>FN@ZNW5.K]/=C>B+Q5T$DV!0L0NQ
M;GMAC[TI$+>S<BMAJ:ST`6FMX^)V2P6_ZVA%\T`%C-<FO9@N-GSYJZ8STF.6
M%3NS<]S%K9QI>&4`0$@!O)MC[\L@ZYKWW+/*INTL>B#U$3\2=K=:C_JE9>#P
MW)IX9R=NLZZ'&MQFJ4"T/MY'PNUV.R9.QWE@=J],NM`N[&9=#S:X9V=.+66N
MP/Q(^-UR>%N]_D$8QFW9"B[R';8]!V;869YW.?`]2=E29NW66;L&+5FY/?TH
M5+<WV#6E`K&*RLIZI?BF?[GV<6_#UBX=`VZ!^Q%QO>T,:)6.S79B^\:6[J`/
MA;EMMB(8ISE,I2#$U-A":1T56>A"B;-I*&&!C+#^YU]?J-AS335JBO!J#.AR
M((O(D`V#*JM1IC8IGC^K59]HK6;WN1>K8J4]1!TKI]E3J%?]/0&7:3S_IAFT
MEP'[Q.<V"08S33^>W[S#Q`Z)_@H^&'-ILW&8O:#/9-33N6Q6.+]0BX1E3,BB
MS8HOO#%UD3^=GU\3@,N%6I./69KY9T$A*8SJ#:;L<.5I]O+H\N/GFZ-C4W<Y
M2:2'Z?58^J#PADF=4?^#J89!&D=A$IO\V2CRI9M=["7NI?&PJYE+*S^)<,U$
M,$5417ZI#%7'#(MC`+O+*>&^D$><!.$(ZTC)"LH@2I!YXP(RODJFE-@OP3\!
M*!.;<6D+7W[&$E[62>OY"@"F$CPSY4[G)<$`')/%+TV%;Y[?Q#Q3@$:5/G)F
MCER"(,$B`9NC/!*@+%3+P\?0B,%ZARG)BCD]*OMQ##+NA5$J4R!3Y]@]Z546
M&,@96/^LL`!6'1WZT"7.+UFC`E=X8&J.RE-IU10[9,KP89?6W#>%[IGOGYZ4
MVTW;)0^HV-BT/<B&=G-8NEAQ)9Z')GO+BW3:PRW)OEJBF9(2R@1?+4(Y0*0R
MZ)0.#2I0/`256[J]3KO;J4]FX;*!!EX,86<M%2&"];C&@NP@SNQK;LEOLJE<
M]YJ5(JX%3##CBGBR"PZYGR/Y\R*6)^_:/OM[6##OC0KIBMK^%/S9;UX.=@4N
M!7<QX8D'>'D@F$">>-*F^.6>!E8QXF)1[7-@U>)2F3.9.7MY`OROA,![2.(I
M>H>XQ5?1&BVQ\7]&6,L:*1%Q93U`(%(91\D4]^=A3)1O`DQ,Z@G>!>"Z(HKS
M<K!?`V**[!X1>T[?ZN%$8>K6Y;S)`)[/S'TNE1<$$#F`W9]3$``>(I7495>C
M8&6:]3P+L*Q,PABK[W3J+]-VYT$9LKYIM7]8P<Y5V;/,QWO$?9*ZG@H!\4%<
M'K<IUV:T($P!7]DS.8P405A%JM:8./>0+2S'5#U[(=J*1R/*M*"^OC`O#=0P
MDH%=W&=9K7*#N.$>!K)&$"]1[C:V@J8!\H?7M6!N-443>=MC&B/IT64(`4A/
M:Z[FMH*3XINHY%50X)/1'85:9J*K+C^&OR[HRTL8K"@>B226+H1NX.&<-&Q1
M")9]CX`,R>ERNI>(Y,)8D./"[+7#YU4K7.;%I71L82G`'4+]2"4@Z48BCX+5
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M`W5XUNCB(6UB*<W-(;E;*/Q>YL7TP*HLG(P8LEV-"S73^ZWDW<ZP7S*Z&_!]
M55ZV6L]WY0(4R5QC1=^!B$PT5Y&>G3:]AK@92U$_I*UW3!IO=_IG9=FO1/#@
M!-<IS#@K)=36(CC/<?&*=Z;S].LO%-AX]OLO:8B_E+5TG=[+6_&QF'V3?;IE
MIE9B^I9,;?<YI*6!VLQ3=DUP'+)SEW9=6#K"#49CW,B2SVF8E_BQ$+Z$MO]*
M!=GSZU:+X5Q]M(^#U^UN^2]EG>[`[&=[%@_+$]B-+\4KO6H>1%D(!*#8_\\S
MIJ=_QM1^[H=,7U;=<<<N[#6Q3^K0R<@"W[YB>%6&=+]Q5I6,<1LT+]3&G?P*
M">/Z:;:HG^6!W27>P]3J5=V"7?2I\[NI2Y=BIQ(%*9H[A.^$_>P?`'KA.-G=
M4?2)33U-+T&M/NKX1Z$S![\F_TQG$11Y_@7$Y\DDT3'RT<^VJZ5UOS$XH*M?
M[^G*?W_.G,9P\3JKP@65&;L\9B]Z)V>]/-S;EMY^#7('E>3FC":!$A.IS:AL
MH+8/$6).K;F,RX)9:'M'%UGB09$Y]PP8J#YH!M`L[H5R\3[;2$E#RHO!2:\`
M]=AF#W)L<8OW6(.2NNEW&2`BA57Q>5Z#6GTO=SKH6*>H2VK8/QE^EP[FBCO2
MS(A7GQ=GFH8'QAD><Q$QTI9^743&]!3/M^80?J5#[#70!?4$9D_B..*-K:#)
M<4AWN=*7.M,,P7<A5_1EXO>VQ;>\Z?:1K3(?L]-C>TIH1Z)I#ST7+J)]EA-C
MS?KR.PGGUM[22\I/)S5I#F_A+GXZ$SY:O-;W/'M]=%RZD+?ZG+5\+3!,V;M`
MT&X&'>,7_`,D9@6@]","GL`:71E0CC:/J^X=UO8#/#8#V5Y0`&_IVG/%?KO\
M8%(4"(!5&6DF*X*#]S_@QWS`9"@\;P[$6+H2?F].(4F_"&"W`.P1-=D:2X=.
MLQ46B3:?)<#GPM1NS\R5.[B,9FD0#0:M,'-&X)>*R*@L)&)C7H6?"%K/;NVG
MBQ;0`%MYDD`U-^7$$),;[]J/DMJ-V=1^YDY>)5,@TQ=MLQBN&E-<,\WB%H2E
M&Z6SKRGEJ_LX,1:ZZKYI,Z28(>!.PU#39?X>V-1P%>H9]S`!P;A'&,8J"1`H
M+*B\S]KFCF^7!G4`F[WX5:,G:K&OD_CT`J:[F>,_)1R=(;'\=;5G89S1*-))
M@;U(X8?<J&8?@+!F":656D<[(6PN##KV]AYU+'#`2A!O\?L+^335^+6*P"7K
M)\>T)MQCP0.9"FZ_?&0S76(5^KEK0]?9D$FC9!QS1SM,CY?R&--6LB_G;+9P
MUE87ZC?PXVCXX8F\(Y#W4@)DC=]VD3&M%)O@`C%65F:U`DV#A<EBFP+!8%L`
M$]Y:_Z+=SGQ\1#4ZID;0`PQC3M@S=:674@)1]RJ2^VB1RC[EMCB>5ISTN;<7
M3J/?-<)&2/#GT*$_%^\<KC3/'_W$C1.;S&:''>$:1)S*KG#9S9/_5J0]%M*Q
M*C[0@4F!86#"J,(L6.3)%OKX^3THI@1HDPRRC,J,5,*9WS.2?]TDY8';FJ)%
MC/,T7:Q.:N<S_1X&#@B.0)[_F*FB4,7/*1E'BV="QIC;+NLA>GMT<Z26L\1/
MTU/-=Q7!,)T(S)UDGW#'FUUPY8>%AL<KW=\"6:BXV;</.42?LRC31DMRUAH_
MZVB3I)688"QHO1*0P!\BSO6ML%)LFIHEAXF:I[F4H*,4`2#J=!%*"1*Z`M$Z
M8+<A0DJ_,[2YXX@'?Z@DBMTYS19P7N$'\H_NL^F^U!"=,/U_[7U[<QLWLN__
MM^I\A[D^3D6NHA2^]&"RNU6R+&>U)[%]+">N4Z=NI88S(#GQ<(:9AV3NI[_]
M`#"8X?`I2B9%5-U[UJ$P0`/H;C0:W;_&$W2F4:7,D3[@Z,&:#C@'\;NSTH>*
MNB1(OS@#M._TU2&AXD6'*E:#&)\Y26H,CB6QDN732`E+OE,F<E4=_KCE*:]5
M7-%U(G<,`[V]N?WCMW<W;Z[??;IY>W/]YH]/EZ]_N?[C3#?\P=UPISRZ9!N/
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MW`*K4#][P"N'*B-K[GAO+W;\_.RD>WI8F_V=E>K#V.B#ENKF^6%M]B*IGF/=
MW(^"3!R@;3/S\FD5XF'(R$$K1&OF6*E^EAM]T%)MS1SKQ$&XUJ5!6U8;'H:`
M'*XV;%^<-)N'M=G6QCF0C;92?4";;5TY"RV<NFASJP</0S1>'IKZ.V^T.A>8
MJG58^_P8YYV5[%W>\8.3[(O&::]K)=MZ<LK9^>LGS%D-:27G>:O*SDGSXK#V
MVCIV#F2C#UFH.YW#VFOKUUD0HE,'>E#`)BQ%/5#`'8/<!O0<CD0=KO;L]:Q;
MW$KU\]QH*]4'M-DVH*?.+/I8#WUD->!A",7A:L#V2=O>"JU0/\>-/ERA;IU<
M]`YKKU>T:G:A;,V:R[1M3$.%SQK%B%D9)`7BYDH8[X2*C"]C0903`C'&/P\C
M&!L!7C5LJZHR@J.A_P@(^H*5(>"#,8-X"M<;.7_E;@+FEH,@[PA[C+CINF`$
M`A7S'[`G*B(RE("VI4(P5'QD3%CDCPM5N6:-<?NS_;F69XH:=VN4FS.*W$U4
M3;]XX/RB,97?B/Y,[;ZB[?L!MOP$#;'=PZH2GI<+]<T;Y'$IWK1BZE)J0>/E
M!&T,&LBG^A<U1"+XO/"OW20"U9@:G[SA+S8IDWK</FV=GW<K:[MLI$>F>X5J
MJ<?M;KO;[6U*]X<D]G,/[ML89Y&+F=JAMVXHTH_\QY_CV$_KJ]"NP;^M[D69
M@^N&V"Y]:U;"/&NO3A_6FXLR1/!>L<:E_L`6M=S[HI87AU[34C%S,%M0Q5X!
M:JX`QGJ1X8SEC;!\BJP:$L;W7#3$B],,#7"VUAMF\:E8OOP&28JS:,A_Q6#J
M'[V]>?O^E:S@=)BX\>8"8]4*+*;H*Q0,#2B_%!/^,=;F04CM-1TI,-6'H;>O
M1*D%+]TE@-G-()CW'V+YUWD`[99-[%)8B5D"2FXYY1'`NVUEDUW:/%N;H%X-
MV)(@3W&0'O+Z6+&S=32^\5%LKZ)/':1B2PA89CCX>5LA.&!F.."(;??>P6*_
M2>"&BYY^;$CG,Y*)@P,M:35.6Q:.R$KVL]_Q0Y3L9L=*MDW.-VR:SS%&24?.
M)(D]D5JKQLK$,U>"%Q9KT0JXW?'G*^#GO:85\"?PW"P+`]AYT^=M$`7I2/C.
M$./;MR`F#WRUV@'9V::V7/6M\]F(UZILLN+"[(>V;36:V_(6[<NC[]-PB54F
M5ID<H#)IGUIE\FV\5M45ZS[<GMO%)=M4_W:M_JVJ&5@2QX_S?BCV2[2VX?A?
M=4'V0_%V&IWS+14J>*#<?'ONL%K$:A&K13;4(H]U%WR>6F2E'/$=@@":19-9
M!.R@X2)NO9'P\Y`JG-SF_53\E6-YD^L[PF?YWT^4$[P`/4)]_WY0?,T?/R*(
MA/%/BR?QF''QK;-#!Y28D8F'JHSJY)\EZL%GX8S<.^$(K!Y`$$2"%8H[0'PW
MQ#[HNZ$;><))1T)D!#B'*DBG5#NH'0@K+I\@3!Q^0HWN$6HB%%B#($B=1$SB
M)#M,:`F#->4"*?P\`K^KK"7!]7GQ>!(*0J"(8.FE[O8=/!Y`5S*0WJUPT\`7
MSL5%P_GE@^/G"?X)^Y^()(@)O>)RD@2AH[8I&R5Q/APY<9[@YF!SVJO$#:C;
M('+<X3`10_S1G4R2^&N`P;KAU'EYVNVA68)MADF<IASM(OS4&8!$T["X";@H
M:A<6KVBMYDY=/N+:I_H!TNQQ<7[.:D-4K`IL0R./W$2"T:B?D!!<*MB-<1P!
M#7A(POSAG(P$(;[Q1A#.(2P;H1SB]E%:&6Q7`,=Z[5[!E__*855;O#.M6@S'
MZ\$`1[D3#;F-G177@V=\CH?GG4BRP'-#)0PD!J#W>2FR46F^!@,R:@QIA,KL
M:F:#TJ\P)J,8B(-3G3Y+Q-@-$$B,F@R@P]`Y;=+..KS>T,R%3N,\!':%3Y+[
M()4ZJ8^E35*L7YN#F"2L1S0AL^?=&O\V(+J6FT6%"89P7AH64V1H6U>M+)@Y
M_'P9^;^J)EBY)4K%PZ#/VIWSLS*TV-R!'HG<M9#0.NWVVN1^,+`&;TG2;M(T
MIZ/G*DZS&?RV#QH.D%JKQM3V88M]6J9]T4!/0_VFF(DK44Y_PC+1(DF_=Z[_
MRA$']ET,!\"*N'1F!_PY?FU!ZO;_4G%Z\)>*&MFP]XKU5E.MY14;4;2DSWM-
MYBS`^\C1L#JM#ME:332;T/@&,^MEB^RB13:VZRCSN-7HMB\:I^<M94;!;WD$
MACO"UB54)LXP6<$(O83?P]!-G0_0?NPZ-Y%WXB#:]\OS$Q@0+@S<$UT!8-C@
M#J\`_#DLCR=MKAHK]4.>X+&B[S9H.:8*.&^2P]7&30T#DJS+80(?`)6U5+E.
M=A\[4^$F[(_%O@BJ$,S)00XK@".1A<WVM0OGWYT(XPG9IVCOX.01C!QV_M^,
MD^[%,$P_EJCI9,/F>"D=N@223K3FJ5`&?R:\412'\7#:0%/=!0,U"?U[-'G[
M8/FF#4<!I6>)<#,:&#X-P5;'VT+D!P0'?0(3<O!@PO^BB9-A2VOAXRQP2.@@
MC2,ZR,0`NH7S'_Z"5V<8EW=4DIUFL">%$8[#WPH/;GU9(`V]ZZ^R##(*6Y"F
M^!5AO3-?T"<%PY1X!"<$OR-_Y1,)%9F@/9S2U.IVJHX;/@/581HOV^$HCH[O
M8C0#G1C,[@37+865Q-7&#7@=P\;@N&^"!.Y`<9+J<H;,$S`K7Z0@V'131?<"
M$`]+X^)]R1FSE$$C[.S6"^`OP2#PG$O_+D@1<Y<&J)T!@NU79#&+,^`Z+8LH
MLR#(,)#OB*_XF[PEL9W-E1@5*_'J2IA.>:W';9DK(/.):C=.VV=$DQ_`U3`1
M:%VJ&I#4F:)0DZ<6C2I$FN2EM7?;>Y>^Q0<5^#;%LMI`<1Q)_O8%C(K:16$J
MJVJ2KH?MW&B*&UIR&*5SI@-7.6,2U7&K`SEI`,T:*%J>F&2Y&V)9`QP9U]_4
MDYH1@';>AXD;^$Y_.H<3LRP)^CG;D5*!I06[N(I=^L2/R*$\[/K\V]![L42[
MU:W7OBB\!E;?&I&B<:&70OF!^`B^6031':@4Z@"8ATN5SF5Y6:2B$)C`X`UW
M'.>1+#TABZ.BP'N@$0L5!NL<!@R-R^RB2V?(7_1N*)]9HD\Q]'\8+>>['@[%
M?"FYK!HSCBZWK$QF55NM\XBKV2)+LOC%J!64RTC9.Z[4P6CFD)OYK-$!7=@^
M:QOG656=S66K@B`\X0+\/*=3%XY,T!@XL"(2?NSG,.D5AD,E#RP?(+\"J<I5
MB[U);^:BCU&SH?,=E`VR).CT+VF#!3O"FZS3`;7O3DW/?&4DEE%>GK+HM9NJ
M#729YOT_05JTMH/%3P=<OX*,@ASH`1:8Z@F8]LQE5C]R:>/`>I0Z_67WY!3]
MB:/`&Z$"<$,6THN+[^H6X?O4N8O#?"SDC0*%'%;$':+:<7W=-\P"9OK[Y\L/
M#=/KG8GH&):H:,L2'<`2^@%[L>'S.%%3K^X4NL(;VA=><7^?S3?.:5G2PLE?
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M=DR]ON(/W\,5`"^DY/(I[^19<ZEI@//''[7WB+I9Y`J:Z0)N.<,A66ID&2C)
M4B=A9?XX8)334-"9TM3X>H#7)/4:)XI-(;N)3G8V[_&^+C7[93Z$P9`!+K1;
M23N4Z$F0S)OZ(G8I7>W3/(1KEYO.QATTU*W:O,*6:8(_2!+8<`4RJ'Y&#G>(
M*(,33,Z=IH8&5+O1;'4;IZT53+T:MCD].3\MV.:9WQ165^KOZ58HRZ8Y5#?-
M,0NG/>]UFK,HES4<3;)GHJ_+N];/"3IY_AFGDP!UW6T^F:`+!)T8K&)\]!.B
M*P/M^`DL<$3N`N=?[H2NXCZ)$J\__AG+0I*'IR\BJNR%&O0^8I$_/6E]1]^<
MGG2^:Z`(3C@2`<>4\A#G69I!&]1D]3[%9\[]<W;UC6&1C[`R.:Q'-DIK8WWX
M<J@NTT%$6FG&Q&Z?TPF!;5^V+Y2IG<13-P0Q\NC)N"8JA>QJB@&0.W8E0F(/
MJ6#/NS\Y%\WF#U<?;YW;:9J),1KN6#,M5>?"=9[$$R'YYS(-W.,/KD>>,?3,
M1,!Q.;$%7"62(5Y=Q[+LT,1X%,"A?P']B%$%V,]'2?BEOH4KS]@E5P-5K7^X
MTFXMH['V?<LZHL?L0V)9</Z,`VB#`1PYGMHFY]8?,=I.0-;VU]@[VC)EBJ!O
M$._)SA"D23J8U'([QGKS.J?2:1>E^9C.G51D\K*TRJ3P\,&C"@OS'?=I]`QU
M*9@5Z@"705S2K?*RU6AVP4H!SFG..VA7UD2J?.M5G$RT?W&N)CD[Z;$F.0>5
MLK$FD?JK5E4UZ0:]?-U6#ABR/S]9Y/O*H2-%M<P49:7A7+']5HU%X3_+/VY2
MS+,+33JE\)]2E]NA8X7BG%T@XWP%.E[#'<0C\?`#4#<"`_$J'B,E2"Q91X'Z
MYZLJT9_EEY?\X3NZ`;P?O.&.;^FC]X:LKA5DU:X&69UW+[J]GC'!-8??R258
M&*DULP2M7J][WKQX^!)\%&C\T1.(YZ8C/E[P'WCEO@,;()J-0"N^N8*6EQ']
MSW71_ET<>9O+4>>T62DLN^IHWVI2*PCE=B8EZ)@E?BV>\6HF0NV@TS=%J^W$
MDEYTSJK3F#_6(U.^7EAILWN^`>6L.>M5]$9G1*_5;-?HYLT&7('O3ENGG>ZB
M`6^*1U4P?.*Q0`,(7^;2F>TIFG)+U>Z!/%6B;MX8CTKO6IRT)KU&)"S8FG`M
M009CTU?Y-"BHMN&0CI9&N8X)7A0]6W3]?F!V+/NE;JG3U]BGZM+&U.YI1&GO
MX$-J24"(F4N"M#]AM3Q]_.N/#CKC`F_7O*V<@/!^<KBN5<,)Q\%5*N,.4\N4
M\Z9XM6`'JAEI*+X*+R?75CP8!![<3YV8U[/T`N6:"7-%<$IOV9M.@]U8`_C]
MF**/\`!"BO$%@GPB:E3RC=W']:TTS2<.QK50T"5G]%'`GPY$I/"E>S?Q4QV8
M*6>MQZ%PC?9)RXP%IK&KJT,-6R<=\YG#X6`M?*C13AQY"'KF82FD%8@O):U&
MYYR`U!N@;2B:#"<WIL,4YC<0`7IMT@9'3/1U,-B_.410=W4G'Z,*UY)>)HZ`
M2)?ZH7>%:U</3=@5BI?(66N1G#7JA(PN>2+)7+BC8Y!ET42,)V$\%6(]06PW
M3K<HB`4-3R66Y5%)]CHGW;,%HMDY:3U4--L@FJ>[(9J'?(P;#A`^T2^)5^R!
MOMJ!7J-=6C,'<U*L\>*84?D.@3N`(<=%P!HF:^1A."76IL1N-\HQ?K+5I">3
MSDS(I23G>_8%!!'2S#)>?N"ZXIAZ'5F"ORGYF1NHMX&XGYUR_-Y#I=D*\P)A
M_B`2?++#S`AY^['B7<(A42=@NWO6:+?I"-,+Q@Q<E55U=A8!2>UFLZM2F&\B
MC+%$+OT04EBV\U;T$Y+,N8@+GXH#>9+$=QC=I8R1XA#.H=>PD'(%K1$[KC<*
MQ%WQB3$#9QB[88K'*-Q?&3"]/]5"KJ62TK:R3,AC>[:#>Y&(XGF#ET5F.@SB
M,(SO*7*9Z2!'T8].W,\D!H.BZ^V;2\<+P7"ACL%FH7@#L$J<HV[SNU<-V0%U
MY62P801$HE)Q@LC#E#6A,T(&0>K!MV0)\4/YS*NQ<]3FCM&:0><:@XU0\-[8
M_3-.*ODJV'4EQ^6'.*E)<Y%&E-24WZ=%!`--I7Z35<Q;1A%P(XKEFNJ$K/HU
MQY"9`(,$U.KZC07;YR#L!:ZU3`P#.8)%RV0ZGM+Z)86.20Z@?G$W'(3*,1-/
MF".+#:[P7NTLWU,^@9M$BE+9"T-M4!XBHW,(Q-=`*N@?LZS=`5XL)\,89Y4.
M*%?3*'6/IQ`EAT@&598C31:6G,ESCEQ<9)B\B\+%/[Z2])XX&@5%TU5$_IF1
M`VI^N%L&>@D/'B!K9F`H@V)@J=$90N@7ID3)A0+)?&(RAY<$5,42)NL3Z@GA
ME8S!7N9(Q54VZ5U<?RJK?#AY"JNX+;8?4KV7ZX2KZ%"CPXS*NHDJ[&-D(;?/
MS_#"L^43YZ$'3%6)/M41XZY]PCRE1F^L<YZE*O4(SJPPA[7&EOJP0Y)0*#@-
MR!S\\M,_K]]=.@,,\.X'(>YMAO5J*<H.C/$H\)SQ-/8PEQ)_Q<O`&#3!#(57
MUQ011T/I+=/S:9VJ,W';!V[;.3K=TNGG;G[XI8]Q]LU,=;W3#Z\X?.[-/?7X
MVM9=[]CC?O'`JS_N"AJ^]4%PF/K_4TE_\1MGFH^A-7P+7(X6!LHY7;[E#5?=
MUTVA6'PNK+,//WZ+?9!I9\7;ZSJ/O0ORUWH/>O]=B5)_TQI:&]&E)=.9?:/=
MK%K&FF34N!;JW@A*A,&1"]L&E+5?@$5ZG[B3O[_@_WUP39CF\N=FQ1([\>`\
MUX>ZGJ#LUF3J'41E'EAQWV>5\[=G7RM7^\.**E)UO^5)A@?_C!?!XWV>R1M\
M7'R+CXN_X^/B\U01VRV]N4]5-LV0<[BP55Q+*T64K5J.N)A3+<3RNN;3REI^
M=KTW9JQMD"`K@12E0S:A03YE;%$"'V]-#I1-7GX[[C@]N6CO/FMLLSK>-U:Y
MZWD,?F;OL%6NNZI<V6N_^Q)TN&SR#95KYZ3;W7W6>%86[7KJ]7?RO5OMNJ/:
MM;G[PC-_-2Q+/`9++*)AUWCC,6LZ5]\7=E_77N'351@*_P?Y*+D5Q;M=;]"F
M;+[,T;H#DK@.B5N1U",50[FSOC\B\]5>,]Y.&<N+EF0WW!-/N6G;-:L7E='=
M1^]Q.0SA$0Z"[NX<!&89Z%T]">;1N*->DB?>[3WBP)T^$;H//Q&V[%-YRDU[
M1E[LM50_>UD>1>O;2[;UNUB6L'Z7IX!JF8N+8#$\G]'/L_B@#P3'TOA=1614
MP_E5N-BA!!^;Y(C:5:IT2R'1"Q"[L#/JR^B).[(U;_<>GZO5.72`KD)63%%9
M%'7\U$I_5W-,WA;@+F-CY2B%BH'195JA^=<&Y8YBWF`V/<:T$X)7-UO,2R1,
MQ"!&./#!@F%]P:FPU50^-TWSL8+1P1PP61N2,KV\8$(5-#B7%ZL$4MI:X*G<
M%A?1)S%=*PQ<SH^;5S.*4VXPJPW386!5[T3HC`*1X&UD2@@^F$H59+"ZLB87
M*E(<5.<-X]0X*XJJ%`98DY3K?R:8:UE,?^Y*<0U#!_/GYBT6_HV*8C&)F`8D
MAR^HI>*#J9<$?5Q.`1-;FL,C61/KK02#Z2K<N7J=J2W(1^U=M$8"%I2Z0N%0
MHRTV^A<5M)HQ+2\Z/"UL\UA#_4);W?K1^>\\IK(87%(-*R!SPCD+!3-'@"L6
M8-ZERSBN!OL'0@(9F=0^(EOTOCE;+*3@.7!%N\H5R`-I`!VY23T'S/+-3\Y?
M,UT4;&3T%U`E#59$T(MB.T[.302=$-SU3Y0N/(Y]$1ZS_O,+_4@?<\(SIM-B
M=60\3%PJM4IJ%3OC>K5D1,Y0;+GX>7%QYT>RY"1W*(:A0B.UIZKFGSBB1/HQ
M&!CS^"B/=H:3'ON8_/:IRA(L`JNL<-:RSM@O@7616D(-8>HE4B/WVMY!9[`)
M0QA182C$J>?BW6`I[959\Z"4YJVD+R_W"2YZ_.ZV;8KR0N?E0J+W-7_RM1L2
MG@!A!2WV..Q(R,4FN[W[;-AJ;CNEM]/=6Y;$2S(<*^M[@/:82TLOPU:3VZ3X
M!TC0.F_L6UJR+;[L;5'!K[K1EE&_#:-*SY?E4,NA.\VA5H=:#MUM#NT<EE6\
M1GPD6L.[$Q^Y^KYR:;T9%]BN!<!M()&&Q#TZ>;L6F&;WS.Z9W3.[9W;/G@B%
M8K>._[F)T>5RTHL/_0--B_B&*"[ML\99]PR+$^V^%%D&L0QB&637&.38\H7E
MB_WDBU5S5I?;85OFE]5?*9\?R]J$P#V\#^[N(EC>L+QA></RAN4-ZZ_:\!FR
MB/3>^3>K;\TX5IZLKK6\87G#\H;E#<L;.^&\VEL+;8XY]B'/G)B`%0IP!/NJ
MN%N^WZ-6XZS;W*E'HTVAD"U?'-:;@.4+RQ>6+W:$+_;@'#D`5]F\`K5N@@7<
MK!6VL])S?GJ^T[)CN<*>M?:LM7QA^6*'^6+G3Y$=`4>U*$G/'%O#HB0]M;AO
MLK%[E>MML9$,1K382%9_6[B$S27HC?#$N"\2!8]DP6=V3=U;7M4Q=18>R7+H
M'G"HA4>R'+K;'&KAD?;C$6WU?;7P2,\Q7,_NF=TSNV=VS^R>'62ZF85'VLO'
MST[3HM]8!K$,8AG$AM58OC@POK#P2#O(L@\DX>#2)"UO6-ZPO&%YP_*&Y0WK
MK[+P2%:>=D^>+&]8WK"\87G#\H;E#0N/9.&1GKOO]ZC5Z+5V&];"\H5]$[!O
M198O+%_L,%_LP3ER`*XR"X^TI])SUMYM8`O+%?:LM6>MY0O+%SO,%SM_BFP$
MCS3?B*K->IS-:YQC%.%8KA.Y8QCH[<WM'[^]NWES_>[3S=N;ZS=_?+I\_<OU
M'^>ZX0^N^E<_<7YX!+)+J_N)5O<=K.['&M.O=;&6[2></!7.7WF<"1\;?1&9
M,TD"#T;(8L<7F4C&(&].-A+.``%/[@CP)!XX<9XX7B4KH.'<CP)OY'AQE`9I
MALW&<22FJN=!'OG0\<C-'#<1CA>Z:1H,`A@ZB!R9:H\?548;!2)Q$V\T/5FV
MKLO1LO9SD^2JPY)/<L-2A\T+HJ'C1LJ3BEN'O\`"QLG4Z;LIK&T:C//0I;^[
MD1M.$;_F*#@1)PW'=7X%(H1SY29A;#1\Y1RE0H!F@+^UVJ].G-?"<Y%3TG@L
MU`X%$1!#?(*$(8D\R#CV82-Q@T4`[1+LQHG[J4CN"&I,<IMDLSBAIMC&%TEP
MQW^)O&#BAN'4&8`*P39>G"1Q/TY<_+0_-?N3S.6[F8M_P99"SA<^C(F$L7`C
M8$\D>U+C>'9@20QN=%/)C1UD3,N-)C=^PM6(PS"^)T:C'4CS,;2&;U-:+&_D
M1D/D#V(,M9*UZTY+.A..\10+^2`8O+J<>WD:7CP(&F\E2I>])IY=/(M(YIK8
MGD=.:-Q+>(5/HP14-9RSV2AU!!#E+W;@[`$\WD-`%59$TT`9V1W7W.J[O?ZS
MJ85&VQ]9_A4-"X6+MAU,G[U!3#F(,\UFY&^7I$=YMMFMLV$>#JF`7R.TP?L,
MC6N?;7;,X:8?/6L4S>[YW!X<?+;H6-D+B7HCO$2X*5U<C?M^(KQX&,'GY*6*
M)W#[SU#LQ->)B%*Q&A3&QBOW=%&83PC^]Q0D;D6&V^?;CEIXRKW>[N%8I;R[
M;_)]'?G;/2X7K<@W%@H@Q?'CO!^*[0ONZF?J6J1MZ=`]D878MGGH/L)&[VAQ
MD&_N7E[AX>VB\O!V%8_'<02S`<J<20XW:#S$[SFL*76"-,WY[/;B*!(>^4[N
M@VQ$WNG+?)BG&5RWFQ?X[G#G9H)>M+*I`Q/V"-,?V)7>)[+$]<DZ<.'_03]W
MPDF%ER>44RB?(1KP1WI`2'-OU'#NH;<4.`*[G7U#@U],2ODU!YM5GG/H1>7$
MV$S]KUOC/2:%'0P&@8?!7/)M!E]6C)>20-/-Q*8-(A/)]<Q%-!\"&\Y=C*\I
MZ&CBR25!^L49H-,17V-JR?JT;*INF,9`CA<G$WK3H;UP8:?&-'-HT(]S?##,
M\D1O".XDJNZ4R(`>88!@/($IX2,4+H$?WP-+Q7F$CTAQ)C=[(%SLYEF]8MU7
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MKQ2/DXZ$R+@RNU-V`\R\+\S[M_W9_KRC/ZM__^V'/#T>NN[D1ZS\_CL*FE'W
M_8:>$=\$J1?&^-LGT#BO4;7\XS_^C^/\[?\>'U^YDR`#:</'S`D]*X=HJA\?
M<PO5N6SV"_[M?1^4&+T!IC<12C*+'VJSCV+P]Q<>REBSU6QE,?VKTVF]<'*0
M9/KK;\TF_*<OO&#LABD^`/VC64QBR3B/379+D]U:3C8V;FY`.VZ40SOE%#N3
M.O^+F^/0[OR_ZCSTWAH?Z+U<NOC_J/#1TG^N]6ZGO64/>J1;9B5G\:0Z8F<C
M8_A;>:1/+M2$6]W9`VAY=&;-`O3V=04*"5BP$`=HK*W^KO$VB,#(03/I)DJS
M)!_7E;][7HLS/P_=9Z58"B8)HD&<C&5^.47MN&'H#/2R!<6R(3Z`(&,XYGB:
MLA,*[<Z23=D`VA*)*1!D&.$R23"`R2.M"1:LCJTJZ#EQ,+S#-]0]6*6JG5^)
M2JJE$HWILAE+\49OA"?&?:!=_MK"Z"ZPWC5(@J_2\>_<(#1C>DHKA-%ADTD2
M3Y(`"3<"CF!E8C\]<:X0/0&NF=3%G[D_I%,W0#7AB31UDRD;[S#L)('NS<@A
M[-[':)5X4CMI7AV,@8+9^\%@`#.(=!=F`!8LO.S`(`X:3OGZX3K8=8)+)Z`7
M+U,7A]JE=L=Q#BM[N.%&GILD=)62*T&,3?`9N&.S.!IX_:)V("$BH`BQ!FSY
M'?PU3N#>V)"72C)XHDQ>+HWO)NZ4/X)?$HQ_5'Y=&I`_+MU#D2>_5H7)\7.A
M8NO249QDQ\CK3D3Q=$58GR$\A[G%B*."(9+_GH^ELB`,%$/,!L%7^(I"(7W1
MSTA31H4JJ8VRO!G4CZ8B$?77%(?JN:&'\!XK4B#!0\B5(+DLG,[J-FI/>D/%
MKH:Q&\G(4[@192X[*;-1$N?#$6H-#)B=,M]+3:<^]>(0"4S<\`1.6ZU9]9\E
MLYM#HQS-K)VKFJ2@(%T?=2=8U]!&LK)<M6D@0M!I%"&*^C9TAO&=2"+2MUE"
ME[NI&>)+4<-I`/SC)@[2ENK`4QCW,%G_<M7#DKQ*PV$BAA4=(X-Y"QUI!@W#
M:4ANJ.]3<YO#.!JR*B)6I7/83650YVQYEZ?8B,>*R.Q]PXC,14\Z5"[QB8)8
M=BC@ZVS;`5_M%3!B;<#7M]MYRY+[PY(SI\[SY,K-PA`/I;ZM#4/<TCN\W3.[
M9W;/[)X=[IZM>=#:Z](#^.RYY\>L]!*WQT:I9<>]8L<KY6RS+&E9<C=8TFI(
MRXX[Q(Z'H"&M)\G>ENP-U^Z9W3.[9W;/]BW9?R_*B[Z=%[6QV**R2?]KC+P=
MK-MNH],\VZD2<8LVQ#+(-V"0TU;;,HAED/D,TFZU+(-8!EEPQ'3WA$%V.2F*
M(W0?$.);[QM;Y@B3^3ZXJ%3;DV)O,=,&4P[PAY>MQEFK0W`%&-0+_WG19?2"
MNN3P>8'"B4@G@F"*PUF`6IM`?K`_+TC$KDO6U5G`;\1`4`[R1W$GHGPF=5G]
M7?ZY)LEW:8+R:>O\K)2A7.ES:[2T6NVEM+2[W95H>4])0)<R<^A=',G\BBI-
MU(Z;%8TV6:76>:],66W/CT3?"BO7.C]OKT.?QLRZEKE5,Y2I%JK!P[+W+WJ]
M,I?-]+]5VM9+T6_W>A<K$F<(`6S4%?PKR!9M<,'`4<:M'\:'W0JEB_I_&J)7
M$>OF/*E>0+19&J'A3%R5<G,41(Z/R59)ZL`V.>G(3<2K&4P'^OH6/_[@)N^3
MVPSS.DGA?A#)[8AJ>"]?_HXYDYMW;U_\HWD"\S/@'):/\PUG5+,W6YT1M1K%
MH2^2]'OGFDL=7&99$O3S3"4Z0R\U/&9^*C_<0!S.+DZ;)=::[?:)B%U!#'J]
M[MFJQ'Y(E,Q*=GE)VU1PS4_.*5JG9*$2PZ2.FV>C&.L`^#\YQ\UC];,L(D*Y
MLT96(S"=MF21_NJ<-05$)2.1;+!#QG1K>MRS^:ZPR2O.]Q?M3WZ#-Y%%L"[8
M]!.TQ(86SF5/P4S.#AW-I<SP"Q;#5I-BBM]'SJV89.QAZ+&#@6HR8;P1@8[`
M<>5"&P2U<R['(O+'$AP/<X_I!ZD&/XJ4#G'GE]AE&(];3@R'\V^8""X4=132
M']5_O^*,\9]%1-GEUZ'PX*3T'(6I=27+'R'"QM'/UU=7KQK.;1`&0`U&'85B
MZKQVHR_.T>WOKU_1F.^_#N+$=QB41I0[R.(A@:MPJO6+7Y#V)'T!?4[R!"LG
MT;P8305;R`:.`@WF+.Q)$L2<W$Z9_+"ROH:`D+G8#BV:KF\D,2W(`=0^/6DZ
ML(\A480:E];K%1::ZO\IBDI-G#TO00#\@#%'X*(%6YO`DDDTF/)RSBTUI<>1
M:!<IHZ/`CB&6BVMFC@.1O9.+\^_(2'2C*!_7]OK!6+%90@A/`6W%!$$[$@86
M&+M?T`Q]Y63W(KR#?[;:KQ#4`Q8(<0Z`6;CR%K#N*)P:RS=QIXP[0PO8;%QT
M.@I,91`D*2*[3`G$QH6-\Q`AQ(<#G?II4-TN$5&5,/CFO9?%R.K:EW84,$%1
M-CV.@@BH:O<VH.JB38;#=LAJ<QDQ("U@IHZ1KM8K0N,)9TFH4L!>1.[KE(`B
M\*QE]$JD3D-,^'+#LQ*+C-R4P3-!+;%X`_,&8;E;6<8M*SJK]M,H2<0]L#QS
M@*NF(8D?""'7&WCD]#OGZ&6KT3XE&^S53*>UO/A9$.Q.@+<[/57H#WH&1A^0
M/@NE:$T2`0.OT.G-;#F\RO3B&MU)C"]M0RD92HOHTFY(A2K"ET](5T0&\`-,
MN=5I-RYZ+65K2OR14@4Z%%O<(9%X02H8V(3XH'."!JVZX,W3"*52<R"G`7"C
MCWA+P.*R4[+4<)-IZ\3729"(NCE?'":L1T6MRH-PDT.Q@?O&ITZ)$132%_S5
M`!^"#7H)4GVF#Y%$C%T"US+O(2Z&DC#7XD$D"^K-"AYR3+?50V%CY*N(4')B
M3P@_K1%I=P#'AJEW0N)N%C6<GD)1DMA?%<(O"KJ7<LVN;/3^&76?A8*YPCU'
M8V6$`#_:>`/]3B]3X]BG<IBDX=(`>:VP/.3>*\8V6%VBT;R'88F?BC_1EB.P
M$L(H`RLB>#)L>P&C)DM_@A).\3\UC@WA>PT0FD:-R[21!:J@LYPC"1]'3,J`
M:_0Q'C$:(FE1WU0PLM#,\!M:0%*O%L>J$KR^`,-`\(D.]PX]<[R_$(@3F*\N
M@QZ!.=9J?J>(C]72T#(7,ZC5QI>P50D*;3CE(Y-E*4UC+R!J]=DSNQ>D\-E?
MT9@CW?HP;6CZQ=<@)==W'H%EFF0$+UA^JZ1ZG'-VF0;M4)P+GPU]PJ^3_;@I
M:3'_SSS-E)+0QJ;4#@ZB2&E>4ZMV.3.]HMXK0^BA(:;[8@8XS,,')3R$,9B;
M2[A1<Y5WB9V+PU_R!&U_7$`%%^AF7$:6:ZW>F;A4Z>J5;6>*#5=L(RS-JM#7
M?(D4I[;^->;-'-]ZHSA$6XC0%X_+A7^=SWS;D%RHOJRA>88>9-?R$WW[C%_D
M:WDT7)$M&_+LC>J:)-K,.SGK?`<&^J!LELNQ6'FDJ,O!?.437,(-8K]W4KA\
M,7#S,"/=(:'I>1E8K]_'.:BNOC"[X:.^X`Q<?HTL1U+<9Q,9=/@P(#M08O,/
M)`P=&?4(N.B%.1L<"@9N6LP3E&+Y($#<4U0'T)/6070DH%5Q['KRKJBP&L57
MU3M^@=V&:,;G=`?"@CR(DD=M?\(?[@+4'B-0ZG=\QP<;.2AAI#E^C.ZG&&\M
MT)V+):^A%_I?/"7(42#K!\].Q\VS&-$^/9J+TGP^&G$^`XXBN:("RK:([/KS
MH"82A*X5=+I2E>[Q)`SHA-)5N@N<5EQ/K&Q0_.(!)T=N'?3DWL:*S$8ZU/JO
MM2/\VDT0)#%U/H!,\RO6(F>X:JZ>HJQ#?$_]P4@OF(M@./W]Q2!(_\BC`$DC
MR_(/6OH_3G7#'US\5ZMIG>@I/Q$3[S^]$WT/[;'7;AIXA=>%H:;I5!U/<EG*
M'F@/Z#"+"/$:_B2HU@VN-ER3PP*TVW3TR(=;=2#S%N(9"6><.X2[2$ZN&+X&
MT5?29V0X`_R\N!V))`"CV7D3A$37WI!L.N'U4=O`\]W'J8!]Q<=VT;GA""R/
M0X8!FT5%H:"2\Z1LC6IKKT"\)1><O(`X'^),D(53&8?.:W7EQ!8)^D"`>G.L
M?I[!-4SY\7QIWZ+[1%JH%.Z)CR*9>K:F(QY6A3#3Z9Y*RS+;#+KP&4@;#2]>
M1WWY%MNX.NVC:X3VG$U+9$I<&;6!Y*M@;C)1C?5E6'$%VM6QY#SH(U0*DR7)
MK41[U,D&>V705JQ6=Z^+`6;/LIO*NQAQ?UHV[H%^17K]>TW=',O\JM>D;K[I
M@@D3H[<N&J?=;J-Y<4XDMWJ-LVZOT;GHU,U5,^.2*7^[2.=9"W.N46A$P(%L
MH=-&US$P+F*SX6]%8_AW*/`?EY%_:5[>'A0-V6XW*P%QRT=\PKFL%SW9JP;W
MK3$7##8+,EFZ@A]4\>J)SV^S89]&8^CORFRZ8F32US3X,0I"T'Q)+EXX/SP^
M'?410W/IN%0U$#YP#00BYE*60?BEJ'G0<*[J0S=5!_)[7'?^VOCX:O/PT[-F
M)81MC?%V8Y*KA*MV.MT'3_(=VV5<W#B(]+LB:>O"V8#O,KHZF;2=J*!,M1I&
M=0TP8M9-1^^3#VZ2R?^X1#=-2J85I2YS^/>E=-ZT'J:SSGNGI479@("]6IRU
ME."6UJ6(XGD;ND,U*U\$/^J_X!^6^SH&0)CXVP\S7Q8*3XK'VR`%4\+Y'^$F
MSC7F-(%);(XKVW$S;`6-L,UR$HZ/6^WC3HN)F-=-<:C%'K\D?>`[11TMJ@TW
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MX3O6+0><W_)5ZWWA`:BAJ\B-X.9&ZQHBN]7M;%<MC8NSB[-N]Z)$]((Q9M6E
MJ;_?PH]IG<(LU"XU64UEEI5EI8NYA$CUO804;K4B,?_=JB/%Z&*6F$_32>W)
M@;\O'[#5//[O\I#XW6PV5<))B>0'8E?2!(Y\S<[>-/M:36!,/W)+M`TV2GCI
MG,JKX]+>GX#>%6SI#>C]S.XU?1,H$RC_JO^XR2*>GYX7-%4[W!8=*RS.67L5
M.MZ3WW$.&?S'!ZU&ZZQK;%&EP^U0L4H":Z^U`A5ON#XD"?DB)M:MELC;>O6G
M%W7^2"2NF<C::9G"MIC0CR(5Y-T;%O$F5%RQ1*AJ]3,U@JLOIS8_:"D[!9'U
MW3\.C6NM97=E&C_%F`]A;KM2;R4BJ5EI3[C1UI9RW@"/1NBZO'FZ!JU7(S<:
MDF^@'"&DWEY*%'/CFTAC*KP??%911`]:W5;'T$D+1GE\LM=:ZT[WO+4=NOG-
M2U=;G2ZC?_EQM,;J']/QN&`:\TZ)IYK-6IMRW.X]:#8WD5.@C#OO!PZW7\I2
MLMF3;,4,0VV;Z,=8\8+H&^62?"/D/_@@42X/=MN5:%>?J"_H`]F>FS_PI4CB
M/:PXV!-/9;T3P%2F6YC*JE/8RC:TEY#^-#2OM=Z]AQ-=A?QQI"'I?)@Q:*L#
M5*YZV[?#UQCPV\_P`6;\=N8)JG<>?E,]?PR60TNML6EGB[18=:@GG<9Z.[-(
M@ZTQ#0R)Y2#O,C0/'?Y!N(3QBH#:`D9'?_G`?9H_OX6C[LA<UQ2SAT[V@TKH
MH+`<G?&)B<7C21A/A9#Q7C)TC',VZZX"JJ>WT-&U[.?]X%KV0LY@::S`]7,[
M=YM>UW`^;33^SJ[#6FQP=M[=UCK\QAKJ.LTHK3*MC62G<7ZC;E4[&\2^I_'8
M[4,/2/^-Q5QSL@U)7S$_G<`.$AVOBG@66'I*YX)S?A!EJ'-4&F4711A8C)X(
M3F'C*!A\>Y09LIB&-V3$%LSI\CP$!/`5(LEOH`7AOPC0C2)M+L<B"3Q708&D
M0'#D#H6"D2%,"*&5&6<(I_E8*7%.G],9??@\+WR)J$+]R]0T_#`L(J7HOWV-
M>BJGSS%TV=QO,DZ\,V`QZI:IR*2MHT<^@)6RX<UX]D2'-,A@_+IPW?<Y(H6D
MF9,"-U&2-E!=7B4/HY/Q-=3<(=A>BA`,HKL8,582X<70`:5$2L(:CD!?%8-?
M#N/8ITPV#-(-QA,W2!B2`)L0.`D0,LDSY=6BPTAN'K''^W`ZGN2I";13?%S$
ML/L"LRB#2"V"N<5YRMPSINAZ;$%AQ<<<UH[Y"+"&S,0J?QCGKP;!1-A[C(/G
MJ&H_SOO9(`^+\"UL#.L!),=)(&:SX`Y"'5QR`B+(7QZ2,8.!XYR8K^.]4T,0
M:[E2^740#2H>!YX!363F@B+``\@ZLBC";B))7Y2X`5O"5H8$^8(Z1OZM0=))
M8?,:3"F(1HP:D$<R2Y-S8]/<&RTA]%>M8KY/%RD72M"X"\0]/5P/\]!-,`M?
M)\J3\E%2':3&1P-,Z2RTWDJJM<AFH4C^*76E)(,36_J(+@"LG+K);,#[5AGU
MB:+G%QFBA1]7PGU=WKE!J/S@<\U:V=IL;&W;/37M.H=NV]:QOK5O5\OD"AC.
MV:?T1,Q)8H/S9:_1D6!H7&2AW6B>,US))FE7Y1RD>O@QRBEC=+U\+/,&?0%F
M6Z!0_UJ-\_/NW$H/]4``.H$1SZ1[.0I92SAA0BS`SL\;YZVN,=UFX_2,_QL.
ME$%."+6)$VO`<Q<G(S/;'K@>R""X88I#ZBO`S-9;K9TO<1Y^0->7F,SPAK1+
M"NKE/A>9FSA#C'Y)X'1)@,W8G,$<R\`73@IS]Y@OT`9,<6<\EKG#-`0+TTA?
M#B@G%@T/MD'X;H=0,C%F$V">8`&AA,_=>88W*F7)`&?\@&P4.W&?H#3,Q%NI
MW6A+[F![8K@JR"TA8$)I.\'.$IIR/Q42\:QN;-Y8Y@0R.:.8S+F$LF`]@KAQ
MAO!1)'-\^4<]GS0?H$CRU/F21NF9"/12,)@'UZ[4(<%`D#T#3I#-.L)5DZA'
MK+0YS3.GI:"49/T[@01*)$^Z)QN-I4'(JWF8O/B&KWMM!9P(USN7A%G!':)O
M%!%I9!IBH;CN1WB'2`-0MID;"6`KQ.9$3%+2<'I?BCU3B@`6/\TG>`4W6(G4
MVS")[[/10A4_<GV^'2`<"S)!&'S!I&[%PM@[-L1&L/7#F)/G6:X2%_W5)>E`
MUJ[35C6*&ZE$=<UP?S[GN&O5W!=3N(K5`UD.I"`@[HT/LT>(6Q%I:%;&EJ'[
MH*94^#F*88[#<5@:7N%U()4$__3Q0H\A^"2HIF`6=T'J2B<08X_:6X_W>VSJ
M4)UT4B"#`2+<4J'T>&!N8TZ1Z?7'AKE+YD9(-X>H98>86`!=]N3X22EZ4I$8
M868]IO,#0Y$VZB,(`-S*=AE!IW+G6G1+FA]]//_658T<ME>N/;UQG![ZE6N&
MZ>U]:Y7[EGH');=O!7@83PF$G$0$.QCQR(_OH8<8C[!)$F<,HOR*,?I*R*2@
M>$,S%YLZ]RB(+JV$5IJIN7C_$0K3ZPBO!*_6`"/4H9FU*)OWI8D2=&II>F4D
MFI?GI_,+^#4DK"][7656,=S0.EQAA&`T"K"-)5&]JU_6#M.8O%4`MB:V-=@[
M:/8@O'@PF-(2CH0_%,:C28,P8.2EQF"];#&0I;H#Z$L4W"O9/1XB9F#!G@R>
M3DYKU&P2QJ4,OVW@_R02:ILP&JLPW3@7L+=4@KHTB4M@->Q0;RBH71R7;6OI
M?O7K)V:.)&%V(_7H4P+;+`1E$./+"P,F:9_ZCUMFEUG=/P^F.2R@WM[>W/[Q
MV[N;-]?O/MV\O;E^\\>GR]>_7/_1J4"];<#E'B(G)8;EL(&I<K$M2V5.!5A)
MR3'__*/3GGS516!/SQY:!=99T6)8@ZC6GAH2\^&ORNOCQ<@-L";M%ZM6\>W3
MG4BO5I^N1+!F#KTR%2O77+YTDF5W8O%:Q>(1S.EZ4K=K4RB?NAM8U59&[/I8
M'7+0.F2FO+<5DXW%Q+BL9XG3'X+,Q,G?7_RGYPDQ&+Q8<QD-BVF#)3ON/7#-
M>NO<?;"",(6CX%O#2AQ$/2R;^PK<0OT\";MLZXB1,]]`H:ZA,+_5LAB:I772
M.7>F<`U=%"^[GBSLDO;8,CM807C&@G#6LH*PWIEY/PHR\9Q/3+-,NO29L2_;
M*HW#D(Z7V]OHWEYL=/NDVSNL+;:6@!7J9R_4[>9A;;'U!"RT:SX&Z9?C`3X0
ME\K-605HI>-Y:\+F2?OLL/;Z.RO4A['1ARS4K0.[LRP2ZD/UU>C7#9D\O#AD
MTZJ^9R0.AZOZSM%M?5B;;0V:`]GHPY7JL]Y)[^*P-GL#B^80_#24$H#!TT8H
M]A'6U)1AV*^L,CP,^3@XGW7SI'-@*M`^1%FA?OY"O84(^'W:XG4?H@X\?[3&
MB>,$J:Q=7X"WQ)$S"E)$ZD-HPZ+MB?//NI_!6DH)(I#JDG/BFN]B1RII+>ZG
M(KDK`2A@*+@!Q$9%$A.$M8DC7X'/"3.BMIK\=^)\1O"9,!!W@C-$QR(;Q93L
MBL@)B">A$^YX!,HBG6`B:91)O`0)AT`#%37692*B,47")YE'4UJAJLA!),"*
M",$<L-`G@\LQQ:L,P3`3!+@3#.J2!(-4@5]`SQ)($*>;<(UY2FN=LY.?S(&H
M>\T(<20Q,M7H!`OH,GAA_59@;TG]JR?VRTB"YH^41YL0V"0A=V#=0P0IS#"%
M$G,WTRS)&;1O@D4OTQ$0UI]23V^%C[BG#E9K2F`I7\=NXNL=1K!1'&8E'EJ,
M95&;N5Q*!PW3&%.1)>XF0ASE21G=L!_GF=IL";<8P-\9*U-B'`8,^^EIHFM3
MMU7N\R[C7ZSW<P4M8RZZA5$D3)5NH'Q?6I6Y8!FZ;()N:^$R=NA,7R?SY/S0
MX3)J&']_#!Z>.?[U1P?A<`+OFQI!'\@^R)Q;-YR%,3\(,_"S@9B@4=C(6)C(
MM4EQ;1BBJHPR@"!0+I[+",T$1S6:&H2*`,;7C\Y1\`IM.CC>4K2NQ%W@*RPY
MMXQ;+;Z"69(VX`OXQ`>;"(P?-)?@!/484)+^!G\DP%X".)&'HY>#03,&2P<.
M^T'PE?$:%((OJ6$\5H^"NU>85A'*PU.>_(EV^6EH:K1%@SOZD`Q$M-3@OZ8,
M:R?\PT3R>(O`,&'(G$#@%3D"ISG]@&M@3_+$&V'5%P8.P]:$DXX(@D,P`L<,
M\;Z`!VJ-+Z7H),X*@=N8+$D[I,$^<K@M%-Q3X8\&#H]30,.4;:U$@.GF,PK:
M?02,.@HF!HIEFO?)#B583<3XB%)9QZ;*>@12#_]G$@=S)H+KQR0CO*'\#D4J
M5FM`<T2J&(N?!D"")@SS'R,"-2W\K*S2O+$MK;)$KTO`5O4DB$\M2;>J<QQT
M!/\G+*`6&6<1Y!A,KY`G3/A_FG#\FQ>"2`2#0!"JB21F+N:/^O9[6&^PX(>,
M'P@=3]RI1O>&?W,1`L9G3!!&)5,U``BJ!?9*[S#AJ4@(%E],!$F&NJ_@[H&%
M36#EQ)<H[+`#ZI(G&>E`L><-?J2+$@,Y.8C=B-4DU!JC&@2N(Z0<1*ZA+^0"
MWF9B?$O@B'*CS[L_.5=@XCJOW>B+<X36+EPAHR^OB&VQ)H!'T'^&WL>K7N!+
MD$*USP@:-#&UM/D%,`P*L4F?]#&P/@]=B;X3AK(^AB>D*Z!>"F`6CB85EF,Z
MP<LQ`TBF<"J1IB)_1BB^$BF$>(^7-PF\")P$PXC,!9;\$L7W(:(9,=H/WDB!
M@!+\8AP1-XYCX-S:-?2%_`:&3:;Q4$2!Y^!-^M^HQ8J2#*0L8C#_8OI/@R(2
M#`3K=?$*#U*5$<(JWMJ_$/#F-(6!">U585_2'A63ASFAIJ9%D">D.1?0BV$H
M-PU%-Y&N`=4&OY-NCP*<J/29W%J]\G,P/OO."!22FBU<?4<1%]@@18E.A(B0
M9O7`J`^*2BAR&A+83#J8<.Q\0CH-M@*S$$UEH>[<LN`(LGR]1K^\?>VX.3`6
MV#W,=,,\\(D:D:*=C5Z*%,_!$B^.`J`-#DM&OJH6X2BW)=8S6%V!EQF^&;"R
MW%<.J%X_3HX1!1HKDX"&_9/QH(L#]^C%[[?OKU^\^LDYZJ,9%23^,94G-YM\
M^D`M@+`C[Y5C5(597-L!M0F=#VHW#3M!K\4<X60/X(Q,:]]3=6I_Y7$F/T*A
M=*E]L?]DI&ITT7KT53X@#&1C7!EMU%!UDPRE*OU>GQ*X)"9SD]9"5QFH5T'H
M8K"/C%1&]!#3$U3L?432;E:_Z*-#2JUH/<YX87P@LU,E&U4NJ"*.Q/&:STO6
M15\,4,F0WTLIAP7"B^8V&3ZL[#+AZ[(;"?>$*@(LXHP=K"XS-Y4S$E1JC1A6
MH[C--04*8FB99B@*\$J+SD5%F8$RC+,E&MCJ*`V?KC#^)?KH4*YA<7TW1`W`
M[KS2RDDGI;+YE+::H^FI*A`8(71-4#!U,?L7>9S$-]"LR9CS$951:NIHZL`M
MF*KH$-8<G!0ISG?*KTAI+2:B-JOK1;)B.6ND[Y*0H7_4#3V)CL\FL;:F*][?
M>MG%D]`%C61T6Z\AV.6IF599%/<5#:\`FDW=SB59I.E=(1):L<L53$.CH!,I
M]>*:6CU]OJ'-M]3[P7;<`PS!E=[,E!UX!>>TB+*B(-EM4!2WNE+RL.(,_X3V
MP6"Z70S!N4]ZNVQ:KX0)VG"R>WRG`7;.#-V#VC<AX,E.ZSME;*NKGL'Z2K+_
MRN$4%\G<FF67:>`>?W#I]&PX[^($%(@J`(?2=)DC7G@88#FX(7(!6_EE4-BS
MWBJDK`"#NK2H1NV:E(EI,S%9C&XGQ&E''3O/B5-?V\,R]/89NM4@@[JR>5*M
MX^\I5Q.3EAOS>'LEQEJ'QQ>Q<:>Y#39NK<#&U1F3(;6<M;N=A[%V:U76_N9<
MM:$<[-CY^5'68J#]?5.48SA(I])G01#+Q1L",#18O52[%*TP%QVO.17*2,QU
M,\I8&&8MF[K]&-''==T1AR`#27<8?BE5\1([NQ71EY@-ZR'&4$3R>0*N7Q'5
MX<00"1+S=ZXL^G$#IF&0Y;(XZC^%&\*81R_>W?SS13V&N3*N<;;H=Z8IS9D%
MQ2"8CE(1X(6J6($A(=_'Y0[D$J;2K\E^(RX)Q(CGLZZQ191B/PD8Z#Y[AQ,1
MC/M82(/&0I<J:R50.,?QX'@";()H[JI2*H?H2'+905R]D0P+0&Q4J(FOG,*E
M2=)10+/'CX*H=LISYE'J2'&8]/_S<.P]'"8(X5Y<F?GV8LQWOH>Z=F;\[%#J
MH5IPDB[">*2!TN=!Y[*WJI:*)5;@$#**4>*QI,NUK'#`S)>@@B527:*,0?QK
MQ6B^%+&7OW!VN,X7,2U/E+T^>($(2_>W95/Q<-.@(951X](WZAANR.N:46"*
M*33GQ4X/"MTJ/3^DRU?V0#4SVPVH`4!=R74U=US^^_AJBO[D!BA%[T1=J=O-
MYJDL-]<\6U[Q1XMD/H%A\$E*T,,7'M?0V\OV1:,#UJ(LT:"O]FH+&^QMP!A$
M]$_.\^&)K[(\0^EQT!/"9\<CZ6#RB*&'5#FT:Z?I1MKKPL_%P"X300%NRC$C
M7\"N1)A3N$7AKK\E9[KTVK.+.@[C(3]/R2JY>D;HU:!':.P;W4GP=UG=%MVR
MBDH9(6:*M2[&2X%DJC\JEE84Y5+.COED`K]E>"#/U8)JPE6U4O(WXHL;N][4
M`SOI0'Y.ERJWB,DB+1P8.RVULRX_[GHCC()4IY$<2D\2Y$&`N1PA:_!9Z]+:
M8<UN.L"ED4'>(G[KH1V85WO+J,-0Z`UU="DE5&5+75W"%[+62&WW'U:@BR)D
MA3P\_%R',A1'.[*:N?C%BRD+JQA`OUS!6%=.XZ/N7_@$[?P.'V%71R_^]?N+
M5^;KDWH_+YT8AGLU4E6703RF>ARC0AN7!ZS6@5.C_UZ\JU(4J#N9`$.Y)38P
M5R)/9:7#"@M\I!7%___&V'ZZ\>39)&>MKAVW//2\,G%:\^638])'6*40=*2@
MZ!5D8/GL3.L)<A;)(!'C_)^S&>I!1AVS_23^`H<9!FRR:U(_6\R9D'YHQ]*D
M1;B*$7I`M76(,629.QX0F5&*&S2HK(1\!>$EK>?3R[142V[64)$[#]L)>E2&
M'O#[F7PB5+7<&G7=\]NDCP5>@D%1/YO/=CU_#IC09_9\F:8J)U@_+L(8'%ZU
MR@5>EB/T<GP.`/*D><;3++VX<,'R8H%Y\0P/]A*6^EA1"(8'01:2<?MP\W!P
M'8$H^'D>-R>B>&NI]VU(*W]LWOVE%UPIJ')0B%]_C<"BM*U&N]-:J^9NO:/C
M$[X'D0Z+XOK1MN<:)"Y7Q7O-PS#597K(H*:EU\6'56"(69]JJ4D>;V"2RY*X
M\E12E5,Q.+ZA5*)I[8#%`=8924]I]TAWF&RD'$!8I[C;.._QY["&<3X<V=)2
MDC9LJXBK+W-<#97^35H/;Y1G#I7&I0Y0(X4O'0CW@N^:;&3)^Y!I)QJ6(3Z*
M,5^I?H6V_#[A/?=M$(Z+MV3XX5_NQ(T6EZ[&ATKI8(@3K6Q0IV0R)(N<+4;Q
M4GV,%>PX9Z+Z;8_/"`K\DO32021ER-22<^6G4&C,B;CP%0=?R=6W_JXM4SBF
MZ!B&,3]2ZSD;SX.;UQHO3?#!<C<_76UWLC+LS]\T"V9!VLH__N/__.V'K_TD
MA'_\?U!+`P04````"`!F,*I`GHA/L\,+``"EE@``%0`<`&-Y='@M,C`Q,C`S
M,S%?8V%L+GAM;%54"0`#8)*K3V"2JT]U>`L``00E#@``!#D!``#M7=UOVS@2
M?S_@_@>O]]EQW-S'-FAND3I)$2#=!$E[=V\+6J)MHK+HHVC'OK_^2%FR)8H?
M(UF)Z,.^-(TX,YSA_#@<4B/FTZ^;1=1;8Y80&E_U1V?G_1Z.`QJ2>';57R4#
ME`2$]'_]QY__].FGP>`+CC%#'(>]R;;W;4X7"8U[SWC%A8#>=1#@2+`,)'%$
MXA^7\I\)2G!/=!(GEYN$7/7GG"\OA\/7U]>SUXLSRF;##^?GH^&_OSZ\!'.\
M0`,2)QS%`>[W!/UEDCY\H`'BJ88%]LV$1;F`B^&^+R.%_&V0DPWDH\'HP^!B
M=+9)PGZFHFP&=)*3;RKTF4VCCQ\_#M/6/:D01"RB]V:+T>OU=N/':(2?\;0G
M?WY_OM]S!UM.&3D+Z&(HFX9C&B<T(J'TC/A_B.,$AR]<_+K`,4\>IV.4S.\B
M^II\C]$J)(),J)5VP;=+?-5/R&(9X?S9G.'I55]TLA&C-/IP?K$;HY\;=3-\
M"WL>EQ*&`A#)=2PH%DN&YX*(K/$#3=[82'#?K5G^&442&2]SC/D;&&<27]0_
M0%&PBE*S'\3OI:[QAF,A:J^0-*05`]/^<PTB&I1ZC61(H*QL<=9I.K.F*)FD
MTTN$I!E"2S'-1J,ACGB2/Y%C,QJ<C[(8\'/V^/<'@B8D(IQ@Z>(73H,?<QJ%
M(L;=_F=%^#;O,T(3'%WUH>2<<#DP;O)A5X8[374:YY4YSY@C$N/P%K%8K&>)
M6*!6"XEB'-[@*0D(5\R#,V3F0AC*YA<FTC4KCP1B02Y>_+<TBZK+148Q3%:+
M12IM(*;,(N>?,KJP>HLV,+:@^F6O*KO':0\BDS+!DZ4:KYC,YCS[I3.<7(<B
MW@BK4/2$2'@?C]&2<!0IX'!098-DI/(5!C"S`+XW"LH<_L$?AXM5>T'CU(Q_
MHFB%%4^;FK.QJ#;[ZEN'(0"G5B5DWKSPQYM/0A9F#(=&AUHHLJ'04OCJ5K<Y
M`,]JA63._8O#N>\Y%.#LB@+2D]*XN"3+4=))]&\!D[.4\'1_DNY)8BX67[&-
M%Y9I0IN#LA#EC)2G`0>XL;5Q817MWX)7,,F\>3'O4[K4G,:S;Y@M;O"$RY'>
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MKZJ^%&*.":T9M9I?CY6$RJ-D^CH(Z$IL<)_0%DTB+'8"X@E;X=`)X@:<^?%Y
M'4Y?0=+<?`!X:@D'9ND>K`>-AR:=4&;3_^ZGZ<ZS*_.Y3.VSJI(H_X[OKY,$
M<_4$I_PP#P[9P\Y4_4)I^$HB]<V@^CA3]_"X.\@IXTB-RI90M>.2V#E0^[<^
MW<<<Q3,B@V"J[V^8WVZ":"5KUPR>JL.2#0R,Q2</-S#2X'V8)/^.NQ_Y'+-,
M9=/YGY4F/T72T_CD;(@9!N\:6/U;(79+V5?,YS2\C]<XV;UX41SJH,K&PDCE
MDU-AIAC<:F3V[U3J62C'2"!+`5$R3U\U)'.I_QI%4F?CY*W/N"_8@C/ZA(C&
M!AM`4D=>FT=B;55\T"5F?/L4H5B^H9**+R7*Q0)5*?UPD^YK0&RD/J&AAE$&
M_]LE^'=NMM/<<-J@:RMM&;H_*"NLM7HCS`357,2#`Q"]IA1@AP:0A=,-';N/
M.X^UT(RR;37>Z)KV.XEBDX>^L^AN]UJ9T;_]0'YF]HP#+%8XL9\1BMJ/+FVD
MREFEGM1#_]:PS>YONR#_-A#Z'.>:CQ%C6[&7U18!U^'):^9@/!Y"HXFU=HP`
M)7I8<5K-MVJN9^D4T:YAIM/H3T/5R@?Q^[M]?]7D\[:NYK*(-/>Q,"=51YFS
MVK;,3TI;9[%([*SH;HCCV4ZAV\U2>D&UQ467VV6FZS`_R@?Z3LPHV/%-+9Y]
M1@7BZ2Z4N)U(FUE>BCK&7G:Y&4BZ?TEVNA6`SA88<7$K!9XWWN&EEJUPH+C$
M^I?6W\<<,P%A/20,K8?7.N56SYUNMZ9..%#DZ++U0==^S0/33OU<9\U6VT96
MV';KR;QW.<B^.KXW"?0P"]?G<A2>&)7'I2A-CH4[T/FT%)8UU62^%HI]1;R&
MHGN+LE$WVJ.VJ]8<VMLKT!W/43P3L^,.$99N4^6NR/8M`IPA/R@`,'0W]<R#
M3QO86IJ'%='I40%`9)N3$N[VK+2_\A6EF]+LZ`/EZ7C88%TCUQYD^9=1[NZW
MBF119;@@,4FX-&EMV'0`J?-R,!>UIW"H9Z4;$DYY_IT?O^!(R)P)E;\B]@,7
M+%(0X2;,[\FQ$'J*`[!M;@C81'E9I8+%Z,G3[!N\QA%-7Y3K`0"B/=2BV&@]
MA4$="]U(<$@#EIYT,CCZW8DK<=4/27EOHI&A2W\:[](-^<\WRE%4\$+^394"
M<1=99JB9K#V-<_1\21,*@:'T#,LP)?5$REQ4B;K#F7.8*="T$N),4HMS497V
M#JEW22/+UY!6JOV'D`8JOWT),P[L3*,X#S\)<H148,"!1%:S*`_W(DPH_<3H
MM')-H:8EWV,46[I+EU$DO\1-AU9^)I!4RZ1L)'F*K"7I#J6Z4:<@2TK(+(A)
M4V$M>X;&<W_0.*8)?YRF&K[0*%3<:6C=7R6EM'KG1+O^-O]5.'6NTV5J'@58
M<SR!Q-02-W#O[L6+!/>9N?T5@I;?L8YX5.BCN:S;K_J\)\R(K%((F+QYZ@;O
M?JJ1IP&KM5K/Q-I=P1#F4D4QP]9$./_S]KMPY'U\1V(4!_(4)>!DK;O:K3[C
MH50*S-C=-R!HFP$Y_>KY/DE6\@YQ&8_5@8"0YM^`6$D[#6)U?4EK&:Z&.F!O
MZ;<DUEYT`;'C^@)A5X!QF!9$Y=J*>'BXZE;%#Y3^\"&1B_[DD%1S"(Z!D[NK
M=[CPK*C%[0:S@"1"B]O%,J);C%,]=N\HY4&)X37A43(T6*HAXY3QU72H6L)<
MC>Y]?%>QW$?CXC5#E3-1.]G^5-1$=FKX`AI\!(3,/>AJ_[O>$39*F^D1.65I
M9.OTGA9KU>C5O^HM@_:[:KP&";R%T9[`:QD[3^"_T>M`@(!AXS?)AG0>SJ@D
M]Q!&[P*<S>OTB$&!A#Q-W\7$'](GM,SXA(.@>UZ^11#4]NK?VPR#]OLSM+I!
MT,)H#X):QO;V#:KG#JG`X3;MM*R11)7WFXUX#Y]"U>'U+KS9_$F/&QI(A--T
MGWT\5:?;]ZC24%5ZG-KO=@;3&X"DH3]U\+B&H$7`:+IJ]4`,"!)%"4N-10-.
M`W"LG*<.(?BPM`@F:Z=>?L=5UO\^AEQ>ZP!D/2$&;$*%G#I,&PU6BXB%]M_F
M01ITW3S<-.1:,:N4IK6R2'GJV#&;W>;Z6.Q$5^W[YNF35""[I@..!BV##10*
MP_\%-FR#T#9$E+YT%]1YM]CEMV)!UC0-K7'I*M&>.I)LIK>Z$)6Z@1[)>Y$L
M'6[9`J=&519G(E1D.7U0.0?B39*<8F\9Q'[Q"V)_7,MS%,J.O*>G+LQJ7-SS
MT2.<O<P1PY_%S$CO#\-QDMJO`,M.E->`&XA.#3H@8X_`BDE^?B#92B%YW=L2
M`%_-*X2NVQ%.,&B`C3["^[8^<@3\<7&"7R`XHH8)CH)*I=+(HS>"J5F),/2.
MLANZFO#I*LH3J6HAG9/T4"]G(3TUX-0P_`CDV'O)H>/1?0S7"\HX^6]J[.-T
M7P:45AS++\E)HH517;;\GF<PVZG!J^&`'`$U>(\Y[#SZLQ,W>,EP0%+EQ?\C
MG+HV#HM&*9"KP[+_?AG"<FI0:S`01\`,UEL.,8_^SL6;W&[L/SILIAT!`T5L
M[F^?_B9DRS5H[K*HMZA!T_;J^$C#^"5DUB#_F8ANQ9/_`5!+`P04````"`!F
M,*I`?,Z%C/DW``"4UP(`%0`<`&-Y='@M,C`Q,C`S,S%?;&%B+GAM;%54"0`#
M8)*K3V"2JT]U>`L``00E#@``!#D!``#M?6MSY+:9[O=3=?X#UKM5F:F29D9R
MDHV=I+?DD<91[5A2C>3DG$J=2E$D6LTUFVB3;&GD7W\`\`[BQ84`FQS9'Q)K
MR/?"!IX'>'%[\9?_^KQ-T"/.\IBD?_WJY,V[KQ!.0Q+%Z<-?O]KGQT$>QO%7
M_[7ZW__K+_]V?/P]3G$6%#A"]\_H;D.V.4G1)[POJ`%T%H8XH2K'3#B)TY^^
M9?]W'^0842=I_NWG//[K5YNBV'W[]NW3T].;IZ_?D.SA[>F[=R=O_\\/'V_#
M#=X&QW&:%T$:XJ\0E?\VYP\_DC`H^!=VU#_?9TEMX.NWC2]0@OWKN!8[9H^.
M3TZ/OSYY\SF/OJH^D;TV<%*+?Q[(5[_IY)MOOGG+WS:BU%"L,-W\;%IZ")7E
MEY$$?\)KQ/[[XZ=+4/N;MTSB;8J+C\$]3JA+KEX\[_!?O\KC[2[!];--AM=R
M.TF6-698Z7S#2N?DCZQT_KVU_-;E\QX8=.Y($21^OI/;&W[KP(W[1U_Y*EK5
M)U_Y+&7*2'R`4NZX<?_H&YS%)+I(H^D_7'3EZ^-OBR`[`%2&SMQ_P/1?+?G4
MA#WZ2/_J^<6?"YQ&.*H],]N*MI.[YHTMM]S8)F'/:L)Z$9))?PXWN`[R>VZ5
M]F(/0;"CUD].WN*DR.LGQ^S)\;N3JMOX]^KQOVC?1_9ID7_"(8X?@_L$4S*_
MWV<93HO:'_^I?_W*1+2("_:#U:)O^S^66>_]W`SG9)^%6/!O\LG_2NX3J[+O
M0:?\>`L_VX1^'`LX<'K\X^U7*(XLU%>U!,H:D2-$>RQ$*`-PCK-'G+.__^/D
M3_]Y].[=.Q2D$?_W[__S]_S?<8IHM9[RYZQ^CYC:#H=%_(B3Y[^\;4MO6.)G
M61]C01;6Y4#_U)1=)?$V)+3CWQ7'O6)<9V1KB!9B7ZM5)7&/WR*5%BH(,K?^
M=C8&1E',0L0@N0GBZ#)]'^QB&@&(Y%-+U;R#I%PI)[?KE6U*%TJB*317[4NT
MHV]ID(["\OW,]-#4)[$J?($4<H4>'U0VYZ/"EF1%_`L?,5VO/\0I'5?0\=Q[
MDA?Y61J=QWG)8I$;EFHU68S57-ECZ,@KG>Q\*OEE8VK5E6:=5837F#:S$5K7
MBBADFKS3BO!]@:+*P,R$M`41<:M@@;*&%GH<MO(Z'ZF3A#RQ"8(/)#LG^_MB
MO4^&W3$0<H[1K>EMI^O*<1MO7HD^PK&2[=;VY'%L'<#.S.I1`"(>ZE7@MXV9
M'LGM_<_&=#JJ+_"6?D?3&M'P@N0\T#B[SXLL"$6"VZA4)6JFXDAG$R<^66SA
M3T5>8S.K]]=7M]<?+\_/[B[.$?W'^<75+?WKN[./9U?O+]#MWRXN[F[1JQ^O
MSGX\OZ0RK]$_:P/_;UY*6T&&C*_2/H%-M+N\-?<V&UW?!_F&Q@GL/Q<_[VE#
MDM#/S<^*]T&6/=-`XN]!LA?Y8:53E:"ACB-CC;SXI*R-0Q5GS>VLF`R/FT/V
M!VZEYV6D'2B(0YWU.6FDWB6EA;]#H?'$!HX[:*9^)#)/?$'S1(%-%!3H'C_$
M:<K&?G1$6/Z*EP[9DT-C]N1PH#VU!^U@;6PD9$]]0?94`UE<SK7_.L!Z>FBP
MGLX8]URF!:9,*-C,I\`$V:NJ2/JO')G6->8S)I'859%E(+ZJG\P+>&DU$'WQ
M]=';E>J"=*@](Q3##`<Y/L?E?R_3>FQ_$SRS@3TE$WV2[7'T,0[NXX2.'[`X
M_>UFI('W."/.1!CCUB]E'+Y`3:[1AML9M5TIRGNIH!1&^/,.I_G<,VN.J",^
M,2#R?HR]?@LQ_HL6V):T\X3&+<=01=M.=%4F:Q5:)\9M@&JOD&E3,'`[COB"
M&=G$^5))+0&$$87E%69*V%;;C)ZBMP/AT&H0/ZXS&CKT`<$3%O&5(NA5+?R:
M[2MJH/GI5P)-8+P^%3:'H_4Y>XK+])$.U$AF$EQ*9,&^H2?KG8P=ZP?I#8;^
M[#@HZJ\Z#Y9&+EDM*UD%5(:.31TU-8T&]J>&TX2-NL23$Y+@9OP%(\RXP1X+
ML64UT=<[=H")[>\IM^H!"^KVBF#C#2MZIQ[D:MJ!OL:K'265QAIZYNA55*GD
MG*!\ZCD,]GEY-"W<4(]4BKXAM4$4Y#FN-LPE[7#SVZ416@LT);M-(*!C.F1#
M37NUY_F6Y\EV&Q=;/H&>1N])RCX1IR&M>K:U+R'Y/L-W^'/Q'?V(G\1U^E'*
M]8*]I;+KLI.5.]LFX1%G]T0\428L/HWY`.4BE+W!54>',[VG-?/ZTS@P$1]5
M+"Q(6=GIK4R-^(*#X]I;R#G.M5](GV@PC5H]]$^FB;CJS+O+YL`ZM%7@@&"?
M,]9E7TO2VX)^RNTFH*0ZVQ<;&H7_@L7E60/)3A<&2GK@-6#;Z_XRK1L=7U7:
MJU(`Y4SB".5<!@6-$'I%0]#RZ>OY&:FK=&)=.T.J`4HBKY2VE\.ARSS?Z_G3
MEX*X4TOYYDUI=U+.]%Q8\:6C*>=*S`46S!.A<E4<&=:$AA^E@I(;79O+X<7U
MOF#I2EB:&!TY)*(00WJBOFG2,3[1X$?CSHHWHKJ</*256C"#9`A0T0BH*0V7
M.EI*0@VL3PPTKZ,1G2,7C)TT(+LM059*':&.W,M"EF+$X`-:"QD-2`^@`*^'
M+;.G8R6"P8FB%>/#(C(5H8G]CW=OWKT[0;L@0X],YL_HFS^P="$\9<@@T/\S
M^L.?CGY_^J>C/[[[(Q^D_^&/1W_XYO='?_S3UT*DP[./=`"UY.PC($SD)-,=
M-!$D`2[!QT<.29^\N%Y_3TB4WY)D.`"0OFW(([QUYD[/GE_JR$RKF3/46+&'
M?)=_1J)]6%``/^)T/_]\J[R6B%'1BM#M"?:1*[$Q&W`[&RGEN0!@@>H7RP0<
M$3PT:0OB8I@TL(]DT(4*S(#2BN<.1&%UC+RS6#@OH!551TP+NP_KH6P7V9"E
M2=#@+4R&S=M#@8;$G1='J'KUY<(`B'C'X&#.Z';X1<`^#KT@V.IYVZ<!F_;9
ME6N]V*%?2',P;`IGWC=A4+%*,NCW1<`Z:FXL9-_#1Y(^W.%L>X[O"WZ6D&_*
M^,CV:ES?)_$#SW<D;E.U4ZJI8ZCD2B,C-UXI9>-122]S0RLF>UQ0843:5TT^
MRSK)UQ%*<)XW(<J.I;`BZ<R4M`,/<:E:@:I&^CW:6GB<C<(70<8.^^<W../S
M2^=QLB\&JU$:J:JD0"E'5@)V?=)0[4+%.Y7FZKL@C\,R?5[YF',L(916.YRA
ML)H,8GI\;CTB21)DY4O^=.9I=EV]$ZM*ZA,*4.@R2&ESS@V_9(L_TDK\0`N)
M'9XOGG_`Q89$;%=R7F[F$*!LI=-N\S71<=_AJ_<RS9D-8[^:[;V&=E;ERY)^
M#-\H;B38#.G_D)C^P?:5[[/Y3U!9P(4XU.9@GZY>7=BB:^KO4#BU&N0;K+I:
M.?:"U)/?H"JMT$-AU3T]C[$KJ_0\FB,3YAZ]H/24'Y6@LN@5DWY=XK0";JF!
M.BHO':5`7I[I4#IG7AX>C='@%D?OR9:EN.!C&8$,:J$Z12@@Y)H45&K6YXA!
MZ4&9^!-67/&UR6-V^U/$!@?-VYG3>*HKDM@4NY"J4RK?2\ZIL+@P^$-Y<XV$
ME73PERM7:7YZ>MCDQ]4;6'&98RZ$>@!:3`)<L[K7,L@@Z:U23\^HA<PHFXVF
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MDI=_OT`?KV^7><>.#A*#N6QE_<DFKP<*P^EJP.:<>>,I3F*6_I<G9+K"Q<7G
M,-FSPS!L%_U3G"0#:IFKM'GF#53<\\]KG?AEH+$_3;YZ,S.K5K+<@C8WG2Q@
M0,97TR#_O59;R(MOZ&V^4%E.,X!*WN@R!24L8-^'=OVOF2,H!6SUT)3!;R$0
MJV^'D$]L`&^%.T)\35P(]B;9,"7S8')G2&\^HGY8WTTP>W,KK23)#2+:609!
M4':/B&H6P4.->\Q#*[5M6=DGG=J^^')K&]S_8U/=\X[MRF2US[2;'C12PU=-
M"]5]Y0S6UIC?:'%@5PU20;R;5WL1T9^D.HB^&$5DME)]6(K:2SC<)B`&OG?(
MYV5"#C<$V1S3M3N6UCV8N\0#N3)$&EVS`]R=H[L0Q[%2ISAM:WG,=GB^]DNJ
M3/U!6D5M+N3H[%D:\4UM&Y)$.,O+)5.XR5&*#]LA0-P?CJ4.IFRQ5`X-00^;
M&+9M?%DR[TC_CE^N6<R<$\88$7+R:&L-))14$V"9PLL!`#A%ZZITYHJ^?CO,
M@7?Q@J&F;[R]8&W)S;P^7X*1FF&S/T4N!:6CB3(KF/ATX6)_94RDY&VO+Z@P
M^>H<K^,P+F8^C6H-'`O*6N5J4%JP8?!"ELNZ)]6!C$ZPA"1#@[><3D.;4^5>
ML$CH!&@U"4RJ1`DLE4(B2[2PG`P*JM0^ZJ*'<R/(<OM`MF8#_!4NV,7G-QEY
MC",<???\8XZCR_1#G`9I&*</9RPSHFQVQ%ZQ*BD;14?6F+OR/I"Q=JTBFJ6Q
M%9MMXW<T[2H-=DO3NI9&02,^+P%'0(BX5FZ?KN8VNBRV]7Q0%'L;#=F[]0?A
MDQ+#3`/==##\BFFA.'V-&D5T]BM$,S"D.@2<YQQFF7\I,.`:;\"Z\_(V"+-W
MZ3,R'.W=3V,@;%YD[<$Z(4]5*@A9ES9SICP'A(UJ#?2C-7M;XQJ'A8S@@`\N
M3R6-"&@5BNHV0:HX35L@<76H@!9V/:(!@(RU`>V^[/^K)#!?0#"K@H^>\)J*
M-2*ZQ(8!P4'/!T7PU,&LPJT_^.J#V49QZ<'L)&BV"V:]PGF!P:SD2^V"60,#
MUAW7U,&LPN4!@EF]=S^-@3J8E75IRPQF31`VJC48'<PJ;(UK')8=S#:7?]L&
MLPI%=9L@59RF+9"X.E0P"[L>T0!`QH;!+*DEEQ[,JN"C)[RF8HV(+K%A0'#0
M\T$1/'4PJW#K#[[Z8+917'HP.PF:[8)9KW!>8#`K^5*[8-;`@'7'-74PJW!Y
M@&!6[]U/8Z`.9F5=VC*#61.$C6H-1@>S"EOC&H?E!+-M2M<A_8?O6F9WW[F3
MMK7FF8\#PQJJ"?*\9V6)KF<GBJ0NB$$1#N#=B@G(%?5]5ZI5K&4R7!B:MZK;
MDR^W<N&(QK!V9[V8E[:0_,:9?,/V&3X&"<M+=X.SF"6J"S-V!<TY+O\K8&N,
M:GTGJ96JZX6E%LZ\#Z1'.%?>=VIKCK,JJIZPL30?6+/MN_P/W!J9^7;4,6`B
M[I4LW*MJ8:5WZ:JU]P-CVM^M[R,<^P3T215*,P3S/SI:1ZC40[4BVXU>_C7S
M=O1#HQNZ2?Y`\)ZS0[L--SC:)_AZ?86?SD)^/1T-]NDH(*5_ACSU%-MA_WY#
M(8GSR[0K$Z=AO$MP?H<_%]_1C_Q)H-\TQNN$[IZ-NR:`]_HYMAVK0<KK23Y0
MF6?>O\/5)QRR+?"M).J;FSDI_31X)X=`F9#TWJN?7I+\"7[!XJCK+7Z8YM,.
MRUH:@]1&V<D=:A;F;QFHE*99^-T3K*VC?]X%]]08\X*XF[DOH_@">0_$/%\2
M\6==H*!?7<^,EM,3\EQI6KEZ4A*6<YW+@BS[7P77>%+.<"EUJ_0*I-C@;!GI
MU?3U2BRK0)@.@U1Z4V-JNU,"Q]_BL\[+:-2P.=+.>U3?J5>)S#S&]0<@:$+5
M&4%SMJ_7_:^2+/$H)*J"D$HXDD)BTWL["OM0<0'26K4;*.9?+E!5&C$NY3[0
M)<)=B(.VID&"MX9187\$#$ZZ..C=+OHE`P)H^L8A8M;F+GL(TO@7GL;@/4ES
MDL11>7M<&MU0(-+8F/_S>EV=E`J2)C-\?A[G(:7V/L/01-Q4YNN&UKMY5VYZ
M_J`)IN,F^D1ETS"%R]5W01[G;&#?-3%SHS(5W,EA(":T9IX]]9K"27[%`MGK
MKUN>Z.,.35P6$'3,'J&>83X/US7-"-X81ZUUU)I'_US,A-R7V@!`\<P7U@+,
M&DFQ.:+R[@YYPBU8H(YF)`*N+=K`Y!01!>1$V;3(E5;\.0JKE%,!%YB9TW"]
M$=.2%F@UD.T1`[`T"13\=4^@>7L4G-0P*-_0+J)\]^7B`&I?1P!A]C;.=`7"
M3+C;]DVW%J$V/U6;Z+(N86"@(DFU++&`NQ8,:UQDRXA5"K7>@$33KE?H7?AM
M99U6+DPL5,!:\"+&%$A3M=&>H#9GVTUCZC6FO4B9L_9V$U!4G^V+#<GB7W`D
M0-M,N"HHG;`CO=3F?9Y\,?*D(I>!@54C4R;I/T(Y%T-!(X=>Q6GU=&::&<*`
MC*FL/LO4>EV6F7A8%,DN\WQO1+"^H()<M>`$Q"I-3TVJGA=;0G6403+%7&;9
M1!*J6T.B8<7H"53JZ,C3M;PHXESOB[P(4G8#J@%[)-(*"O6D)^!1Q_[49!JZ
MLF64:`&D%6D%E\TM&1@T!`-J3,^RCJ*.:@,?"^';39!=9WQV-?I[D.SQ#<[X
M!RMIIU.2L@]6\DI"R,UT7-1X-*>DTM"0F;L@0X],CA,R(DD29#FB(Y"2G(OB
MIA8Q($5-ZE/%5$@?)JS:XXR\)2'&4?Z!%B_KN`-:]-?K]V2[)2G_[@%E#>4;
MMFKEG8FJ\>"7HV;.U/0TL;&JQ<J\(7E0'CH(N5A)UKFI:(H$,K*R1`)J5/O<
M,_(S)^UHDUH\WU"4%&=IQ(Y7[MA*Y/#^7Q/1EFP*47>>@<8]4TSG1\,NM?JJ
MEN!;`W#]>@'3W48U3>QK9,`C4$N@D,;ZG.QYC/.8I!](=D[V]\5ZGU2';,3-
MU2:B+7L4HN[L`8U[9H_.CX8]:O55>\:^SB[QFIUO"Y*$/+%6%JU)1L/&4A4%
ME>[LQ-*#@-A7UH!8H)9`+(WU^8@5///M,'?D+*1TSS#8"(@TLU:L26>AZ$I!
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M'MM[M9.Q,.(M>8N?-;_'O,0/$WD9P`%;8S?DS-O.%D&<XN@BR-(X?<C/PG"_
MW?-NXAROXS`>MKBF"DW;JU=P9H[.A<^98V-O:BX9&5EUGJ.H?#$WEXSKGXRM
M(9%>.MT^T<P\S9=_-4AP_@D_XG2/OR<DRH<KF2J1.A>J5,0U+:+$J$_F*.PK
M$Q1":FR%,MJ'!<K*EW,G`U55&S$O9B$_GT2ZEV4/M#8;Q-EU>"FU_:R?9C(1
MK<I#+>H(?97Q"4ZI&;A3,4*KOJHE9K\ZRZB"B7U%]$FBTNJ216]]8AQY"^1-
M'+E`Z*3%T/,R9V)\(PN([GU!:QDYWV_W]SG^>4^_].*1+V%H$[EK-0;9V14:
MWO(V@SXF:*S-O9JE659;6;6O4?E^*:F.]4B0YB\VJBHH)S&H+$\TK/%U&/A-
MD`M<Z\\#\H2LW0,8+C@)]Q3(U*;+]@G-63L'G"3LMK\T^B'(?L+L_+0\KX1>
ML.X*%(*N%`1->QVHZKPHZ:967O$!&]^'L:W?S\PC?;T2VQH02`/J]+BBL3P?
M0^KT5]=K=L7/!W9+*7`+K8EHS1*EJ"M/%,:],D7O1\D5G?KJ_?75[?7'R_.S
MNXMS1/]Q?G%U2_^ZO:,/?KBXNKM%UQ_0^[/;OZ$/'Z__<8M>_7AU]N/Y)95^
MC?Y9FYJ[HS(!!;&O/(%D"JT>S;369]]62WM+=O:D/I#RGN3#_>H&HL+66;FH
MIZV&,N,3;H]5N#/94PBJK_B?BSU*95+IDCV"NLJ1;PJ4:<FV`<+6)\:6]XVK
M*D<NL.IN3F5#"WX*K99"7.QE`4NSW=056;,.%]@7;4@2X2QG^UR+9S`4T@DV
M@1`LZ!P&0::GF"?2.5-'0DKE5??][_AQA.+YV[G#&FT%$]NJ$$,:2*<?T*@M
M3XHA?Y,]6C?CX7,BXJ<465"`[`])T+R-!R@MJ]F](@76+[!:ZX&-,JCGG5^`
MIX,TV6K?=A14V9(2<FDLU$%%24J#6M11%#"A9JS2[R&Q.F'7H/'J#:90Q\%4
MEKDJ?#@0&W<TOE$\:S>TW^T2/GL4)/7LT66Z)MFVO$(`&`K8:=5=D*F6*ZG-
M_'B=-K5RJ:2SA:555QA%+7W9)`_516LV%XCB5GWN$88E;HA3I0H\-C/08[&-
MS]DHK+HJ0W5+AM\+,ISNQM!>J&A[*8;D/HSR`MHEW8>AO0+!\!8,\-X#_W=?
M3'?MA?6-%[+++A9US85]]0(1B'G]SAE)]#X&B!N4,K)FR5M,(+7J,P)0.3"&
ML;!4VFNK9NZZU54'H5K?+4O%09`OI,O]!XX?-@6.SAYQ%CS@J_WV'F?7Z_,X
MV=.GNJ3+([6K<K/6=F2.I3^?G!KG6L6V,1;Y_9@AW^`3E7+HJ3*#@M).LZ1:
M9G=>3$;GL4@C7JJ_3W1+0]TF8-0WS'@$D[91<4B_C(T9SE+^'S8)\!@D;!'P
MBM:7-%BW5VR.9)HK.A_--'7E]XBFI5?U44TK8ZM6OAQ4LX:`_X%;G;G/<%H#
MA[A6J7BFT]1&_VRGG><Y*8UI/;!//,>/."$\&91\5ZV1;$M<E:P[5V'KGNFI
M=:1AI$9_58N4W7`K-#OQ#.J:C*B2`;U@-8%1.OLS#Q"E(T+I$-#3F&^BN2CC
MH5UW]FDYLT[PR$TW5!N.S3S.+$TPI60^E]2;1%I^)2EGB^2U-.?\$#M/F1>L
M.2IO\[M,"TPQ(0;!.K'.X7&YF(<#OS+#$QT:5[C2G?8%55?UOU#,7\Y_K%=9
MH<2N\(>G>64:XDE>V.J$>/%Z.%SE9"Q4JD/AY>OJ9M(C5$N\#-PHCH&[`&?.
MIK3=1\"O]F#!'5^0K/(!\FW%?%;DNR!GZ0&K[+;`CC)/UJKB=;;FR$='_Q,T
M\WZ^2$5Q'QY67."82Z"ND7E;`5_@)),@I-^D.!KNMCQ>OG%^)GGK`#U]R\0D
MHMWI>6\33M=.G>2U/!YSA$J^W7.^-8=IEK/O;IG$`SKS93%O_E5XY?*[<MW=
M\X+[A*=SI`[T@_S^$OMRQOKZ)773M71X$=WK,9JA2:O67IN.7V[?KH(7-9MC
M5\/*V1VS*AZV0^YU?.IW<DXT;5>]IW7U+N;@TYB:/G6OZ=,9>YP/09SQBUU_
MP`'K-LOA\FY?&%Q*,DJW*B9+74<F6'F;H+<;XU]%)GM[*Z:"N`[J*,W<M(Y#
M$/%0L7VV6IGIDGF$_T-#V=LH;I1GKR@^Z<+XJ(MC5.H=]4]!+2M!VN'!#D0A
MAT/[G&.I]\$N9FO![*[/Z_;2C,MR4THDT,M0NBI(K;0CR37V?>[^,'.EHK&)
MA54EU-[<B!(F/R\C32N=C*J9/NDTBEV:&?F8/V)L.0\N3AC)BA&A7-97MRFS
M/F7$I_!GU#>"^IVN<"']FK*29?V8KBZ`;DNF)NVF8/M3H\E_T*7RY`2D7E#5
MB9^6-)WM'V*ZT,@98[.N,.,U9CU%=0^%N&(L?UNO`(MO7=>A^O:F6*&5>E`N
M%DDT5O7#A5Q?`M42,2I:88&E+]A;,)'9\%_E_I82Y;8M:_ND4]W5XR^QMJ'U
M-*OJGK.ANBXV."LG1,%S-4J9ZH<#,HXXEEJ=H`%3^5$!&]9;\5>+V+"LKCYB
M4=I]D$O%NU!7V)L*%]Y:.:6'49`XJ3%1'[)O7W_I^`!:P?$`F;5%W&%V5WB3
M:QW:#*"5JUM&6,Z5!9!EG[-3.B=*+BAU5\UKA*OW,Y_1UU<IL2Q]@1"02H\4
M:KO+X86.#SH>^,>_]Z-*D`<KT'</,)$!Y!>&>".D6R!<B6P_L8#,JK\X`+)N
M#8&3;H-W\877/M3C6U?_,B9ITN(]_6]<@$,@$]'!](U,U-O`?FA\THD=T)W9
MN!]07[6WHD?MY,_<`;%194OG!=25`LT1#+7D$P:0]8DQ-<',$>S(!4[].25:
MBJ70<D9:OH&EG7UR0]:<;3-K&.YHNW".[Z%D:"J1JD#D(HY\D1GU.>)2V%>Q
M`U3K-++LW6+V>BKKCYB7=Q_\,NDNZ&%K\^V3X<FO>,KCFR"[SOB%5!%?V[K!
M&3\L(>Z5,=>H]\N8:+CNF='[\+IOQMB=<N^,H975^\ZM3T=H%V3HD:_7LF1E
M$4F2(,L1C7#+Q&4SYRVSP0<978'"]AJ]<F^+C:FO!=TP(>`>%@#OC)@@X;[W
M20_0A5T6_>ZT1RZYK&=I:?%EA%"7MB[/O3JAO9?876YVPHL63.)T2$M^=<)9
M463Q_;[@6X5IB='68/9`W04=QM<@Z.$Q9P!^DU6C`_YIO%T6,*B0J"^:E$FX
MW@$XM.DSJ(#-*^_[`[16S8LZ;OB/=V_>O3MIPX<_HS\<O7OWCOVOSGX:[(L-
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MIW*SW#]PY>,K9VO:+H(LI5^8US-74-2GE:M*6"'GV,J`EB>(`'6^5,V#6I?V
M^7DYV\I?SLM:?:42R_+O\PQ4Z1)(8W=*U'B+#K5>1@.&1HGU>W13HV9!D:(_
M"`$1HSN&YMVHL\MP&/-#N/3O!//;`]/H;$NR(OZ%/Q]LV#%7:3;NF*@X;[;0
M._$9R5GX4V^],#2SZDKR."OHB,R]_<("$V1\G8F[,?3:_5T9IMYF7;".>5[?
MG%TZ0E(6JF$:I`TV!1M(=A:H04D/"].`;=\+TFHWNH5HE?:J(U#>H=,5F7^]
M65?-Q+H^ANO+@)*XKJRT/5]JR>A_]F4V[/R.?,*L..,$7^$J.38+:>\(&PC=
M9.0QCG#TW?./.8XNTV;C;#L"@A)43NBB3G,YB0O7/'L3?)3/EF'"[U-F_)O*
M[:ICF9$OJVVC%!<H88,S^I3]S>=@]BQ';YQV3C\L9LIE4L:0PR%4R'TX@;=>
M!L7)?LU\K7,8DCW]/3?!,]N)P`*N,,SV./H8!_=QPC\5N"/<7K-N2VTT79M(
M<U\33`79>U>V:Y;65K4"VI4:Y<"DU%G(2:PQ*"+.U2LT&^9&>JV!K>_#0MG?
M?5CV?CVB^*0#XYL.C"LEU-%:R@7N!X4TE/#Y()B>/85'V?'2S]2=6C<2[B;U
M4`C[R.(`FO=ZB-W$DS:K@]I`E=VAO#(,O:IZE==S'VDWJV\QRX-1K4BR/8!Z
M@[0/&@]+G-O2;TD8HZN?_YIBLX&-MP/-D8W;1F!M;S"/UI]*6LKIJ'%8,IMD
MLUKEMS%C.!&WN/5[62Y!@.,FHHI\JMX8K#+ND[`&?FR37_;I"*3%7PP1C2I<
MD_A23S.5EB[KY4)(5-WP=!-DQ?-=%J0YF^0C*40D4_'FJG>=N/-M[VH'/DEE
MZ$M]Y[N!B57W#7J*BPVZ3IZWNWU.V_5L1[)R]7$I5#.&!!E7;>*E\&K-_KWP
M)E[F.ZJXO\_QSWO:;EX\\@Y73CF=6'UL$11S/:T&&/9)+8T/Y;DUE>JJ?8O*
MUXNAC;9:B5T5"`?7`(W>\36EU=EH4>TFO<X8;ZM_G(4_[^,\9NS]$'_&4749
M%'N:X>A$0*Z#A:H41UEPY-D(GSXI.-Z]BIUCK:ZN,+_(/6.7.;!5R!TMN4W`
MDE.1-=IE;%&R>.8CP?9J#"J?[*-RU3(0%@_F);L+(HDWB/2;B!'&NJW'Z&^9
M,=3ER9O9RN=#RC\2#')U@DUX"PLZ![:0:;\AK<:+.IA5*J_J/-H=@<7TO@95
M3&PK0PQ4(9U^B*JV[$B6'(=O'LCCVPC')4_H'R(]Z*-_G='V,V)MZ(<D>!!7
MRF7OZK7P_KN1F!]\@0^(0T9EB);+KII'B#V;>5E.6@M$4WC"JEI7C*$0T#T0
MZ*J5N`]Q'@;)_\5!=I%&YW3`)L[/:\3JJ7A0S`&5D%%?`-78A["J5%O5"Z/E
M:\3>(RJ`F,3,T^.ZJB3FQ2Y,>`,:-<K5%@\$^',2[AG3;G`6DTB.=J5,?>9!
M+N.`<ZE%7R!7&8<0#NNLZE>H?+<0:*OKC1@6LW`(029>(UIAZT!PODCIYS[_
M`R?)?Z?D*;VE0S62XNB2I3S)!)`9R=;G*-6R#C!76O8%=Q,G$.SUNJM2!#&9
MXY^8$*JE4"DV\Z$XHXHFEO4AG(M3J=7\,+!]4)[\G23[M`BRYP]Q@C/QR(U2
MIL>+@8PS'P2+?GD@-Z[&OTRGQGWS#I4OEX!VJ-J(82G+T"V(]U$MM750-%?Q
MU">\8^?;T@>6"'(O![5:M(=M2-09XG+#?I&N]*$&O$*UQGT=U#<RJ!1:`OXU
M-4SL:D+&!KE6GQ0JRP?E!B?E>QJ-/9!,S#ZJD.@Q09!P)D#/GE_<RTRKX3[4
MJ%'.WZ#ZU1*P+:\J8E2V,B3WA/L`EM@Y*&YO]O=)''Y(2"!.B(/O>YCMO7=&
M;,>:7[P.#:O1*LK76"V?(_YB"4B550\Q*%$92CNB?8P.;!P4H9_P0\QFQ]/B
M*MB*T%&)]'`JBCA#M6_0+UJEMM6`E:C4F&U?(?9N";`%*HR8%;`,O'WI/GYE
ME@X;.-,0)0N2RS3"G_\;R\,#0*8?*HLR[C%RWZ+GX%AJ7!,52W2:<+A\A_A+
M1-\N`<I0O1'#8I9&OGUQ(>25V3HLG-L+`7CVH?RZS7(LQ[:!0A_H2@5WU"O,
M>Z:`WI.&#SH##3G*2R]NR^35I2SJ""^"*R8X(&-J2LHBA:Y`*:V7`R\6M4M6
M'^@3<8I%(R4L&`VD/"P9"39]+QK)S>N6C61:[<)1=V&4OU_&TA%4A\2XP.7+
M1X*"N(`DM3<+R,NE+#W,)7)2H/?DO$&]8W4:L`\=F,%=U!L`OEHP71SD9?4I
M!3U0]"K8=U3DP!_8/##T[ZA9`.W=5P+`RU<>,,T,^89QQZ8.N8UH"U;V:!GH
M[)4_49>;'(-,2H1=JSD":>%S\9FAZ?3=UQ66V)/.I9!\.V'>/?DB@LM`M`:;
M4G0D^+3?:XO&J"I767904V<RF)KIKJHG['(8EEZB>R5NN?TUV+*-Z"C@.]?O
M`^HGQ"C?8%R@B&J^:6[^;#3B'`4HJ5)6/-/'I0>*HZ"1V64DVG<3H3^C-<G0
MTR8.-XW0ACI-28&>J:][C%.>\NLA9;?4O$'?XQ33P6/R?(2"%.%RZ,`$LDCR
M*YXV5#TNF`".'^GOI/S)XPA7A]$8<>C7T4:T(%N<46_T:^AO#S<Q?F1?&>*L
M".(4A5E<T!8W0,4F*-"6RE-9M*4?R#Z_]D9_*GW:?BW;T4\=4I$M^TI^)N[[
ML[.;-W/G)C7@$K'$O-"2*+18,1F:GI*LSJEZC+V,IFGWDN$*8_E10RQ&W9DG
MD+PB27O#L`.4QI]S,C)_:H,E10HS8V>C(77ZJX+4Z820.O49"?TCR-CL?IWP
M28Q^H-?5SQJ^=@&[:,U[9`,X`#$ME>_F<J`1RE,IDU>A1,![<7Z6CL*:]=$T
MIE@SC?(BW:3-K%5VR^&&NF8WWZ5=L>[1/)9A%->)_5^QO*.OW_!4"I4L<U)L
M<([;;Z$1T;9,,Q$AEJ&<A0;[+&.!Q7V0T[?[G/V])1%.CFE00B.4B%L+RD/T
MU&OU<Y($Y3$-*M9Q&/`C@[L]RRA#?R6YSW'VR#.T\?.#-*JB@4F0_82IP*N/
M%+P)^OKUS!$'B%]B@+D^=T7)AJ]R$[Z)X"=J@"Q;48!&!]7C)A_?S&WWJ&H&
MNGVK>G;LWF4FO7;ID`.K^CYMZSOY@NL;Z).MZMMKWWN]8ZTMU/4";ZN/'[QU
M@:%@S'N_*[</8E`F+O2ZA(MT!OU5)\BN2V)SMFUGW.U)F4#.KF#G$V?43)W'
MD"IW^F'6X0;\*/;K?D+O.HGNG[FE3G?-X@#N\8E-6V2F_6_3XZ("AYLT_GF/
M.WTO23&SM643`T`?O$^_B%X8@C+1XZ_/54&PH:K4@&=&^.F``<,V7*#=;_ET
M*;WOB.H%^EZ+^G7L>246O7:\@'V;>CYMZGDAO>Z(>@;Z7(MZ]MKCGK/VD/#L
M)_7H&LAI82#9S/HK)-WF?D##/J<1M4X44SX:W55'HIGT^78Q22U,ZIA85H8X
MWP-J=:9[=)8G!)'G^4.MK[%8.@6P]&(`!$X8.@-HN@94L6:JE)(UG/Y62J5&
M)U@D5?DQ@[FX-'JW:58_>=(N_!B3?9ZP549V1HM/G'>FR]M%1SI*V*=LBK"S
M`,G7"]EPI+,JR/]5OH[V?#32#IEF7QI40T9*([,%0:F"G#U^EP%!PQ-TW5:+
M?PH]H9E=T.J,,SY,^F@[@/CLFR==UU/Z&0.4?G^\L'4\9Z28=,9V2/':"7_"
M.6WLP\WW?+'G+(WX71,"PM1"19V03R[D@FJY3>\=L-(-"&F%5I-_K^I(!SUD
MN6DG)>EQN9FH;1_;B_YXALW,V!#MV*M+CO+]EG7Z6Y+B9Q0\!5E4[6!JMAHQ
ME`59]HS(OD`!RG<X9#."+-/GCK*?=>Z[ZB(Z-A7XP.?K@X<,EZGF9^[?-7`D
MQN#I4U(NWS!296X:C/OIVM7V1Z#[A,&[?%DBHT0J8>^_<&``W?IH9#AVZK!A
MKWVZVLT(A)R^7(0`W?EHA'CMS.]($222(;R`+9U8]=-@,1=,0U:]=^H:1R"L
ME7JKLP?:"SZP7'!F/7/62<!+^V1@T%W9.OHM(AA':RVBB07Z^LR&-!INJTU.
M114_L8'.PRB2T/B`O^Z.<>J4S#.???*"$R!(<`**8Z"@,FT5*A3,$!@HZ-R,
M@LMI#9=(,BG_`N`"1`Q.</$:-;SGNU4NT^:FK.MUM5U)#!P,)*L?J91T0;K"
ML/<(0N\+!+Q.=54*"#MUNUN`O\A-2"]_$[`)!8@=5OOM@D*I:1JTAB=DF)_`
MP\#)6&Z=Z,GU8B`$A"(>,.08D&BL>YV^,/`U%DNG6BPM93^51U`!`8L'4$T=
MMJ@W09LKP$&,UZW2>ON'"&DL-U0;6@!Y\]MNZR]IM[4%9Q2MB_&>;+VNJJGQ
MOG/;S,=D$9'M_FY3$\;<?*'8,X^:W,#G/X::>J>YN4M'$"H"JU\)",VC+#<0
M'B;F,I@I$@1U,9;_>:+*[N%BJC&S1%W-WV*HEQU#&8W,)*@U;#&4P[*>V>F(
M-G%L-&JRJ*=:<^PR19U3H=?KZEC1\J:*QD''-N0QQ<Y4(<Y!9HD$5R,Q].6'
M,K9@L@U=3,'D-52YK"XP/\?E?_F.F^J>FO)N;`&0Y@K5SS91<"&'WK[W4,;8
M)<@50PO\?`J+-,K`H[N+)6MN6:JBF2IT"9J=-RV_^":KL+J>J0Q:WC37-97_
MYI$""UW"*H\?3VX7)/P0"XM\*/AHH40\@PZ+=VC<\<RR$[^J8JJ49-L@Z<1!
MX7.8X",4KU%"Z+=G<\<7%L`EHZ#5I[E>MZ&[J9OI6>(G#C'WY<@/&I?4@JB6
M1.66PAK=I?`+11X0KGB'GF/X8N;$+(SYIL1>RINX"`QCS%TZ0I!E#)`TKR\4
M<$!(XQUPTX<XYK&->5`S631SR##&(7Z9*'!)*="%V.5*?&0<O@3K@II\(=&+
M#9='Q2LFY)TT0CE(:.(2DQ@%(XL-0L8!R";LL$/0%('&(2,,E]!"$E,L-I88
MAQN;Z,$.-Y/&"T)R8$42CA&:0#RAU/1)$86CR>,-O6]C!NE,6<8CZO-'[4SE
M4;5RU!PM8I;82DWP$[N+(*7P+5>/V'']=4*C$R;)%F/B$.?\TH,R5J&NV<T!
MU,?]L_!5U<FC]NJ$,,@W+*8IHR.FQN]MZ-]V4*4AP7R',;^V@-V:4"8D":HW
M;$%H86&-"6.@UL80RNK&1V$$;(RTC@](V&G")`.GOJ@J#:.:-/9UPH#Z2I.;
M^9-?'!#"AH'7!!CV')AIO$T:J!GX]H7EQ5_`<$#L&@9_$V!WVLFDM>!=-Z4$
MR4,32T-YKR,DT?STDTR`1_/!DM2`98#W6TAWN`$CB'APV*@"I6;L**K"(TBY
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M"B;S6L1;&@T&!?W):;MQ>Y_SC=OW.,7KN&"_FR<+*D.[.C4`SU'$BY[]HHCE
M%J*ER(+4P5IG]Q[2^@?RCRIH';8+GN7Z)S,IN>=U6>VK6<L`M;7&A%4WNTHS
M8!-LX/R@C=,T0:>16W_-DC08Y8T)4^O&I/4M:4SS5X5IPY!U(E![#F6U_B8-
M:XV\^P,W#7>9S/&P>_U5`=@P&)X(P%Z#Y)N,A!A'^0=:CA>?<1;&+#2_V.X2
M\HSQ;4'"GZI-_6=I!&22<K)1%>%(&RY,'N72>Q#M\A4@L<<;Y4$UG^B+TW5"
MGMCN#A+&?"F`7TM;M'=1---\/`#<D(0&A#D-Z[B_*K*.:4C*W%7'9\JLEW7J
MGIE#.3?<$E\PZC<BH\PUC8G#Q\Q")3\AGY-[_R2B(6"M6U*CH@0?:^%*7T&+
M7S4K@.!P)EHX!HNC_=KE^:3-+GQ6TND;_)/C]#=R>(#%(LCA-QL%C3EN@C@Z
MYY-R-WP6[@/)@%L8#:7KO!0Z::=CSVKC'@_.FSF"3SZ;Z*^8%-I1L7IZM$Y$
M3K+E7-!H6OUD1!T)YZ#5FNUA:",/$^/,[QE[,W\N<#M5P^W%80PZ:^\/8UZ;
MY._8FL'U^J99+2`IT!P;2%8_62GI0@^%87]-L($3D`]:W1678&%05V8Q;:Y)
M'1/+RNCS0*'5<$!OV1_^?^1Q4%[$VZ``[X-6"U4_$!)R`;S<IC^LJ^V#,%>I
MK7XLP_SF]6+`K:E%8E[F?4C+%1HT*^U-!>0[_+GXCJK_I$3R0$H*Y8Z4/RPW
M1KU/MJK]&&*ZK\9&L^PFG;R]?^=W;!)T1TU5"='8A;M\DR:[PZ?:)DE9L([3
M(`WC(&D3N?&4:12F;&\EVV?`9UP?<(JS($F>41`R_/);A$(V`\OC)1H+A/$N
MP<WV@IP[VY=4V]*O>"CW%^#Z!\P\[:K#F9QL4E"HR-8H`&P3#$X$WRG:XH&#
M,<"M6N/K7FO,)!`7651[/`HC1BVR%4@<!W`*RUX';AH_8\!R.NRZOWA\`(,Q
M!WQXG@_;Q460G#T&<5)M.P/GPK22S3R80M)M;@(T['/^2^M$,1FAT5U5$J@K
MLICPU*2*B65=B',0H%9G_D%G>5+X0W&KB2A,`$\1K,JR]S#6P)D-$X2`5L:$
MQ<$?;O)-:T*+_V';KS<])80F:T7-XTF],M".+B:P]`HE\[;4'DO.JP5J\YZ7
M"O3.1F/J],6W2."R@`<8>8U)/^&0=DO)\UDS_7"3D93^&9:S%T"`:JM6%8.Y
MFMNU[&9>_+7`MAX5=[;;&%K5XJB51WV%Q<2[UH@A+K4IWOYN9J)S'[R53W]T
MK/9B-#>$`/33B54_'Q9SH1=DU1^==!Y`^J@55]5KU-[5LA1V:"N4V!1^'_V0
M2H-VC<WIT`T-_[1R`+X]#?Q`L]Y'?3I/QD`7QGOG<1XFA-WP4N9ZJ/>'M1?/
M5,L-F&_+8(D<.C<CU(<B8YR7RQ6=VV<Z8G'G[AIV9A,'64I;RAR]HJ[SUV_*
M"SM*V>H"G!RWW_+;+33*%@"./8W@J6X"AD&GQNAD=)JFPS`?_FHT95W&8@:^
MGB!CV&U88L9QL*NT[76DJ_4T#CNG$NR\"+@`0UM'N'@>U%;YN/C9=-9Y0)&&
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MS'&/"0.)'57$P3^HU!GO:PQ/2'!?,U!:)V.IS>>9ZNRGC<B"XB"/$`(GD)PQ
MY!@/::Q[C8@,?(W%TJD42R\&/D!LY`$^GM-H45]4.`:W0"LDFI18$@FW+!P#
M@SXSR(#&%:DT`)U5Y\UB9A!5-48,BUC,?3&0[F2X@"SY0^E'DN<W.+O=T-`%
M@*E*I/HQ<A$7H,HL^D.JRCH(55AIQ5ZQ$UB(OUP,7)4U1TQ+N@]8F7B#6(4M
M?Y!M[DT%\`J^KWZ(Y+T+4@?F_,$4-`UB%-!8=:YU7@HXX6HB1B7;A^5`ML$D
M9,4?(,^K&8&S-+K@!QDN^4$$U<$_&Y7JAYJIN"#9Q(,_<-MX`_%N;F15B_)1
M>2F,.M*+X845-,C8JNNSQT2](92%KQ*-W?+\2/^B#^M']/_N@QS3)_\?4$L#
M!!0````(`&8PJD!'@9D(;1@```]V`0`5`!P`8WET>"TR,#$R,#,S,5]P<F4N
M>&UL550)``-@DJM/8)*K3W5X"P`!!"4.```$.0$``.U=W7/;.))_OZK['WR>
M9\=QYF[ODIK<EN/84ZYU+)?C;':?IB@*DG!#$1J0M*W]ZP_@E_B!CP9(F8`G
M+Q./V&B@&S\T&D"C\<M?GS?1T2.B"2;QQ^.S-V^/CU`<D@6.5Q^/L^0D2$*,
MC__ZO__^;[_\Q\G)KRA&-$C1XFB^.WI8DTU"XJ-[E*6,P=%Y&**(%3GAQ!&.
M?__`_S,/$G3$*HF3#\\)_GB\3M/MA]/3IZ>G-T\_OR%T=?KN[=NSTW]\N?D:
MKM$F.,%QD@9QB(Z/&/V')/_QAH1!FK>P4?QY3J.*P<^G=5U2"OY_)Q79"?_I
MY.S=R<]G;YZ3Q7'91/X94$E%_MRC+V4Z>__^_6G^M29EC+""=2TVT][14:$_
M2B)TCY9'_-]O]]?2TN]/.<5IC-*;8(XB5F5>/-UMT<?C!&^V$:I^6U.T%/.)
M**W9<.V\Y]HY^PO7SD][SJ=#FK?BT'D@:1"-T\Z<7[^MO6J&-_IV+-6JFGP[
MII;9B$0OH.5&-<,;?8<H)HO+>''XAG>K&JOQ7].`O@!4^I4-%^#PK39H:KA+
M"<5O0K(I&'_-Y@GZ(T-Q>OG(_I/HV\DX/+-VG+U[^W-AXW_J\[!J24K"W]<D
M6C#H7_Z1X71GU18!%YO67`68_CV(,F33B$;A075_04&24;2Q[1@)(YLV/=`@
M3H*0.PO)=YRN9]%NL\V2"T*WA.8^A$T#(5QM6GM!-AN<YN*>QXL+$J?,[V+^
M%T96>E2RLVG?#4D29FJ^K@-J!;!V>:O1QHMREXN)L]DBU@NV?2CC9-.JZY@;
M$/:373^UBMO4?X\8@XR1AF058UN-B+C8H21>L17`YC.:IW8H:9:W:<'W@+(1
MFM[@8(XC2XO<YV'7,R'K6K84(ED^^NXHB=F?H;UQU'&TLCO!%C/W^/PQP-$`
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M845.S:4J=9<O61,4OEF1Q],%PFP9?';&_^`2GYV\/2LW!']B/_U6M.`>K3"O
M.$YO@PWJB*@B*442D[1%:(+AG+;%"6A8<61_MI#0WT8L*4ZW^=`^"=<XJD&T
MI&1CV"D$)&&S]1^.(!4<I>1(S)A0MB3^>/R6[T0SODM$:;EQH)`Z%SEJ[BZ\
M$#8NF)PTB*[96'W^&]H)P2&A::&C1^,9/-0R#L%'CW,)D#/7`7*14:[C*YRP
MR?6?**"7\>(SF\<Z&-&1E2J4DWF#%*"D=F"1,R_Q\LYUO!3B?4=1]+>8/,5?
M49"0&"VNDR1#5&A8-+0M`R.E]08^)C(/,3C2&DH@_>P'D/Y.HHQI@.ZN<(1H
M(@20A*8%G!Z-9X!1RS@$*#W.)4#^TP^`E!;S'FT)Y?M*?#&<B7&B)FT[,A)2
MSU`#DGB06R.IH,30?_F!H1SY%VR:71$J=GZ%%"W$="@\`XI*OB'XZ/`M8?$7
M/V!QE\TC'%Y%).CN"$B_MR#1^NX9(.2R#8%#BVL)AO_V`PS\4)+$^7EW?@27
MS+*4ASKQ$#/Q;`,HT)YSE`4\PX^!](/F'V4U)<+^QW6$53+OEWU7[)>N$Z.A
MZNP\]JB\`1!,3CO42'F74'GO%U2*^"D]6`1T0KBTZ#P%C%S6,2#3XE[MX3F_
MRUO)\,#82H#2_-3!1O').S@()!J&@()AU>G.[]R>LS8O<N1&0==%$7XKE=3Y
MYDV_JV2RZ_@.QZKGG=^#K>2KHX,%&_9*FHX!Z-!X@PB(C,-,0H=SA9"AFZN_
MG/94>\-^.,BQNTELPC#X+H-DGDN=)2>K(-@6&$91FE2_=,%<_OQ;'>$R6U[A
MF+4,LYF8)%AQ:&]2I(0"K,C`,6ROA/,D89TA$5?\L;+HG8\3BU!N&BHED="T
M!.K13"87#RWC\5;L'QX%_QA$B`<OIQ<!I3NV%&V%ME<GIB9EJN-36)G)#+2Z
M[XB=T&T++:PB/SJ%L9XZ,&/`X"EB9Q,>2<O$FT?H%J6E(KIC"$!:#24EJ;M(
M,A`1""`UQZGC->QQ4X7I[Y@X'9R(/I5*:W]R%P<*$8#]WN8P=9R%?3_/TC6B
M+2D[O2TG*!4F(G"WY[7B`/M?Q,<^2.(1T3GI7":=VM-2>5@JS\KEWA^AX\5]
M;A'WD/8N:4^F,:VJ)!ZU2&527>UY^.M-W5&R133=W;&%;K[<9S[CEB_^^K,D
MA+14HYK406P8R*:#B)J5O_[3/6(RXI!OCPB7&+<D#H5VUKQ@J6F3@@YBREIN
M'<),&/OKQQ7WZ+^@=$T6W#=-TM:ERRK(0$U511;(J!R$#4PB'4:D7+QWZ1I^
MJM3D*&GZ7K[CA@0BC0X/$A[VSIXC:+AF,L<K/(]0*1Q*+Y_#*..1+[\2LGC"
M4=0!ATF1>A<`4L1!Z%C(JD,2C.74D:_VB)*@1J(MIWO?LH=[O3A9H.K0A;]P
MQ2]<ZCO9?\+VPI:H0^)*G5C'&QU<$LW)7UMG$-9[38ZQRG=DLJRRH6#$TR+T
MDU9)CB)-BY5*AQ=S02'JTU@]85]H=\YEJR.=NV#'SW-8;[!?:,;`VVNMY`3-
MH&3G0`U4<C(K`^A7,D0+;<,CKZUY\`:JQ7];1.+50YDF2HP]!44UV$04CF-)
M+Y4)9H3<_-UCU-HC[8#ST+J,:D04ML)B#]`)3]#8_1#J%.090JL2:WK:\R!9
MHI^R]C(]8'*/HJ!(%I5V[WA"2*N06"6I5U`QD-H>+.I*[`VV(Y-Y1SPUKM10
M\AL]AP+,$",^&",2RR)+TUGVNC2+9Z$:68).3_I=(YU]Q_<93WAB(^GYV;:(
MMQ=WO.1K=>S2_>I5MZMEL^_U'E_O#V;V!BQ.+]B_.)6>UD%(>Y.%B-0K*!E(
M/<8T(JK$_I#&$9`UE[]Y'$2>P?@&!0F:S2.\*E+`*O85](4$6PVJ0EY!T$H3
M`U9,P.K\/75J:$.^<2'?L?`-/E*91EE5'^8(ZR6O0^G?@Z@N00%>CBBO/ND?
MA?`$/7"9[=&DK&/JM"A#[H$"3^[`9W5.GL[=59V2MTYT>5!!44<B"R@F/-2&
MC`R]5-WS;-48$'+S-V"]D>I(>)U4\KEA/MN?'<>"1AX3(/19^7M0=+Y8Y.$:
M0707X,5U7/J2W=-K-55U4BVC<AP:,.E,$"+EZ&\4^3U*`QRCQ65`8S;W)^=A
MF&VR?/.=K8UQB/NW%:`%ZEL*^@*.(\E89A-009A/G8QY3%=,ZX)I72_G\:*5
MR00?(F:>WT&T60Z!777[U9"J"OO$?ZYL!6H4(=^/49(#8QD]`YNA]*-LYT@J
M&I`\T(FQ;AJG;!E,:Q?!#*]LI*6`HQF[VD^C_4C?-?G%C!_INY"49CJYHH@\
M\=%S1>AGDLW391;ULP%)`L5MRE9Z,"OK<#*.`4J`)NLPJV+D?3Z';D7YD,?#
M83?$Z>M2*7-0G%]0_.DN2_TI3YV8YSBC^0A8Y)OF=XCF+RPH#Z)TA81G4_)"
MCN\&6<EN?X(EK\#?0ZVVA,43'N=9NF;KG7_M5T-"K,F(A1CK$WN%+8VL]ICJ
M,_;W:$PD6?[H(01';4(%ABI"#_$CE'$H=BJF_IZ4B:22/^X$I%8@R(UGG>QA
M!'W)R1Q+HL>;/#P::\0;`+TH@Q+]>`YO_2=SJ2VC/K2>TV1OG8X",HW;!*#L
M@\H[APDNI26(I*Z2AZF>>F()_20-E0PTGGA(,.D&@:7C&WD8UV_PZJ7!BX^.
MOG1IB9MQ_"'02Y86%P)440J.']:[$1DR<J89A[?&?YS0'_2$OM9,,EO.MH@6
MM[[RZQD;5O6:$>%'=$,2!Q[<NHZ9+*ANL62_6T-5YQ"54$VWH1]$/!-%GF"`
MYWQ,^CG?5235)KZ09++1KNL,`A*J/9@E/'/+*>3E[T[T!4F8R<HE^4JBOBLL
M_%K[,YVO+H-`+0JX_WML_-TX_I4RFWM'R;(7$R_X4J6_;7YQN;OE(H"[NL7B
M$#FUAJ5Y>D01R=^9J'(,268K`&6=;$%!>:"F*Y)3*:E$378B)15$W00J7ANK
M"M9%[@<)RPES1TH@<,_$8JI<_\I3WW!?,$]7WT&`FFC_9HB0R/7^!PEGU/TR
MCA,F&Y/T_@.WB`)I.OVO(RN5)"=S'0-``8U0(.?I>59(P)P/G^G`/H"2I?]/
MJQ3+\7AU^;SE:W69"Z&EJW-]2>FF?,8J-XO,(#8ZLVR@9,91TG8F'@GM9.-$
MWU?$3-#V6)&R;TY!$K;^KI*_HHCQ7#&YO@3T=]20O[M_HB6L=E$4A&YC!RRB
M`7!4/#U>8*.8R1SQQ.Z+#8XQES?%CT@,'2!UM1#74;L-(C-A#9"D93Q%P);$
M#[Y8!_$*7<=7`:9Y@,9L668#[>6+TE-6>W(J2K<Q`1?2``]*INYE6A4T5YU\
M%5Y`#A!W4K3:XL0D3:LI7%Y?JM:>!G3NOL[-=QTQ.H$,`")@91\/Y<O"&KK^
M`R^K%0S]#4VLA2H$YR?:LH'5I^@.K2:%%]"0BF0.BB:K0PRNEWZ\MI"'/PVN
MV68!$3>?LU403_A":_7Z<-&ZZSA%#`+](`HU61U%(2.;;LJ!=1,!R]B9?I3L
MBQ=996R]?R6L$D6\1)9\W3_:V_[J!4)4$ID#H\/-8N_D?8&'&*WX">+4>,AE
MOB4Q:<\-8GC`B)OV4T'L`7B,Y#7%DH[YA._3C!GKQ[V,*Z;W(OKR"TK79+&W
MKUT'SJA,*PY06\8#O-E(;V["0'5X?_0&M6G0X>VW)3N4$=/;+U]33D*69B;+
M"?@J3</5WTL_MRB5KMR%WZJAU_[F,B148H`1T&'B^:,=59KBZG+L9QQE:>].
MH(:J5*&4RF5,P$0#HT/*SM_G-[XCO%HS&<Z9[Q"LT&VVF2,Z6Y:2Z2X(6I:N
MGDTT+>TRU(:I`@Q!XVKLDR&[>]7J(DC65Q%Y<N!65>-N7-TJ??Y3*6D_[ZF`
M=$HO@C?GCI)'S#KST^X;ZYCKN-[</@]3_%C<_Q.KP)[!WA\Q9O##Z;*T>@-Z
MR\@?,Z]'[JIY&(!WOOB_K%S\/Y![%)(XQ!%JB?=`AHV[0U91OSQSB"HF?/*5
M@2C$.4+9WQ'*QUN\.-\0FN)_Y;]WE&Q2I+[B`RDR7=[:0\*&6&FL;3D.T<`B
M-![2,(]-3D..^E)_O.(70/GMFL\X*;(P=\V(8;'*-("+O5JD6VKN9=`.;YR_
M\<JY2A(FH"#7>`?E$-(Z%Z"*]-6BV4!#+X-@=8-^A$6_0@S:1E0?"H*O)1@;
M@,,.H2[X^D^&0K%V)@-AW1SO0[OSS<U/08+R[$HH3D2+,#51M;TF(7JU,`5I
MY64@*FN*OYDW?P3;O`R(AX?H'`K39H$])N$#;D4L,CDI8D/W,RK^;2BF?%Y9
MGE7.L.`>\^""#JFE_XJ55B'R(E)5B(I,>41JVL7$2@^]HU)@M>5`!51GL:_G
M^CCE=BCFIZR]"W$@6BD$6[3>8T\N^;B@:]4S81R[9&W8;7`>%E>]+Y<_C*;!
MD+R`!$BB`IZC2:N#,2$EJLQBUVL*7,$!!4?2:X+0RV"G`QJ3C2K7I[YJAK\+
M=GQZYZ=X84@SUM1]NFJP=P9AHO77U$P\!ZV5K@[CTZD;,,5E;*!A_%RVIDS+
MIL@D:E%2`D]E2<\Q"=?*F$!4UFJQW?72L_.R(X!NCI;1RV;J/KWG,--I8-19
MNU_7A-M+0$C=D'CU@.AFW_0XS6TRCK26#516`C5-6<]A9Z*9,2&HJ=?B[@P`
MCJ]K/]MN4_3%-K7!S;._)R7TI;R)<7Z!N-HQ0J4/TTQ_@\'@6NQ'[1L6-+ZW
MX.U8L-;-2)<!P)5[GBP<=(W(J#],'P'K56O6`V,\Q^:H!2F.>P?<A`(P4%L4
M)8/IHF^#73G[G(=_9)@BUFP&C'1W%P5QRN_:LU_SA-K=6%SC@E5DKD%!UPPN
M!`1D@&Y`!E?1B#SBUJ!R[\]3X2JR'N76H]M;^%KK9@SXFE1N[^>^!G\!/B.-
MXB\HJWMU*X[ZKHVMOP!@H+8H2@83/FRR+>>7V7*_S33O*D5'5C]G(B-SS71"
MNI.`Y0892D65Q;,GLJHFG-4EV\U,M!"A11&$^8QHB/D^^>5F&Y$=0OE[Q&4T
M//-/)-=N!O'8WPJSX>$I&,?0V!A(M6S'@-D=T>DO132EODZ2C&F(2=UX>5Z!
M;R6]`,L2^E>`6X@FQL:HI,XI+BN.N\B?+7-1*OGR:\229;V*M+.0%Y/ZBCVX
M_*/`3EF=]S%?<*58.]76SK2W$+76S1B`-:G<\V2G`Y?G\`7@*,MS977^3EU<
M5.85\G_XON5C$'%S>8<HYE>XVN?@'1MB4[2Z,6U4U'F$#M"$&3;-*K*_>^]$
M#E>QL.=L=%*Z8P,QO^8-PJ2DC!*,O3*>HE`M^QCPZ]5@/R]M<R2S9M#TU:+O
MMW=_9OSUI#\D`BVNU!<(O(PG=^V_9MMME*LBB"I57,=+0C=%GTLRK9J5JK)"
M0$N-F(6%NU@!7GS.*.NV8@:[(E0B%I"Z,:"4U),_A,1;UXOZ[7_J/(%4?)K,
M#D`[@2B%:8]W#<_F\T<%KY$#9U[2C!H.36(*^XXEA557&55E-8=Y@,S!*<S.
M?)I-8>`Z_'USHQ+KEL0A^W-_LATO!,MHGF4Q(DE&D<+ZC\&N,3T,8S>A8O/P
M\YO\'LP\PJL<,@E;^O$;T-TI!4A=JT5#/>G$,TK_$U.=]">K(>TH;*VF?H\C
M0PNUS"B_Z%?^3QXBEV`NXQ5^1HOBMG49.+<XZ^Y*VW/8/YAESN%5`'NX[L8'
MNU6;1@YU<M#+&'D^,U]!#ZM\I"M/+_FNRJ<@P<EL>==@:/%NBF0I*V`N<60`
ME&6?*BFG>[>5KH*X3)>]?ZJF2!#?;&J=2CN(]H_7[*'TP/KN4]2/T#@4^^IM
MV-'93V9I($`B!U=HV_`HVI2_,#AZ6\9=E;ZD.?J6QV<QL\N6?"@9SQ*U^4J,
MD)JH[%H9T7@;@.T:9"9!0R5LK0L#5*-D`I6L/<3$7/GHDG+S=Y!45ZT?`QP5
MR6MVXXT4`7/IYH.6LKV`%E..N7/>JT8V>B"D\L:[,(X@VB=&@G97.5+^C=6Z
MA*^_8XOG_(S3,EL4W_.E)&9_AL5L.]XP*^J)=K*:)&/.M%A]VP%:;+I3O7"-
M%EG$C/4M>I*V,UX4Z>R3.J-73H.95[2-Y)/E89A79X0C,Y_,I!B#BQQ8LVV+
M!&U>?I0P<K/\-6CEK88JS=V(GD*7L\1DZ<BJAW^E9.,Y"-TZ9.9"2R=ILPN#
M6*MN`I>O/?YDG/,GB.4<_1TZ_&Y;6MUMFVI>;%ZPDXPP%4G9DV*2R2;[9G-D
M@U!)(Q#+A<&G[`D"DZD]Z$0<^8"3</)WL-49,4.RBK'E/O18-XV[39%ZXSK"
MVO^6$XXWO?5KD8TM`*6TY2Z,,X#BB8F474=3QKVX_:S@ZN_X:[X_,&*RSYJI
M9`@I*.H8/P'%A'&*16MV^D,;"&E'1C'IA+E(Y9U#C`3LYACM\2WB&57\_!U:
M^?-F\Z#[O)E;;^;)PJ9!Q,HW]!P8M7M`Y3>KZZ:5^;?S2Z_[QM=YK"0#>R1N
MU7OO0[E-%]4!PP896V.=L`YE*_*7VX?6[J_IX6E<[Q#-I1MO6F]RE:Y)Y23U
MXDU$,IF-N`QHC.-5W239Z-?2E>(IZ"9<GRIZA<!EZZY1^USYN%-P\W=$\<0<
M.*WWCTF^9XSBT,YO'BGX6=XF?0BY3=GJ:-2L['3!X9!V2H^*K0J;:,@%RV`'
M`S)0/9TC9Y,VY(?0AG7[:W4>:,"<EC"/B/^.T_4LVFVV67)!Z);0:9<3S3=L
MFLV4[IG!R.O])QWYA`D)Q4W3FQ2+DAIUN&5,P'U,ANBBNVFGKK/8NC.HR]Y8
M])/`O:2IN`HPS2][?T$!%\DV<&6<05*W9J]CF66`D)9=KR:=S"*(5'\=;S-(
MB+=5V:XZ8&4GLPN@'B;#=-&V"JH:N44PK,E?!Z(6=+Q=@)JE;CSK!K%+([>!
M$^U(5=$J#)53(U$Y_``"2H:;<(R)V?D[IO+$B6L2L?8G/.>*57#52'OZO:;(
M]O.UA-5>OH)PNB#17J-N28KTDZMQ.:D2I.4FO%NI[5%BKX'N%4I977G0);P.
MCP=]-D_0'QEC=ODXJ6?=;8@T[Y&:K$YT)"-S("*\VSA]F+>V1"]V6U%BPL0X
MFKXC-C)WL^&(ZVA'42MXO]10+K_P__"S=/;+_P-02P,$%`````@`9C"J0&*]
M`&-;"```V4H``!$`'`!C>71X+3(P,3(P,S,Q+GAS9%54"0`#8)*K3V"2JT]U
M>`L``00E#@``!#D!``#M7-]SXC@2?K^J_1^TO-SN`P&2F;E-:K);))`9JIB0
M"F1GW[:$+4"UMN21Y`3^^VO)&`LL;'[,[L&5GV*D[E9_7[?;DFGR\;=Y&*!7
M(B3E[+;6NFC6$&$>]RF;WM9B6<?2H[3VVZ\__.OCC_7Z)\*(P(KX:+Q`HQD/
M)6?HF<0*#*"VYY$`5.I:>"YOI#<C(48*BRE1CS@D,L(>N:W-E(IN&@UOH;B@
M%QX/&Y?-UF7SZJH%:P<D)$P]<!%VR`3'@;JM?8MQ0">4^#4$SC)Y,Y<K(V]O
M;Q=O5Q=<3,%(L]7XXTM_:)9-96&5>?&2B1SXK181R2Q/L!P;N^F,5FG5FZUZ
MIA10]M>:*_.Q"%)GKAIZ>HPE6?F=DU^ZWKJ^OFZ8V94H&*(%IBF3"C./V/*^
M6BG8PN\;R60J2MDKD1NBDG@74_[:2.8<2%D<NKWQE6AH>AH@003U5@J<[:##
M67U#SR?4[1I,V'Y!CB&DLPPSQA56D+YF:#D8191-^'($QC2W-VD\GLD$&;9O
MM!>W-4G#*-!4FK&9()/;FLZ;>IHD?T:"7(!_J8C@`2D(CIYN@(J$3#:>];.%
M4Q-8>#DKN6P`(SPB0E'(OBR9&M\-EH>#?6&!BA<')XTJP.-]48$*"?Y>/-K.
M"!`@??'RW',5)>-+AWNQKH%MYG>9HFK1@TP6H:&\AJA_6RN46"V;+NR3"674
MW"!-*)'-)JJCU()]B9F/$G/(LO>QL6EDTWXLB3]@OYKKS:1?:B]%BC0W\FIW
MQ<RS[7K+T30$AT;FGC/)`^KK!R!<^X3!,G<XT(5X."-$R1>&8Y\J_:C2@=I'
MH3!N$#43MR%02Y:!NQ\\#@?]7J<]ZG;TAT[W<0A7=^U^^_&^BX:?N]W1$/WT
M\MA^Z?1`YN<JE`>%\@D+X&%&%`5@>\=U7;LDR*WC@XQ^6ENQ"GI9T%=LR\%D
M$.G=+;@BH;3>\Q#HF($0?25]+G>ZN0^Q5I@4E[O?^<,1#'SI/D)"#![0X*G[
MW![U0!2U'[78EZ?G[F>0[/W>1?W!L"H-AV;)/9:SAX"_[9T0#L7"V%\=&OO[
M]O`S>N@/OE9!WA+D.RPI1.3)`ID$T351&*0/Z9:*2B_@,A8$/A@KB$^0;:?B
M/^/_19+!I"L5A5TFD0GU&V,EK%_F60<#FO.5B8IPJZKAB"H<M%\QA<,.#6";
MOZQ:CHD2ZJ_RU"^M(-M,17]&_S/Q]('-\W@,1RPV?1*<P:67/!J22)3(E`3E
M73XHB4&4643K)JL`90'ZBH7`3/7IVLV1&RT)POM\$)8FT,I&Q7K&>I^SJ2+Z
M7>]8)8ROC92P_2'/ME:O:WVD#514VQ7HE;"80$W@TV3)M.KDQDMH_X^KTA@C
MR+)2<9]QWV-`CQY*MSKV0`G;O^39MK0KEC.6AS,LB'[Y:@[;</JRMO5;YDJX
MO\YS;PS5[[0E9)NJ`F%7=2F?B#!4I57=&BDFO=5T574I441$PGY%M?VR(@RI
M,KLY\Y+);/,(\U:5IDB@)!".<ZUES7Q?L&:OBDL6EQ'L^23VS-N_KU3-!L$B
MC&)YST7$A567=I`KB9+C'&P;16]@%2W-(LMN%:TL6@^8BM]Q$),O!&L.K4.9
M>ZHD)HX#LK:#C"%D6ZJBX(C"!O-E;#M.OAG;%<'6!DEQ[Z\9#WPB9/=;O#KE
M.L9+*'><<VTC_T:)F8I\B_QX+,FW&`!V7[/RDALM(=YQY,U,H,3&_S'K'QL;
MS3W)P'H+D&X`HB$\YQ1BN:XSNZUKBG&TUNN4=*SUN6>,K?<A.14;)%`R':EG
MIB[FTD];0`K=*6IQ*G1G4T=?'.V`H_UK%Q\LM>7UT9Z8-Y9BL;<KME[ZX7AG
M8B%@BWN`-[;BZM/1_I"Y-]O;EY62N3K:!X:I)_=V(M-*+H]V0U)O;R=2'7UQ
MB`.;/63728%G9(K-=\%;?%A3"X18TZIK._769;WUX7@_U-X^J$/67R=516+_
M2*1*YNI[Q,+NC-V%`Z.B/]53/<W$E6;B""_>-83N(=S1`2.MEWU7;_Y2;S7W
M"T"NRW?'55,%O?#[PY"Z^WAW6=_6?$P4C[X#\IW(^WERN!O%K>*';RJ,K>]3
MH9:-K."JI^ID'@688=B?+A[@\^[5PK;2S8P4<+;LYS<^WM8Z9$+@&>@OORZ0
MSR3`28]<>A31G;Q_%HLE;<"F0?XFY%"[L%CT%`GU-A&@P&Y8415K()\$CZ-4
ME()(#3$:!'BL.WJ5T`=-#-("T-S6)C@PG?I&.()4X/[(K)04!I5.C9,V/W`5
M/*1J.UCW-XH&8'[J7$`-HF3;GL>4FSD72!W(LH!'>B1-N/9RM;6<+)"RH<(8
M9=/O`#3YG,?IQ^D+Q)T0;;G#MDC\TT'+P.P9M6<XM4(YFGW2-Y)^M3U0,R(L
MB-L$S@;A",ZT@2/M+(S;1<X&Y?T,LRGIL=7;OL%D61UMH(52)X/5)^,]H6XO
MI[L(GSWPDA"OA,X%:(]!NF-).B3Y:TK.O3GVJ[:49"VG=Q$^&>!EM[$3S&Z0
MSQ[KQG9URR-W+ZVSY6(PV<!5%/V\[-GBUGUG(].VEB):;N]I4)@%)7IGP\>3
MX!XAOGP0/.S.B?"H:>8.HX`O"#'?#2VK.>S$'`_X`_5/AI^R)R"6LR=,_4ZL
M#P=/QN(#%XYS1JGDB9TU'+^7<*`JE#HQ1.L_0W"`V29PTCA&9*[N`KB-M@*Q
M)!(DR4_X;U0Z_L_<6-MOH=SO%)RW3X'4B07(X:LK2L5BIQBJY'<'P6+;3QD<
M<=M=Y<2"N/DJSX%MN\B)8W%E8X',::;B9G>["U2AU"G"LCK`'0GGG#VQ7+,[
M@AT0W-,GAF'UJL(!P#%W8MX7_1<1UPOPG<3_AQA-*U#R319\^B]02P$"'@,4
M````"`!F,*I`YHT]MVI=``"TKP,`$0`8```````!````I($`````8WET>"TR
M,#$R,#,S,2YX;6Q55`4``V"2JT]U>`L``00E#@``!#D!``!02P$"'@,4````
M"`!F,*I`GHA/L\,+``"EE@``%0`8```````!````I(&U70``8WET>"TR,#$R
M,#,S,5]C86PN>&UL550%``-@DJM/=7@+``$$)0X```0Y`0``4$L!`AX#%```
M``@`9C"J0'S.A8SY-P``E-<"`!4`&````````0```*2!QVD``&-Y='@M,C`Q
M,C`S,S%?;&%B+GAM;%54!0`#8)*K3W5X"P`!!"4.```$.0$``%!+`0(>`Q0`
M```(`&8PJD!'@9D(;1@```]V`0`5`!@```````$```"D@0^B``!C>71X+3(P
M,3(P,S,Q7W!R92YX;6Q55`4``V"2JT]U>`L``00E#@``!#D!``!02P$"'@,4
M````"`!F,*I`8KT`8UL(``#92@``$0`8```````!````I('+N@``8WET>"TR
M,#$R,#,S,2YX<V155`4``V"2JT]U>`L``00E#@``!#D!``!02P4&``````4`
,!0"_`0``<<,`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7T-/3D1%3E-%1%]"04Q!3D-%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].4T],241!5$5$7T-/3D1%3E-%1%]"04Q!3D-%,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-/3E-/3$E$
M051%1%]#3TY$14Y3141?4U1!5$5-13PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-/3E-/3$E$051%1%]#3TY$14Y3141?4U1!5$5-
M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y"87-I
M<U]O9E]0<F5S96YT871I;VX\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#8N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y5<V5?;V9?17-T:6UA=&5S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`W+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^0V%P:71A;%]!=F%I;&%B:6QI='D\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,#@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y296-E;G1?06-C
M;W5N=&EN9U]0<F]N;W5N8V5M96X\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#DN:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y787)R86YT7TQI86)I;&ET>3PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q
M,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DQO;F=T97)M7T1E8G0\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y2979E;G5E7U)E8V]G
M;FET:6]N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#$R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M26YV96YT;W)I97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,3,N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y3:&%R94)A<V5D7T-O;7!E;G-A=&EO;CPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-"YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/DQO<W-?<&5R7U-H87)E/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#$U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]M;6ET;65N='-?86YD
M7T-O;G1I;F=E;F-I97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,38N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y4<F%N<V%C=&EO;G-?=VET:%]/;'EM<'5S7T-O<G`\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,3<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y&86ER7U9A;'5E7TUE
M87-U<F5M96YT<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q."YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D9A:7)?5F%L=64\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y3=&]C:VAO;&1E<G-?17%U:71Y/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(P+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4W5B<V5Q=65N=%]%=F5N=',\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,C$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`\
M+W@Z17AC96Q7;W)K<VAE971S/@T*("`\>#I3='EL97-H965T($A2968],T0B
M5V]R:W-H965T<R]R97!O<G0N8W-S(B\^#0H@(#QX.D%C=&EV95-H965T/C`\
M+W@Z06-T:79E4VAE970^#0H@(#QX.E!R;W1E8W13=')U8W1U<F4^1F%L<V4\
M+W@Z4')O=&5C=%-T<G5C='5R93X-"B`@/'@Z4')O=&5C=%=I;F1O=W,^1F%L
M<V4\+W@Z4')O=&5C=%=I;F1O=W,^#0H@/"]X.D5X8V5L5V]R:V)O;VL^#0H\
M+WAM;#X\(5ME;F1I9ETM+3X-"CPO:&5A9#X-"B`@/&)O9'D^#0H@("`\<#Y4
M:&ES('!A9V4@<VAO=6QD(&)E(&]P96YE9"!W:71H($UI8W)O<V]F="!%>&-E
M;"!84"!O<B!N97=E<BX\+W`^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P1413044^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M1&]C=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO;B`H55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^07!R+B`S,"P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$Q/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1O8W5M
M96YT(&%N9"!%;G1I='D@26YF;W)M871I;VX@6T%B<W1R86-T73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@4F5G
M:7-T<F%N="!.86UE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y#
M651/4DD@5$A%4D%0155424-3+"!)3D,N/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V5N=')A;"!);F1E
M>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C`P,#$P.34Y
M.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-U<G)E;G0@1FES8V%L(%EE87(@16YD($1A=&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/BTM,3(M,S$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!796QL+6MN;W=N
M(%-E87-O;F5D($ES<W5E<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^3F\\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5N=&ET>2!6;VQU;G1A<GD@1FEL97)S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#Y.;SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-U<G)E;G0@4F5P;W)T:6YG
M(%-T871U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^665S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/D%C8V5L97)A=&5D($9I;&5R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@4'5B;&EC($9L;V%T
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(R-RPR.30L-#$T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%;G1I='D@0V]M;6]N(%-T;V-K+"!3:&%R97,@3W5T<W1A;F1I;F<\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X+#8X-BPT-#@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M
M96YT($9I<V-A;"!996%R($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XR,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@4&5R:6]D($9O8W5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y1,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@5'EP
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,3`M43QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UE;F1M
M96YT($9L86<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/F9A;'-E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y$;V-U;65N="!097)I;V0@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/DUA<B`S,2P-"@D),C`Q,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-#<V,F8U-69?.#5B-U\T8S)E7SDS
M.&-?-#5E-6,V8V9F,V,Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S0W-C)F-35F7S@U8C=?-&,R95\Y,SAC7S0U935C-F-F9C-C,2]7;W)K<VAE
M971S+U-H965T,#(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5134%'/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,3X\<W1R;VYG/D-/3E-/3$E$051%1"!#3TY$14Y3140@0D%,04Y#12!32$5%
M5%,@*%5.055$251%1"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N="!A
M<W-E=',Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,S0L,SDY+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S8L.3(R+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C
M;W5N=',@<F5C96EV86)L92P@;F5T(&]F(')E<V5R=F5S(&]F("0Q.#<L,#`P
M(&%N9"!O9B`D-#<T+#`P,"!I;B`R,#$R(&%N9"`R,#$Q+"!R97-P96-T:79E
M;'D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#(U+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M,C8P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^26YV96YT;W)I97,L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPS-S0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPS,3@L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!C=7)R96YT
M(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ,S4L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.#,W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT,"PS,S,L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,L,S,W+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O
M<&5R='D@86YD(&5Q=6EP;65N="P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#,V-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<Q,2PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@8V%S
M:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5S=&UE;G0@:6X@:F]I;G0@
M=F5N='5R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PW.30L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PW-S(L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1A;F=I8FQE<RP@;F5T
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S8L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DR+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1V]O9'=I;&P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M.3(R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L.3(R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&%S<V5T<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#DL,3`R+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Q+#4S-"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0W5R<F5N="!L:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L92!A;F0@86-C
M<G5E9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-BPP-#8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-2PS,S0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT('!O<G1I;VX@;V8@;&]N9RUT
M97)M(&]B;&EG871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT+#DQ,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#0X-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&QI86)I;&ET
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PY-3<L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-RPX,C$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E<RP@<F5L871E9"!P87)T>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPU,C`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPU,C`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$969E<G)E9"!R979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-2PQ-S8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-2PR-#0L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(&QI86)I;&ET
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4W+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8R-RPP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]P=&EO;B!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L-C0P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L.3$P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]N9RUT97)M(&1E9F5R<F5D
M(')E;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Y."PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M,#0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y,;VYG+71E<FT@;V)L:6=A=&EO;G,L(&YE="!O9B!D:7-C;W5N
M="P@;&5S<R!C=7)R96YT('!O<G1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$Y+#<P-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,2PY-C(L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;&EA8FEL
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0R+#(U,BPP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT,2PU.#@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUM:71M96YT<R!A;F0@8V]N=&EN9V5N8VEE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@97%U:71Y.CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R
M960@<W1O8VLL("0P+C`P,2!P87(@=F%L=64[(#4L,#`P+#`P,"!S:&%R97,@
M875T:&]R:7IE9#L@+3`M('-H87)E<R!I<W-U960@86YD(&]U='-T86YD:6YG
M(&EN(#(P,3(@86YD(#(P,3$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM;VX@<W1O8VLL("0P+C`P,2!P87(@=F%L=64[(#DU+#`P
M,"PP,#`@<VAA<F5S(&%U=&AO<FEZ960[(#4X+#0R."PV,#8@86YD(#4V+#4Y
M-"PV.#,@<VAA<F5S(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@:6X@,C`Q,B!A
M;F0@,C`Q,2P@<F5S<&5C=&EV96QY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@<&%I9"UI;B!C87!I
M=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3@L-38V+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(U,BPS,S@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!D969I8VET/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@R-3$L-S<T+#`P,"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-#(L-#0Y+#`P,"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!S=&]C:VAO;&1E<G,G(&5Q=6ET>3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-BPX-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PY-#8L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;&EA
M8FEL:71I97,@86YD('-T;V-K:&]L9&5R<R<@97%U:71Y/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#0Y+#$P,BPP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4Q+#4S-"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S0W-C)F
M-35F7S@U8C=?-&,R95\Y,SAC7S0U935C-F-F9C-C,0T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\T-S8R9C4U9E\X-6(W7S1C,F5?.3,X8U\T-64U
M8S9C9F8S8S$O5V]R:W-H965T<R]3:&5E=#`S+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5$-!
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#3TY33TQ)1$%4140@0T].1$5.
M4T5$($)!3$%.0T4@4TA%1513("A53D%51$E4140I("A087)E;G1H971I8V%L
M*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT(&%S<V5T<SH\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@
M<F5C96EV86)L92P@<F5S97)V97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,3@W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-#<T+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E
M<G,G(&5Q=6ET>3H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!P87(@=F%L=64@*&EN(&1O;&QA
M<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&%U=&AO
M<FEZ960@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R
M97,@:7-S=65D("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@;W5T<W1A;F1I
M;F<@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V86QU92`H:6X@9&]L;&%R<R!P97(@
M<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@875T:&]R:7IE9"`H:6X@
M<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.34L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CDU+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&ES<W5E9"`H
M:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3@L
M-#(X+#8P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4V+#4Y-"PV.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&]U='-T
M86YD:6YG("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU."PT,C@L-C`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-38L-3DT+#8X,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?-#<V,F8U-69?.#5B-U\T8S)E7SDS.&-?
M-#5E-6,V8V9F,V,Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S0W
M-C)F-35F7S@U8C=?-&,R95\Y,SAC7S0U935C-F-F9C-C,2]7;W)K<VAE971S
M+U-H965T,#0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$57-4%%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/D-/3E-/3$E$051%1"!#3TY$14Y3140@4U1!5$5-14Y44R!/1B!/
M4$52051)3TY3($%.1"!#3TU04D5(14Y3259%($Q/4U,@*%5.055$251%1"D@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0T].4T],241!5$5$($-/3D1%3E-%1"!35$%414U%3E13
M($]&($]015)!5$E/3E,@04Y$($-/35!214A%3E-)5D4@3$]34R`H54Y!541)
M5$5$*2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R;V1U8W0@<F5V96YU97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,2PT.#$L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#,V,BPP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O<W0@
M;V8@<')O9'5C="!R979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.#4S+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@T,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F]S<R!P<F]F:70\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8R."PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,C`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D1E=F5L;W!M96YT(')E=F5N=65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$979E;&]P;65N="P@<F5L871E9"!P87)T
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C,Q+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5S96%R8V@@9W)A;G1S(&%N9"!O=&AE<CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&1E=F5L;W!M96YT(')E
M=F5N=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,C,U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY/<&5R871I;F<@97AP96YS97,Z/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N
M9"!D979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPX,S8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RPP-#<L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y386QE<R!A;F0@;6%R:V5T:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#,W-BPP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(R-BPP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#DR-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#4T-"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!F
M86ER('9A;'5E(&]F('=A<G)A;G0@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,S`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPT-S$L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@
M9F%I<B!V86QU92!O9B!O<'1I;VX@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@R-S`L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Y,"PP,#`I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;W!E
M<F%T:6YG(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XX+#DY-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,BPY.3@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!E<F%T:6YG(&QO<W,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@L,S8U+#`P,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,2PR-#,L,#`P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY/=&AE<B!I;F-O;64@*&5X<&5N<V4I.CPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!I;F-O
M;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DEN=&5R97-T(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#@V-2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-S,X+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&5X<&5N<V4L(&YE=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#<L,#`P*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0W+#`P,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5Q
M=6ET>2!L;W-S(&9R;VT@:6YV97-T;65N="!I;B!J;VEN="!V96YT=7)E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U,"PP,#`I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#8L,#`P*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L(&]T:&5R(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#DV,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH.#(Y+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@Y+#,R-2PP,#`I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q,BPP-S(L,#`P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0F%S:6,@86YD(&1I;'5T960@;F5T(&QO<W,@<&5R(&-O;6UO;B!S:&%R
M92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#`N,38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@P+C(S*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:6,@86YD(&1I;'5T960@
M=V5I9VAT960@879E<F%G92!C;VUM;VX@<VAA<F5S("AI;B!S:&%R97,I/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-RPT.#0L.3DP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3$L.3DT
M+#<P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M-#<V,F8U-69?.#5B-U\T8S)E7SDS.&-?-#5E-6,V8V9F,V,Q#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S0W-C)F-35F7S@U8C=?-&,R95\Y,SAC
M7S0U935C-F-F9C-C,2]7;W)K<VAE971S+U-H965T,#4N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$4U54%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-/3E-/3$E$051%1"!#
M3TY$14Y3140@4U1!5$5-14Y44R!/1B!#05-(($9,3U=3("A53D%51$E4140I
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-
M87(N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-A<V@@9FQO=W,@9G)O;2!O<&5R871I;F<@86-T:79I
M=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M.2PS,C4L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,3(L,#<R+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@
M=&\@<F5C;VYC:6QE(&YE="!L;W-S('1O(&YE="!C87-H('5S960@:6X@;W!E
M<F%T:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,C`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DT+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06UO<G1I>F%T:6]N(&]F(&1E9F5R<F5D(&9I;F%N8VEN9R!C;W-T<R!A
M;F0@9&5B="!D:7-C;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C,W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(T,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DEN8W)E87-E("AD96-R96%S92D@:6X@86QL
M;W=A;F-E(&9O<B!D;W5B=&9U;"!A8V-O=6YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,C0L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA;F=E(&EN(&9A:7(@
M=F%L=64@;V8@=V%R<F%N="!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$S,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS+#0W,2PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!F86ER
M('9A;'5E(&]F(&]P=&EO;B!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#(W,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,CDP+#`P,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O
M;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.30R
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@X,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5Q=6ET>2!L;W-S(&9R;VT@:6YV97-T;65N="!I;B!J
M;VEN="!V96YT=7)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC<F5A<V5S("AD96-R96%S97,I(&EN
M(&-A<V@@8V%U<V5D(&)Y(&-H86YG97,@:6X@;W!E<F%T:6YG(&%S<V5T<R!A
M;F0@;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%C8V]U;G1S(')E8V5I=F%B;&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C@U.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-S@L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E;G1O<FEE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-38L,#`P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$W-"PP
M,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/=&AE<B!C=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,CDX+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q,S`L,#`P*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@87-S971S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,BPP,#`I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.3(R+#`P,"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@97AP96YS97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@S+#`P,"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X-30L,#`P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F
M97)R960@<F5V96YU97,L(')E;&%T960@<&%R='D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q+#(S,2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C@L,#`P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$P+#`P
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DQO;F<M=&5R;2!D969E<G)E9"!R96YT/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@V+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q,BPP,#`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@=7-E9"!I
M;B!O<&5R871I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-RPW,30L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$P+#4V-"PP,#`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@
M9FQO=W,@9G)O;2!I;G9E<W1I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V5S(&]F('!R
M;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#(U+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q,S$L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('5S960@:6X@:6YV
M97-T:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(U+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q,S$L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H(&9L;W=S(&9R;VT@
M9FEN86YC:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R:6YC:7!A;"!P87EM96YT<R!O;B!L;VYG
M+71E<FT@;V)L:6=A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#<Q+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&5X97)C:7-E(&]F(&5M<&QO
M>65E('-T;V-K(&]P=&EO;G,@86YD('=A<G)A;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY-#<L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C<T+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O
M;2!S86QE(&]F(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-"PS.38L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]S=',@9G)O;2!S86QE(&]F(&-O;6UO
M;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-38L,#`P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@8V%S:"!P<F]V:61E9"!B>2!F:6YA;F-I;F<@86-T:79I=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PR,38L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C<T
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!D96-R96%S92!I;B!C87-H(&%N9"!C87-H(&5Q=6EV86QE
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#4R,RPP,#`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,3`L,#(Q+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',@870@8F5G
M:6YN:6YG(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S8L.3(R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4R+#8V."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A
M;&5N=',@870@96YD(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S0L,SDY+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0R+#8T-RPP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V%S:"!P
M86ED(&1U<FEN9R!P97)I;V0@9F]R.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-C(U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0Y.2PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5P<&QE
M;65N=&%L('-C:&5D=6QE(&]F(&YO;BUC87-H(&]P97)A=&EN9RP@:6YV97-T
M:6YG(&%N9"!F:6YA;F-I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%P:71A;"!E<75I<&UE;G0@
M;&5A<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#$L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@:6YC<F5A<V4@:6X@<'5R8VAA<V5S(&]F('!R;W!E<G1Y(&%N9"!E
M<75I<&UE;G0@:6YC;'5D960@:6X@86-C;W5N=',@<&%Y86)L93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W.34L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/D)A<VES(&]F(%!R97-E;G1A=&EO;CQB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D)A<VES
M(&]F(%!R97-E;G1A=&EO;B!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A<VES(&]F(%!R97-E;G1A=&EO
M;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX\9&EV/CQD
M:78^/&1I=CX\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$
M,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/'1R/CQT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.B`S)3LG/CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA
M<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z
M(&)O;&0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SXQ+CPO9&EV/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@<W1Y;&4],T0G=VED=&@Z(#DS
M)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SY"87-I
M<R!O9B!0<F5S96YT871I;VX\+V1I=CX\+W1D/CPO='(^/"]T86)L93X\+V1I
M=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY/=7(@86-C;VUP
M86YY:6YG('5N875D:71E9"!C;VYS;VQI9&%T960@8V]N9&5N<V5D(&9I;F%N
M8VEA;"!S=&%T96UE;G1S(&%S(&]F($UA<F-H(#,Q+"`R,#$R(&%N9"!F;W(@
M=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q,B!A;F0@,C`Q
M,2!H879E(&)E96X@<')E<&%R960@:6X@86-C;W)D86YC92!W:71H(&%C8V]U
M;G1I;F<@<')I;F-I<&QE<R!G96YE<F%L;'D@86-C97!T960@:6X@=&AE(%5N
M:71E9"!3=&%T97,@;V8@06UE<FEC82!F;W(@:6YT97)I;2!F:6YA;F-I86P@
M:6YF;W)M871I;VXN)B,Q-C`[)B,Q-C`[06-C;W)D:6YG;'DL('1H97D@9&\@
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M(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%T($1E8V5M8F5R(#,Q+"`R,#$Q+"!B
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M:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$R(&%R92!N;W0@
M;F5C97-S87)I;'D@:6YD:6-A=&EV92!O9B!T:&4@<F5S=6QT<R!T:&%T(&UA
M>2!B92!E>'!E8W1E9"!F;W(@=&AE('EE87(@96YD:6YG($1E8V5M8F5R(#,Q
M+"`R,#$R+B8C,38P.R8C,38P.U1H97-E(&9I;F%N8VEA;"!S=&%T96UE;G1S
M('-H;W5L9"!B92!R96%D(&EN(&-O;FIU;F-T:6]N('=I=&@@=&AE(&-O;G-O
M;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!A;F0@;F]T97,@=&AE<F5I
M;B!I;F-L=61E9"!I;B!O=7(@86YN=6%L(')E<&]R="!O;B!&;W)M(#$P+4L@
M9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$Q+CPO9&EV/CPO
M9&EV/CPO9&EV/CQD:78^/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E5S92!O9B!%<W1I;6%T97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY5<V4@;V8@17-T:6UA=&5S(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^57-E(&]F($5S=&EM871E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/&1I=CX\9&EV/CQD:78^/&1I=CX\=&%B;&4@8V5L;'!A9&1I
M;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^/'1R/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P('-T>6QE/3-$
M)W=I9'1H.B`S)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,"XX
M<'0[)SXR+CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T
M;W`@<W1Y;&4],T0G=VED=&@Z(#DS)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P
M<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I
M;BUR:6=H=#H@,"XX<'0[)SY5<V4@;V8@17-T:6UA=&5S/"]D:78^/"]T9#X\
M+W1R/CPO=&%B;&4^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I
M;BUL969T.B`Q.'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@
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M=7)I;F<@=&AE(')E<&]R=&EN9R!P97)I;V0N)B,Q-C`[)B,Q-C`[3W5R(&UO
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M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O/CPO
M9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86X[(&UA<F=I;BUL969T.B`Q.'!T.R!F;VYT+7-I>F4Z(#$P<'0[
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M;6%T97,N)B,Q-C`[)B,Q-C`[36%N86=E;65N="=S(&5S=&EM871E<R!A;F0@
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M/CQB<B`O/CPO9&EV/CPO9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I
M=CX\9&EV/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?-#<V,F8U-69?.#5B-U\T8S)E7SDS.&-?-#5E-6,V
M8V9F,V,Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S0W-C)F-35F
M7S@U8C=?-&,R95\Y,SAC7S0U935C-F-F9C-C,2]7;W)K<VAE971S+U-H965T
M,#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#
M87!I=&%L($%V86EL86)I;&ET>3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<&ET86P@079A:6QA8FEL:71Y(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V%P:71A;"!!=F%I;&%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQD:78^/&1I=CX\9&EV/CQD:78^/'1A8FQE(&-E;&QP
M861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P
M,"4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/CQT<CX\=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O<"!S='EL
M93TS1"=W:61T:#H@,R4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z
M(#`N.'!T.R<^,RX\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$=&]P('-T>6QE/3-$)W=I9'1H.B`Y,R4[)SX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F
M=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M
M87)G:6XM<FEG:'0Z(#`N.'!T.R<^0V%P:71A;"!!=F%I;&%B:6QI='D\+V1I
M=CX\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D:78^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SY792!I;F-U<G)E9"!N970@;&]S<V5S(&]F("0Y+#,R
M-2PP,#`@86YD("0Q,BPP-S(L,#`P(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N
M9&5D($UA<F-H(#,Q+"`R,#$R(&%N9"`R,#$Q+"!R97-P96-T:79E;'DN)B,Q
M-C`[)B,Q-C`[5V4@:&%V92!A;B!A8V-U;75L871E9"!D969I8VET(&]F("0R
M-3$L-S<T+#`P,"!A<R!O9B!-87)C:"`S,2P@,C`Q,BXF(S$V,#LF(S$V,#M!
M9&1I=&EO;F%L;'DL('=E(&AA=F4@=7-E9"!N970@8V%S:"!O9B`D-RPW,30L
M,#`P(&%N9"`D,3`L-38T+#`P,"!T;R!F=6YD(&]U<B!O<&5R871I;F<@86-T
M:79I=&EE<R!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@
M,C`Q,B!A;F0@,C`Q,2P@<F5S<&5C=&EV96QY/&9O;G0@<W1Y;&4],T0G9&ES
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M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M.R!M87)G:6XM;&5F=#H@,3AP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM
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M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O/CPO9&EV/CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA
M<F=I;BUL969T.B`Q.'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H
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M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E)E8V5N="!!8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4F5C96YT;'D@06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT<R!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E
M8V5N="!!8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\9&EV/CQD:78^/&1I=CX\9&EV/CQT86)L92!C
M96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W=I9'1H
M.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SX\='(^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@
M<W1Y;&4],T0G=VED=&@Z(#,E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I
M9VAT.B`P+CAP=#LG/C0N/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#H@.3,E.R<^/&1I=B!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN
M+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L
M9#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/E)E8V5N="!!8V-O=6YT:6YG(%!R
M;VYO=6YC96UE;G1S/"]D:78^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/&1I
M=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG
M/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`Q.'!T.R!F;VYT
M+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^26X@36%Y(#(P,3$L
M('1H92!&05-"(')E=FES960@=&AE(&9A:7(@=F%L=64@;65A<W5R96UE;G0@
M86YD(&1I<V-L;W-U<F4@<F5Q=6ER96UE;G1S('1O(&%L:6=N('1H92!R97%U
M:7)E;65N=',@=6YD97(@1T%!4"!A;F0@26YT97)N871I;VYA;"!&:6YA;F-I
M86P@4F5P;W)T:6YG(%-T86YD87)D<R`H(DE&4E,B*2X@5&AE(&=U:61A;F-E
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M96-E;6)E<B`Q-2P@,C`Q,2X@5&AE(&%D;W!T:6]N(&]F('1H:7,@9W5I9&%N
M8V4@9&ED(&YO="!H879E(&$@;6%T97)I86P@:6UP86-T(&]N(&]U<B!C;VYS
M;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',N/"]D:78^/&)R("\^/"]D
M:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CPO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-#<V,F8U-69?.#5B
M-U\T8S)E7SDS.&-?-#5E-6,V8V9F,V,Q#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S0W-C)F-35F7S@U8C=?-&,R95\Y,SAC7S0U935C-F-F9C-C
M,2]7;W)K<VAE971S+U-H965T,3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY787)R86YT($QI86)I;&ET>3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E=A<G)A;G0@
M3&EA8FEL:71Y(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!,:6%B:6QI='D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^/&1I=CX\9&EV/CQD:78^/'1A
M8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G
M=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/CQT<CX\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1'1O<"!S='EL93TS1"=W:61T:#H@,R4[)SX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@
M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G
M:6XM<FEG:'0Z(#`N.'!T.R<^-2X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.B`Y,R4[)SX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M
M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^5V%R<F%N="!,:6%B:6QI
M='D\+V1I=CX\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D
M:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SY787)R86YT<R!W:71H(&5X97)C:7-E('!R
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M9F5A='5R92!I;F-R96%S960@=&\@)#<U-RPP,#`@87,@;V8@36%R8V@@,S$L
M(#(P,3(L('=H:6-H(')E<W5L=&5D(&EN(&$@)#$S,"PP,#`@;&]S<R!F<F]M
M('1H92!C:&%N9V4@:6X@9F%I<B!V86QU92!O9B!W87)R86YT<R!F;W(@=&AE
M('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q,BX\+V1I=CX\9&EV
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^
M/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY3:6YC92!T:&5S92!W87)R
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\82!N86UE/3-$
M1DE37U5.241%3E1)1DE%1%]404),15\S/CPO83X\8G(@+SX\+V1I=CX\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG/CQT86)L92!C96QL<&%D
M9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`X,"4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R<'@[('=I9'1H.B`U-B4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P
M<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I
M;BUR:6=H=#H@,"XX<'0[)SXF(S$V,#L\+V1I=CX\+W1D/CQT9"!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=VED=&@Z(#$P)3LG
M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`Q+CAP=#LG/D%S(&]F
M/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#$N.'!T.R<^
M36%R8V@@,S$L(#(P,3(\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I
M9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[
M)SXF(S$V,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q
M)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SXF(S$V
M,#L\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#)P>"!S;VQI9#L@=VED=&@Z(#$P)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z
M(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R
M9VEN+7)I9VAT.B`Q+CAP=#LG/D%S(&]F/"]D:78^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM
M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD
M.R!M87)G:6XM<FEG:'0Z(#$N.'!T.R<^1&5C96UB97(@,S$L(#(P,3$\+V1I
M=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3LG/CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA
M<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z
M(&)O;&0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SXF(S$V,#L\+V1I=CX\+W1D
M/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`U-B4[)SX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D
M:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M;6%R9VEN+6QE9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/D5X<&5C=&5D('1E<FT\+V1I=CX\+W1D/CQT9"!A;&EG;CTS
M1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[)SX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G
M:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D:78^/"]T9#X\=&0@86QI9VX]
M,T1R:6=H="!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE
M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#$N.'!T
M.R<^,2XS-R!Y96%R<SPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN
M+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N
M.'!T.R<^)B,Q-C`[/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I
M;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P
M+CAP=#LG/B8C,38P.SPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@8V]L
M<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#H@,3`E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`Q+CAP=#LG/C$N-C$@>65A
M<G,\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[
M(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C,38P
M.SPO9&EV/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1'=H:71E/CQT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`U-B4[
M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!M
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M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[
M/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT
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M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/C(N-#D\+V1I=CX\
M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C,38P.SPO9&EV/CPO
M=&0^/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I
M>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SXF(S$V,#L\+V1I=CX\
M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B0\+V1I=CX\+W1D/CQT
M9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#H@.24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q
M,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^,BXR,#PO9&EV/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M(#$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T
M.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D:78^/"]T9#X\+W1R
M/CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@-38E.R<^/&1I=B!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3EP=#L@9&ES<&QA
M>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I
M;BUL969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SY2:7-K+69R964@:6YT97)E<W0@<F%T93PO9&EV/CPO=&0^/'1D(&%L
M:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q
M)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[
M(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SXF(S$V,#L\+V1I=CX\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q
M)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C,38P.SPO9&EV/CPO=&0^/'1D(&%L
M:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Y
M)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[
M(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SXP+C(V/"]D:78^/"]T9#X\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[
M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
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M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN
M+7)I9VAT.B`P+CAP=#LG/B8C,38P.SPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R<^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM
M<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D:78^/"]T9#X\=&0@86QI9VX],T1R
M:6=H="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#DE.R<^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN
M+7)I9VAT.B`P+CAP=#LG/C`N,3D\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I
M9VAT.B`P+CAP=#LG/B4\+V1I=CX\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W
M:&ET93X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#H@-38E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@+3EP=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY%>'!E8W1E9"!V;VQA
M=&EL:71Y/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T
M.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG
M/B8C,38P.SPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z
M(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^
M)B,Q-C`[/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#DE.R<^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T
M.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG
M/C<Q+C8Q/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
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M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[
M(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C,38P
M.SPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@
M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[
M/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z(#DE.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[
M(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/C8Y+CDX
M/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT
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M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SY297-U;'1I;F<@9F%I<B!V86QU92`H<&5R('=A<G)A
M;G0I/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P
M<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C
M,38P.SPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P
M=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)#PO
M9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.B`Y)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F
M;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SXP+C,X/"]D
M:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A
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M="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D
M:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A
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M.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/C`N,S(\+V1I=CX\+W1D
M/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C,38P.SPO9&EV/CPO=&0^
M/"]T<CX\+W1A8FQE/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G
M:6XM;&5F=#H@,3AP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z
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M96-T960@=&5R;2!O9B!T:&4@=V%R<F%N=',N)B,Q-C`[)B,Q-C`[)B,Q-C`[
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M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/DQO;F<M=&5R;2!$96)T/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&]N9RUT97)M($1E8G0@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y,;VYG+71E<FT@1&5B=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/&1I=CX\9&EV/CQD:78^/&1I=CX\=&%B;&4@8V5L;'!A9&1I;F<],T0P
M(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/'1R
M/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H
M.B`S)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SXV
M+CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@<W1Y
M;&4],T0G=VED=&@Z(#DS)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H
M=#H@,"XX<'0[)SY,;VYG+71E<FT@1&5B=#PO9&EV/CPO=&0^/"]T<CX\+W1A
M8FQE/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@
M,3AP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/D]N
M(%-E<'1E;6)E<B`Y+"`R,#$Q('=E(&5N=&5R960@:6YT;R!A(%-E8V]N9"!!
M;65N9&UE;G0@=&\@=&AE($%M96YD960@86YD(%)E<W1A=&5D($QO86X@86YD
M(%-E8W5R:71Y($%G<F5E;65N="`H;&]A;B!A9W)E96UE;G0I('=I=&@@1V5N
M97)A;"!%;&5C=')I8R!#87!I=&%L($-O<G!O<F%T:6]N("A'14-#*2P@4VEL
M:6-O;B!686QL97D@0F%N:R`H4U9"*2!A;F0@3WAF;W)D($9I;F%N8V4@0V]R
M<&]R871I;VX@*'1O9V5T:&5R+"!T:&4@(DQE;F1E<G,B*2P@<'5R<W5A;G0@
M=&\@=VAI8V@@=&AE($QE;F1E<G,@:6YC<F5A<V5D('1H92!P<FEO<B!T97)M
M(&QO86X@;6%D92!T;R!T:&4@0V]M<&%N>2!T;R!A('!R:6YC:7!A;"!A;6]U
M;G0@;V8@)#(U+C`@;6EL;&EO;B`H5&5R;2!,;V%N*2P@<W5B:F5C="!T;R!T
M:&4@=&5R;7,@86YD(&-O;F1I=&EO;G,@<V5T(&9O<G1H(&EN('1H92!L;V%N
M(&%G<F5E;65N="XF(S$V,#LF(S$V,#M4:&4@5&5R;2!,;V%N(&%C8W)U97,@
M:6YT97)E<W0@870@82!F:7AE9"!R871E(&]F(#DN.#<E('!E<B!A;FYU;2XF
M(S$V,#LF(S$V,#M0=7)S=6%N="!T;R!T:&4@;&]A;B!A9W)E96UE;G0L('=E
M(&%R92!R97%U:7)E9"!T;R!M86ME("AI*2!T=V5L=F4@*#$R*2!E<75A;"!C
M;VYS96-U=&EV92!M;VYT:&QY('!R:6YC:7!A;"!P87EM96YT<R!O9B`D,C`L
M.#,S(&]N('1H92!F:7)S="!D87D@;V8@96%C:"!C86QE;F1A<B!M;VYT:"P@
M8V]M;65N8VEN9R!O;B!/8W1O8F5R(#$L(#(P,3$L("AI:2D@='=E;G1Y+6YI
M;F4@*#(Y*2!E<75A;"!C;VYS96-U=&EV92!M;VYT:&QY('!R:6YC:7!A;"!P
M87EM96YT<R!O9B`D.#(U+#`P,"!O;B!T:&4@9FER<W0@9&%Y(&]F(&5A8V@@
M8V%L96YD87(@;6]N=&@L(&-O;6UE;F-I;F<@;VX@3V-T;V)E<B`Q+"`R,#$R
M+"!A;F0@*&EI:2D@86YD(&]N92`H,2D@9FEN86P@<')I;F-I<&%L('!A>6UE
M;G0@;V8@)#@R-2PP,#`@;VX@36%R8V@@,2P@,C`Q-2X@26X@861D:71I;VXL
M('1H92!M871U<FET>2!D871E(&]F('1H92!497)M($QO86X@:&%S(&)E96X@
M97AT96YD960@=6YT:6P@36%R8V@@,2P@,C`Q-2P@86YD(&%T(&UA='5R:71Y
M(&]F('1H92!497)M($QO86XL('1H92!#;VUP86YY('=I;&P@;6%K92!A(&9I
M;F%L('!A>6UE;G0@9F5E(&5Q=6%L('1O(#4E("@D,2PR-3`L,#`P*2!O9B!T
M:&4@5&5R;2!,;V%N+B8C,38P.R8C,38P.U=E(&UA>2!I;F-U<B!A9&1I=&EO
M;F%L(&9E97,@:68@=V4@96QE8W0@=&\@<')E<&%Y('1H92!497)M($QO86XN
M)B,Q-C`[)B,Q-C`[26X@8V]N;F5C=&EO;B!W:71H('1H92!497)M($QO86XL
M(&]N(%-E<'1E;6)E<B`Y+"`R,#$Q+"!W92!I<W-U960@=&\@=&AE($QE;F1E
M<G,@=V%R<F%N=',@=&\@<'5R8VAA<V4@=7`@=&\@86X@86=G<F5G871E(&]F
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M<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`Q.'!T.R!F;VYT+7-I>F4Z
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M;V8@)#0Q.2PP,#`N(%1H92!N970@<')O8V5E9',@;V8@=&AE(%1E<FT@3&]A
M;BP@869T97(@<&%Y;65N="!O9B!L96YD97(@9F5E<R!A;F0@97AP96YS97,L
M('=E<F4@87!P<F]X:6UA=&5L>2`D."XV(&UI;&QI;VXN/"]D:78^/&1I=B!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@
M;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,3AP
M=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/E=E(&%C
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M<R!W:71H:6X@,3`E(&]F('1H92!O<FEG:6YA;"!D96)T(&EN<W1R=6UE;G0N
M)B,Q-C`[)B,Q-C`[06-C;W)D:6YG;'DL('1H92!F965S(&%S<V]C:6%T960@
M=VET:"!T:&4@86UE;F1E9"!497)M($QO86X@;V8@)#,P,"PP,#`L(&9I;F%L
M('!A>6UE;G0@9F5E(&]F("0Q+#(U,"PP,#`L(&%N9"!T:&4@97AI<W1I;F<@
M=6YA;6]R=&EZ960@9&5B="!D:7-C;W5N="!F<F]M('1H92!/<FEG:6YA;"!4
M97)M($QO86X@;V8@)#,S,BPP,#`@=VEL;"!B92!A;6]R=&EZ960@87,@86X@
M861J=7-T;65N="!O9B!I;G1E<F5S="!E>'!E;G-E(&]V97(@=&AE('1E<FT@
M;V8@=&AE($%M96YD960@5&5R;2!,;V%N('5S:6YG('1H92!E9F9E8W1I=F4@
M:6YT97)E<W0@;65T:&]D+CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M
M87)G:6XM;&5F=#H@,3AP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG
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M(&]F('1H92!W87)R86YT<R!A<R!A(&1I<V-O=6YT(&]F("0R-C<L,#`P(&]V
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M<F-H(#,Q+"`R,#$R+"!W92!W97)E(&EN(&-O;7!L:6%N8V4@=VET:"!O=7(@
M9FEN86YC:6%L(&%N9"!N;VXM9FEN86YC:6%L(&-O=F5N86YT<RX\+V1I=CX\
M+V1I=CX\+V1I=CX\9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\
M9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CPO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M-#<V,F8U-69?.#5B-U\T8S)E7SDS.&-?-#5E-6,V8V9F,V,Q#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S0W-C)F-35F7S@U8C=?-&,R95\Y,SAC
M7S0U935C-F-F9C-C,2]7;W)K<VAE971S+U-H965T,3(N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY2979E;G5E(%)E8V]G;FET
M:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4F5V96YU92!296-O9VYI=&EO;B!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=64@4F5C
M;V=N:71I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^
M/&1I=CX\9&EV/CQD:78^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A
M8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/CQT<CX\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#H@,R4[)SX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^-RX\+V1I=CX\
M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I
M9'1H.B`Y,R4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#`N.'!T
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M86X[(&UA<F=I;BUL969T.B`Q.'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^4')O9'5C="!386QE<SPO9&EV/CQD:78@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\8G(@+SX\
M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,3AP=#L@9F]N="US:7IE.B`Q,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/E=E(')E8V]G;FEZ92!R979E;G5E(&9R
M;VT@<')O9'5C="!S86QE<R!W:&5N('1H92!F;VQL;W=I;F<@9G5N9&%M96YT
M86P@8W)I=&5R:6$@87)E(&UE=#H@*&DI('!E<G-U87-I=F4@979I9&5N8V4@
M;V8@86X@87)R86YG96UE;G0@97AI<W1S+"`H:6DI(&1E;&EV97)Y(&AA<R!O
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M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM
M;&5F=#H@,3AP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P
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M('-H:7!M96YT(&9R;VT@;W5R(&9A8VEL:71I97,N)B,Q-C`[)B,Q-C`[4VAI
M<'!I;F<@86YD(&AA;F1L:6YG(&-O<W1S('1H870@87)E(&)I;&QE9"!T;R!O
M=7(@8W5S=&]M97)S(&%R92!C;&%S<VEF:65D(&%S(')E=F5N=64N)B,Q-C`[
M)B,Q-C`[5&AE(&-U<W1O;65R)W,@;V)L:6=A=&EO;B!T;R!P87D@86YD('1H
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M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,3AP=#L@9F]N="US:7IE.B`Q,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/D9O<B!S86QE<R!T:&%T(&EN8VQU9&4@
M;75L=&EP;&4@9&5L:79E<F%B;&5S+"!S=6-H(&%S('-A;&5S(&]F(&]U<B!3
M=&5M4V]U<F-E)B,Q-S0[($-E;&P@0F%N:R`H8V5L;"!B86YK*2P@=V4@86QL
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M(&5V:61E;F-E("@B5E-/12(I.R`H8BD@=&AI<F0M<&%R='D@979I9&5N8V4@
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M(&%G<F5E;65N=',N)B,Q-C`[)B,Q-C`[4F5V96YU92!F;W(@=&AE('9A<FEO
M=7,@9&5L:79E<F%B;&5S(&ES(&-A;&-U;&%T960@86YD(')E8V]G;FEZ960@
M8F%S960@;VX@=&AE(')E;&%T:79E('-E;&QI;F<@<')I8V5S(&]F(&5A8V@@
M9&5L:79E<F%B;&4N)B,Q-C`[)B,Q-C`[1G5T=7)E('-E<G9I8V5S('-U8V@@
M87,@=V5B(&AO<W1I;F<@86YD(&]N9V]I;F<@;6%I;G1E;F%N8V4@87)E(&1E
M9F5R<F5D(&%N9"!R96-O9VYI>F5D(&EN=&\@:6YC;VUE(&1U<FEN9R!T:&4@
M>65A<B!F;VQL;W=I;F<@=&AE(&EN<W1A;&QA=&EO;BX\+V1I=CX\9&EV('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R
M("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+7-T>6QE.B!I=&%L:6,[('1E>'0M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE
M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/D-O;F-E;G1R871I;VX@;V8@4VEG;FEF:6-A;G0@0W5S=&]M97)S/"]D:78^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F
M=#H@,3AP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/D9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$R+"!T
M=V\@9&ER96-T(&-U<W1O;65R<R!C;VUP<FES960@,S$E(&]F(&]U<B!R979E
M;G5E(')E8V]G;FEZ960@9F]R('1H92!Q=6%R=&5R+B8C,38P.R8C,38P.T]U
M<B!!<VEA+5!A8VEF:6,L($YO<G1H($%M97)I8V$@86YD($%U<W1R86QI82!R
M96=I;VX@<V%L97,@86-C;W5N=&5D(&9O<B`V.24@;V8@;W5R(')E=F5N=64@
M<F5C;V=N:7IE9"!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S
M,2P@,C`Q,BXF(S$V,#LF(S$V,#M!9&1I=&EO;F%L;'DL('1W;R!D:7)E8W0@
M8W5S=&]M97)S(&%C8V]U;G1E9"!F;W(@,CDE(&]F('1O=&%L(&]U='-T86YD
M:6YG(&%C8V]U;G1S(')E8V5I=F%B;&4@87,@;V8@36%R8V@@,S$L(#(P,3(N
M/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G
M:6XM;&5F=#H@,3AP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/D9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R
M,#$Q+"!O;F4@9&ER96-T(&-U<W1O;65R(&%N9"!O;F4@9&ES=')I8G5T;W(@
M8V]M<')I<V5D(#(Y)2!O9B!O=7(@<F5V96YU92!R96-O9VYI>F5D(&9O<B!T
M:&4@<75A<G1E<BXF(S$V,#LF(S$V,#M/=7(@07-I82U086-I9FEC(')E9VEO
M;B!S86QE<R!A8V-O=6YT960@9F]R(#,P)2!O9B!O=7(@<F5V96YU92!R96-O
M9VYI>F5D(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R
M,#$Q+B8C,38P.R8C,38P.T%D9&ET:6]N86QL>2P@;VYE(&1I<W1R:6)U=&]R
M(&%N9"!T=V\@9&ER96-T(&-U<W1O;65R<R!A8V-O=6YT960@9F]R(#0S)2!O
M9B!T;W1A;"!O=71S=&%N9&EN9R!A8V-O=6YT<R!R96-E:79A8FQE(&%S(&]F
M($UA<F-H(#,Q+"`R,#$Q+CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`Q.'!T
M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[
M/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T
M>6QE.B!I=&%L:6,[('1E>'0M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z
M(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/E)E
M<V5A<F-H(&%N9"!$979E;&]P;65N=#PO9&EV/CQD:78@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N.R!M87)G:6XM;&5F=#H@,3AP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/E=E(&5A<FX@<F5V96YU92!F;W(@<&5R9F]R;6EN
M9R!T87-K<R!U;F1E<B!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@86=R965M
M96YT<R!W:71H(&)O=&@@8V]M;65R8VEA;"!E;G1E<G!R:7-E<RP@<W5C:"!A
M<R!/;'EM<'5S(&%N9"!396YK;RP@86YD(&=O=F5R;FUE;G1A;"!A9V5N8VEE
M<R!L:6ME('1H92!.871I;VYA;"!);G-T:71U=&5S(&]F($AE86QT:"`H(DY)
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M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R
M("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY792!R96-E:79E9"!F=6YD<R!F
M<F]M($]L>6UP=7,@86YD($]L>6UP=7,M0WET;W)I+"!);F,N(&1U<FEN9R`R
M,#`U(&%N9"`R,#`V+B8C,38P.R8C,38P.R8C,38P.U=E(')E8V]R9&5D('5P
M9G)O;G0@9F5E<R!T;W1A;&EN9R`D,C@L,S$Q+#`P,"!A<R!D969E<G)E9"!R
M979E;G5E<RP@<F5L871E9"!P87)T>2XF(S$V,#LF(S$V,#M);B!E>&-H86YG
M92!F;W(@=&AE<V4@<')O8V5E9',L('=E(&%G<F5E9"!T;R`H82D@<')O=FED
M92!/;'EM<'5S+4-Y=&]R:2P@26YC+B!A;B!E>&-L=7-I=F4@86YD('!E<G!E
M='5A;"!L:6-E;G-E('1O(&]U<B!#96QU=&EO;B8C,3<T.R!3>7-T96T@9&5V
M:6-E('1E8VAN;VQO9WD@86YD(&-E<G1A:6X@<F5L871E9"!I;G1E;&QE8W1U
M86P@<')O<&5R='DL(&%N9"`H8BD@<')O=FED92!F=71U<F4@9&5V96QO<&UE
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M;R!T:&4@2E8N)B,Q-C`[)B,Q-C`[5V4@<F5C96EV960@=7`M9G)O;G0L(&YO
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M=&%N=&EV92!V86QU92!D96QI=F5R86)L92!T;R!T:&4@2E8N)B,Q-C`[)B,Q
M-C`[4F5V96YU92!W:6QL(&)E(')E8V]G;FEZ960@87,@=&AE(&%B;W9E(&UE
M;G1I;VYE9"!2)F%M<#M$(&UI;&5S=&]N97,@87)E(&-O;7!L971E9"XF(S$V
M,#LF(S$V,#M/9B!T:&4@86UO=6YT<R!R96-E:79E9"!A;F0@9&5F97)R960L
M('=E(')E8V]G;FEZ960@9&5V96QO<&UE;G0@<F5V96YU97,@;V8@)#$L,C,Q
M+#`P,"!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q
M,2XF(S$V,#LF(S$V,#M4:&5R92!W87,@;F\@9&5V96QO<&UE;G0@<F5V96YU
M97,@<F5C;V=N:7IE9"!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C
M:"`S,2P@,C`Q,BXF(S$V,#LF(S$V,#M!;&P@<F5L871E9"!D979E;&]P;65N
M="!C;W-T<R!A<F4@97AP96YS960@87,@:6YC=7)R960@86YD(&%R92!I;F-L
M=61E9"!I;B!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS92!O;B!O
M=7(@<W1A=&5M96YT<R!O9B!O<&5R871I;VYS+B8C,38P.R8C,38P.U1O(&1A
M=&4@=6YD97(@=&AE(&-O;G1R86-T+"!O9B!T:&4@)#(X+#,Q,2PP,#`@;W)I
M9VEN86QL>2!D969E<G)E9"P@=V4@:&%V92!R96-O9VYI>F5D(&$@=&]T86P@
M;V8@)#(T+#<Y,2PP,#`@=&AR;W5G:"!-87)C:"`S,2P@,C`Q,BX\+V1I=CX\
M9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M<VEZ93H@,3!P=#LG/E5N9&5R(&$@
M1&ES=')I8G5T:6]N($%G<F5E;65N="!W:71H(%-E;FMO+"!W92!G<F%N=&5D
M('1O(%-E;FMO(&%N(&5X8VQU<VEV92!L:6-E;G-E('1O('-E;&P@86YD(&1I
M<W1R:6)U=&4@8V5R=&%I;B!4:&EN($9I;&T@<')O9'5C=',@:6X@2F%P86XN
M)B,Q-C`[)B,Q-C`[5V4@:&%V92!A;'-O(&5A<FYE9"!O<B!W:6QL(&)E(&5N
M=&ET;&5D('1O(&5A<FX@861D:71I;VYA;"!P87EM96YT<R!U;F1E<B!T:&4@
M1&ES=')I8G5T:6]N($%G<F5E;65N="!B87-E9"!O;B!A8VAI979I;F<@8V5R
M=&%I;B!D969I;F5D(&%N9"!S=6)S=&%N=&EV92!R97-E87)C:"!A;F0@9&5V
M96QO<&UE;G0@;6EL97-T;VYE<RX\+V9O;G0^)B,Q-C`[)B,Q-C`[/&9O;G0@
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M9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?-#<V,F8U-69?.#5B-U\T8S)E7SDS.&-?-#5E-6,V8V9F,V,Q#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S0W-C)F-35F7S@U8C=?-&,R
M95\Y,SAC7S0U935C-F-F9C-C,2]7;W)K<VAE971S+U-H965T,3,N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);G9E;G1O<FEE
M<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/DEN=F5N=&]R:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV96YT;W)I97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^/&1I=CX\9&EV/CQD:78^/'1A
M8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G
M=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/CQT<CX\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1'1O<"!S='EL93TS1"=W:61T:#H@,R4[)SX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@
M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G
M:6XM<FEG:'0Z(#`N.'!T.R<^."X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.B`Y,R4[)SX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M
M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^26YV96YT;W)I97,\+V1I
M=CX\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D:78^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SY);G9E;G1O<FEE<R!A<F4@8V%R<FEE9"!A="!T:&4@
M;&]W97(@;V8@8V]S="!O<B!M87)K970L(&1E=&5R;6EN960@;VX@=&AE(&9I
M<G-T+6EN+"!F:7)S="UO=70@*$9)1D\I(&UE=&AO9"X\+V1I=CX\9&EV('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R
M("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY);G9E;G1O<FEE<R!C;VYS:7-T
M960@;V8@=&AE(&9O;&QO=VEN9SH\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D:78^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)SX\=&%B;&4@8V5L;'!A
M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([('=I9'1H.B`Y,"4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/CQT<B!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([)SX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.B`V-B4[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO=&0^/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M(#$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C
M,38P.SPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$P)3LG/CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E
M:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`Q+CAP=#LG/DUA<F-H(#,Q+#PO
M9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT
M.B`P+CAP=#LG/B8C,38P.SPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R<^/&1I=B!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R
M9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@
M8F]L9#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C,38P.SPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z(#$P)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z
M(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R
M9VEN+7)I9VAT.B`Q+CAP=#LG/D1E8V5M8F5R(#,Q+#PO9&EV/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M(#$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C
M,38P.SPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@-C8E.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L@/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[)SX\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I
M9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D:78^
M/"]T9#X\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L
M:60[('=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H
M=#H@,2XX<'0[)SXR,#$R/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W
M:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#`N.'!T
M.R<^)B,Q-C`[/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@
M,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q
M-C`[/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R<'@@<V]L:60[('=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T
M.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA
M<F=I;BUR:6=H=#H@,2XX<'0[)SXR,#$Q/"]D:78^/"]T9#X\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,G!X.R!W:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG
M:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`V-B4[(&1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[(#PO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE
M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T
M.R<^)B,Q-C`[/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z(#$P)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`Q+CAP=#LG/B8C,38P.SPO9&EV/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE
M.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D:78^/"]T
M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z
M(#$P<'0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SXF(S$V,#L\+V1I=CX\+W1D
M/CQT9"!A;&EG;CTS1&QE9G0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,3`E.R<^/&1I=B!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG
M:'0Z(#$N.'!T.R<^)B,Q-C`[/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[)SX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M
M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H
M=#H@,"XX<'0[)SXF(S$V,#L\+V1I=CX\+W1D/CPO='(^/'1R(&)G8V]L;W(]
M,T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.B`V-B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#EP=#L@
M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/E)A=R!M871E
M<FEA;',\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z
M(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^
M)B,Q-C`[/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
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M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[
M(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/C$L-3$X
M+#`P,#PO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P
M=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q
M-C`[/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P
M<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C
M,38P.SPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P
M=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)#PO
M9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.B`Y)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F
M;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SXQ+#4P,RPP
M,#`\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[
M(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C,38P
M.SPO9&EV/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1'=H:71E/CQT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`V-B4[
M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/E=O<FL@:6X@<')O8V5S<SPO9&EV/CPO=&0^
M/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z
M(#$P<'0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SXF(S$V,#L\+V1I=CX\+W1D
M/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C,38P.SPO9&EV/CPO=&0^
M/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.B`Y)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z
M(#$P<'0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SXX,S@L,#`P/"]D:78^/"]T
M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z
M(#$P<'0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SXF(S$V,#L\+V1I=CX\+W1D
M/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE
M.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D:78^/"]T
M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@
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M.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^-SDP+#`P,#PO9&EV/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE
M.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D:78^/"]T
M9#X\+W1R/CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X
M.R!W:61T:#H@-C8E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@+3EP=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY&:6YI<VAE9"!G;V]D
M<SPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3LG/CQD
M:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P
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M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T
M.R<^)B,Q-C`[/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O
M;&ED.R!W:61T:#H@.24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N
M="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^,2PP,3@L,#`P
M/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[)SX\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[
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M="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D
M:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('=I9'1H.B`Q
M)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C,38P.SPO9&EV/CPO=&0^/'1D(&%L
M:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=VED=&@Z(#DE.R<^/&1I=B!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA
M<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT
M.B`P+CAP=#LG/C$L,#(U+#`P,#PO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P
M>#L@=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US
M:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D:78^
M/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$=VAI=&4^/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P
M>#L@=VED=&@Z(#8V)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C,38P.SPO9&EV
M/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[('=I9'1H.B`Q)3LG/CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M
M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H
M=#H@,"XX<'0[)SXF(S$V,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#1P>"!D;W5B;&4[('=I9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P
M<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B0\
M+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!W:61T
M:#H@.24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q
M,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^,RPS-S0L,#`P/"]D:78^/"]T
M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@-'!X.R!W:61T:#H@,24[)SX\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
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M;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q
M,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D:78^/"]T9#X\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!W:61T:#H@,24[)SX\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[
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M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P
M<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/C,L
M,S$X+#`P,#PO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#L@=VED=&@Z(#$E
M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M
M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D:78^/"]T9#X\+W1R/CPO
M=&%B;&4^/"]D:78^/"]D:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV
M/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CPO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-#<V,F8U-69?
M.#5B-U\T8S)E7SDS.&-?-#5E-6,V8V9F,V,Q#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S0W-C)F-35F7S@U8C=?-&,R95\Y,SAC7S0U935C-F-F
M9C-C,2]7;W)K<VAE971S+U-H965T,30N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY3:&%R92U"87-E9"!#;VUP96YS871I;VX\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY3:&%R92U"87-E9"!#;VUP96YS871I;VX@6T%B<W1R86-T73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92U"87-E
M9"!#;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQD:78^/&1I=CX\9&EV/CQD:78^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C
M96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/CQT<CX\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#H@
M,R4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^.2X\
M+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P('-T>6QE
M/3-$)W=I9'1H.B`Y,R4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z
M(#`N.'!T.R<^4VAA<F4M0F%S960@0V]M<&5N<V%T:6]N/"]D:78^/"]T9#X\
M+W1R/CPO=&%B;&4^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4]
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M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G
M:6XM;&5F=#H@,3AP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/D1U<FEN9R!T:&4@9FER<W0@<75A<G1E<B!O9B`R,#$R+"!W92!I
M<W-U960@=&\@;W5R(&1I<F5C=&]R<R!A;F0@97AE8W5T:79E(&]F9FEC97)S
M(&]P=&EO;G,@=&\@<'5R8VAA<V4@86X@86=G<F5G871E(&]F('5P('1O(#8Y
M,"PP,#`@<VAA<F5S(&]F(&]U<B!C;VUM;VX@<W1O8VLL('=I=&@@9F]U<BUY
M96%R('9E<W1I;F<@9F]R(&]U<B!O9F9I8V5R<R!A;F0@='=O+7EE87(@=F5S
M=&EN9R!F;W(@;W5R(&1I<F5C=&]R<RX@5&AE(&=R86YT(&1A=&4@9F%I<B!V
M86QU92!O9B!T:&4@87=A<F1S(&=R86YT960@=&\@;W5R(&]F9FEC97)S('=A
M<R`D,BXQ,"!P97(@<VAA<F4@86YD('1O(&]U<B!D:7)E8W1O<G,@=V%S("0Q
M+C,U('!E<B!S:&%R92X@5&AE(')E<W5L=&EN9R!S:&%R92UB87-E9"!C;VUP
M96YS871I;VX@97AP96YS92!O9B`D,2PS-S,L,#`P+"!N970@;V8@97-T:6UA
M=&5D(&9O<F9E:71U<F5S+"!W:6QL(&)E(')E8V]G;FEZ960@87,@97AP96YS
M92!O=F5R('1H92!R97-P96-T:79E('9E<W1I;F<@<&5R:6]D<RX\+V1I=CX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N.R!M87)G:6XM;&5F=#H@,3AP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/B8C,38P.SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T
M.B`Q.'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M1'5R:6YG('1H92!F:7)S="!Q=6%R=&5R(&]F(#(P,3$L('=E(&ES<W5E9"!T
M;R!O=7(@9&ER96-T;W)S+"!E>&5C=71I=F4@;V9F:6-E<G,@86YD(&-E<G1A
M:6X@;F]N+65X96-U=&EV92!E;7!L;WEE97,@;W!T:6]N<R!T;R!P=7)C:&%S
M92!A;B!A9V=R96=A=&4@;V8@=7`@=&\@-CDR+#4P,"!S:&%R97,@;V8@;W5R
M(&-O;6UO;B!S=&]C:RP@=VET:"!F;W5R+7EE87(@=F5S=&EN9R!F;W(@;W5R
M(&]F9FEC97)S(&%N9"!E;7!L;WEE97,@86YD('1W;RUY96%R('9E<W1I;F<@
M9F]R(&]U<B!D:7)E8W1O<G,N(%1H92!G<F%N="!D871E(&9A:7(@=F%L=64@
M;V8@=&AE(&%W87)D<R!G<F%N=&5D('1O(&]U<B!O9F9I8V5R<R!A;F0@96UP
M;&]Y965S('=A<R`D,RXT-B!A;F0@=&\@;W5R(&1I<F5C=&]R<R!W87,@)#,N
M,34@<&5R('-H87)E+B!4:&4@<F5S=6QT:6YG('-H87)E+6)A<V5D(&-O;7!E
M;G-A=&EO;B!E>'!E;G-E(&]F("0R+#,W-2PP,#`L(&YE="!O9B!E<W1I;6%T
M960@9F]R9F5I='5R97,L('=I;&P@8F4@<F5C;V=N:7IE9"!A<R!E>'!E;G-E
M(&]V97(@=&AE(')E<W!E8W1I=F4@=F5S=&EN9R!P97)I;V1S+CPO9&EV/CQD
M:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M<W1Y;&4Z(&ET86QI8SL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I
M;BUL969T.B`Q.'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B
M;VQD.R!M87)G:6XM<FEG:'0Z(#!P=#LG/E)E<W1R:6-T960@4W1O8VL@07=A
M<F1S/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SLG/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`Q
M.'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^1'5R
M:6YG('1H92!F:7)S="!Q=6%R=&5R(&]F(#(P,3(L('=E(&ES<W5E9"!T;R!O
M=7(@97AE8W5T:79E(&]F9FEC97)S(#$Y,"PP,#`@<VAA<F5S(&]F(')E<W1R
M:6-T960@<W1O8VLN)B,Q-C`[)B,Q-C`[5&AE('-T;V-K(&%W87)D(&ES('-C
M:&5D=6QE9"!T;R!F=6QL>2!V97-T(&]N($IA;G5A<GD@,3`L(#(P,3,L('-U
M8FIE8W0@=&\@=&AE(&]F9FEC97(G<R!C;VYT:6YU960@96UP;&]Y;65N="!W
M:71H('1H92!#;VUP86YY('1H<F]U9V@@=&AE('9E<W1I;F<@9&%T92XF(S$V
M,#LF(S$V,#M4:&4@<F5S=6QT:6YG('-H87)E+6)A<V5D(&-O;7!E;G-A=&EO
M;B!E>'!E;G-E(&]F("0V-30L,#`P('=I;&P@8F4@<F5C;V=N:7IE9"!A<R!E
M>'!E;G-E(&]V97(@=&AE(')E<W!E8W1I=F4@=F5S=&EN9R!P97)I;V0N/"]D
M:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SLG/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@
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M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D
M:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SY792!G<F%N=&5D(#(T-BPR,C4@<&5R9F]R
M;6%N8V4M8F%S960@<F5S=')I8W1E9"!S=&]C:R!A=V%R9',@=6YD97(@=&AE
M(#(P,#0@17%U:71Y($EN8V5N=&EV92!0;&%N(&EN($9E8G)U87)Y(#(P,3$N
M)B,Q-C`[)B,Q-C`[5&AE(&%W87)D<R!P<F]V:61E(&-E<G1A:6X@96UP;&]Y
M965S('5N=&EL($IA;G5A<GD@,2P@,C`Q,B!T;R!A8VAI979E(&-E<G1A:6X@
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M92!#;VUP86YY)W,@<')O9'5C=',@*#0P)2DN)B,Q-C`[)B,Q-C`[5&\@=&AE
M(&5X=&5N="!T:&%T(&%N>2!O9B!T:&4@<&5R9F]R;6%N8V4@9V]A;',@=V5R
M92!P87)T:6%L;'D@86-H:65V960L('1H92!#;VUP96YS871I;VX@0V]M;6ET
M=&5E(&UA:6YT86EN960@=&AE(&1I<V-R971I;VX@=&\@8V]N=&EN=64@=&AE
M('9E<W1I;F<@;V8@86QL(&]R(&$@<&]R=&EO;B!O9B!T:&4@87=A<F1S(&9O
M;&QO=VEN9R!*86YU87)Y(#$L(#(P,3(N)B,Q-C`[)B,Q-C`[3VYC92!E87)N
M960L('1H92!A=V%R9',@=V]U;&0@:&%V92!R96UA:6YE9"!U;G9E<W1E9"!U
M;G1I;"!*86YU87)Y(#$L(#(P,3,N(%1E<FUI;F%T:6]N(&]F(&5M<&QO>6UE
M;G0@<')I;W(@=&\@=F5S=&EN9R!W;W5L9"!H879E(')E<W5L=&5D(&EN('1H
M92!F;W)F96ET=7)E(&]F(&%N>2!E87)N960@*&%S('=E;&P@87,@=6YE87)N
M960I(&%W87)D<RX@169F96-T:79E($IA;G5A<GD@,C`Q,BP@=&AE(&]U='-T
M86YD:6YG(&%W87)D<R!W97)E('1E<FUI;F%T960@:6X@=&AE:7(@96YT:7)E
M='D@8F%S960@=7!O;B!T:&4@9&5C:7-I;VX@8GD@=&AE($-O;7!E;G-A=&EO
M;B!#;VUM:71T964@=&AA="!P97)F;W)M86YC92!C<FET97)I82!H860@;F]T
M(&)E96X@;65T(&%S(&]F($IA;G5A<GD@,2P@,C`Q,BXF(S$V,#LF(S$V,#M.
M;R!C;VUP96YS871I;VX@97AP96YS92!W87,@<F5C;V=N:7IE9"!R96QA=&5D
M('1O('1H97-E(&%W87)D<R!D=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E
M9"!-87)C:"`S,2P@,C`Q,B!A;F0@,C`Q,2X\+V1I=CX\9&EV('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D
M:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SY);B!*86YU87)Y(#(P,3(L('=E(&=R86YT
M960@,C<V+#,W-2!P97)F;W)M86YC92UB87-E9"!R97-T<FEC=&5D('-T;V-K
M(&%W87)D<R!U;F1E<B!T:&4@,C`P-"!%<75I='D@26YC96YT:79E(%!L86XN
M)B,Q-C`[)B,Q-C`[5&AE(&%W87)D<R!P<F]V:61E(&-E<G1A:6X@96UP;&]Y
M965S('5N=&EL($1E8V5M8F5R(#,Q+"`R,#$R('1O(&%C:&EE=F4@8V5R=&%I
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M+"!O8G1A:6YI;F<@0T4@;6%R:R!F;W(@8V5R=&%I;B!P<F]D=6-T<R`H,34E
M*2P@86YD(&%C:&EE=FEN9R!A('1A<F=E=&5D(')E=F5N=64@:6YC<F5A<V4@
M9F]R('1H92!F:7-C86P@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,B`H
M-24I+B8C,38P.R8C,38P.U1O('1H92!E>'1E;G0@=&AA="!A;GD@;V8@=&AE
M('!E<F9O<FUA;F-E(&=O86QS(&%R92!P87)T:6%L;'D@86-H:65V960L('1H
M92!#;VUP96YS871I;VX@0V]M;6ET=&5E(&UA:6YT86EN<R!T:&4@9&ES8W)E
M=&EO;B!T;R!C;VYT:6YU92!T:&4@=F5S=&EN9R!O9B!A;&P@;W(@82!P;W)T
M:6]N(&]F('1H92!A=V%R9',@9F]L;&]W:6YG($1E8V5M8F5R(#,Q+"`R,#$R
M+B8C,38P.R8C,38P.T]N8V4@96%R;F5D+"!T:&4@87=A<F1S('=I;&P@<F5M
M86EN('5N=F5S=&5D('5N=&EL($IA;G5A<GD@,3`L(#(P,30N(%1E<FUI;F%T
M:6]N(&]F(&5M<&QO>6UE;G0@<')I;W(@=&\@=F5S=&EN9R!W:6QL(')E<W5L
M="!I;B!T:&4@9F]R9F5I='5R92!O9B!T:&4@87=A<F1S+B8C,38P.R8C,38P
M.TYO(&-O;7!E;G-A=&EO;B!E>'!E;G-E('=A<R!R96-O9VYI>F5D(')E;&%T
M960@=&\@=&AE<V4@87=A<F1S(&1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N
M9&5D($UA<F-H(#,Q+"`R,#$R+CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M.R!M87)G:6XM;&5F=#H@,3AP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/E1H92!F;VQL;W=I;F<@=&%B;&4@<W5M;6%R:7IE<R!A
M8W1I=FET>2!W:71H(')E<W!E8W0@=&\@=&AE('!E<F9O<FUA;F-E(&)A<V5D
M(')E<W1R:6-T960@<W1O8VL@87=A<F1S(&1U<FEN9R!T:&4@=&AR964@;6]N
M=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$R.CPO9&EV/CQD:78@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\8G(@+SX\+V1I
M=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG/CQT86)L92!C
M96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@=VED=&@Z(#DP)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/'1R('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CLG/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED=&@Z(#8V)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,G!X.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF
M(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P
M>"!S;VQI9#L@=VED=&@Z(#$P)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P
M=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SY297-T<FEC=&5D(%-T;V-K(#PO9&EV/CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H
M=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY!=V%R9',\+V1I=CX\+W1D
M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H
M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W
M:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/CQT
M9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=VED
M=&@Z(#$P)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SY796EG:'1E9"`\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^079E<F%G92!'<F%N="T\+V1I=CX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL
M969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[
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M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`V-B4[)SX\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y
M.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN
M+6QE9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/D]U='-T86YD:6YG(&%T($IA;G5A<GD@,2P@,C`Q,CPO9&EV/CPO=&0^
M/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED
M=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,C0V+#(R
M-3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
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M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`V-B4[)SX\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P
M;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R
M9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SY'<F%N=&5D/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXR-S8L,S<U/"]T9#X\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D(&%L:6=N/3-$<FEG
M:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA
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M(&9O;G0M<VEZ93H@,3!P=#LG/C,N-#0\+W1D/CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$
M(V-C965F9CX\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#H@-C8E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!T97AT+6EN9&5N=#H@+3EP=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`Q.'!T.R!F
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
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M<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`Q.'!T.R!F;VYT+7-I>F4Z(#$P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^0V%N8V5L;&5D+V9O<F9E:71E9#PO
M9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB
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M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,C0V+#(R-2`\+W1D/CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^*3PO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@<&%D9&EN9RUB;W1T
M;VTZ(#)P>#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXU+C@R/"]T9#X\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1"-C8V5E9F8^/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#1P>#L@=VED=&@Z(#8V)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=&5X="UI;F1E;G0Z("TY<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@.7!T.R!F
M;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^3W5T<W1A;F1I
M;F<@870@36%R8V@@,S$L(#(P,3(\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I
M9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M-'!X.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE
M.R!T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE
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M=&]M.B`T<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
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M('-T>6QE/3-$)W=I9'1H.B`V-B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#EP
M=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/E9E<W1E
M9"!A="!-87)C:"`S,2P@,C`Q,CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG
M:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA
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M;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,#PO=&0^/'1D(&YO=W)A<#TS1&YO
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M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/&1I=B!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P
M.SPO9&EV/CPO9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV
M/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CQD:78^
M/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\
M+V1I=CX\9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO
M9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CQD:78^/"]D
M:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DQO<W,@<&5R(%-H
M87)E/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^3&]S<R!P97(@4VAA<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S('!E<B!3:&%R93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX\9&EV/CQD:78^
M/&1I=CX\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S
M='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/'1R/CQT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.B`S)3LG/CQD:78@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I
M;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SX\82!N86UE/3-$9FES7W5N:61E
M;G1I9FEE9%]T86)L95\U/CPO83XQ,"X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.B`Y,R4[)SX\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I
M9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^3&]S<R!P97(@4VAA
M<F4\+V1I=CX\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D
M:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SY"87-I8R!P97(@<VAA<F4@9&%T82!I<R!C
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M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`Q.'!T.R!F;VYT
M+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^5V4@:&%V92!E>&-L
M=61E9"!A;&P@<&]T96YT:6%L;'D@9&EL=71I=F4@<V5C=7)I=&EE<R!F<F]M
M('1H92!C86QC=6QA=&EO;B!O9B!D:6QU=&5D(&QO<W,@<&5R('-H87)E(&%T
M=')I8G5T86)L92!T;R!C;VUM;VX@<W1O8VMH;VQD97)S(&9O<B!T:&4@=&AR
M964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$R(&%N9"`R,#$Q+"!A<R!T
M:&5I<B!I;F-L=7-I;VX@=V]U;&0@8F4@86YT:61I;'5T:79E+B8C,38P.R8C
M,38P.U!O=&5N=&EA;&QY(&1I;'5T:79E(&-O;6UO;B!S:&%R97,@97AC;'5D
M960@9G)O;2!T:&4@8V%L8W5L871I;VYS(&]F(&1I;'5T960@;&]S<R!P97(@
M<VAA<F4@=V5R92`Q."PU-#0L,#@W(&%N9"`Q.2PV-#DL,S@S(&9O<B!T:&4@
M=&AR964@;6]N=&@@<&5R:6]D<R!E;F1E9"!-87)C:"`S,2P@,C`Q,B!A;F0@
M,C`Q,2P@<F5S<&5C=&EV96QY+CPO9&EV/CPO9&EV/CPO9&EV/CQD:78^/"]D
M:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-#<V,F8U-69?.#5B-U\T8S)E
M7SDS.&-?-#5E-6,V8V9F,V,Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S0W-C)F-35F7S@U8C=?-&,R95\Y,SAC7S0U935C-F-F9C-C,2]7;W)K
M<VAE971S+U-H965T,38N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<SQB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O
M;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6ET;65N
M=',@86YD($-O;G1I;F=E;F-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQD:78^/&1I=CX\9&EV/CQD:78^/'1A8FQE(&-E;&QP861D:6YG
M/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/CQT<CX\=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O<"!S='EL93TS1"=W
M:61T:#H@,R4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#`N.'!T
M.R<^,3$N/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O
M<"!S='EL93TS1"=W:61T:#H@.3,E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P
M=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN
M+7)I9VAT.B`P+CAP=#LG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S
M/"]D:78^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/&1I=B!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O/CPO9&EV
M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86X[(&UA<F=I;BUL969T.B`Q.'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA
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M(&]F($UA<F-H(#,Q+"`R,#$R+"!W92!H879E('!R92UC;&EN:6-A;"!R97-E
M87)C:"!S='5D>2!O8FQI9V%T:6]N<R!O9B`D-C`L,#`P("AW:&EC:"!A<F4@
M97AP96-T960@=&\@8F4@9G5L;'D@8V]M<&QE=&5D('=I=&AI;B!A('EE87(I
M(&%N9"!C;&EN:6-A;"!R97-E87)C:"!S='5D>2!O8FQI9V%T:6]N<R!O9B`D
M,3(L-C`P+#`P,"`H)#0L,3`P+#`P,"!O9B!W:&EC:"!A<F4@97AP96-T960@
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY$=7)I;F<@,C`P."P@
M=V4@96YT97)E9"!I;G1O(&$@<W5P<&QY(&%G<F5E;65N="!W:71H(&$@;6EN
M:6UU;2!P=7)C:&%S92!R97%U:7)E;65N=',@8VQA=7-E+B8C,38P.R8C,38P
M.T%S(&]F($UA<F-H(#,Q+"`R,#$R+"!W92!H879E(&UI;FEM=6T@<'5R8VAA
M<V4@;V)L:6=A=&EO;G,@;V8@)#(L,3DQ+#`P,"`H)#$L,S0Q+#`P,"!O9B!W
M:&EC:"!A<F4@97AP96-T960@=&\@8F4@<&%I9"!W:71H:6X@82!Y96%R*2X\
M+V1I=CX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z
M(#$X<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY7
M92!H879E(&5N=&5R960@:6YT;R!S979E<F%L(&QE87-E(&%G<F5E;65N=',@
M9F]R(&]U<B!H96%D<75A<G1E<G,@;V9F:6-E(&QO8V%T:6]N(&%S('=E;&P@
M87,@:6YT97)N871I;VYA;"!O9F9I8V4@;&]C871I;VYS(&%N9"!C;W)P;W)A
M=&4@:&]U<VEN9R!F;W(@;W5R(&5M<&QO>65E<R!O;B!I;G1E<FYA=&EO;F%L
M(&%S<VEG;FUE;G1S+B!!<R!O9B!-87)C:"`S,2P@,C`Q,BP@=V4@:&%V92!R
M96UA:6YI;F<@;&5A<V4@;V)L:6=A=&EO;G,@;V8@)#$P+#(U.2PP,#`@*"0Q
M+#<X-2PP,#`@;V8@=VAI8V@@87)E(&5X<&5C=&5D('1O(&)E(&-O;7!L971E
M9"!W:71H:6X@82!Y96%R*2X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D:78^/&1I=B!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@
M;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SY792!A<F4@<W5B:F5C="!T;R!V87)I;W5S(&-L86EM<R!A
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M)B,Q-C`[)B,Q-C`[36%N86=E;65N="!B96QI979E<R!T:&%T(&%N>2!L:6%B
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M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G
M:6XM;&5F=#H@,3AP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/E)E9F5R('1O(&YO=&4@-B!F;W(@82!D:7-C=7-S:6]N(&]F(&]U
M<B!C;VUM:71M96YT<R!A;F0@8V]N=&EN9V5N8VEE<R!R96QA=&5D('1O(&]U
M<B!L;VYG+71E<FT@;V)L:6=A=&EO;G,N/"]D:78^/&1I=B!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O/CPO9&EV
M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86X[(&UA<F=I;BUL969T.B`Q.'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^4F5F97(@=&\@;F]T92`Q,B!F;W(@82!D:7-C
M=7-S:6]N(&]F(&]U<B!C;VUM:71M96YT<R!A;F0@8V]N=&EN9V5N8VEE<R!R
M96QA=&5D('1O(&]U<B!T<F%N<V%C=&EO;G,@=VET:"!/;'EM<'5S+"!I;F-L
M=61I;F<@*&$I(&]U<B!O8FQI9V%T:6]N('1O('1H92!*;VEN="!696YT=7)E
M(&EN(&9U='5R92!P97)I;V1S(&%N9"`H8BD@8V5R=&%I;B!P=70@86YD(&-A
M;&P@<FEG:'1S(&5M8F5D9&5D(&EN('1H92!A<G)A;F=E;65N=',@=VET:"!/
M;'EM<'5S+CPO9&EV/CPO9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I
M=CX\9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV
M/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CQD:78^/"]D:78^
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E1R86YS86-T:6]N<R!W
M:71H($]L>6UP=7,@0V]R<&]R871I;VX\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY4<F%N<V%C=&EO;G,@=VET:"!/
M;'EM<'5S($-O<G!O<F%T:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A;G-A8W1I;VYS('=I=&@@
M3VQY;7!U<R!#;W)P;W)A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/&1I=CX\9&EV/CQD:78^/&1I=CX\=&%B;&4@8V5L;'!A9&1I;F<]
M,T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M/'1R/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I
M9'1H.B`S)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[
M)SXQ,BX\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P
M('-T>6QE/3-$)W=I9'1H.B`Y,R4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T
M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM
M<FEG:'0Z(#`N.'!T.R<^5')A;G-A8W1I;VYS('=I=&@@3VQY;7!U<R!#;W)P
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M.B`Q.'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M26YI=&EA;"!);G9E<W1M96YT(&)Y($]L>6UP=7,@0V]R<&]R871I;VX@:6X@
M0WET;W)I/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SLG/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T
M.B`Q.'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M26X@,C`P-2P@=V4@96YT97)E9"!I;G1O(&$@8V]M;6]N('-T;V-K('!U<F-H
M87-E(&%G<F5E;65N="!W:71H($]L>6UP=7,@:6X@=VAI8V@@=V4@<F5C96EV
M960@)#$Q+#`P,"PP,#`@:6X@8V%S:"!P<F]C965D<RXF(S$V,#LF(S$V,#M7
M92!R96-E:79E9"!A;B!A9&1I=&EO;F%L("0Q,2PP,#`L,#`P(&9R;VT@3VQY
M;7!U<R!I;B!!=6=U<W0@,C`P-B!F;W(@=&AE(&ES<W5A;F-E(&]F(&%P<')O
M>&EM871E;'D@,2PY,#`L,#`P('-H87)E<R!O9B!O=7(@8V]M;6]N('-T;V-K
M(&%T("0U+C<U('!E<B!S:&%R92XF(S$V,#LF(S$V,#M792!R96-E:79E9"!A
M;B!A9&1I=&EO;F%L("0V+#`P,"PP,#`@9G)O;2!/;'EM<'5S(&EN($%U9W5S
M="`R,#`X(&9O<B!T:&4@:7-S=6%N8V4@;V8@,2PP,#`L,#`P('5N<F5G:7-T
M97)E9"!S:&%R97,@;V8@;W5R(&-O;6UO;B!S=&]C:R!A="`D-BXP,"!P97(@
M<VAA<F4@86YD(#4P,"PP,#`@8V]M;6]N('-T;V-K('=A<G)A;G1S("AW:71H
M(&%N(&]R:6=I;F%L(&5X97)C:7-E('!R:6-E(&]F("0X+C4P('!E<B!S:&%R
M92D@=6YD97(@82!P<FEV871E('!L86-E;65N="!O9F9E<FEN9RX\+V1I=CX\
M9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY!<R!O9B!-87)C:"`S
M,2P@,C`Q,BP@3VQY;7!U<R!H;VQD<R!A<'!R;WAI;6%T96QY(#8N.24@;V8@
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M;BUL969T.B`Q.'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^1F]R;6%T:6]N(&]F('1H92!/;'EM<'5S+4-Y=&]R:2!*;VEN="!6
M96YT=7)E/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SLG/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T
M.B`Q.'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M26X@,C`P-2P@=V4@96YT97)E9"!I;G1O(&$@:F]I;G0@=F5N='5R92!A;F0@
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M87)C:"`S,2P@,C`Q,BP@=&AE(&-A<G)Y:6YG('9A;'5E(&]F(&]U<B!I;G9E
M<W1M96YT(&EN('1H92!*;VEN="!696YT=7)E(&ES("0R,#`L,#`P+B8C,38P
M.R8C,38P.U=E(&%R92!U;F1E<B!N;R!O8FQI9V%T:6]N('1O('!R;W9I9&4@
M861D:71I;VYA;"!F=6YD:6YG('1O('1H92!*;VEN="!696YT=7)E+"!B=70@
M;6%Y(&-H;V]S92!T;R!D;R!S;RXF(S$V,#LF(S$V,#M792!M861E(&YO(&-A
M<V@@8V]N=')I8G5T:6]N<R!T;R!T:&4@2F]I;G0@5F5N='5R92!D=7)I;F<@
M=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q,B!A;F0@,C`Q
M,2X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+7-T>6QE.B!I=&%L:6,[('1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N.R!M87)G:6XM;&5F=#H@,3AP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/E!U="]#86QL<R!A;F0@1W5A<F%N=&5E<SPO9&EV
M/CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,3AP=#L@9F]N
M="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/E1H92!3:&%R96AO
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M96YT=7)E('1O($-Y=&]R:2`H=&AE(")0=70B*2!A="!T:&4@:&EG:&5R(&]F
M("AA*2`D,C(L,#`P+#`P,"!O<B`H8BD@=&AE(%!U="=S(&9A:7(@=F%L=64N
M/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SLG/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`Q.'!T
M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^070@36%R
M8V@@,S$L(#(P,3(@86YD($1E8V5M8F5R(#,Q+"`R,#$Q+"!T:&4@97-T:6UA
M=&5D(&9A:7(@=F%L=64@;V8@=&AE(%!U="!W87,@)#$L-C0P+#`P,"!A;F0@
M)#$L.3$P+#`P,"P@<F5S<&5C=&EV96QY+B8C,38P.R8C,38P.T9L=6-T=6%T
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M9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY4:&4@=F%L=6%T:6]N
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M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@
M,3AP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/E1H
M92!F;VQL;W=I;F<@87-S=6UP=&EO;G,@=V5R92!E;7!L;WEE9"!I;B!E<W1I
M;6%T:6YG('1H92!V86QU92!O9B!T:&4@4'5T.CPO9&EV/CQD:78@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&$@;F%M93TS1$9)4U]53DE$14Y4249)141?5$%"3$5?-CX\+V$^/&)R
M("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)SX\
M=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS
M1"=W:61T:#H@.3`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
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M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M
M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D:78^/"]T
M9#X\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[
M('=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@
M,2XX<'0[)SY-87)C:"`S,2P\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P
M<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I
M;BUR:6=H=#H@,2XX<'0[)SXR,#$R/"]D:78^/"]T9#X\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,G!X.R!W:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z
M(#`N.'!T.R<^)B,Q-C`[/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W
M:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#`N.'!T
M.R<^)B,Q-C`[/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R<'@@<V]L:60[('=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I
M;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[(&UA<F=I;BUR:6=H=#H@,2XX<'0[)SY$96-E;6)E<B`S,2P@/"]D:78^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#$N.'!T.R<^,C`Q,3PO
M9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R<^/&1I=B!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H
M=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C,38P.SPO9&EV/CPO
M=&0^/"]T<CX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#H@-C8E.R!D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q
M)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C,38P.SPO9&EV/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM
M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,2XX
M<'0[)SXF(S$V,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL
M969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP
M=#LG/B8C,38P.SPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE
M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T
M.R<^)B,Q-C`[/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z(#$P)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`Q+CAP=#LG/B8C,38P.SPO9&EV/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE
M.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D:78^/"]T
M9#X\+W1R/CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@-C8E.R<^/&1I=B!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3EP=#L@
M9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SY%>'!E8W1E9"!V;VQA=&EL:71Y(&]F($-Y=&]R:3PO9&EV
M/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT
M+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SXF(S$V,#L\+V1I
M=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C,38P.SPO9&EV
M/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.B`Y)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A
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M:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)3PO9&EV/CPO=&0^
M/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z
M(#$P<'0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SXF(S$V,#L\+V1I=CX\+W1D
M/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C,38P.SPO9&EV/CPO=&0^
M/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.B`Y)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z
M(#$P<'0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SXW-BXP-SPO9&EV/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q
M,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)3PO9&EV/CPO=&0^/"]T<CX\
M='(@8F=C;VQO<CTS1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`V-B4[)SX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B
M;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE
M9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
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M="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D
M:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A
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M="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^-S8N-#4\+V1I
M=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B4\+V1I=CX\+W1D
M/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE
M.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D:78^/"]T
M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@
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M.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^-S8N,#<\+V1I=CX\+W1D
M/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B4\+V1I=CX\+W1D/CPO='(^
M/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`V-B4[)SX\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y
M.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN
M+6QE9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/D)A;FMR=7!T8WD@<F5C;W9E<GD@<F%T92!F;W(@0WET;W)I/"]D:78^
M/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C,38P.SPO9&EV
M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US
M:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D:78^
M/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z(#DE.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/C(X+C`P/"]D:78^
M/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL
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M:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C,38P.SPO9&EV/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q
M,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D:78^/"]T9#X\
M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z(#DE.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/C(X+C`P/"]D:78^/"]T9#X\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P
M<'0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SXE/"]D:78^/"]T9#X\+W1R/CQT
M<B!B9V-O;&]R/3-$=VAI=&4^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#8V)3LG/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TY<'0[(&1I<W!L87DZ(&)L
M;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F
M=#H@.7!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M0F%N:W)U<'1C>2!T:')E<VAO;&0@9F]R($-Y=&]R:3PO9&EV/CPO=&0^/'1D
M(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P
M<'0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SXF(S$V,#L\+V1I=CX\+W1D/CQT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P
M=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B0\+V1I=CX\+W1D/CQT9"!A;&EG
M;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@.24[
M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M
M87)G:6XM<FEG:'0Z(#`N.'!T.R<^-RPQ,S@L,#`P/"]D:78^/"]T9#X\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@
M,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@
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M(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T
M.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D:78^/"]T9#X\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@
M,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@
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M<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R
M9VEN+7)I9VAT.B`P+CAP=#LG/C@L-3DT+#`P,#PO9&EV/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E
M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M
M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D:78^/"]T9#X\+W1R/CQT
M<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#H@-C8E.R<^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3EP=#L@9&ES<&QA>3H@
M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL
M969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
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M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T
M.R<^)B,Q-C`[/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F
M=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[
M)SXF(S$V,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#H@.24[)SX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE
M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T
M.R<^,RXP.#PO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z
M(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^
M)3PO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T
M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SXF(S$V
M,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[
M(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C,38P
M.SPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.B`Y)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T
M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[)SXS+C,S
M/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT
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M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T
M.R<^)B,Q-C`[/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
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M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T
M.R<^.3DN,#`\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T
M.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG
M/B4\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P
M=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q
M-C`[/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F
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M=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^.3DN
M,#`\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[
M(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B4\+V1I
M=CX\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`V-B4[)SX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M
M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@;6%R9VEN+6QE9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/E)I<VL@9G)E92!I;G1E<F5S="!R871E/"]D:78^
M/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B8C,38P.SPO9&EV
M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US
M:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D:78^
M/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z(#DE.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/C(N,C,\+V1I=CX\
M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.B`Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/B4\+V1I=CX\+W1D/CQT
M9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q
M,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]D:78^/"]T9#X\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#H@,24[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM
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M;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q
M,'!T.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^,2XX.3PO9&EV/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M(#$E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T
M.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^)3PO9&EV/CPO=&0^/"]T<CX\+W1A
M8FQE/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@
M,3AP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/E1H
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M/CQB<B`O/CPO9&EV/CPO9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I
M=CX\9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV
M/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CQD:78^/"]D:78^
M/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\
M9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CQD
M:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I
M=CX\+V1I=CX\9&EV/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?-#<V,F8U-69?.#5B-U\T8S)E7SDS.&-?
M-#5E-6,V8V9F,V,Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S0W
M-C)F-35F7S@U8C=?-&,R95\Y,SAC7S0U935C-F-F9C-C,2]7;W)K<VAE971S
M+U-H965T,3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY&86ER(%9A;'5E($UE87-U<F5M96YT<SQB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64@365A
M<W5R96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU92!-96%S=7)E;65N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^/&1I=CX\9&EV/CQD
M:78^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y
M;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/CQT<CX\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#H@,R4[)SX\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM
M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD
M.R!M87)G:6XM<FEG:'0Z(#`N.'!T.R<^,3,N/"]D:78^/"]T9#X\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#H@.3,E.R<^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/D9A:7(@5F%L
M=64@365A<W5R96UE;G1S/"]D:78^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^
M/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SLG/B8C,38P.SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`Q.'!T.R!F;VYT
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M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D
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M>F4Z(#$P<'0[)SY,979E;"`Q.B!1=6]T960@<')I8V5S(&EN(&%C=&EV92!M
M87)K971S(&9O<B!I9&5N=&EC86P@87-S971S(&]R(&QI86)I;&ET:65S+CPO
M9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@.7!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/B8C,38P.SPO9&EV/CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#EP=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`Y<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$X,SL\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SY,979E;"`R.B!1=6]T960@<')I8V5S(&9O<B!S:6UI;&%R(&%S<V5T<R!O
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M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`Y<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@.7!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#EP=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
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M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/B8C,38P.SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`Q
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M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/B8C,38P.SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R<^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL
M<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#DP)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/'1R/CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#L@
M=VED=&@Z(#0R)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I
M;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^0F%L86YC92!A<R!O9CPO9&EV/CPO
M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED
M=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[
M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^
M/'1D(&-O;'-P86X],T0Q,"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@
M=VED=&@Z(#,T)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SY"87-I<R!O9B!&86ER(%9A;'5E($UE87-U<F5M96YT<SPO9&EV/CPO
M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED
M=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\+W1R
M/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R<'@[('=I9'1H.B`T,B4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED
M=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('=I9'1H
M.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M36%R8V@@,S$L(#(P,3(\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@
M=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\
M=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('=I
M9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ
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M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=VED=&@Z
M(#$P)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY,
M979E;"`R/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L
M:60[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('=I9'1H.B`Q
M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D(&-O;'-P
M86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R!W:61T:#H@,3`E
M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#!P=#LG/DQE=F5L
M(#,\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P
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M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+W1D/CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q,"4[(&1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L
M<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#H@,3`E.R!D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
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M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!B
M9V-O;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#H@-#(E.R<^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3EP=#L@9&ES<&QA>3H@8FQO
M8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T
M.B`Y<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY#
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M('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^,C8L-C0V+#`P,#PO=&0^/'1D(&YO=W)A<#TS1&YO
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M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXR-BPV-#8L,#`P/"]T9#X\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D(&%L:6=N/3-$<FEG
M:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA
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M(&9O;G0M<VEZ93H@,3!P=#LG/BT\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI
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M9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^+3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`T,B4[(&1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$
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M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES
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M;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\
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M/3-$)W=I9'1H.B`T,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#EP=#L@9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SY,:6%B:6QI=&EE<SH\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B
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M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@
M,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
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M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!B9V-O
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M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXH,2PV-#`L,#`P/"]T9#X\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/BD\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A
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M=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT
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M=#LG/BT\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@<W1Y
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M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*#$L
M-C0P+#`P,#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
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M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SY787)R86YT(&QI86)I;&ET>3PO9&EV/CPO=&0^/'1D
M(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
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M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B@W-3<L,#`P/"]T9#X\
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
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M:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA
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M(&9O;G0M<VEZ93H@,3!P=#LG/BT\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI
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M9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^*#<U-RPP,#`\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^*3PO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CQD:78@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V
M,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG/CQT
M86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$
M)W=I9'1H.B`Y,"4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`T,B4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W
M:61T:#H@,3`E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/D)A;&%N8V4@87,@;V8\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R<'@@<V]L:60[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L
M9#LG/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0Q,"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#)P>"!S;VQI9#L@=VED=&@Z(#,T)3LG/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE
M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SY"87-I<R!O9B!&86ER(%9A;'5E($UE87-U
M<F5M96YT<SPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`T,B4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M<'@@<V]L:60[('=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P
M<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^1&5C96UB97(@,S$L(#(P,3$\+V1I=CX\+W1D/CQT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#)P>"!S;VQI9#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B
M;VQD.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R<'@@<V]L:60[('=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL
M969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[
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M)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#)P>"!S;VQI9#L@=VED=&@Z(#$P)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z
M(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SY,979E;"`R/"]D:78^/"]T9#X\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M<'@@<V]L:60[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C
M,38P.SPO=&0^/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X
M('-O;&ED.R!W:61T:#H@,3`E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T
M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/DQE=F5L(#,\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E
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M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q,"4[
M(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,3`E.R!D:7-P;&%Y.B!I
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M(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@-#(E.R<^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@
M+3EP=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SY#87-H(&5Q=6EV86QE;G1S/"]D:78^/"]T9#X\
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M=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,S`L-C0V+#`P,#PO
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXS,"PV-#8L,#`P
M/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M=&0^/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
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M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@
M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@
M,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B0\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^+3PO=&0^/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G
M8V]L;W(],T1W:&ET93X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.B`T,B4[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@
M,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
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M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`T,B4[)SX\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P
M;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R
M9VEN+6QE9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@
M8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY,:6%B:6QI=&EE<SH\+V1I=CX\
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M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL
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M:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N
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M,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,2PY,3`L,#`P/"]T
M9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/BD\+W1D/CQT9"!A
M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@
M,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
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M<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES
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M86X[(&9O;G0M<VEZ93H@,3!P=#LG/BT\+W1D/CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V
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M('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^*#$L.3$P+#`P,#PO=&0^/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$(V-C
M965F9CX\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#H@-#(E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@+3EP=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY787)R86YT(&QI86)I
M;&ET>3PO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT
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M=#LG/B@V,C<L,#`P/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/BD\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM
M/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M=&0^/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
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M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@
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M="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*#8R-RPP,#`\+W1D/CQT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/"]T<CX\+W1A
M8FQE/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&$@;F%M93TS1$9)4U]53DE$14Y4
M249)141?5$%"3$5?-SX\+V$^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE
M9G0Z(#$X<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SY792!U<V4@<75O=&5D(&UA<FME="!P<FEC97,@=&\@9&5T97)M:6YE('1H
M92!F86ER('9A;'5E(&]F(&]U<B!C87-H(&5Q=6EV86QE;G1S+"!W:&EC:"!C
M;VYS:7-T(&]F(&UO;F5Y(&UA<FME="!F=6YD<R!T:&%T(&%R92!C;&%S<VEF
M:65D(&EN($QE=F5L(#$@;V8@=&AE(&9A:7(@=F%L=64@:&EE<F%R8VAY+CPO
M9&EV/CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,3AP=#L@
M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/E=E('9A;'5E
M(&]U<B!P=70@;&EA8FEL:71Y('5S:6YG(&%N(&]P=&EO;B!P<FEC:6YG('1H
M96]R>2!B87-E9"!S:6UU;&%T:6]N(&%N86QY<VES("AI+F4N+"!A($UO;G1E
M($-A<FQO('-I;75L871I;VXI("AS964@;F]T92`Q,BDN($)E8V%U<V4@<V]M
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M9"!A<R!,979E;"`S(&EN('1H92!F86ER('9A;'5E(&AI97)A<F-H>2X\+V1I
M=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY4:&4@9F]L;&]W
M:6YG('1A8FQE('-U;6UA<FEZ97,@=&AE(&-H86YG92!I;B!O=7(@3&5V96P@
M,R!P=70@;W!T:6]N(&QI86)I;&ET>2!V86QU93H\+V1I=CX\9&EV('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^
M/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)SX\=&%B
M;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([('=I9'1H.B`X,"4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/CQT<B!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([)SX\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.B`V."4[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[
M(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P
M.SPO=&0^/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$P)3LG/CQD:78@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN
M+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L
M9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY4:')E92!M;VYT:',@96YD960\+V1I
M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E
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M969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^4'5T(&]P=&EO;B!L:6%B:6QI='D\+V1I
M=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M<'@@<V]L:60[('=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P
M<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^36%R8V@@,S$L(#(P,3(\+V1I=CX\+W1D/CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^/"]T<CX\='(^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@-C@E.R!D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO=&0^/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$P)3L@9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@
M-C@E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN
M9&5N=#H@+3EP=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY"96=I;FYI;F<@8F%L86YC93PO9&EV
M/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
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M,"PP,#`@/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
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M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY$96-R96%S92!I;B!F
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M=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=&5X="UA;&EG
M;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,C<P+#`P,#PO=&0^/'1D(&YO=W)A
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M=&]M.B`T<'@[('=I9'1H.B`V."4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#EP
M=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/D5N9&EN
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M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B@Q+C8T,"PP,#`@
M/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@-'!X.R!W
M:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/BD\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q
M-C`[/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\82!N86UE/3-$1DE37U5.241%
M3E1)1DE%1%]404),15\X/CPO83Y#;VUM;VX@<W1O8VL@<'5R8VAA<V4@=V%R
M<F%N=',@:7-S=65D(&EN(&-O;FYE8W1I;VX@=VET:"!O=7(@075G=7-T(#(P
M,#@@<')I=F%T92!E<75I='D@<&QA8V5M96YT(&1O(&YO="!T<F%D92!I;B!A
M;B!A8W1I=F4@<V5C=7)I=&EE<R!M87)K970L(&%N9"!A<R!S=6-H+"!W92!E
M<W1I;6%T92!T:&4@9F%I<B!V86QU92!O9B!T:&5S92!W87)R86YT<R!U<VEN
M9R!T:&4@;W!T:6]N('!R:6-I;F<@;6]D96PN)B,Q-C`[)B,Q-C`[4V]M92!O
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M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N.R!M87)G:6XM;&5F=#H@,3AP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/E1H92!F;VQL;W=I;F<@=&%B;&4@<W5M;6%R:7IE
M<R!T:&4@8VAA;F=E(&EN(&]U<B!,979E;"`S('=A<G)A;G0@;&EA8FEL:71Y
M('9A;'5E.CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CLG/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L
M;'-P86-I;F<],T0P('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@=VED
M=&@Z(#@P)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^/'1R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG
M/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#8X)3L@9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#H@,3`E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@
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M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T
M9#X\+W1R/CQT<CX\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('=I9'1H
M.B`V."4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#EP=#L@9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY7
M87)R86YT(&QI86)I;&ET>3PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=VED=&@Z(#$P)3LG/CQD
M:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY-87)C:"`S,2P@
M,C`Q,CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q
M-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.B`V."4[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@
M,3`E.R!D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
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M=&]M('-T>6QE/3-$)W=I9'1H.B`V."4[)SX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C
M:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z
M(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/D)E
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M('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^*#8R-RPP,#`@/"]T9#X\=&0@;F]W<F%P/3-$;F]W
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M;BUL969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SY$96-R96%S92`H:6YC<F5A<V4I)B,Q-C`[)B,Q-C`[:6X@9F%I<B!V
M86QU92!R96-O9VYI>F5D(&EN(&]P97)A=&EN9R!E>'!E;G-E<SPO9&EV/CPO
M=&0^/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
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M.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,3,P+#`P,"`\+W1D/CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO
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M97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T
M.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B0\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93L@=&5X="UA
M;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*#<U-RPP,#`@/"]T9#X\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@-'!X.R!W:61T:#H@,24[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/BD\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D:78^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SY.;R!O=&AE<B!A<W-E=',@;W(@;&EA8FEL:71I
M97,@87)E(&UE87-U<F5D(&%T(&9A:7(@=F%L=64@;VX@82!R96-U<G)I;F<@
M8F%S:7,L(&]R(&AA=F4@8F5E;B!M96%S=7)E9"!A="!F86ER('9A;'5E(&]N
M(&$@;F]N+7)E8W5R<FEN9R!B87-I<R!S=6)S97%U96YT('1O(&EN:71I86P@
M<F5C;V=N:71I;VXL(&]N('1H92!A8V-O;7!A;GEI;F<@8V]N<V]L:61A=&5D
M(&-O;F1E;G-E9"!B86QA;F-E('-H965T(&%S(&]F($UA<F-H(#,Q+"`R,#$R
M+CPO9&EV/CPO9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV
M/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CQD:78^
M/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\
M+V1I=CX\9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO
M9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CQD:78^/"]D
M:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I
M=CX\9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV
M/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
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M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^1F%I<B!686QU93QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER
M(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/CQD
M:78^/&1I=CX\9&EV/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I
M;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\='(^/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1T;W`@<W1Y;&4],T0G=VED=&@Z(#,E.R<^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E
M:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/C$T+CPO9&EV/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@<W1Y;&4],T0G=VED
M=&@Z(#DS)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,"XX<'0[
M)SY&86ER(%9A;'5E/"]D:78^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/&1I
M=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG
M/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`Q.'!T.R!F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/D9I;F%N8VEA;"!);G-T<G5M96YT<SPO9&EV/CQD:78@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\8G(@+SX\+V1I
M=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N.R!M87)G:6XM;&5F=#H@,3AP=#L@9F]N="US:7IE.B`Q,'!T.R!M
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M86YD($1E8V5M8F5R(#,Q+"`R,#$Q+"!W97)E(&1E=&5R;6EN960@=7-I;F<@
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M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G
M:6XM;&5F=#H@,3AP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z
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M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D:78^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SY792!U=&EL:7IE('%U;W1E9"!M87)K970@<')I8V5S
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M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^
M/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@,3!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY!="!-87)C:"`S,2P@,C`Q,B!A;F0@
M1&5C96UB97(@,S$L(#(P,3$L('1H92!A9V=R96=A=&4@9F%I<B!V86QU92!A
M;F0@=&AE(&-A<G)Y:6YG('9A;'5E(&]F('1H92!#;VUP86YY)W,@9FEX960@
M<F%T92!L;VYG+71E<FT@9&5B="!W97)E(&%S(&9O;&QO=W,Z/"]D:78^/&1I
M=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG
M/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R<^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!W:61T:#H@.3`E.R!F;VYT+69A
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M)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0V(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,G!X('-O;&ED.R!W:61T:#H@,C(E.R<^/&1I=B!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G
M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B
M;VQD.R!M87)G:6XM<FEG:'0Z(#!P=#LG/DUA<F-H(#,Q+"`R,#$R/"]D:78^
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M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T
M9#X\=&0@8V]L<W!A;CTS1#8@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[
M('=I9'1H.B`R,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^1&5C96UB97(@,S$L(#(P,3$\+V1I=CX\+W1D/CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^/"]T<CX\='(^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@-#(E.R!D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
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M(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.B`Q,"4[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\
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M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,3`E
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M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`T,B4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R<'@@<V]L:60[('=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I
M;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^1F%I<B!686QU93PO9&EV/CPO=&0^
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED=&@Z
M(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I
M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D
M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R!W:61T
M:#H@,3`E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@
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M9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R<'@@<V]L:60[('=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA
M<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z
M(&)O;&0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^1F%I<B!686QU93PO9&EV/CPO
M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED
M=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[
M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^
M/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R!W
M:61T:#H@,3`E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL
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M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.B`Q,"4[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#H@,3`E.R!D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
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M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q,"4[(&1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
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M=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT
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M=#LG/C(T+#,P-BPP,#`\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B
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M,T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y
M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^,C0L-3$R+#`P,#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z
M(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z
M(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXR-"PR,3$L,#`P/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T
M:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE
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M93H@,3!P=#LG/C(T+#,T,2PP,#`\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/&1I
M=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG
M/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#$X<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I
M>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^0V%R<GEI;F<@=F%L=64@
M:7,@;F5T(&]F(&1E8G0@9&ES8V]U;G0@;V8@)#$L-C$S+#`P,"!A;F0@)#$L
M.#0W+#`P,"!A<R!O9B!-87)C:"`S,2P@,C`Q,B!A;F0@1&5C96UB97(@,S$L
M(#(P,3$L(')E<W!E8W1I=F5L>2X\+V1I=CX\+V1I=CX\+V1I=CX\9&EV/CPO
M9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CQD:78^/"]D
M:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I
M=CX\9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV
M/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CQD:78^/"]D:78^
M/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7S0W-C)F-35F7S@U8C=?-&,R95\Y,SAC7S0U935C-F-F9C-C,0T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\T-S8R9C4U9E\X-6(W7S1C,F5?.3,X
M8U\T-64U8S9C9F8S8S$O5V]R:W-H965T<R]3:&5E=#(P+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%
M<75I='D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S
M,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>2!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K:&]L
M9&5R<R<@17%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M9&EV/CQD:78^/&1I=CX\9&EV/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L
M;'-P86-I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\='(^/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@<W1Y;&4],T0G=VED=&@Z(#,E
M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/C$U+CPO
M9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@<W1Y;&4]
M,T0G=VED=&@Z(#DS)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@
M,"XX<'0[)SY3=&]C:VAO;&1E<G,G($5Q=6ET>3PO9&EV/CPO=&0^/"]T<CX\
M+W1A8FQE/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F
M=#H@,3AP=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SY#;VUM;VX@4W1O8VL\+V1I=CX\9&EV('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R
M("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY/;B!$96-E;6)E<B`Q,RP@,C`Q
M,"!W92!R86ES960@)#$P+#`P,"PP,#`@:6X@9W)O<W,@<')O8V5E9',@9G)O
M;2!A('-A;&4@;V8@,2PT,C@L-3<Q('-H87)E<R!O9B!U;G)E9VES=&5R960@
M8V]M;6]N('-T;V-K('1O($%S=&5L;&%S(%!H87)M82!);F,N(&9O<B`D-RXP
M,"!P97(@<VAA<F4@:6X@82!P<FEV871E('-T;V-K('!L86-E;65N="XF(S$V
M,#LF(S$V,#M0=7)S=6%N="!T;R!T:&4@=&5R;7,@;V8@=&AE('!U<F-H87-E
M(&%G<F5E;65N="P@=V4@9W)A;G1E9"!!<W1E;&QA<R!0:&%R;6$@26YC+B!A
M('1W;R!Y96%R(')I9VAT(&]F(&9I<G-T(')E9G5S86P@=&\@96YT97(@:6YT
M;R!A(&1E=F5L;W!M96YT(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!C;VQL86)O
M<F%T:6]N('=I=&@@=7,@<F5G87)D:6YG('1H92!U<V4@;V8@;W5R('1E8VAN
M;VQO9WDL(&]N(&$@=V]R;&1W:61E(&)A<VES+"!F;W(@=&AE('1R96%T;65N
M="!O9B!L:79E<B!C;VYD:71I;VYS+B!);B!A9&1I=&EO;BP@=V4@:&%V92!A
M9W)E960@=&\@=7-E(')E87-O;F%B;&4@969F;W)T<R!T;R!F:6QE(&$@<F5G
M:7-T<F%T:6]N('-T871E;65N="!W:71H('1H92!396-U<FET:65S(&%N9"!%
M>&-H86YG92!#;VUM:7-S:6]N('1O(')E9VES=&5R('1H92!S:&%R97,@;V8@
M8V]M;6]N('-T;V-K(&9O<B!R97-A;&4@=7!O;B!T:&4@<F5Q=65S="!O9B!!
M<W1E;&QA<R!0:&%R;6$@26YC+B8C,38P.R8C,38P.U=E(&%L<V\@9W)A;G1E
M9"!!<W1E;&QA<R!0:&%R;6$@26YC+B!A(&YO;BUV;W1I;F<@;V)S97)V97(@
M<V5A="!O;B!O=7(@0F]A<F0@;V8@1&ER96-T;W)S(&%N9"!T:&4@<FEG:'0@
M=&\@9&5S:6=N871E(&$@<F5P<F5S96YT871I=F4@;65M8F5R('1O(&]U<B!3
M8VEE;G1I9FEC($%D=FES;W)Y($)O87)D+B8C,38P.R8C,38P.U1H92`D,3`L
M,#`P+#`P,"!I;B!T;W1A;"!P<F]C965D<R!W92!R96-E:79E9"!E>&-E961E
M9"!T:&4@;6%R:V5T('9A;'5E(&]F(&]U<B!S=&]C:R!A="!T:&4@8V]M<&QE
M=&EO;B!O9B!T:&4@<'5R8VAA<V4@86=R965M96YT+B8C,38P.R8C,38P.U1H
M92`D,BPU,C8L,#`P(&1I9F9E<F5N8V4@8F5T=V5E;B!T:&4@<')O8V5E9',@
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M-C`[)B,Q-C`[5&AE(')E8V]G;FET:6]N(&]F('1H:7,@9&5F97)R960@86UO
M=6YT(&ES(&5X<&5C=&5D('1O(&]C8W5R('5P;VX@=&AE(&5A<FQI97(@;V8@
M=&AE(&5X<&ER871I;VX@;V8@=&AE('1W;R!Y96%R('!E<FEO9"!O<B!T:&4@
M=&5R;6EN871I;VX@;V8@=&AE(&%G<F5E;65N="X\+V1I=CX\9&EV('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^
M/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@,3!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY/;B!*=6QY(#$Q+"`R,#$Q+"!W92!E
M;G1E<F5D(&EN=&\@82!C;VUM;VX@<W1O8VL@<'5R8VAA<V4@86=R965M96YT
M('=I=&@@4V5A<VED92`X."P@3%`@<F5L871I;F<@=&\@=&AE(&]F9F5R:6YG
M(&%N9"!S86QE(&]F(&$@=&]T86P@;V8@=7`@=&\@-BPS,C8L,C8R('-H87)E
M<R!O9B!O=7(@8V]M;6]N('-T;V-K+B8C,38P.R8C,38P.U1H92!A9W)E96UE
M;G0@<F5Q=6ER97,@=7,@=&\@:7-S=64@86YD(%-E87-I9&4@=&\@8G5Y(#$L
M,S(V+#(V,B!S:&%R97,@;V8@;W5R(&-O;6UO;B!S=&]C:R!A="!A;B!I;FET
M:6%L(&-L;W-I;F<@86YD(#(U,"PP,#`@<VAA<F5S(&]F(&]U<B!C;VUM;VX@
M<W1O8VL@;VYC92!E=F5R>2!T=V\@=V5E:W,L(&-O;6UE;F-I;F<@,S`@9&%Y
M<R!A9G1E<B!T:&4@:6YI=&EA;"!C;&]S:6YG+"!F;W(@=7`@=&\@86X@861D
M:71I;VYA;"`R,"!C;&]S:6YG<RP@<W5B:F5C="!T;R!T:&4@<V%T:7-F86-T
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M9R!A<'!R;WAI;6%T96QY("0V+#`P,"PP,#`@:6X@9W)O<W,@<')O8V5E9',N
M($%T('-U8G-E<75E;G0@8VQO<VEN9W,L('1H92!O9F9E<FEN9R!P<FEC92!W
M:6QL(&5Q=6%L(#DP+C(U)2!O9B!O=7(@8V]M;6]N('-T;V-K)W,@=F]L=6UE
M+7=E:6=H=&5D(&%V97)A9V4@=')A9&EN9R!P<FEC97,@9'5R:6YG('1H92!T
M96XM9&%Y('1R861I;F<@<&5R:6]D(&EM;65D:6%T96QY('!R:6]R('1O(&5A
M8V@@<W5B<V5Q=65N="!C;&]S:6YG(&1A=&4N)B,Q-C`[)B,Q-C`[5V4@<F%I
M<V5D(&%P<')O>&EM871E;'D@)#$W+#8X-"PP,#`@:6X@9W)O<W,@<')O8V5E
M9',@9G)O;2!T:&4@<V%L92!O9B`U+#4W-BPR-C(@<VAA<F5S(&EN(&]U<B!S
M8VAE9'5L960@8VQO<VEN9W,@=&AR;W5G:"!-87)C:"`S,2P@,C`Q,BX\+V1I
M=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQD
M:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('=I9'1H.B`Q
M,#`E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z
M(#AP=#LG/CPO9&EV/CPO9&EV/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`Q
M.'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/E=A<G)A;G0@061J=7-T;65N=',\+V1I=CX\9&EV
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^
M/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY/=7(@36%R8V@@,C`P.2!O
M9F9E<FEN9R!O9B`T+#<W,2PQ-S0@<VAA<F5S(&]F(&]U<B!C;VUM;VX@<W1O
M8VL@86YD('=A<G)A;G1S('1O('!U<F-H87-E('5P('1O(&$@=&]T86P@;V8@
M-BPV-SDL-C0T(&%D9&ET:6]N86P@<VAA<F5S(&]F(&]U<B!C;VUM;VX@<W1O
M8VL@=VET:"!A;B!E>&5R8VES92!P<FEC92!O9B`D,BXU.2!P97(@<VAA<F4L
M(&]U<B!-87D@,C`P.2!E<75I='D@;V9F97)I;F<@;V8@,2PX-C0L-S@S('-H
M87)E<R!O9B!O=7(@8V]M;6]N('-T;V-K(&%N9"!W87)R86YT<R!T;R!P=7)C
M:&%S92!U<"!T;R!A('1O=&%L(&]F(#,L,C8S+#,X,"!A9&1I=&EO;F%L('-H
M87)E<R!O9B!O=7(@8V]M;6]N('-T;V-K('=I=&@@86X@97AE<F-I<V4@<')I
M8V4@;V8@)#(N-C(@<&5R('-H87)E+"!O=7(@8VQO<VEN9W,@=VET:"!396%S
M:61E(#@X+"!,4"!T:')O=6=H($UA<F-H(#,Q+"`R,#$R+"!O=7(@3V-T;V)E
M<B`R,#$P(&]F9F5R:6YG(&]F(#0L-C`P+#`P,"!S:&%R97,@;V8@;W5R(&-O
M;6UO;B!S=&]C:R!A;F0@;W5R($1E8V5M8F5R(#(P,3`@<V%L92!O9B`Q+#0R
M."PU-S$@<VAA<F5S(&]F(&]U<B!C;VUM;VX@<W1O8VL@=')I9V=E<F5D(&%N
M(&%D:G5S=&UE;G0@=&\@=&AE(&5X97)C:7-E('!R:6-E(&%N9"!N=6UB97(@
M;V8@<VAA<F5S(&ES<W5A8FQE('5N9&5R('1H92!W87)R86YT<R!I<W-U960@
M=&\@:6YV97-T;W)S(&EN(&]U<B!!=6=U<W0@,C`P."!P<FEV871E('!L86-E
M;65N="!F:6YA;F-I;F<N)B,Q-C`[)B,Q-C`[07,@82!R97-U;'0L(&%S(&]F
M($UA<F-H(#,Q+"`R,#$R+"!T:&4@8V]M;6]N('-T;V-K('=A<G)A;G1S(&ES
M<W5E9"!O;B!!=6=U<W0@,3$L(#(P,#@@87)E(&-U<G)E;G1L>2!E>&5R8VES
M86)L92!F;W(@,BPP,30L-3$R('-H87)E<R!O9B!O=7(@8V]M;6]N('-T;V-K
M(&%T(&%N(&5X97)C:7-E('!R:6-E(&]F("0U+C<U('!E<B!S:&%R92X\+V1I
M=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
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M=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY!<R!O9B!-87)C
M:"`S,2P@,C`Q,B!A;F0@1&5C96UB97(@,S$L(#(P,3$L($=R965N($AO<W!I
M=&%L(%-U<'!L>2P@26YC+BP@;W5R(&1I<W1R:6)U=&EO;B!P87)T;F5R(&EN
M($IA<&%N(&%N9"!A(')E;&%T960@<&%R='DL('=A<R!A(&)E;F5F:6-I86P@
M;W=N97(@;V8@-2XQ)2!A;F0@-2XS)2P@<F5S<&5C=&EV96QY+"!O9B!O=7(@
M;W5T<W1A;F1I;F<@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RX\+V1I=CX\9&EV
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^
M/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY$=7)I;F<@=&AE('1H<F5E
M(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q,B!A;F0@,C`Q,2P@=V4@:6YC
M=7)R960@87!P<F]X:6UA=&5L>2`D,C<L,#`P(&%N9"`D,C@L,#`P(&EN(')O
M>6%L='D@8V]S=',@:6X@8V]N;F5C=&EO;B!W:71H(&]U<B!S86QE<R!O9B!O
M=7(@0V5L=71I;VXF(S$W-#L@.#`P+T-24R!3>7-T96T@<')O9'5C=',@=&\@
M=&AE($5U<F]P96%N(&%N9"!!<VEA+5!A8VEF:6,@<F5C;VYS=')U8W1I=F4@
M<W5R9V5R>2!M87)K970L('!U<G-U86YT('1O(&]U<B!,:6-E;G-E(&%N9"!2
M;WEA;'1Y($%G<F5E;65N="!A;F0@=&AE($%M96YD960@3&EC96YS92]#;VUM
M97)C:6%L($%G<F5E;65N="!W:71H('1H92!/;'EM<'5S+4-Y=&]R:2P@26YC
M+B!J;VEN="!V96YT=7)E+"!R97-P96-T:79E;'DN)B,Q-C`[)B,Q-C`[061D
M:71I;VYA;&QY+"!D=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C
M:"`S,2P@,C`Q,BP@=V4@<'5R8VAA<V5D('-E8V]N9"!G96YE<F%T:6]N($-E
M;'5T:6]N("8C,3<T.R!3>7-T96US(&%N9"!C;VYS=6UA8FQE('-E=',@9G)O
M;2!/;'EM<'5S+4-Y=&]R:2P@26YC+B!J;VEN="!V96YT=7)E+"!A="!A(&9O
M<FUU;&$M8F%S960@=')A;G-F97(@<')I8V4@86=G<F5G871I;F<@=&\@)#$L
M,#0X+"`P,#`P+B8C,38P.R8C,38P.T%S(&]F($UA<F-H(#,Q+"`R,#$R(&%N
M9"!$96-E;6)E<B`S,2P@,C`Q,2P@3VQY;7!U<R!#;W)P;W)A=&EO;B!W87,@
M82!B96YE9FEC:6%L(&]W;F5R(&]F(#8N.24@86YD(#<N,24L(')E<W!E8W1I
M=F5L>2P@;V8@;W5R(&]U='-T86YD:6YG('-H87)E<R!O9B!C;VUM;VX@<W1O
M8VL@86YD(&$@8F5N969I8VEA;"!O=VYE<B!O9B`U,"4@;V8@3VQY;7!U<RU#
M>71O<FDL($EN8RX@:F]I;G0@=F5N='5R92X\+V1I=CX\+V1I=CX\+V1I=CX\
M9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CQD
M:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I
M=CX\+V1I=CX\9&EV/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\9&EV
M/CPO9&EV/CQD:78^/"]D:78^/&1I=CX\+V1I=CX\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N=',\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6)S97%U96YT
M($5V96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-U8G-E<75E;G0@179E;G1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/CQD:78^/&1I=CX\9&EV/CQD:78^
M/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4]
M,T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/CQT<CX\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1'1O<"!S='EL93TS1"=W:61T:#H@,R4[)SX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F
M=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M
M87)G:6XM<FEG:'0Z(#`N.'!T.R<^,38N/"]D:78^/"]T9#X\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#H@.3,E.R<^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E
M:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P+CAP=#LG/E-U8G-E<75E;G0@
M179E;G1S/"]D:78^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/&1I=B!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O
M/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`Q.'!T.R!F;VYT+7-I>F4Z(#$P
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M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,3AP
M=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/E-U8G-E
M<75E;G0@=&\@=&AE('%U87)T97(@96YD960@36%R8V@@,S$L(#(P,3(L('=E
M(&-O;7!L971E9"!O;F4@<V-H961U;&5D(&-L;W-I;F<@=VET:"!396%S:61E
M(#@X+"!,4"!D=7)I;F<@=&AE('!E<FEO9"!O9B!!<')I;"`Q+"`R,#$R('1H
M<F]U9V@@;W5R(&9I;&EN9R!D871E(')A:7-I;F<@:6X@86=G<F5G871E(&%P
M<')O>&EM871E;'D@)#4T.2PP,#`@:6X@9W)O<W,@<')O8V5E9',@9G)O;2!T
M:&4@/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^<V%L92!O9B`R-3`L,#`P/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^<VAA<F5S
M/"]F;VYT/B!O9B!O=7(@8V]M;6]N('-T;V-K(&EN(&-O;FYE8W1I;VX@=VET
M:"!T:&4@86=R965M96YT('=E(&5N=&5R960@:6YT;R!W:71H(%-E87-I9&4@
M.#@L($Q0(&]N($IU;'D@,3$L(#(P,3$N)B,Q-C`[)B,Q-C`[169F96-T:79E
M+"!!<')I;"`S,#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="US:7IE.B`W,"4[('9E<G1I8V%L+6%L:6=N.B!T97AT+71O<#LG/G1H/"]F
M;VYT/BP@,C`Q,BP@=V4@=&5R;6EN871E9"!T:&4@86=R965M96YT('=I=&@@
M4V5A<VED92`X."P@3%`@86YD('=E('=I;&P@;F]T('-E;&P@=&AE(')E;6%I
M;FEN9R!A;F0@9FEN86P@-3`P+#`P,"!S:&%R97,@=&AA="!W;W5L9"!O=&AE
M<G=I<V4@:&%V92!B965N('-O;&0@=6YD97(@=&AI<R!A9W)E96UE;G0N/"]D
M:78^/"]D:78^/"]D:78^/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T-S8R9C4U9E\X-6(W7S1C,F5?.3,X
M8U\T-64U8S9C9F8S8S$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M-#<V,F8U-69?.#5B-U\T8S)E7SDS.&-?-#5E-6,V8V9F,V,Q+U=O<FMS:&5E
M=',O9FEL96QI<W0N>&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQX;6P@>&UL;G,Z;STS1")U<FXZ<V-H96UA
M<RUM:6-R;W-O9G0M8V]M.F]F9FEC93IO9F9I8V4B/@T*(#QO.DUA:6Y&:6QE
M($A2968],T0B+BXO5V]R:V)O;VLN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#`Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,BYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#,N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#`T+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970P-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#8N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`W+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$P
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,2YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,3(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#$S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q
M-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,34N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$V+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,3@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Y+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970R,"YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,C$N:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'10
L87)T7S0W-C)F-35F7S@U8C=?-&,R95\Y,SAC7S0U935C-F-F9C-C,2TM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Capital Availability<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_CapitalAvailabilityAbstract', window );"><strong>Capital Availability [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_CapitalAvailabilityTextBlock', window );">Capital Availability</a></td>
        <td class="text"><div><div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="top" style="width: 3%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">3.</div></td><td align="left" valign="top" style="width: 93%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">Capital Availability</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">We incurred net losses of $9,325,000 and $12,072,000 for the three months ended March 31, 2012 and 2011, respectively.&#160;&#160;We have an accumulated deficit of $251,774,000 as of March 31, 2012.&#160;&#160;Additionally, we have used net cash of $7,714,000 and $10,564,000 to fund our operating activities for the three months ended March 31, 2012 and 2011, respectively<font style="display: inline; font-weight: bold;">.&#160;&#160;</font>To date, these operating losses have been funded primarily from outside sources of invested capital.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Management recognizes the need to generate positive cash flows in future periods and/or to obtain additional capital from various sources. In the continued absence of positive cash flows from operations, no assurance can be given that we can generate sufficient revenue to cover operating costs or that additional financing will be available to us and, if available, on terms acceptable to us in the future.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">During 2011, we expanded our commercialization activities while simultaneously pursuing available financing sources to support operations and growth.&#160;&#160;We have had, and we will likely continue to have, an ongoing need to raise additional cash from outside sources to fund our operations for remainder of 2012 and beyond.&#160;&#160;If we cannot do so when required, we would need to reduce our research, development, and administrative operations, including reductions of our employee base, in order to offset lack of available funding.&#160;&#160;&#160;We continue to evaluate available financing opportunities as part of our normal course of business.</div></div></div><div></div><div></div><div></div><div></div><div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_CapitalAvailabilityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_CapitalAvailabilityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_CapitalAvailabilityTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Capital Availability</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_CapitalAvailabilityTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQMAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 34,399,000<span></span></td>
        <td class="nump">$ 36,922,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of reserves of $187,000 and of $474,000 in 2012 and 2011, respectively</a></td>
        <td class="nump">1,425,000<span></span></td>
        <td class="nump">2,260,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
        <td class="nump">3,374,000<span></span></td>
        <td class="nump">3,318,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
        <td class="nump">1,135,000<span></span></td>
        <td class="nump">837,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">40,333,000<span></span></td>
        <td class="nump">43,337,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">2,367,000<span></span></td>
        <td class="nump">1,711,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash and cash equivalents</a></td>
        <td class="nump">350,000<span></span></td>
        <td class="nump">350,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in joint venture</a></td>
        <td class="nump">200,000<span></span></td>
        <td class="nump">250,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump">1,794,000<span></span></td>
        <td class="nump">1,772,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangibles, net</a></td>
        <td class="nump">136,000<span></span></td>
        <td class="nump">192,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
        <td class="nump">3,922,000<span></span></td>
        <td class="nump">3,922,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">49,102,000<span></span></td>
        <td class="nump">51,534,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">6,046,000<span></span></td>
        <td class="nump">5,334,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term obligations</a></td>
        <td class="nump">4,911,000<span></span></td>
        <td class="nump">2,487,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">10,957,000<span></span></td>
        <td class="nump">7,821,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_DeferredRevenuesRelatedParty', window );">Deferred revenues, related party</a></td>
        <td class="nump">3,520,000<span></span></td>
        <td class="nump">3,520,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenues</a></td>
        <td class="nump">5,176,000<span></span></td>
        <td class="nump">5,244,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_WarrantLiability', window );">Warrant liability</a></td>
        <td class="nump">757,000<span></span></td>
        <td class="nump">627,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_OptionLiability', window );">Option liability</a></td>
        <td class="nump">1,640,000<span></span></td>
        <td class="nump">1,910,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Long-term deferred rent</a></td>
        <td class="nump">498,000<span></span></td>
        <td class="nump">504,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term obligations, net of discount, less current portion</a></td>
        <td class="nump">19,704,000<span></span></td>
        <td class="nump">21,962,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">42,252,000<span></span></td>
        <td class="nump">41,588,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized; -0- shares issued and outstanding in 2012 and 2011</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 95,000,000 shares authorized; 58,428,606 and 56,594,683 shares issued and outstanding in 2012 and 2011, respectively</a></td>
        <td class="nump">58,000<span></span></td>
        <td class="nump">57,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">258,566,000<span></span></td>
        <td class="nump">252,338,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(251,774,000)<span></span></td>
        <td class="num">(242,449,000)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump">6,850,000<span></span></td>
        <td class="nump">9,946,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump">$ 49,102,000<span></span></td>
        <td class="nump">$ 51,534,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_DeferredRevenuesRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Related parties deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_DeferredRevenuesRelatedParty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_OptionLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair Value of option liability for the period which are included in the statement of income (or changes in net assets) in operating expenses; the fair value of which was or is measured on a recurring basis using valuation techniques in which one or more significant inputs are unobservable in active markets (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_OptionLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_WarrantLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair Value of warrants which are accounted for as fair value liabilities with changes in fair value included in net earnings (loss). Fair value for these warrants is measured on a recurring basis using model-derived valuations in which all significant inputs are observable in active markets (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_WarrantLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br> -Section S99<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Publisher FASB<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 5<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.26(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Technical Bulletin (FTB)<br><br><br><br> -Number 85-3<br><br><br><br> -Paragraph 2<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 13<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph b<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453417&amp;loc=d3e39927-112707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRentCreditNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.12)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 323<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382870&amp;loc=d3e33749-111570<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityMethodInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph e<br><br><br><br> -Clause 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 43<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 68<br><br><br><br> -Subparagraph l<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph e<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 34<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905597&amp;loc=d3e13816-109267<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 72<br><br><br><br> -Subparagraph d<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Goodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 42, 45<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph ((a)(1),(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsNetExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer plus capital lease obligations due to be paid more than one year after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 6<br><br><br><br> -Section H<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtAndCapitalLeaseObligations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the portions of the carrying amounts as of the balance sheet date of long-term debt, which may include notes payable, bonds payable, debentures, mortgage loans, and commercial paper, which are scheduled to be repaid within one year or the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 129<br><br><br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_BasisOfPresentationAbstract', window );"><strong>Basis of Presentation [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
        <td class="text"><div><div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="top" style="width: 3%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">1.</div></td><td align="left" valign="top" style="width: 93%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">Basis of Presentation</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Our accompanying unaudited consolidated condensed financial statements as of March 31, 2012 and for the three months ended March 31, 2012 and 2011 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information.&#160;&#160;Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements.&#160;&#160;Our consolidated condensed balance sheet at March 31, 2012 has been derived from the audited financial statements at December 31, 2011, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.&#160;&#160;In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Cytori Therapeutics, Inc., and our subsidiaries (the Company) have been included.&#160;&#160;Operating results for the three months ended March 31, 2012 are not necessarily indicative of the results that may be expected for the year ending December 31, 2012.&#160;&#160;These financial statements should be read in conjunction with the consolidated financial statements and notes therein included in our annual report on Form 10-K for the year ended December 31, 2011.</div></div></div><div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_BasisOfPresentationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_BasisOfPresentationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 15<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6970148&amp;loc=SL6228881-111685<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name Statement of Position (SOP)<br><br> -Publisher AICPA<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS140-4/FIN46(R)-8<br><br> -Paragraph 8, C1, C7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name FASB Interpretation (FIN)<br><br> -Publisher FASB<br><br> -Number 46R<br><br> -Paragraph 4, 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 852<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 2-6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359553&amp;loc=d3e288-107754<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Use of Estimates<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_UseOfEstimatesAbstract', window );"><strong>Use of Estimates [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_UseOfEstimatesTextBlock', window );">Use of Estimates</a></td>
        <td class="text"><div><div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="top" style="width: 3%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">2.</div></td><td align="left" valign="top" style="width: 93%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">Use of Estimates</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period.&#160;&#160;Our most significant estimates and critical accounting policies involve recognizing revenue, evaluating goodwill for impairment, valuing our put option arrangement with Olympus Corporation, valuing warrants, determining the assumptions used in measuring share-based compensation expense and valuing allowances for doubtful accounts and inventories.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Actual results could differ from these estimates.&#160;&#160;Current economic conditions, including illiquid credit markets and volatile equity markets, contribute to the inherent uncertainty of such estimates.&#160;&#160;Management's estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the consolidated financial statements in the periods they are determined to be necessary.</div><div style="text-indent: 0pt; display: block;"><br /></div></div></div><div></div><div></div><div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_UseOfEstimatesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_UseOfEstimatesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_UseOfEstimatesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Provides an entity's explanation that the preparation of financial statements in conformity with generally accepted accounting principles requires the use of management estimates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_UseOfEstimatesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ETCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, reserves</a></td>
        <td class="nump">$ 187,000<span></span></td>
        <td class="nump">$ 474,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="nump">5,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
        <td class="nump">95,000,000<span></span></td>
        <td class="nump">95,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
        <td class="nump">58,428,606<span></span></td>
        <td class="nump">56,594,683<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
        <td class="nump">58,428,606<span></span></td>
        <td class="nump">56,594,683<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6965416&amp;loc=d3e5074-111524<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Transactions with Olympus Corporation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Transactions with Olympus Corporation [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Transactions with Olympus Corporation</a></td>
        <td class="text"><div><div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="top" style="width: 3%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">12.</div></td><td align="left" valign="top" style="width: 93%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">Transactions with Olympus Corporation</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Initial Investment by Olympus Corporation in Cytori</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">In 2005, we entered into a common stock purchase agreement with Olympus in which we received $11,000,000 in cash proceeds.&#160;&#160;We received an additional $11,000,000 from Olympus in August 2006 for the issuance of approximately 1,900,000 shares of our common stock at $5.75 per share.&#160;&#160;We received an additional $6,000,000 from Olympus in August 2008 for the issuance of 1,000,000 unregistered shares of our common stock at $6.00 per share and 500,000 common stock warrants (with an original exercise price of $8.50 per share) under a private placement offering.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">As of March 31, 2012, Olympus holds approximately 6.9% of our issued and outstanding shares.&#160;&#160;Additionally, Olympus has a right, which it has not yet exercised, to designate a director to serve on our Board of Directors.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Formation of the Olympus-Cytori Joint Venture</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">In 2005, we entered into a joint venture and other related agreements (the "Joint Venture Agreements") with Olympus.&#160;&#160;The Joint Venture is owned equally by Olympus and us.&#160;&#160;We have determined that the Joint Venture is a variable interest entity or VIE, but that Cytori is not the VIE's primary beneficiary.&#160;&#160;Accordingly, we have accounted for our interests in the Joint Venture using the equity method of accounting, since we can exert significant influence over the Joint Venture's operations.&#160;&#160;At March 31, 2012, the carrying value of our investment in the Joint Venture is $200,000.&#160;&#160;We are under no obligation to provide additional funding to the Joint Venture, but may choose to do so.&#160;&#160;We made no cash contributions to the Joint Venture during the three months ended March 31, 2012 and 2011.</div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Put/Calls and Guarantees</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">The Shareholders' Agreement between Cytori and Olympus provides that in certain specified circumstances of our insolvency or if we experience a change in control, Olympus will have the rights to (i) repurchase our interests in the Joint Venture at the fair value of such interests or (ii) sell its own interests in the Joint Venture to Cytori (the "Put") at the higher of (a) $22,000,000 or (b) the Put's fair value.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">At March 31, 2012 and December 31, 2011, the estimated fair value of the Put was $1,640,000 and $1,910,000, respectively.&#160;&#160;Fluctuations in the Put value are recorded in the consolidated condensed statements of operations as a component of change in fair value of option liabilities. The estimated fair value of the Put has been recorded as a long-term liability in the caption option liability in our consolidated condensed balance sheets.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">The valuations of the Put were completed using an option pricing theory based simulation analysis (i.e., a Monte Carlo simulation).&#160;&#160;The valuations are based on assumptions as of the valuation date with regard to the market value of Cytori and the estimated fair value of the Joint Venture, the expected correlation between the values of Cytori and the Joint Venture, the expected volatility of Cytori and the Joint Venture, the bankruptcy recovery rate for Cytori, the bankruptcy threshold for Cytori, the probability of a change of control event for Cytori, and the risk free interest rate.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">The following assumptions were employed in estimating the value of the Put:</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><a name="FIS_UNIDENTIFIED_TABLE_6"></a><br /></div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 90%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 66%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">&#160;</div></td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">March 31,</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">2012</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">&#160;</div></td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">December 31, </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">2011</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">&#160;</div></td></tr><tr><td valign="bottom" style="width: 66%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 1.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 1.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Expected volatility of Cytori</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">76.45</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">%</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">76.07</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">%</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Expected volatility of the Joint Venture</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">76.45</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">%</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">76.07</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">%</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Bankruptcy recovery rate for Cytori</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">28.00</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">%</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">28.00</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">%</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Bankruptcy threshold for Cytori</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">$</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">7,138,000</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">$</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">8,594,000</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Probability of a change of control event for Cytori</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">3.08</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">%</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">3.33</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">%</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Expected correlation between fair values of Cytori and the Joint Venture in the future</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">99.00</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">%</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">99.00</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">%</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Risk free interest rate</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">2.23</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">%</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">1.89</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">%</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">The Put has no expiration date.&#160;&#160;Accordingly, we will continue to recognize a liability for the Put and mark it to market each quarter until it is exercised or until the arrangements with Olympus are amended.</div><div style="text-indent: 0pt; display: block;"><br /></div></div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 3A<br><br> -Section 04<br><br> -Paragraph b<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 57<br><br> -Paragraph 1-4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph k<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EDSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">CYTORI THERAPEUTICS, INC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001095981<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 227,294,414<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">58,686,448<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,
         2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityPublicFloat</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
        <td class="text"><div><div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="top" style="width: 3%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">13.</div></td><td align="left" valign="top" style="width: 93%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">Fair Value Measurements</div></td></tr></table></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Fair value measurements are market-based measurements, not entity-specific measurements.&#160;&#160;Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability.&#160;&#160;We follow a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values.&#160;&#160;The basis for fair value measurements for each level within the hierarchy is described below:</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; text-indent: 9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#183;</font><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Level 1: Quoted prices in active markets for identical assets or liabilities.</font></div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; text-indent: 9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#183;</font><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.</font></div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; text-indent: 9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#183;</font><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets.</font></div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">The following table provides a summary of the recognized assets and liabilities that we measure at fair value on a recurring basis:</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 90%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="padding-bottom: 2px; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Balance as of</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="10" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 34%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Basis of Fair Value Measurements</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">March 31, 2012</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Level 1</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Level 2</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Level 3</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Assets:</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Cash equivalents</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">26,646,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">26,646,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 42%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Liabilities:</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Put option liability</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,640,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,640,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Warrant liability</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(757,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(757,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr></table></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 90%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="padding-bottom: 2px; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Balance as of</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="10" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 34%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Basis of Fair Value Measurements</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">December 31, 2011</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Level 1</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Level 2</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Level 3</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Assets:</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Cash equivalents</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">30,646,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">30,646,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 42%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Liabilities:</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Put option liability</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,910,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,910,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Warrant liability</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(627,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(627,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr></table></div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><a name="FIS_UNIDENTIFIED_TABLE_7"></a><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">We use quoted market prices to determine the fair value of our cash equivalents, which consist of money market funds that are classified in Level 1 of the fair value hierarchy.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">We value our put liability using an option pricing theory based simulation analysis (i.e., a Monte Carlo simulation) (see note 12). Because some of the inputs to our valuation model are either not observable quoted prices or are not derived principally from or corroborated by observable market data by correlation or other means, the put option liability is classified as Level 3 in the fair value hierarchy.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">The following table summarizes the change in our Level 3 put option liability value:</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="text-align: center; width: 80%; font-family: times new roman; font-size: 10pt;"><tr style="text-align: center;"><td valign="bottom" style="width: 68%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Three months ended</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr><td align="left" valign="bottom" style="border-bottom: black 2px solid; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Put option liability</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">March 31, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr><td valign="bottom" style="width: 68%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Beginning balance</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,910,000 </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Decrease in fair value recognized in operating expenses</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">270,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Ending balance</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1.640,000 </td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr></table></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"><a name="FIS_UNIDENTIFIED_TABLE_8"></a>Common stock purchase warrants issued in connection with our August 2008 private equity placement do not trade in an active securities market, and as such, we estimate the fair value of these warrants using the option pricing model.&#160;&#160;Some of the significant inputs are observable in active markets, such as common stock market price, volatility, and risk free rate.&#160;&#160;The fair value of these warrants also incorporate our assumptions about future equity issuances and their impact to the down-round protection feature. Because some of the inputs to our valuation model are either not observable quoted prices or are not derived principally from or corroborated by observable market data by correlation or other means, the warrant liability is classified as Level 3 in the fair value hierarchy.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">The following table summarizes the change in our Level 3 warrant liability value:</div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="text-align: center; width: 80%; font-family: times new roman; font-size: 10pt;"><tr style="text-align: center;"><td valign="bottom" style="width: 68%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Three months ended</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr><td align="left" valign="bottom" style="border-bottom: black 2px solid; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Warrant liability</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">March 31, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr><td valign="bottom" style="width: 68%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Beginning balance</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(627,000 </td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Decrease (increase)&#160;&#160;in fair value recognized in operating expenses</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(130,000 </td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Ending balance</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(757,000 </td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">No other assets or liabilities are measured at fair value on a recurring basis, or have been measured at fair value on a non-recurring basis subsequent to initial recognition, on the accompanying consolidated condensed balance sheet as of March 31, 2012.</div></div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the fair value measurement of assets and liabilities which includes [financial] instruments measured at fair value that are classified in stockholders' equity. Such assets and liabilities may be measured on a recurring or nonrecurring basis. The disclosures which may be required or desired include: (1) for assets and liabilities measured on a recurring basis, disclosure may include: (a) the fair value measurements at the reporting date; (b) the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3); (c) for fair value measurements using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (i) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (ii) purchases, sales, issuances, and settlements (net); (iii) transfers in and transfers out of Level 3 (for example,  transfers due to changes in the observability of significant inputs); (d) the amount of the total gains or losses for the period in subparagraph (c) (i) above included in earnings (or changes in net assets) that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date and a description of where those unrealized gains or losses are reported in the statement of income (or activities); (e) the valuation technique(s) used to measure fair value and a discussion of changes in valuation techniques, if any, during the period and (2) for assets and liabilities that are measured at fair value on a nonrecurring basis (for example,  impaired assets) disclosure may include, in addition to (a) above: (a) the reasons for the fair value measurements recorded; (b) the same as (b) above; (c) for fair value measurements using significant unobservable inputs (Level 3), a description of the inputs and the information used to develop the inputs; and (d) the valuation technique(s) used to measure fair value and a discussion of changes, if any, in the valuation technique(s) used to measure similar assets and/or liabilities in prior periods.  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19279-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 33<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19296-110258<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19207-110258<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 6<br><br> -Footnote 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementInputsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EW5AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product revenues</a></td>
        <td class="nump">$ 1,481,000<span></span></td>
        <td class="nump">$ 1,362,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of product revenues</a></td>
        <td class="nump">853,000<span></span></td>
        <td class="nump">842,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
        <td class="nump">628,000<span></span></td>
        <td class="nump">520,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_DevelopmentRevenuesAbstract', window );"><strong>Development revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_DevelopmentRelatedParty', window );">Development, related party</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,231,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_ResearchGrantsAndOther', window );">Research grants and other</a></td>
        <td class="nump">3,000<span></span></td>
        <td class="nump">4,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_TotalDevelopmentRevenues', window );">Total development revenues</a></td>
        <td class="nump">3,000<span></span></td>
        <td class="nump">1,235,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">2,836,000<span></span></td>
        <td class="nump">3,047,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
        <td class="nump">2,376,000<span></span></td>
        <td class="nump">3,226,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">3,924,000<span></span></td>
        <td class="nump">3,544,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_ChangeInFairValueOfWarrants', window );">Change in fair value of warrant liability</a></td>
        <td class="nump">130,000<span></span></td>
        <td class="nump">3,471,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_ChangeInFairValueOfOptionLiability', window );">Change in fair value of option liability</a></td>
        <td class="num">(270,000)<span></span></td>
        <td class="num">(290,000)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">8,996,000<span></span></td>
        <td class="nump">12,998,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
        <td class="num">(8,365,000)<span></span></td>
        <td class="num">(11,243,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump">2,000<span></span></td>
        <td class="nump">2,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num">(865,000)<span></span></td>
        <td class="num">(738,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
        <td class="num">(47,000)<span></span></td>
        <td class="num">(47,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity loss from investment in joint venture</a></td>
        <td class="num">(50,000)<span></span></td>
        <td class="num">(46,000)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
        <td class="num">(960,000)<span></span></td>
        <td class="num">(829,000)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (9,325,000)<span></span></td>
        <td class="num">$ (12,072,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted net loss per common share (in dollars per share)</a></td>
        <td class="num">$ (0.16)<span></span></td>
        <td class="num">$ (0.23)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Basic and diluted weighted average common shares (in shares)</a></td>
        <td class="nump">57,484,990<span></span></td>
        <td class="nump">51,994,708<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_ChangeInFairValueOfOptionLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change in fair value of option liability for the period which are included in the statement of income (or changes in net assets) in operating expenses; the fair value of which was or is measured on a recurring basis using valuation techniques in which one or more significant inputs are unobservable in active markets (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_ChangeInFairValueOfOptionLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_ChangeInFairValueOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change in fair value of warrants for the period which are included in the statement of income (or changes in net assets) in operating expenses; the fair value of which was or is measured on a recurring basis using model-derived valuations in which all significant inputs are observable in active markets (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_ChangeInFairValueOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_DevelopmentRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of previously reported related party deferred or unearned revenue that was recognized as revenue during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_DevelopmentRelatedParty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_DevelopmentRevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_DevelopmentRevenuesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_ResearchGrantsAndOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from non-product related activities and revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_ResearchGrantsAndOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_TotalDevelopmentRevenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue earned during the period from recognition of related party deferred revenue, non-product related activities and revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_TotalDevelopmentRevenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to goods produced and sold during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 2<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfGoodsSold</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 11, 12, 36<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 20<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1252-109256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 7<br><br> -Paragraph 18<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrossProfit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382870&amp;loc=d3e33749-111570<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 18<br><br> -Paragraph 19<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 18<br><br> -Paragraph 6<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 11<br><br> -Article 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.12)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromEquityMethodInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeStatementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cost of borrowed funds accounted for as interest that was charged against earnings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 34<br><br> -Paragraph 21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher OTS<br><br> -Name Federal Regulation (FR)<br><br> -Number Title 12<br><br> -Chapter V<br><br> -Section 563c.102<br><br> -Paragraph 9<br><br> -Subsection II<br><br> -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy.  It will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherIncomeAndExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 1<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueGoodsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SellingAndMarketingExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1505-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Revenue Recognition<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_RevenueRecognitionTextBlock', window );">Revenue Recognition</a></td>
        <td class="text"><div><div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="top" style="width: 3%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">7.</div></td><td align="left" valign="top" style="width: 93%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">Revenue Recognition</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Product Sales</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">We recognize revenue from product sales when the following fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred, (iii) the price to the customer is fixed or determinable and (iv) collection of the resulting accounts receivable is reasonably assured.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">For all sales, we use a binding purchase order or a signed agreement as evidence of an arrangement.&#160;&#160;Revenue for these product sales is recognized upon delivery to the customer, as all risks and rewards of ownership have been substantively transferred to the customer at that point.&#160;&#160;For sales to customers who arrange for and manage the shipping process, we recognize revenue upon shipment from our facilities.&#160;&#160;Shipping and handling costs that are billed to our customers are classified as revenue.&#160;&#160;The customer's obligation to pay and the payment terms are set at the time of delivery and are not dependent on the subsequent use or resale of our products.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">For sales that include multiple deliverables, such as sales of our StemSource&#174; Cell Bank (cell bank), we allocate arrangement consideration at the inception of the arrangement to all deliverables using the relative selling price method.&#160;&#160;Stem cell banks typically consist of a complex array of equipment, proprietary knowledge, and services, including one or more StemSource&#174; devices, a cryogenic freezer, measuring and monitoring equipment, and a database patient tracking system. In addition, we typically provide consulting services, installation and training services concurrent with the installation of the cell bank.&#160;&#160;Web hosting and technical and maintenance services are generally provided for a period of up to one year subsequent to the date of sale.&#160;&#160;FASB authoritative guidance establishes a selling price hierarchy for determining the selling price of a deliverable, which is based on: (a) vendor-specific objective evidence ("VSOE"); (b) third-party evidence ("TPE"); or (c) management estimates.&#160;&#160;For our cell bank sales, we establish relative selling prices for all deliverables based on vendor-specific quotes for comparable services when available.&#160;&#160;In the absence of VSOE, we use competitors' products or services considered largely interchangeable with our own or management's best estimate.&#160;&#160;A substantial amount of consulting services are provided to customers before the equipment installation and training has been completed, and therefore we treat this as a separate unit of accounting.&#160;&#160;The equipment with installation and initial training activities are treated as separate units of accounting.&#160;&#160;Also of standalone value to customers is the transfer of the proprietary knowledge, most notably in the form of standard operating procedures, and any license or exclusivity rights associated with the agreements.&#160;&#160;Revenue for the various deliverables is calculated and recognized based on the relative selling prices of each deliverable.&#160;&#160;Future services such as web hosting and ongoing maintenance are deferred and recognized into income during the year following the installation.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; font-style: italic; text-indent: 18pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Concentration of Significant Customers</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">For the three months ended March 31, 2012, two direct customers comprised 31% of our revenue recognized for the quarter.&#160;&#160;Our Asia-Pacific, North America and Australia region sales accounted for 69% of our revenue recognized for the three months ended March 31, 2012.&#160;&#160;Additionally, two direct customers accounted for 29% of total outstanding accounts receivable as of March 31, 2012.</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">For the three months ended March 31, 2011, one direct customer and one distributor comprised 29% of our revenue recognized for the quarter.&#160;&#160;Our Asia-Pacific region sales accounted for 30% of our revenue recognized for the three months ended March 31, 2011.&#160;&#160;Additionally, one distributor and two direct customers accounted for 43% of total outstanding accounts receivable as of March 31, 2011.</div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; font-style: italic; text-indent: 18pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Research and Development</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">We earn revenue for performing tasks under research and development agreements with both commercial enterprises, such as Olympus and Senko, and governmental agencies like the National Institutes of Health ("NIH").&#160;&#160;Revenue earned under development agreements is classified as either research grant or development revenues depending on the nature of the arrangement.&#160;&#160;Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with grants are recorded as research grant and other within development revenues.&#160;&#160;Research grant revenue is recorded at the gross amount of the reimbursement.&#160;&#160;The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations.&#160;&#160;Additionally, research and development arrangements we have with commercial enterprises such as Olympus and Senko are considered a key component of our central and ongoing operations.&#160;&#160;Accordingly, when recognized, the inflows from such arrangements are presented as revenues in our statements of operations.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">We received funds from Olympus and Olympus-Cytori, Inc. during 2005 and 2006.&#160;&#160;&#160;We recorded upfront fees totaling $28,311,000 as deferred revenues, related party.&#160;&#160;In exchange for these proceeds, we agreed to (a) provide Olympus-Cytori, Inc. an exclusive and perpetual license to our Celution&#174; System device technology and certain related intellectual property, and (b) provide future development contributions related to commercializing the Celution&#174; System platform.&#160;&#160;The license and development services are not separable and as a result the recognition of this deferred amount requires achievement of service related milestones, under a proportional performance methodology.&#160;&#160;If and as such revenues are recognized, deferred revenue will be decreased.&#160;&#160;Proportional performance methodology was elected due to the nature of our development obligations and efforts in support of the Joint Venture ("JV"), including product development activities and regulatory efforts to support the commercialization of the JV products. The application of this methodology uses the achievement of R&amp;D milestones as outputs of value to the JV.&#160;&#160;We received up-front, non-refundable payments in connection with these development obligations, which we have broken down into specific R&amp;D milestones that are definable and substantive in nature, and which will result in value to the JV when achieved.&#160;&#160;As our research and development efforts progress, we periodically evaluate,&#160;&#160;and modify if necessary, the milestone points in our proportional performance model to ensure that revenue recognition accurately reflects our best estimate of substantive value deliverable to the JV.&#160;&#160;Revenue will be recognized as the above mentioned R&amp;D milestones are completed.&#160;&#160;Of the amounts received and deferred, we recognized development revenues of $1,231,000 for the three months ended March 31, 2011.&#160;&#160;There was no development revenues recognized for the three months ended March 31, 2012.&#160;&#160;All related development costs are expensed as incurred and are included in research and development expense on our statements of operations.&#160;&#160;To date under the contract, of the $28,311,000 originally deferred, we have recognized a total of $24,791,000 through March 31, 2012.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt;">Under a Distribution Agreement with Senko, we granted to Senko an exclusive license to sell and distribute certain Thin Film products in Japan.&#160;&#160;We have also earned or will be entitled to earn additional payments under the Distribution Agreement based on achieving certain defined and substantive research and development milestones.</font>&#160;&#160;<font style="display: inline; font-size: 10pt;">There was no development revenue recognized related to this agreement during the three months ended March 31, 2012 and 2011, respectively.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div></div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_RevenueRecognitionTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Describes accounting policy for product as well as research and development revenue recognition. If there are different policies for different types of revenue transactions, the policy for each material type of transaction should be disclosed. If a sales transaction has multiple element arrangements, the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_RevenueRecognitionTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Long-term Debt<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAbstract', window );"><strong>Long-term Debt [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-term Debt</a></td>
        <td class="text"><div><div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="top" style="width: 3%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">6.</div></td><td align="left" valign="top" style="width: 93%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">Long-term Debt</div></td></tr></table></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">On September 9, 2011 we entered into a Second Amendment to the Amended and Restated Loan and Security Agreement (loan agreement) with General Electric Capital Corporation (GECC), Silicon Valley Bank (SVB) and Oxford Finance Corporation (together, the "Lenders"), pursuant to which the Lenders increased the prior term loan made to the Company to a principal amount of $25.0 million (Term Loan), subject to the terms and conditions set forth in the loan agreement.&#160;&#160;The Term Loan accrues interest at a fixed rate of 9.87% per annum.&#160;&#160;Pursuant to the loan agreement, we are required to make (i) twelve (12) equal consecutive monthly principal payments of $20,833 on the first day of each calendar month, commencing on October 1, 2011, (ii) twenty-nine (29) equal consecutive monthly principal payments of $825,000 on the first day of each calendar month, commencing on October 1, 2012, and (iii) and one (1) final principal payment of $825,000 on March 1, 2015. In addition, the maturity date of the Term Loan has been extended until March 1, 2015, and at maturity of the Term Loan, the Company will make a final payment fee equal to 5% ($1,250,000) of the Term Loan.&#160;&#160;We may incur additional fees if we elect to prepay the Term Loan.&#160;&#160;In connection with the Term Loan, on September 9, 2011, we issued to the Lenders warrants to purchase up to an aggregate of 132,891 shares of our common stock at an exercise price of $3.01 per share.&#160;&#160;These warrants are immediately exercisable and will expire on September 9, 2018.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">The Term Loan amended the Amended and Restated Loan and Security Agreement, of which an aggregate balance of approximately $15.6 million remained outstanding along with a prorated final payment fee of $419,000. The net proceeds of the Term Loan, after payment of lender fees and expenses, were approximately $8.6 million.</div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">We accounted for this amendment as debt modification since the terms of the amended Term Loan and the Original Term Loan were not substantially different and as present value of cash flows of the modified instrument (using a net method of comparing the present value of cash flows related to the lowest common principal balance between the old and the new loans) was within 10% of the original debt instrument.&#160;&#160;Accordingly, the fees associated with the amended Term Loan of $300,000, final payment fee of $1,250,000, and the existing unamortized debt discount from the Original Term Loan of $332,000 will be amortized as an adjustment of interest expense over the term of the Amended Term Loan using the effective interest method.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">We allocated the aggregate proceeds of the Term Loan between the warrants and the debt obligations based on their relative fair values.&#160;&#160;The fair value of the warrants issued to the Lenders is calculated utilizing the Black-Scholes option-pricing model. We are amortizing the relative fair value of the warrants as a discount of $267,000 over the term of the loan using the effective interest method, with an effective interest rate of 13.63%. If the maturity of the debt is accelerated due to an event of default, then the amortization would be accelerated. The Term Loan is collateralized by the tangible assets of the company, including a security interest in substantially all of its existing and after-acquired assets, excluding its intellectual property assets; provided however, that if the Company does not maintain certain cash ratios, the security interest automatically will be deemed to include the Company's intellectual property assets.&#160;&#160;As of March 31, 2012, we were in compliance with our financial and non-financial covenants.</div></div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-term debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_FairValueAbstract', window );"><strong>Fair Value [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
        <td class="text"><div><div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="top" style="width: 3%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">14.</div></td><td align="left" valign="top" style="width: 93%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">Fair Value</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Financial Instruments</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">We disclose fair value information about all financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate fair value. The disclosures of estimated fair value of financial instruments at March 31, 2012 and December 31, 2011, were determined using available market information and appropriate valuation methods. Considerable judgment is necessary to interpret market data and develop estimated fair value. The use of different market assumptions or estimation methods may have a material effect on the estimated fair value amounts.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">The carrying amounts for cash and cash equivalents, accounts receivable, inventories, other current assets, accounts payable, accrued expenses and other liabilities approximate fair value due to the short-term nature of these instruments.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">We utilize quoted market prices to estimate the fair value of our fixed rate debt, when available.&#160;&#160;If quoted market prices are not available, we calculate the fair value of our fixed rate debt based on a currently available market rate assuming the loans are outstanding through maturity and considering the collateral. In determining the current market rate for fixed rate debt, a market spread is added to the quoted yields on federal government treasury securities with similar terms to the debt.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">At March 31, 2012 and December 31, 2011, the aggregate fair value and the carrying value of the Company's fixed rate long-term debt were as follows:</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="text-align: center; width: 90%; font-family: times new roman; font-size: 10pt;"><tr style="text-align: center;"><td valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="6" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 22%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">March 31, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="6" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 22%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">December 31, 2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr><td valign="bottom" style="width: 42%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Carrying Value</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Carrying Value</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr><td valign="bottom" style="width: 42%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Fixed rate long-term debt</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">24,306,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">24,512,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">24,211,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">24,341,000</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 18pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Carrying value is net of debt discount of $1,613,000 and $1,847,000 as of March 31, 2012 and December 31, 2011, respectively.</div></div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_FairValueAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_FairValueAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19296-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 159<br><br> -Paragraph 17-22, 27, 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13433-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15C, 15D<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13504-108611<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15A<br><br> -Subparagraph a-d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13537-108611<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 133<br><br> -Paragraph 44A, 44B<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19207-110258<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 3, 10, 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15B<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 32, 33, 34<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Loss per Share<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_LossPerShareAbstract', window );"><strong>Loss per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss per Share</a></td>
        <td class="text"><div><div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="top" style="width: 3%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;"><a name="fis_unidentified_table_5"></a>10.</div></td><td align="left" valign="top" style="width: 93%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">Loss per Share</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but unexercised options, warrants, restricted stock and performance based restricted stock awards for all periods presented.</div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">We have excluded all potentially dilutive securities from the calculation of diluted loss per share attributable to common stockholders for the three months ended March 31, 2012 and 2011, as their inclusion would be antidilutive.&#160;&#160;Potentially dilutive common shares excluded from the calculations of diluted loss per share were 18,544,087 and 19,649,383 for the three month periods ended March 31, 2012 and 2011, respectively.</div></div></div><div></div><div></div><div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_LossPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_LossPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1252-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945512&amp;loc=d3e4984-109258<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1278-109256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Inventories<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_InventoriesAbstract', window );"><strong>Inventories [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
        <td class="text"><div><div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="top" style="width: 3%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">8.</div></td><td align="left" valign="top" style="width: 93%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">Inventories</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Inventories are carried at the lower of cost or market, determined on the first-in, first-out (FIFO) method.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Inventories consisted of the following:</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="text-align: center; width: 90%; font-family: times new roman; font-size: 10pt;"><tr style="text-align: center;"><td valign="bottom" style="width: 66%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">&#160;</div></td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">March 31,</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">&#160;</div></td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">December 31,</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">&#160;</div></td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 66%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">&#160;</div></td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">2012</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">&#160;</div></td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">2011</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">&#160;</div></td></tr><tr><td valign="bottom" style="width: 66%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 1.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 1.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Raw materials</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">$</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">1,518,000</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">$</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">1,503,000</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Work in process</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">838,000</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">790,000</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Finished goods</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="border-bottom: black 2px solid; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="border-bottom: black 2px solid; width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">1,018,000</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="border-bottom: black 2px solid; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="border-bottom: black 2px solid; width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">1,025,000</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 66%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="border-bottom: black 4px double; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">$</div></td><td align="right" valign="bottom" style="border-bottom: black 4px double; width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">3,374,000</div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="border-bottom: black 4px double; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">$</div></td><td align="right" valign="bottom" style="border-bottom: black 4px double; width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">3,318,000</div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td></tr></table></div></div></div><div></div><div></div><div></div><div></div><div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_InventoriesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_InventoriesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 3<br><br> -Section A<br><br> -Paragraph 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a, b, c<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-Based Compensation [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
        <td class="text"><div><div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="top" style="width: 3%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">9.</div></td><td align="left" valign="top" style="width: 93%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">Share-Based Compensation</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Stock Options</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">During the first quarter of 2012, we issued to our directors and executive officers options to purchase an aggregate of up to 690,000 shares of our common stock, with four-year vesting for our officers and two-year vesting for our directors. The grant date fair value of the awards granted to our officers was $2.10 per share and to our directors was $1.35 per share. The resulting share-based compensation expense of $1,373,000, net of estimated forfeitures, will be recognized as expense over the respective vesting periods.</div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">During the first quarter of 2011, we issued to our directors, executive officers and certain non-executive employees options to purchase an aggregate of up to 692,500 shares of our common stock, with four-year vesting for our officers and employees and two-year vesting for our directors. The grant date fair value of the awards granted to our officers and employees was $3.46 and to our directors was $3.15 per share. The resulting share-based compensation expense of $2,375,000, net of estimated forfeitures, will be recognized as expense over the respective vesting periods.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Restricted Stock Awards</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">During the first quarter of 2012, we issued to our executive officers 190,000 shares of restricted stock.&#160;&#160;The stock award is scheduled to fully vest on January 10, 2013, subject to the officer's continued employment with the Company through the vesting date.&#160;&#160;The resulting share-based compensation expense of $654,000 will be recognized as expense over the respective vesting period.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Performance-Based Restricted Stock Awards</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">We granted 246,225 performance-based restricted stock awards under the 2004 Equity Incentive Plan in February 2011.&#160;&#160;The awards provide certain employees until January 1, 2012 to achieve certain performance goals established by the Compensation Committee. The performance goals were weighted based on the following achievements: obtaining certain FDA clearance or approval (40%), achieving a targeted revenue increase for the fiscal year ended December 31, 2011 (20%), and entering into a major collaboration for development and/or commercialization of the Company's products (40%).&#160;&#160;To the extent that any of the performance goals were partially achieved, the Compensation Committee maintained the discretion to continue the vesting of all or a portion of the awards following January 1, 2012.&#160;&#160;Once earned, the awards would have remained unvested until January 1, 2013. Termination of employment prior to vesting would have resulted in the forfeiture of any earned (as well as unearned) awards. Effective January 2012, the outstanding awards were terminated in their entirety based upon the decision by the Compensation Committee that performance criteria had not been met as of January 1, 2012.&#160;&#160;No compensation expense was recognized related to these awards during the three months ended March 31, 2012 and 2011.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">In January 2012, we granted 276,375 performance-based restricted stock awards under the 2004 Equity Incentive Plan.&#160;&#160;The awards provide certain employees until December 31, 2012 to achieve certain performance goals established by the Compensation Committee. The performance goals are weighted based on the following achievements: entering into a major collaboration for development and/or commercialization of the Company's products (40%), obtaining certain FDA clearance or approvals, which include FDA approval for and initiation of the ATHENA feasibility trial in chronic myocardial ischemia (40%), obtaining CE mark for certain products (15%), and achieving a targeted revenue increase for the fiscal year ended December 31, 2012 (5%).&#160;&#160;To the extent that any of the performance goals are partially achieved, the Compensation Committee maintains the discretion to continue the vesting of all or a portion of the awards following December 31, 2012.&#160;&#160;Once earned, the awards will remain unvested until January 10, 2014. Termination of employment prior to vesting will result in the forfeiture of the awards.&#160;&#160;No compensation expense was recognized related to these awards during the three months ended March 31, 2012.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">The following table summarizes activity with respect to the performance based restricted stock awards during the three months ended March 31, 2012:</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="text-align: center; width: 90%; font-family: times new roman; font-size: 10pt;"><tr style="text-align: center;"><td valign="bottom" style="padding-bottom: 2px; width: 66%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Restricted Stock </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Awards</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Weighted </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Average Grant-</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Date Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Outstanding at January 1, 2012</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">246,225</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5.82</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Granted</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">276,375</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3.44</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Vested</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">0</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Cancelled/forfeited</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(246,225 </td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 9%; font-family: times new roman; font-size: 10pt;">5.82</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Outstanding at March 31, 2012</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">276,375</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; padding-bottom: 4px; width: 9%; font-family: times new roman; font-size: 10pt;">3.44</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 66%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Vested at March 31, 2012</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">0</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;">&#160;</div></div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 93-6<br><br> -Paragraph 53<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64, 65, A240<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><div><div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="top" style="width: 3%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">11.</div></td><td align="left" valign="top" style="width: 93%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">Commitments and Contingencies</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt;">We have entered into agreements with various research organizations for pre-clinical and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements was estimated based on current schedules of pre-clinical and clinical studies in progress.&#160;&#160;</font><font style="display: inline; font-size: 10pt;">As of March 31, 2012, we have pre-clinical research study obligations of $60,000 (which are expected to be fully completed within a year) and clinical research study obligations of $12,600,000 ($4,100,000 of which are expected to be completed within a year).</font>&#160;&#160;<font style="display: inline; font-size: 10pt;">Should the timing or the budgets of the pre-clinical and clinical trials change, the timing and amounts of the payments for these obligations would also change.</font></div><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">During 2008, we entered into a supply agreement with a minimum purchase requirements clause.&#160;&#160;As of March 31, 2012, we have minimum purchase obligations of $2,191,000 ($1,341,000 of which are expected to be paid within a year).</div></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">We have entered into several lease agreements for our headquarters office location as well as international office locations and corporate housing for our employees on international assignments. As of March 31, 2012, we have remaining lease obligations of $10,259,000 ($1,785,000 of which are expected to be completed within a year).</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">We are subject to various claims and contingencies related to legal proceedings.&#160;&#160;Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions.&#160;&#160;Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate.&#160;&#160;Management believes that any liability to us that may arise as a result of currently pending legal proceedings will not have a material adverse effect on our financial condition, liquidity, or results of operations as a whole.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Refer to note 6 for a discussion of our commitments and contingencies related to our long-term obligations.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Refer to note 12 for a discussion of our commitments and contingencies related to our transactions with Olympus, including (a) our obligation to the Joint Venture in future periods and (b) certain put and call rights embedded in the arrangements with Olympus.</div></div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 14<br><br> -Paragraph 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 9, 10, 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSubsequentEventsTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><div><div><div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="top" style="width: 3%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">16.</div></td><td align="left" valign="top" style="width: 93%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">Subsequent Events</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">We have evaluated events after the balance sheet date of March 31, 2012 and up to the date we filed this report.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Subsequent to the quarter ended March 31, 2012, we completed one scheduled closing with Seaside 88, LP during the period of April 1, 2012 through our filing date raising in aggregate approximately $549,000 in gross proceeds from the <font style="font-family: Times New Roman; font-size: 10pt;">sale of 250,000<font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#160;</font>shares</font> of our common stock in connection with the agreement we entered into with Seaside 88, LP on July 11, 2011.&#160;&#160;Effective, April 30<font style="display: inline; font-size: 70%; vertical-align: text-top;">th</font>, 2012, we terminated the agreement with Seaside 88, LP and we will not sell the remaining and final 500,000 shares that would otherwise have been sold under this agreement.</div></div></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, losses resulting from fire or flood, losses on receivables, significant realized and unrealized gains and losses that result from changes in quoted market prices of securities, declines in market prices of inventory, changes in authorized or issued debt (SEC), significant foreign exchange rate changes, substantial loans to insiders or affiliates, significant long-term investments, and substantial dividends not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 11<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Topic 855<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Name Accounting Standards Codification<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfSubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E5UAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (9,325,000)<span></span></td>
        <td class="num">$ (12,072,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">220,000<span></span></td>
        <td class="nump">194,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred financing costs and debt discount</a></td>
        <td class="nump">237,000<span></span></td>
        <td class="nump">240,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Increase (decrease) in allowance for doubtful accounts</a></td>
        <td class="num">(24,000)<span></span></td>
        <td class="nump">21,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_ChangeInFairValueOfWarrants', window );">Change in fair value of warrant liability</a></td>
        <td class="nump">130,000<span></span></td>
        <td class="nump">3,471,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_ChangeInFairValueOfOptions', window );">Change in fair value of option liability</a></td>
        <td class="num">(270,000)<span></span></td>
        <td class="num">(290,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump">942,000<span></span></td>
        <td class="nump">881,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity loss from investment in joint venture</a></td>
        <td class="nump">50,000<span></span></td>
        <td class="nump">46,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Increases (decreases) in cash caused by changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="nump">859,000<span></span></td>
        <td class="nump">278,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
        <td class="num">(56,000)<span></span></td>
        <td class="num">(174,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_IncreaseDecreaseOtherCurrentAssets', window );">Other current assets</a></td>
        <td class="num">(298,000)<span></span></td>
        <td class="num">(130,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_IncreaseDecreaseOtherAssets', window );">Other assets</a></td>
        <td class="num">(22,000)<span></span></td>
        <td class="num">(922,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
        <td class="num">(83,000)<span></span></td>
        <td class="num">(854,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_IncreaseDecreaseDeferredRevenueRelatedParty', window );">Deferred revenues, related party</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(1,231,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_IncreaseDecreaseOfDeferredRevenue', window );">Deferred revenues</a></td>
        <td class="num">(68,000)<span></span></td>
        <td class="num">(10,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty', window );">Long-term deferred rent</a></td>
        <td class="num">(6,000)<span></span></td>
        <td class="num">(12,000)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(7,714,000)<span></span></td>
        <td class="num">(10,564,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="num">(25,000)<span></span></td>
        <td class="num">(131,000)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
        <td class="num">(25,000)<span></span></td>
        <td class="num">(131,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments on long-term obligations</a></td>
        <td class="num">(71,000)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants', window );">Proceeds from exercise of employee stock options and warrants</a></td>
        <td class="nump">947,000<span></span></td>
        <td class="nump">674,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
        <td class="nump">4,396,000<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Costs from sale of common stock</a></td>
        <td class="num">(56,000)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">5,216,000<span></span></td>
        <td class="nump">674,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash and cash equivalents</a></td>
        <td class="num">(2,523,000)<span></span></td>
        <td class="num">(10,021,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
        <td class="nump">36,922,000<span></span></td>
        <td class="nump">52,668,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
        <td class="nump">34,399,000<span></span></td>
        <td class="nump">42,647,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_CashPaidDuringPeriodForAbstract', window );"><strong>Cash paid during period for:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
        <td class="nump">625,000<span></span></td>
        <td class="nump">499,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash operating, investing and financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Capital equipment lease</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">101,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Net increase in purchases of property and equipment included in accounts payable</a></td>
        <td class="nump">$ 795,000<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_CashPaidDuringPeriodForAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_CashPaidDuringPeriodForAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_ChangeInFairValueOfOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change in fair value of option liability for the period which are included in the statement of income (or changes in net assets) in operating expenses; the fair value of which was or is measured on a recurring basis using valuation techniques in which one or more significant inputs are unobservable in active markets (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_ChangeInFairValueOfOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_ChangeInFairValueOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change in fair value of warrants for the period which are included in the statement of income (or changes in net assets) in operating expenses; the fair value of which was or is measured on a recurring basis using model-derived valuations in which all significant inputs are observable in active markets (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_ChangeInFairValueOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_IncreaseDecreaseDeferredRevenueRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change during the reporting period in related party deferred revenue liability, including the portion taken into income, reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_IncreaseDecreaseDeferredRevenueRelatedParty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change in the long term deferred rent liability balance during the reporting period. Long term deferred liability is a cumulative difference between the rental payments required by a lease agreement and the rental expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in expense more than one year after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_IncreaseDecreaseLongTermDeferredRentLiabiilty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_IncreaseDecreaseOfDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change during the reporting period in deferred revenue liability, including the portion taken into income, reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_IncreaseDecreaseOfDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_IncreaseDecreaseOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change during the reporting period in the aggregate value of other noncurrent assets. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_IncreaseDecreaseOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_IncreaseDecreaseOtherCurrentAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change during the reporting period in the aggregate value of other current assets. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_IncreaseDecreaseOtherCurrentAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options and warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_ProceedsFromExerciseOfEmployeeStockOptionsAndWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The component of interest expense representing the noncash expenses charged against earnings in the period to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include Noncash Interest Expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCostsAndDiscounts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase during the period in capital lease obligations due to entering into new capital leases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligationsIncurred</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382870&amp;loc=d3e33749-111570<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 18<br><br> -Paragraph 19<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 18<br><br> -Paragraph 6<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 11<br><br> -Article 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.12)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromEquityMethodInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInventories</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18, 19, 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.5)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProvisionForDoubtfulAccounts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfLongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Warrant Liability<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_WarrantLiabilityAbstract', window );"><strong>Warrant Liability [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytx_WarrantLiabilityTextBlock', window );">Warrant Liability</a></td>
        <td class="text"><div><div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="top" style="width: 3%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">5.</div></td><td align="left" valign="top" style="width: 93%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">Warrant Liability</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Warrants with exercise price reset features (down-round protection) are accounted for as liabilities, with changes in fair value included in net earnings (loss).&#160;&#160;The fair value of the liability associated with the warrants with this reset feature increased to $757,000 as of March 31, 2012, which resulted in a $130,000 loss from the change in fair value of warrants for the three months ended March 31, 2012.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Since these warrants do not qualify for hedge accounting, all future changes in the fair value of the warrants will be recognized currently in earnings until such time as the warrants are exercised or expire. These warrants are not traded in an active securities market, and as such, we estimated the fair value of these warrants using an option pricing model with the following assumptions:</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><a name="FIS_UNIDENTIFIED_TABLE_3"></a><br /></div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 80%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">&#160;</div></td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">As of</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">March 31, 2012</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">&#160;</div></td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">As of</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">December 31, 2011</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Expected term</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 1.8pt;">1.37 years</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 1.8pt;">1.61 years</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Common stock market price</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">$</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">2.49</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">$</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">2.20</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Risk-free interest rate</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">0.26</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">%</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">0.19</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">%</div></td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Expected volatility</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">71.61</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">%</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">69.98</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">%</div></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Resulting fair value (per warrant)</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">$</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">0.38</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="right" valign="bottom" style="width: 1%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">$</div></td><td align="right" valign="bottom" style="width: 9%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">0.32</div></td><td align="left" valign="bottom" style="width: 1%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Expected volatility is based primarily on historical volatility. Historical volatility was computed using daily pricing observations for recent periods that correspond to the expected term of the warrants. We believe this method produces an estimate that is representative of our expectations of future volatility over the expected term of these warrants. We currently have no reason to believe future volatility over the expected remaining life of these warrants is likely to differ materially from historical volatility. The expected life is based on the remaining contractual term of the warrants. The risk-free interest rate is the interest rate for treasury constant maturity instruments published by the Federal Reserve Board that is closest to the expected term of the warrants.&#160;&#160;&#160;The fair value of these warrants also incorporates our assumptions about future equity issuances and their impact to the down-round protection feature.</div></div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_WarrantLiabilityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_WarrantLiabilityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytx_WarrantLiabilityTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure for warrants which are accounted for as fair value liabilities with changes in fair value included in net earnings (loss). Fair value for these warrants is measured on a recurring basis using valuation techniques in which one or more significant inputs are unobservable in active markets (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cytx_WarrantLiabilityTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cytx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>8</ContextCount>
  <ElementCount>114</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytori.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytori.com/role/ConsolidatedCondensedBalanceSheetsUnaudited</Role>
      <ShortName>CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>010100 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytori.com/role/ConsolidatedCondensedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>020000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytori.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossUnaudited</Role>
      <ShortName>CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>030000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytori.com/role/ConsolidatedCondensedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>060100 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytori.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>060200 - Disclosure - Use of Estimates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytori.com/role/UseOfEstimates</Role>
      <ShortName>Use of Estimates</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>060300 - Disclosure - Capital Availability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytori.com/role/CapitalAvailability</Role>
      <ShortName>Capital Availability</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>060400 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytori.com/role/RecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>060500 - Disclosure - Warrant Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytori.com/role/WarrantLiability</Role>
      <ShortName>Warrant Liability</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>060600 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytori.com/role/LongtermDebt</Role>
      <ShortName>Long-term Debt</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>060700 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytori.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>060800 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytori.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>060900 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytori.com/role/SharebasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>061000 - Disclosure - Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytori.com/role/LossPerShare</Role>
      <ShortName>Loss per Share</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>061100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytori.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>061200 - Disclosure - Transactions with Olympus Corporation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytori.com/role/TransactionsWithOlympusCorporation</Role>
      <ShortName>Transactions with Olympus Corporation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>061300 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytori.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>061400 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytori.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>061500 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytori.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>061600 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytori.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 010000 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2010'</Log>
    <Log type="Info">Process Flow-Through: 010100 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 020000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)</Log>
    <Log type="Info">Process Flow-Through: 030000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</Log>
  </Logs>
  <InputFiles>
    <File>cytx-20120331.xml</File>
    <File>cytx-20120331.xsd</File>
    <File>cytx-20120331_cal.xml</File>
    <File>cytx-20120331_lab.xml</File>
    <File>cytx-20120331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
        <td class="text"><div><div><div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="top" style="width: 3%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">15.</div></td><td align="left" valign="top" style="width: 93%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">Stockholders' Equity</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Common Stock</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">On December 13, 2010 we raised $10,000,000 in gross proceeds from a sale of 1,428,571 shares of unregistered common stock to Astellas Pharma Inc. for $7.00 per share in a private stock placement.&#160;&#160;Pursuant to the terms of the purchase agreement, we granted Astellas Pharma Inc. a two year right of first refusal to enter into a development and commercialization collaboration with us regarding the use of our technology, on a worldwide basis, for the treatment of liver conditions. In addition, we have agreed to use reasonable efforts to file a registration statement with the Securities and Exchange Commission to register the shares of common stock for resale upon the request of Astellas Pharma Inc.&#160;&#160;We also granted Astellas Pharma Inc. a non-voting observer seat on our Board of Directors and the right to designate a representative member to our Scientific Advisory Board.&#160;&#160;The $10,000,000 in total proceeds we received exceeded the market value of our stock at the completion of the purchase agreement.&#160;&#160;The $2,526,000 difference between the proceeds received and the fair market values of our common stock was recorded as a component of deferred revenues in the accompanying balance sheets.&#160;&#160;This difference was recorded as deferred revenue since, conceptually, the excess proceeds represent a value paid by Astellas Pharma Inc. attributable to the scientific advisory board seat, the non-voting observer seat on our Board of Directors, and the two year right of first refusal&#160;&#160;to enter into a development and commercialization collaboration with us regarding the use of our technology, on a worldwide basis, for the treatment of liver conditions, rather than an additional equity investment in Cytori.&#160;&#160;The recognition of this deferred amount is expected to occur upon the earlier of the expiration of the two year period or the termination of the agreement.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">On July 11, 2011, we entered into a common stock purchase agreement with Seaside 88, LP relating to the offering and sale of a total of up to 6,326,262 shares of our common stock.&#160;&#160;The agreement requires us to issue and Seaside to buy 1,326,262 shares of our common stock at an initial closing and 250,000 shares of our common stock once every two weeks, commencing 30 days after the initial closing, for up to an additional 20 closings, subject to the satisfaction of customary closing conditions. At the initial closing, the offering price was $4.52, which equaled to 88% of our common stock's volume-weighted average trading prices, or VWAP, during the ten-day trading period immediately prior to the initial closing date, raising approximately $6,000,000 in gross proceeds. At subsequent closings, the offering price will equal 90.25% of our common stock's volume-weighted average trading prices during the ten-day trading period immediately prior to each subsequent closing date.&#160;&#160;We raised approximately $17,684,000 in gross proceeds from the sale of 5,576,262 shares in our scheduled closings through March 31, 2012.</div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><div><div style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 8pt;"></div></div></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Warrant Adjustments</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Our March 2009 offering of 4,771,174 shares of our common stock and warrants to purchase up to a total of 6,679,644 additional shares of our common stock with an exercise price of $2.59 per share, our May 2009 equity offering of 1,864,783 shares of our common stock and warrants to purchase up to a total of 3,263,380 additional shares of our common stock with an exercise price of $2.62 per share, our closings with Seaside 88, LP through March 31, 2012, our October 2010 offering of 4,600,000 shares of our common stock and our December 2010 sale of 1,428,571 shares of our common stock triggered an adjustment to the exercise price and number of shares issuable under the warrants issued to investors in our August 2008 private placement financing.&#160;&#160;As a result, as of March 31, 2012, the common stock warrants issued on August 11, 2008 are currently exercisable for 2,014,512 shares of our common stock at an exercise price of $5.75 per share.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Other Related Party Transactions</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">As of March 31, 2012 and December 31, 2011, Green Hospital Supply, Inc., our distribution partner in Japan and a related party, was a beneficial owner of 5.1% and 5.3%, respectively, of our outstanding shares of common stock.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">During the three months ended March 31, 2012 and 2011, we incurred approximately $27,000 and $28,000 in royalty costs in connection with our sales of our Celution&#174; 800/CRS System products to the European and Asia-Pacific reconstructive surgery market, pursuant to our License and Royalty Agreement and the Amended License/Commercial Agreement with the Olympus-Cytori, Inc. joint venture, respectively.&#160;&#160;Additionally, during the three months ended March 31, 2012, we purchased second generation Celution &#174; Systems and consumable sets from Olympus-Cytori, Inc. joint venture, at a formula-based transfer price aggregating to $1,048, 0000.&#160;&#160;As of March 31, 2012 and December 31, 2011, Olympus Corporation was a beneficial owner of 6.9% and 7.1%, respectively, of our outstanding shares of common stock and a beneficial owner of 50% of Olympus-Cytori, Inc. joint venture.</div></div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph d<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 1<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
